{
    "65cfad2d1930410b13000014":
    {
        "question": "Concizumab is used for which diseases?",
        "llm_evidence": "Concizumab is a monoclonal antibody that functions as an inhibitor of tissue factor, primarily under investigation for its potential use in hemophilia. It is designed to facilitate hemostasis by blocking the initiation of the coagulation cascade, which is particularly beneficial for individuals with hemophilia A or B who face challenges with bleeding episodes. Additionally, concizumab has shown promise in treating hereditary angioedema (HAE), a genetic condition characterized by recurrent episodes of severe swelling. Clinical trials have demonstrated its efficacy in managing these conditions, making concizumab a potentially valuable therapeutic option for patients with hemophilia and HAE.",
        "paper_evidence":
        [
            "Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors. In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ",
            "Some non-factor products that work by facilitating the coagulation pathway (emicizumab) and blocking the anticoagulant pathway (fitusiran, concizumab and marstacimab) for patients with haemophilia (H) have been developed, and clinical trials using these products are currently ongoing.",
            "A previous trial of concizumab (explorer4) established proof of concept in patients with hemophilia A or B with inhibitors.",
            "Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous administration",
            "In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",
            "This article summarizes the milestones in the development of concizumab leading to this first approval for the treatment of hemophilia B.",
            "Conclusion explorer™3 data support further clinical development of concizumab for use in people with hemophilia, with or without inhibitors.",
            "Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives.",
            "Concizumab is a novel subcutaneous prophylactic therapy for hemophilia.",
            "Concizumab (Alhemo™), a subcutaneously administered humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor (TFPI), binds to the Kunitz-2 domain of TFPI and prevents TFPI from binding to activated Factor X. Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors.",
            "Prophylaxis with subcutaneous long-acting non-factor products that improve in vivo thrombin generation is now under intensive investigation (concizumab, fitusiran) or successfully employed (emicizumab) in haemophilia patients.",
            "Concizumab is a monoclonal antibody (mAb) against tissue factor pathway inhibitor (TFPI), currently in clinical development as a subcutaneous prophylactic therapy for hemophilia A/B with and without inhibitors.",
            "A monoclonal antibody (concizumab) targeting tissue factor pathway inhibitor (TFPI) that can be administered subcutaneously (s.c.) has the potential to alter current concepts of prophylaxis in hemophilia.OBJECTIVES: To evaluate the safety and describe the pharmacokinetics and pharmacodynamics of single-dose concizumab in healthy volunteers and patients with hemophilia A or B.METHODS: In this first human dose, phase 1, multicenter, randomized, double-blind, placebo-controlled trial escalating single i.v.",
            "Concizumab (Alhemo™), a subcutaneously administered humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor (TFPI), binds to the Kunitz-2 domain of TFPI and prevents TFPI from binding to activated Factor X. Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors. In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ",
            "Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent that binds to the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), one of the molecules that contributes to downregulation of coagulation thereby preventing TFPI from binding to and blocking the factor Xa (FXa) active site. When the TFPI inhibitory activity is decreased, sufficient FXa is produced by the FVIIa-tissue factor complex to achieve hemostasis. On the basis of this mechanism of action, concizumab is expected to be equally effective in hemophilia A and B, regardless of inhibitor status. Moreover, the concizumab mechanism of action does not interfere with the regulation of coagulation downstream of TFPI. ",
            "BACKGROUND: Concizumab is an anti-tissue factor pathway inhibitor monoclonal antibody designed to achieve hemostasis in all hemophilia types, with subcutaneous admi",
            "Concizumab is a monoclonal, humanized IgG4 antibody specific for the Kunitz-2 domain of Tissue Factor Pathway Inhibitor (TFPI). Preclinical studies in vitro or on animal models and in vivo have demonstrated the ability of concizumab to restore thrombin generation, promoting the establishment of a procoagulant action; all these results were subsequently confirmed in the studies of EXPLORER program. Concizumab may represent a new opportunity for the treatment of persons with hemophilia, so there is much anticipation for the results of the ongoing trials still.",
            "Concizumab is a humanized monoclonal antibody in clinical investigation directed against membrane-bound and soluble tissue factor pathway inhibitor (mTFPI and sTFPI) for treatment of hemophilia.",
            "BACKGROUND: The anti-tissue factor plasma inhibitor monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without",
            "Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.",
            "Concizumab is a novel subcutaneous prophylactic therapy for hemophilia. It is a hemostatic rebalancing agent",
            "development of concizumab in people with hemophilia. SUMMARY: Background Concizumab is a humanized mAb targeting tissue"
        ]
    },
    "65f7736fc4010b4d78000024":
    {
        "question": "What type of extracolonic tumors does the PMS2 germline mutation cause?",
        "llm_evidence": "PMS2 germline mutations are associated with Lynch syndrome (also known as hereditary non-polyposis colorectal cancer, or HNPCC), which primarily increases the risk for various extracolonic tumors. Key insights include:\n\n1. **Endometrial Cancer**: There is a significantly elevated risk of endometrial cancer in individuals with PMS2 mutations, often manifesting before the age of 50.\n\n2. **Ovarian Cancer**: Although the risk is lower compared to other Lynch syndrome mutations (like MLH1 and MSH2), PMS2 mutations still confer an increased risk for ovarian cancer.\n\n3. **Urinary Tract Cancers**: There is a notable association with urinary tract cancers, particularly urothelial carcinoma.\n\n4. **Gastric Cancer**: Individuals with PMS2 mutations may also have an increased risk of gastric cancer, although this is less prominent compared to other Lynch-related mutations.\n\n5. **Small Bowel Cancer**: Research indicates a potential increased risk for small bowel cancer, a lesser-known but possible outcome of PMS2 mutations.\n\nIn summary, PMS2 germline mutations are linked to an increased risk of various extracolonic tumors, particularly endometrial, ovarian, urinary tract, gastric, and small bowel cancers.",
        "paper_evidence":
        [
            "Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer. ",
            "PMS2 mutation carriers had more extracolonic cancers although these differences were not statistically significant.",
            "pectrum. However, the age-specific cumulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch syndrome. Using a large data set from a worldwide collaboration, our aim was to determine accurate penetrance measures of cancers for carriers of heterozygous pathogenic PMS2 ",
            "PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly"
        ]
    },
    "65f7080fc4010b4d78000019":
    {
        "question": "Do stroke patients have a lower risk of Obstructive Sleep Apnea?",
        "llm_evidence": "Patients who have experienced a stroke may face a higher, rather than lower, risk of developing Obstructive Sleep Apnea (OSA). Research indicates that stroke can lead to various physiological changes, including disruptions in the central nervous system that may impact sleep patterns and respiratory control. Additionally, common factors associated with stroke, such as obesity, hypertension, and cardiovascular issues, are also known risk factors for OSA. Studies have shown that a significant percentage of stroke patients are found to have OSA, suggesting a correlation rather than a protective effect. Overall, the evidence points to an increased risk of OSA in stroke patients, emphasizing the need for thorough screening and management of sleep apnea in this population.",
        "paper_evidence":
        [
            "Sleep-Disordered Breathing and Prognosis after Ischemic Stroke: It Is Not Apnea-Hypopnea Index That Matters.",
            " Sleep-disordered breathing (SDB) is highly prevalent after stroke and is considered to be a risk factor for poor post-stroke outcomes. ",
            "Post-stroke sleep disturbance and recurrent cardiovascular and cerebrovascular events: A systematic review and meta-analysis.",
            "The relationship between sleep and stroke is complex: sleep disturbances are likely both a contributor to, and consequence of, stroke. ",
            "BACKGROUND AND PURPOSE: Obstructive sleep apnea (OSA) is seldom considered in the diagnostic investigation in the poststroke period although it is a stroke risk factor and has adverse prognostic implications after stroke.",
            "Following stroke, patients have a high prevalence of OSA, which diminishes the potential for rehabilitation, increases the risk of secondary stroke, and heightens mortality.",
            "More of the half of the stroke patients have sleep-disordered breathing.",
            "Obstructive sleep apnea, a form of sleep-disordered breathing, is associated with multiple major stroke risk factors but is also an independent risk factor for stroke.",
            "The majority of stroke patients have clinically significant obstructive sleep apnea (OSA).",
            "Obstructive sleep apnea (OSA) has been considered as one of the risk factors for ischemic stroke, but the impact of OSA on wake-up stroke (WUS) is not well studied. We aimed to determine the relationship between OSA and WUS.",
            "Obstructive Sleep Apnea (OSA) is a prevalent disease that has emerged as a new cerebrovascular disease (CVD) risk factor, which is independent of its association to hypertension, age and other known conditions that increase CVD.",
            "Obstructive sleep apnea (OSA) has been found to be an independent risk factor for stroke in large epidemiological studies.",
            "Obstructive sleep apnea (OSA) is prevalent after stroke and associated with recurrent stroke, prolonged hospitalization, and decreased functional recovery",
            "The majority of stroke patients have clinically significant obstructive sleep apnea (OSA). Also, recent evidence demonstrates that OSA serves as an independent risk factor for stroke.",
            "Obstructive sleep-disordered breathing (SDB), which includes primary snoring through to obstructive sleep apnea syndrome (OSAS), may cause compromise of respiratory gas exchange during sleep, related to transient upper airway narrowing disrupting ventilation, and causing oxyhemoglobin desaturation and poor sleep quality. SDB is common in chronic disorders and has significant implications for health. With prevalence rates globally increasing, this condition is causing a substantial burden on health care costs. Certain populations, including people with sickle cell disease (SCD), exhibit a greater prevalence of OSAS.",
            "Obstructive sleep apnea (OSA) has been considered as one of the risk factors for ischemic stroke, but the impact of OSA on wake-up stroke (WUS) is not well studied. We aimed to determine the relationship between OSA and WUS. We prospectively recruited 71 patients with mild to moderate ischemic stroke during hospitalization. Patients were classified into WUS and non-WUS. A full-night sleep respiratory study was performed between 3 and 14 days after stroke onset. Demographic data, sleep respiratory data, heart rate variability, stroke risk factors, stroke classification and sleep-related scales were recorded. We compared the differences in the variables between the two groups and determined the independent variables associated with WUS. Of the 71 patients, 26 (36.6%) had WUS. The patients with WUS had a significantly higher apnea-hypopnea index (23.1 ± 19.4 vs. 12.5 ± 11.9, p = 0.016), obstructive apnea index (7.8 ± 9.7 vs. 3.0 ± 4.0, p = 0.021) and lower mean blood oxygen saturation (95.1 ± 1.5 vs. 95.8 ± 1.3, p = 0.046) than the non-WUS patients. There were no significant differences in demographic data, stroke risk factors, sleep-related scales or heart rate variability. Logistic regression revealed that severe sleep-disordered breathing (apnea-hypopnea index ≥30) was the only independent variable associated with WUS (OR 6.065, 95% CI 1.451-25.350; p = 0.014). We conclude that in patients with mild to moderate ischemic stroke, OSA is the only risk factor associated with WUS, which cannot be distinguished clinically from n",
            "Sleep-related breathing disorders are strongly associated with increased risk of stroke independent of known risk factors. The direction of causation favors sleep-disordered breathing leading to stroke rather than the other way around, although definitive proof of this awaits the results of prospective cohort studies.",
            "Based on a meta-analysis of the cohort studies, treatment with CPAP was associated with a lower incidence of stroke and cardiac events with relative risks of 0.27 [0.14-0.53], and 0.54 [0.38-0.75], respectively, although this could not be reproduced in the RCT and the studies using administrative data.CONCLUSIONS: Treating with CPAP in patients with OSA might decrease the risk of stroke, although there is some conflicting evidence.",
            "BACKGROUND AND PURPOSE: Obstructive sleep apnea (OSA) has been shown to increase the risk of stroke.",
            "CPAP) treatment in these patients. Observational studies have shown an increased risk of ischemic stroke in patients with untreated OSA when compared with patients treated with CPAP; however, results",
            "The relationship between sleep-disordered breathing and stroke risk factors is complex, and likely part of the risk for cerebrovascular events is because of higher cardiovascular risk factors in patients with increased RDI.",
            "poor functional prognosis.CONCLUSIONS: Severe OSA is an independent risk factor for a poor functional prognosis in patients with acute ischemic stroke, and quantitative EEG during sleep showed a significant slow wave enhancement, su",
            "Obstructive sleep apnea (OSA) has been considered as one of the risk factors for ischemic stroke,",
            "Obstructive sleep apnea (OSA) increases the risk of stroke independent of known vascular and metabolic risk",
            "apnea (OSA) is a common disorder and the major sleep-related risk factor for cerebrovascular disease. There is a dose-response relationship",
            "Obstructive Sleep Apnea (OSA) is a sleep disorder with a high prevalence in the general population. It is a risk factor for many cardiovascular diseases, and an independent risk factor for cerebrovascular diseases such as stroke. After an apnea episode, both arterial blood pressure and cerebral blood flow velocity change in function of the apnea duration (AD). We hypothesized that the relative excursion",
            "Obstructive Sleep Apnea (OSA) is a common co-morbid condition in stroke patients. It represents a very important risk factor for stroke in addition to the other established ones such as hypertension, cardiovascular disease (CVD), hyperlipidemia, atrial fibrillation (AF), type 2 diabetes mellitus (T2DM), stress, smoking, and heavy drinking.",
            "Obstructive sleep apnea (OSA), prevalent in patients with stroke, increases the risks of cardiovascular events and stroke.",
            "OSA is an independent risk factor for acute ischemic stroke (AIS) and a contributor to other key risk factors.",
            "Obstructive sleep apnea (OSA), one of the most common and serious sleep disturbances, manifests itself in almost 50% of all stroke patients. Sleep apnea patients who experience a stroke may be at a greater impairment in their rehabilitation potential and have increased risk of secondary stroke and mortality."
        ]
    },
    "65f859b2c4010b4d78000050":
    {
        "question": "Should all babies diagnosed with spina bifida be operated within the first week of life?",
        "llm_evidence": "Spina bifida is a congenital condition characterized by the incomplete development of the spinal cord and surrounding structures. Surgical intervention aims to minimize neurological damage and improve outcomes. Recent evidence suggests that early intervention, ideally within the first week of life, can significantly reduce the risk of complications such as infection and further neurological impairment. Studies indicate that early surgery is associated with improved mobility and quality of life for affected infants. However, the decision should also consider the severity of the condition, potential surgical risks, and individual patient factors. Multidisciplinary evaluation and parental involvement in treatment decisions are crucial. Consequently, while early surgery is often beneficial, it is essential to tailor the approach to each individual case.",
        "paper_evidence":
        [
            "treatment for spina bifida has made great advancements, from surgical closure of the defect after birth to the now state-of-the-art intrauterine repair",
            "Advances in fetal treatment have made minimally invasive prenatal surgery a realistic consideration for spina bifida",
            "Prenatal surgery for spina bifida via open fetal surgery with hysterotomy decreases the rate of ventriculoperitoneal shunt placement and improves motor function compared to standard postnatal surgery",
            "fetoscopic spina bifida repair",
            "prenatal treatment of spina bifida",
            "Spina bifida should be found in utero for the immediate operation after birth.",
            "Babies born with spina bifida require early closure surgery, done within the first 2-3 days after birth.",
            "OBJECTIVES: To determine if the lower extremity motor function of a fetus with open spina bifida deteriorates within a four-week interval between their first prenatal motor assessment at 22 weeks of gestation and second presurgical evaluation in cases operated at later gestational age (26-27 weeks of gestation), and to compare prenatal and postnatal motor function to the anatomical level of the lesion.METHODS: Multicenter cohort study involving cases from two centers that perform percutaneous fetoscopic repair of open spina bifida (SAFER technique).",
            "PURPOSE: Clinical guidelines recommend repair of open spina bifida (SB) prenatally or within the first days of an infant's life.",
            "Infants born in lower level nursery care hospitals with were less likely to have timely repairs (aPR = 0.71, 95 % CI 0.52-0.98) than those born in higher level nursery care hospitals.CONCLUSIONS: Most infants with SB had surgical repair in the first 2 days of life.",
            "To determine simple prenatal imaging parameters that can easily be acquired to predict the need for postnatal CSF diversion (PCD) surgery in fetuses undergoing open fetal surgery for open spina bifida (OSB)."
        ]
    },
    "6446884b57b1c7a31500006f":
    {
        "question": "What is Oculopharyngeal Muscular Dystrophy (OPMD)?",
        "llm_evidence": "Oculopharyngeal Muscular Dystrophy (OPMD) is a rare genetic disorder characterized by progressive muscle weakness, particularly affecting the ocular (eye) and pharyngeal (throat) muscles. It is typically caused by mutations in the PABPN1 gene, leading to the accumulation of abnormal proteins in muscle cells. OPMD often manifests in adulthood, with symptoms including ptosis (drooping of the eyelids), dysphagia (difficulty swallowing), and weakness in the facial and limb muscles. The condition may also result in respiratory issues as it progresses. Diagnosis typically involves clinical evaluation, genetic testing, and muscle biopsies. Treatment options are limited and mainly focus on managing symptoms, such as surgical intervention for ptosis and dietary modifications for swallowing difficulties. Overall, OPMD highlights the importance of genetic factors in muscle degenerative diseases and underscores the need for ongoing research into effective therapies.",
        "paper_evidence":
        [
            "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy, characterized by slowly progressive ptosis, dysphagia, and proximal limb weakness.",
            "Oculopharyngodistal myopathy (OPDM) is a rare adolescent or adult-onset neuromuscular disease that is characterized by progressive ocular, facial, pharyngeal and distal limb muscle weakness. ",
            "Oculopharyngeal muscular dystrophy (OPMD) is a rare, primarily autosomal dominant, late onset muscular dystrophy commonly presenting with ptosis, dysphagia, and subsequent weakness of proximal muscles",
            "Oculopharyngeal muscular dystrophy (OPMD) is a rare late-onset muscle disease associated with progressive dysphagia",
            "Muscle weakness, and its association with mobility limitations, has received little study in oculopharyngeal muscular dystrophy (OPMD) using quantitative and standardized assessments",
            "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping, swallowing difficulties and proximal limb weakness.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant muscular dystrophy which presents typically after the age of 50 with progressive eyelid drooping and an increasing difficulty in swallowing.",
            "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset neuromuscular degenerative disease characterized by ptosis, dysphagia, and proximal muscle weakness.",
            "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant muscular dystrophy characterized by late onset ptosis, proximal muscle weakness and swallowing difficulties.",
            "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant muscle disorder, usually of late onset.",
            "Oculopharyngeal muscular dystrophy is a localized or restricted variety of muscular dystrophy, characterized by bilateral ptosis, myopathic facies, external ophthalmoplegia and dysphagia.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a late adult onset, autosomal dominant muscular dystrophy characterized by ptosis and dysphagia.",
            "OPMD is a unique disease sharing common pathogenic features with other polyalanine disorders, as well as with polyglutamine and dystrophic disorders.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a muscle disease of late onset associated with progressive ptosis of the eyelids, dysphagia, and unique tubulofilamentous intranuclear inclusions (INIs).",
            "Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic disorder with late-onset progressive myopathy affecting mainly head and neck striated muscles.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a rare, primarily autosomal dominant, late onset muscular dystrophy commonly presenting with ptosis, dysphagia, and subsequent weakness of proximal muscles.",
            "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant form of late-onset muscular dystrophy. Ptosis (droopy eyelids) and dysphagia (difficulty swallowing) are the most common presenting symptoms.",
            "RATIONALE: Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset progressive muscle disorder typically characterized by ptosis, difficulty in swallowing, and proximal lim",
            "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a rare inherited muscular disorder, clinically characterized by late-onset, slowly progressive bilateral ptosis, dysphagia, and proximal limb weakness. A short polyalanine expansion in the polyadenylate binding-protein nuclear 1 (PABPN1) gene is a commonly report",
            "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late onset neuromuscular disease characterised by proximal muscle weakness, ptosis, and swallowing",
            "Oculopharyngeal muscular dystrophy (OPMD) belongs to the group of protein aggregation disorders and is caused by extensions of the N-terminal polyalanine stretch of the nuclear polyA-binding protein 1 (PABPN1).",
            "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late onset hereditary myopathy of autosomal dominant transmission characterised by ptosis, dysphagia and limb weakness. The disease is caused by short heterozygous expansions of a (GCN)(10) triplet located in the first exon of the PABPN1 gene at chromos",
            "OBJECTIVE: Oculopharyngeal muscular dystrophy (OPMD) is a rare neuromuscular disorder characterized by late-onset development of bilateral eyelid ptosis, ophthalmoparesis and dysphagia with further progression to proximal limb muscle weakness that is an under recognized condition.",
            "OPMD is caused by a short expansion of the alanine repeat (GCN trinucleotide) in the poly(adenylate)-binding protein nuclear1 (PABPN1) gene.METHODS: We performed a retrospective review of undiagnosed cases that initially presented with ptosis, diplopia, dysphagia, muscle weakness, muscular dystrophy and/or myasthenia gravis from 2000 to 2015 at two institutions in Southern California.RESULTS: Twenty-five patients were identified to have OPMD with genetic confirmation.CONCLUSIONS: Even though a rare condition, the prevalence is disproportionally frequent in certain ethnic groups and in certain regions; thus, we report our experience of OPMD patients in Southern California.",
            "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset syndrome characterized by progressive degeneration of particular muscles.",
            "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant, late-onset muscle disorder characterized by ptosis, swallowing difficulties, proximal limb weakness and nuclear aggregates in skeletal muscles.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a rare, primarily autosomal dominant, late onset muscular dystrophy commonly presenting with ptosis, dysphagia, and subsequent weakness of proximal muscles. ",
            "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant muscle disorder, usually of late onset. OPMD is among the few triplet repeat diseases/ polyalanine (poly(A)) expansion diseases for which the function of the mutated gene is quite well established. The disease is characterised by slowly progressive bilateral ptosis, dysphagia and proximal limb weakness, appearing after the age of 40 years.",
            "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late onset neuromuscular disease characterised by proximal muscle weakness, ptosis, and swallowing difficulty. The only causative mutation described to date is a triplet repeat expansion consisting of two to seven additional base triplets in a repeat sequence in exon 1 of the polyadenine binding protein nuclear 1 (PABPN1) gene. This results in an increase in length of a polyalanine tract in the PABPN1 protein from 10 to 12-",
            "INTRODUCTION: Oculopharyngeal muscular dystrophy (OPMD) presents with progressive ptosis, dysphagia and limb girdle weakness, and is caused by expansion of a trinucleotide tandem repeat within the gene encoding poly-(A) bind",
            "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) has long been characterized by a combination of bilateral ptosis and dysphagia and subsequent limb gird",
            "OBJECTIVE: Oculopharyngeal muscular dystrophy (OPMD) is a late-onset inherited neuromuscular disorder, with progressive ptosis and dysphagia as common mani",
            "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant myopathy with almost benign course.",
            "It has been 10 years since the identification of the first PABPN1 gene (GCN)(n)/polyalanine mutations responsible for oculopharyngeal muscular dystrophy (OPMD).",
            "Oculopharyngeal muscular dystrophy (OPMD) is a late onset myopathy usually presenting in the 5th or 6th decade of life with progressive ptosis, dysphagia and proximal muscle weakness.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a rare progressive disease characterized by bilateral ptosis and dysphagia.",
            "Autosomal dominant oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disease with worldwide distribution.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, primarily autosomal dominant disease caused by a short GCN expansion",
            "Oculopharyngeal muscular dystrophy (OPMD) is an autosomal-dominant, adult-onset disorder defined by blepharoptosis, dysphagia, and proximal muscle weakness.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a muscle disease of late onset associated with progressive ptosis",
            "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscular dystrophy characterised by slowly progressive ptosis, dysphagia, and proximal",
            "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscular dystrophy caused by a polyalanine expansion mutation",
            "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping, swallowing difficulties and proximal limb",
            "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive ptosis, dysphagia and p",
            "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by ptosis, dysphagia and proximal limb",
            "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping (ptosis), swallowing difficulties (dysphagia),",
            "currently no cures. Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant late-onset, progressive disease that generally presents in the fifth or sixth decade with dysphagia, ptosis and proximal limb weakness. OPMD is caused by the abnormal expansion of a (GCG)n trinucleotide repeat in the coding region of the poly-(A) binding protein nuclear 1",
            "BACKGROUND: Oculopharyngeal muscular dystrophy (OPMD) has long been characterized by a combination of bilateral ptosis and dysphagia and subsequent",
            "Oculopharyngeal muscular dystrophy (OPMD) is caused by a small expansion of the polyalanine tract in the poly(A)-binding protein nuclear 1 (PABPN1). Aggregation of expanded PABPN1 into intranuclear inclusions (INIs) in skeletal muscle fibers is the pathological hallmark of OPMD. In this study what we have analyzed in muscle fibers of OPMD patients",
            "OPMD is caused by a small expansion of a short polyalanine tract in the poly (A) binding protein nuclear 1 protein (PABPN1).",
            "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset myopathic genetic disorder characterized by chronic progressive dysphagia and ptosis with or without proximal limb weakness.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscle disorder characterized by progressive dysphagia and bilateral ptosis.",
            "Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disorder characterized by progressive eyelid drooping (ptosis), swallowing difficulties (dysphagia), and proximal limb weakness.",
            "Oculopharyngeal muscular dystrophy (OPMD) is a muscle-specific, late-onset degenerative disorder whereby muscles of the eyes (causing ptosis), throat (leading to dysphagia), and limbs (causing proximal limb weakness) are mostly affected.",
            "utations in the gene encoding poly(A)-binding protein nuclear 1 (PABPN1) result in oculopharyngeal muscular dystrophy (OPMD). This disease is of late-onset",
            "OPMD courses with muscle atrophy and weakness"
        ]
    },
    "65d144731930410b13000040":
    {
        "question": "What is the mechanisms of action of Dersimelagon?",
        "llm_evidence": "Dersimelagon, also known as MT-350, is an investigational drug that primarily functions as a dual agonist of the melanocortin-1 receptor (MC1R) and melanocortin-4 receptor (MC4R). The mechanisms of action of Dersimelagon involve the stimulation of these receptors, which play crucial roles in regulating energy homeostasis, thermogenesis, and appetite.\n\n1. **MC1R Agonism**: Activation of MC1R enhances the production of melanin, which is important for skin pigmentation and may influence metabolic processes. This receptor's stimulation is associated with increased lipolysis and energy expenditure.\n\n2. **MC4R Agonism**: MC4R is pivotal in the regulation of appetite and body weight. When activated by Dersimelagon, it helps curb excessive food intake and promotes weight loss by increasing energy expenditure. This action can potentially benefit conditions such as obesity and metabolic syndrome.\n\nTogether, the agonistic actions on MC1R and MC4R create a synergistic effect that targets both metabolic regulation and weight management, which are vital for treating metabolic disorders. This dual mechanism is essential in exploring Dersimelagon's therapeutic potential for obesity-related diseases.",
        "paper_evidence":
        [
            "Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin",
            "PURPOSE: To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).",
            "Absorption, metabolism, and excretion of [14 C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers.",
            "Dersimelagon (formerly MT-7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin 1 receptor currently being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis (dcSSc). ",
            "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis. ",
            "Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.",
            "Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin.METHODS: We conducted a randomized, placebo-controlled, phase 2 trial to investigate the efficacy and safety of dersimelagon with respect to the time to onset and the severity of symptoms associated with sunlight exposure in patients with erythropoietic protoporphyria or X-linked protoporphyria.",
            "PURPOSE: To describe outcomes from the first-in-human study of dersimelagon, an investigational oral selective MC1R agonist, under development for the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).METHODS: In this double-blind, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of dersimelagon in healthy participants were evaluated.RESULTS: Dersimelagon was generally well tolerated in healthy participants, with the most common TEAEs being lentigo (52.8%) and skin hyperpigmentation (50.0%) after multiple doses.",
            "Dersimelagon (formerly MT-7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin 1 receptor currently being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis (dcSSc).",
            "The purpose of this study is to investigate the potential of dersimelagon, a novel oral MC1R agonist, as a therapeutic agent for systemic sclerosis (SSc).METHODS: The effects of dersimelagon phosphoric acid (MT-7117) on skin fibrosis and lung inflammation were evaluated in bleomycin (BLM)-induced SSc murine models that were optimized for prophylactic and therapeutic evaluation.",
            "Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist.",
            "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis.",
            "Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin.",
            "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment of erythropoietic protoporphyria, X-linked protoporphyria, and diffuse cutaneous systemic sclerosis",
            "BACKGROUND: Activation of melanocortin 1 receptor (MC1R) is known to exert broad anti-inflammatory and anti-fibrotic effects. The purpose of this study is to investigate the potential of dersimelagon, a novel oral MC1R agonist, as a therapeutic agent for systemic scle",
            "Dersimelagon is a novel orally administered selective agonist for melanocortin receptor 1 being investigated for the treatment",
            "xcruciating phototoxic attacks after exposure to visible light. Dersimelagon is a new, orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin.METHODS: We conducted a randomized, placebo-contr",
            "Dersimelagon (formerly MT-7117) is a novel, orally administered nonpeptide small molecule selective agonist for melanocortin"
        ]
    },
    "65f7728fc4010b4d78000021":
    {
        "question": "What proportion of risk is attributable to obesity in colorectal cancer women development?",
        "llm_evidence": "Obesity is recognized as a significant risk factor for the development of colorectal cancer (CRC), particularly among women. Epidemiological studies indicate that approximately 20-30% of colorectal cancer cases in women can be attributed to obesity. The mechanisms underlying this relationship include hormonal changes, inflammation, and insulin resistance associated with excess body weight, which can promote tumorigenesis. Additionally, women with a body mass index (BMI) of 30 or higher have been shown to have a substantially higher risk of developing colorectal cancer compared to those with a normal weight. Overall, the evidence supports that obesity plays a critical role in increasing the risk of colorectal cancer in women, highlighting the importance of weight management as a preventive measure.",
        "paper_evidence":
        [
            "Colon cancer risk increased with increasing waist circumference (per 10-cm increase) in both men (RR: 1.33; 95% CI: 1.19, 1.49) and women (RR: 1.16; 95% CI: 1.09, 1.23) and with increasing waist-hip ratio (per 0.1-unit increase) in both men (RR: 1.43; 95% CI: 1.19, 1.71) and women (RR: 1.20; 95% CI: 1.08, 1.33).CONCLUSIONS: The association between obesity and colon and rectal cancer risk varies by sex and cancer site",
            " The men in the obese/obese group had a higher risk of colon cancer than women (hazard ratio = 1.13 [1.10-1.17] in men, and hazard ratio = 1.04 [1.01-1.18] in women, P = 0.001). ",
            "Compared with individuals with normal weight, overweight and obese young adults had a significantly higher risk of CRC (relative risks (RR):18%, 95% CI:1.08, 1.28； RR:32%, 95% CI: 1.11, 1.56, respectively).",
            "cant from a BMI of 23.4 kg/m2 [spline analysis]) and women (HR for overweight, 1.54; 95% CI, 1.22-1.93; HR for obesity, 1.5",
            "r association than females. Population attributable fraction for colorectal cancer by BMI ≥ 25 kg/m(2) was 3.62% (95% CI 1.91-5.30) for males and 2.62% (9",
            "OBJECTIVE: Excess body weight, defined by body mass index (BMI), may increase the risk of colorectal cancer. As a prerequisite to the determination of lifestyle attributable risks, we undertook a systematic review and meta-analysis of prospective observational studies to quantify colorectal cancer risk associated with increased BMI and explore for differences by gender, sub-site and study characteristics.METHOD: We searched MEDLINE and EMBASE (to December 2007), and other sources, selecting reports based on strict inclusion criteria. Random-effects meta-analyses and meta-regressions of study-specific incremental estimates were performed to determine the risk ratio (RR) and 95% confidence intervals (CIs) associated with a 5 kg/m(2) increase in BMI.RESULTS: We analysed 29 datasets from 28 articles, including 67,361 incident cases. Higher BMI was associated with colon (RR 1.24, 95% CIs: 1.20-1.28) and rectal (1.09, 1.05-1.14) cancers in men, and with colon cancer (1.09, 1.04-1.12) in women. Associations were stronger in men than in women for colon (P < 0.001) and rectal (P = 0.005) cancers. Associations were generally consistent across geographic populations. Study characteristics and adjustments accounted for only moderate variations of associations.CONCLUSION: Increasing BMI is associated with a modest increased risk of developing colon and rectal cancers, but this modest risk may translate to large attributable proportions in high-prevalence obese populations. Inter-gender differences point to potentially important mechanistic diffe",
            "The proportion of all cancers attributable to overweight has, however, never been systematically estimated. We reviewed the epidemiological literature and quantitatively summarised, by meta-analysis, the relationship between excess weight and the risk of developing cancer at the 6 sites listed above. Estimates were then combined with sex-specific estimates of the prevalence of overweight [body mass index (BMI) 25-29 kg/m(2)] and obesity (BMI > or = 30 kg/m(2)) in each country in the European Union to obtain the proportion of cancers attributable to excess weight. Overall, excess body mass accounts for 5% of all cancers in the European Union, 3% in men and 6% in women, corresponding to 27,000 male and 45,000 female cancer cases yearly.",
            "s would be avoided by 2040. The population attributable fractions (PAF) for excess weight were much higher for males (between 13.5% and 18.2%) ",
            "Among men, when the highest and lowest fifths were compared, BMI (HR = 1.35, 95%CI: 1.13-1.61; Ptrend < 0.0001), waist circumference (HR = 1.66, 95%CI: 1.39-1.99; Ptrend < 0.0001), waist-to-hip ratio (HR = 1.58, 95%CI: 1.31-1.91; Ptrend < 0.0001), total body fat percentage (HR = 1.27, 95%CI: 1.06-1.53; Ptrend = 0.002), and trunk fat percentage (HR = 1.31, 95%CI: 1.09-1.58; Ptrend = 0.002) were associated with greater colorectal cancer risk.",
            "Similar associations were observed among women without a family history of CRC and without lower endoscopy within the past 10 years. Both BMI at 18 years of age and weight gain since 18 years of age contributed to this observation. Compared with women with a BMI of 18.5 to 20.9 at 18 years of age, the RR of early-onset CRC was 1.32 (95% CI, 0.80-2.16) for women with a BMI of 21.0 to 22.9 and 1.63 (95% CI, 1.01-2.61) for women with a BMI of 23.0 or greater at 18 years of age (P = .66 for trend). Compared with women who had gained less than 5.0 kg or had lost weight, the RR of early-onset CRC was 1.65 (95% CI, 0.96-2.81) for women gaining 20.0 to 39.9 kg and 2.15 (95% CI, 1.01-4.55) for women gaining 40.0 kg or more (P = .007 for trend).",
            " Compared to women with normal BMI, women who were obese had HRs of 1.39 (95%CI 1.12-1.74) and 1.64 (95%CI 1.24-2.16) for CRC and CC respectively",
            " Compared with the reference group (WC 65-75), the HRs [95% confidence interval (CI)] of colorectal cancer in WC <65, 75-85, 85-95, and >95 groups were 1.01 (0.91-1.11), 1.02 (0.97-1.07), 1.09 (1.00-1.18), and 1.31 (1.12-1.52), respectively, in premenopausal women and 1.01 (0.95-1.17), 1.09 (1.07-1.12), 1.19 (1.00-1.18), and 1.30 (1.25-1.35), respectively, in postmenopausal women. Compared with the reference group (BMI 18.5-22.9), HRs (95% CI) for colorectal cancer in BMI <18.5, 23-25, 25-30, and >30 groups were 0.99 (0.87-1.14), 0.99 (0.94-1.06), 0.98 (0.92-1.04), and 1.06 (0.92-1.20), respectively, in premenopausal women. In postmenopausal women, those values were 0.99 (0.93-1.05), 1.05 (1.03-1.08), 1.11 (1.09-1.13), and 1.20 (1.16-1.25), respectively"
        ]
    },
    "65f490fac4010b4d78000010":
    {
        "question": "Has MDMA(ecstasy) been successfully used to treat PTSD disorder?",
        "llm_evidence": "MDMA (3,4-methylenedioxymethamphetamine), commonly known as ecstasy, has shown promise as a treatment for Post-Traumatic Stress Disorder (PTSD) in recent clinical studies. Research conducted by organizations such as the Multidisciplinary Association for Psychedelic Studies (MAPS) has demonstrated that MDMA-assisted psychotherapy can significantly reduce PTSD symptoms. \n\nKey insights include:\n\n1. **Clinical Trials**: Phase 2 and Phase 3 trials have indicated that patients receiving MDMA as part of their therapy experienced substantial improvements, with many achieving remission from PTSD symptoms.\n\n2. **Mechanism of Action**: MDMA is thought to facilitate therapeutic breakthroughs by enhancing emotional engagement, reducing fear responses, and promoting feelings of safety and connection during therapy sessions, which can help patients confront traumatic memories.\n\n3. **Long-term Effects**: Follow-up studies suggest that the positive effects of MDMA-assisted therapy can be sustained over time, with participants reporting improvements lasting for months after treatment.\n\n4. **FDA Designation**: In 2021, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for MDMA-assisted psychotherapy for PTSD, indicating its potential as a significant treatment option.\n\n5. **Safety Profile**: Clinical studies have generally reported a favorable safety profile when MDMA is administered in controlled settings, monitored by trained professionals.\n\nOverall, evidence from clinical studies and ongoing research supports the potential of MDMA as a transformative treatment for PTSD, leading to significant symptom relief and improved quality of life for affected individuals.",
        "paper_evidence":
        [
            "The application of MDMA in conjunction with psychotherapy has in recent years seen a resurgence of clinical, scientific, and public interest in the treatment of posttraumatic stress disorder (PTSD). Clinical trials have shown promising safety and efficacy, but the mechanisms underlying this treatment form remain largely unestablished.",
            "MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy",
            "Post-traumatic stress disorder (PTSD) is a prevalent psychiatric condition that significantly impacts daily functioning in patients but lacks adequate treatment options. 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy for the treatment of PTSD has been studied increasingly for the last two decades and has shown promising results through quantitative data.",
            "Psychedelics and related compounds have shown efficacy for the treatment of a variety of conditions that are prevalent among older adults, including mood disorders, the psychological distress associated with a serious medical illness, post-traumatic stress disorder (PTSD), and prolonged grief disorde",
            "MDMA-assisted psychotherapy has emerged as an innovative approach to treating PTSD, leading to sustained reductions in symptoms and even promoting post-traumatic growth",
            "MDMA can reduce PTSD symptoms even in treatment-resistant cases by increasing certain neurohormones, i.e., dopamine, serotonin, norepinephrine, and oxytocin",
            "MDMA used as an adjunct during psychotherapy sessions has demonstrated effectiveness and acceptable safety in reducing PTSD symptoms in Phase 2 trials, with durable remission of PTSD diagnosis in 68% of participants.",
            "These findings suggest that MDMA enhances fear memory extinction through a BDNF-dependent mechanism, and that MDMA may be a useful adjunct to exposure-based therapies for PTSD and other anxiety disorders characterized by altered fear learning.",
            "MDMA-assisted psychotherapy for treatment of PTSD has recently progressed to Phase 3 clinical trials and received Breakthrough Therapy designation by the FDA.",
            "Based on the pharmacology of MDMA and the available translational literature of memory reconsolidation, fear learning, and PTSD, this review suggests a neurobiological rationale to explain, at least in part, the large effect sizes demonstrated for MDMA in treating PTSD.",
            "3,4 Methylenedioxymethamphetamine (MDMA)-assisted therapy has been recently found to be highly effective for treatment of posttraumatic stress disorder (PTSD).",
            "Finally, the amount of recovery from PTSD after MDMA-AT correlated with changes in four functional connections during autobiographical memory recall: the left amygdala-left posterior cingulate cortex (PCC), left amygdala-right PCC, left amygdala-left insula, and left isthmus cingulate-left posterior hippocampus.Discussion: Amygdala-insular functional connectivity is reliably implicated in PTSD and anxiety, and both regions are impacted by MDMA administration.",
            "MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?",
            ". A series of six phase-II clinical trials studying MDMA-AT for treatment-resistant PTSD found that 54% of MDMA-AT full-dose participants no longer met the diagnosis of PTSD after two MDMA sessions, compared to 23% in the control grou",
            "MDMA can reduce PTSD symptoms even in treatment-resistant cases by increasing certain neurohormones, i.e., dopamine, serotonin, norepinephrine, and oxytocin.",
            "BACKGROUND AND OBJECTIVE: Intensive psychotherapy assisted with 3,4-methylenedioxymethamphetamine (MDMA-AT) was shown in Phase 3 clinical trials to substantially reduce post-traumatic stress disorder (PTSD) symptoms compared to p",
            "We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma.",
            "MDMA therapy for PTSD is now entering the final Phase 3 stage of drug development, with a target set for licensing by the FDA and EMA in 2021.",
            "A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy.",
            "INTRODUCTION: 3,4-Methylenedioxymethamphetamine (MDMA/\"ecstasy\") is an empathogen that can give rise to increased pleasure and empathy and may effectively treat post-traumatic stress disorder.",
            "Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD).",
            "der (PTSD). A recent Phase 3 clinical trial reported high efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for treating patients with severe PTSD compared to a therapy with placebo group (N",
            "3,4-Methylenedioxymethamphetamine, which activates 5-HT2A receptors, has been successful in the treatment of PTSD and has recently achieved status as a breakthrough therapy.",
            "The FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy. Both agencies have approved pilot studies in chronic posttraumatic stress disorder (PTSD) patients who have failed to obtain relief from at least one course of conventional treatment.",
            "nical trials, MDMA-assisted therapy (MDMA-AT) has shown marked success in the treatment of PTSD and may be promisin",
            "We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma.",
            "RATIONALE: 3,4-Methylenedioxymethamphetamine (MDMA) persistently improves symptoms of post-traumatic stress disorder (PTSD) when combined with psy",
            "Relevantly, enduring improvements in Post-Traumatic Stress Disorder (PTSD) symptoms have been found in response to 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy.",
            "This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post-traumatic stress disorder (PTSD).",
            "o have anxiolytic effects, whereas 3,4-methylenedioxymethamphetamine (MDMA) has been used effectively to treat post-traumatic stress disorder (PTSD), with",
            "Finally, even though MDMA is listed as a Schedule I compound by the Drug Enforcement Agency, MDMA-assisted psychotherapy for patients with chronic, treatment-resistant posttraumatic stress disorder is currently under investigation.",
            "(MDMA, 'ecstasy') has been proposed to have long-term positive effects on post-traumatic stress disorder (PTSD) symptoms when combined with psychotherapy. No",
            "has shown that MDMA, used as a catalyst in psychotherapy, is effective in treating posttraumatic stress disorder (PTSD). This review also examines the psychopharmacological basis for the efficacy of MDMA-assisted psychotherapy. Specifically, the brain regions involved with both PTSD",
            "FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy. Both agencies have approved pilot studies in chronic posttraumatic stress disorder (PTSD) patients who have failed to obtain relief from at least one course of conventional treatment. These studies, the only ones in the world",
            "Background: 3,4-methylenedioxymethamphetamine (MDMA), known recreationally as \"Molly\" or \"Ecstasy\", is a triple monoamine reuptake inhibitor. MDMA specifically acts as a weak 5-HT1 and 5-HT2 receptor agonist, targeting 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its potential use for therapeutic purposes with these pharmacological profiles remains a controversial subject. Studies have shown the potential benefits in clinical trials for post-traumatic stress disorder (PTSD). A larger amount of data has been provided for the push in support of MDMA-assisted psychotherapy in these patients.  Objective: The aim of this article is to compute a meta-analysis and conduct a systematic review of the effects of MDMA on PTSD, discussing the potential benefits and adverse events relative to dosing and stability of treatment. Methods: Articles were collected and analyzed for systematic review: 16 articles were included in the systematic review that met the criteria for the use of MDMA in the treatment of PTSD as well as assessing the safety and efficacy of the drug in human participants. Ten studies were used for the meta-analysis, with a cumulative sample size of 168 patients. The significance of the findings on dosing and efficacy of MDMA in healthy human participants was quantified based on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and PTSD symptom scores. Results: The disorders for which MDMA demonstrated a net positive o",
            "These findings are consistent with a general memory-disrupting effect of MDMA and suggest that MDMA could augment psychotherapy by modifying fear memories during reconsolidation without necessarily enhancing their extinction.",
            "These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities.",
            "In recent human-subject studies MDMA-assisted therapy resulted in significant improvement in PTSD symptoms with a good safety and side effect profile.",
            "Clinical trials have demonstrated that 3,4-methylenedioxymethamphetamine (MDMA) paired with psychotherapy is more effective at reducing symptoms of post-traumatic stress disorder (PTSD) than psychotherapy or pharmacotherapy, alone or in combination."
        ]
    },
    "65f843cbc4010b4d78000042":
    {
        "question": "What is a spillover event?",
        "llm_evidence": "A spillover event refers to the process by which diseases or pathogens jump from one species to another, often from animals to humans. This phenomenon typically occurs when humans come into close contact with wildlife or through environmental changes that disrupt ecosystems. Key insights include:\n\n1. **Zoonotic Transmission**: Many spillover events involve zoonoses, where diseases like SARS, Ebola, and COVID-19 originate from animal hosts and infect humans.\n\n2. **Environmental Factors**: Deforestation, urbanization, and climate change can increase the likelihood of spillover by altering habitats and bringing wildlife into closer proximity with people.\n\n3. **Public Health Implications**: Understanding spillover events is crucial for preventing pandemics, as early detection and monitoring of potential zoonotic diseases can inform public health responses.\n\n4. **Research and Surveillance**: Ongoing research and surveillance of wildlife can provide insights into emerging infectious diseases and enhance preparedness for future spillover events.\n\nIn essence, spillover events highlight the intricate connections between human health, animal health, and environmental integrity.",
        "paper_evidence":
        [
            "importance of assessing the zoonotic potential of widely distributed batborne CoV in order to monitor changes in genomic composition of viruses and prevent spillover events",
            "Japanese encephalitis virus (JEV) is a mosquito-borne zoonotic flavivirus and the leading cause of pediatric encephalitis in the Asian Pacific region. The transmission cycle primarily involves Culex spp. mosquitoes and Ardeid birds, with domestic pigs (Sus scrofa domestica) being the source of infectious viruses for the spillover of JEV from the natural endemic transmission cycle into the human population",
            "Spillover events, which involve the physical transfer of viral particles across species, could therefore be directly promoted by conditions of host ecology and environment.",
            "Bats are the natural reservoir host for many pathogenic and non-pathogenic viruses, potentially spilling over to humans and domestic animals directly or via an intermediate host.",
            "Here we aim to provide a synthetic explanation by arguing that domestication, horizontal gene transfer even between superkingdoms as well as gradual exchange of microbiome (microbiome succession) are essential in the whole scenario. We present a new perspective at the molecular level which can explain the observations of frequent pathogen spillover events at the ecological level.",
            "H5N1 highly pathogenic avian influenza viruses (HPAIV) emerged in wild birds in Chile in December 2022 and spilled over into poultry, marine mammals, and one human.",
            "Forecasting the risk of pathogen spillover from reservoir populations of wild or domestic animals is essential for the effective deployment of interventions such as wildlife vaccination or culling. Due to the sporadic nature of spillover events and limited availability of data, developing and validating robust, spatially explicit, predictions is challenging.",
            "Nipah virus is a zoonotic virus harbored by bats and lethal to humans. Bat-to-human spillovers occur every winter in Bangladesh.",
            "INTRODUCTION: The increasing incidence of pathogen transmission from animals to humans (zoonotic spillover events) has been attributed to behavioural practices and ecological and socioeconomic change.",
            "In the simplest form of human exposure, spillover occurs from the enzootic cycle when humans enter zoonotic foci and/or enzootic amplification increases circulation near humans.",
            "Some viruses, such as Rift Valley fever, Japanese encephalitis and Venezuelan equine encephalitis viruses (VEEV) undergo secondary amplification involving replication in livestock animals, resulting in greater levels of spillover to humans in rural settings.",
            "Pathogen spillover occurs when epidemics in a host population are driven not by transmission within that population but by transmission from a reservoir population.",
            "The detection of a virus in bats does not imply that spillover will occur and several biological, ecological and anthropogenic factors play a role in such an event.",
            "Zoonotic spillover, which is the transmission of a pathogen from a vertebrate animal to a human, presents a global public health burden but is a poorly understood phenomenon.",
            "Further surveillance of spillover events is warranted to assess the emergence and potential onward transmission of mammalian adapted H5N1 HPAIV in South America.",
            "Emerging infectious diseases have posed growing medical, social and economic threats to humanity. The biological background of pathogen spillover or host switch, however, still has to be clarified. Disease ecology finds pathogen spillovers frequently but struggles to explain at the molecular level. Contrarily, molecular biological traits of host-pathogen relationships with specific molecular binding mechanisms predict few spillovers.",
            "Zoonotic spillover is a phenomenon characterized by the transfer of pathogens between different animal species. Most human emerging infectious diseases originate from non-human animals, and human-related environmental disturbances are the driving forces of the emergence of new human pathogens.",
            "Despite their importance, little is known about their enzootic cycles of transmission, amplifying hosts and vectors, and biotic and abiotic factors involved in spillover events to humans.",
            "Molecular data suggest that spillover from other hosts may be responsible for the emergence of this infectious disease, but the scale of such studies is limited.",
            "The concept of environmental \"spillover\" of pathogens to humans is widely used in the scientific literature about emerging diseases with the idea that it is scientifically proven.",
            "Zoonotic spillover is a phenomenon characterized by the transfer of pathogens between different animal species.",
            "For pathogens known to transmit across host species, strategic investment in disease control requires knowledge about where and when spillover transmission is likely.",
            "Pathogen spillover between different host species is the trigger for many infectious disease outbreaks and emergence events, and ecosystem boundary areas have been suggested as spatial hotspots of spillover.",
            "Investigating the processes that lead to spillover fundamentally involves interactions between animals, humans, pathogens and the environments they inhabit."
        ]
    },
    "64467f8657b1c7a31500006d":
    {
        "question": "How can Emery-Dreifuss Muscular Dystrophy (EDMD) be inherited?",
        "llm_evidence": "Emery-Dreifuss Muscular Dystrophy (EDMD) can be inherited in three primary ways: X-linked, autosomal dominant, and autosomal recessive. \n\n1. **X-linked inheritance**: The most common form of EDMD, which is associated with mutations in the EMD gene located on the X chromosome. This primarily affects males, while females may be carriers and present milder symptoms.\n\n2. **Autosomal dominant inheritance**: In this form, the disorder can be caused by mutations in the genes such as EMD or LMNA, and only one copy of the mutated gene from an affected parent is sufficient to pass the condition to offspring. Both males and females are equally likely to be affected.\n\n3. **Autosomal recessive inheritance**: In rare cases, EDMD can result from mutations in genes like LMNA when both copies of the gene (one from each parent) are mutated. This form is more common in siblings from consanguineous unions.\n\nOverall, the inheritance pattern significantly influences the clinical presentation and severity of EDMD among affected individuals.",
        "paper_evidence":
        [
            "X-linked recessive EDMD patient ",
            " Therefore, myoblast/fibroblast cultures from biopsy and tissue sections from a panel of nine Emery-Dreifuss muscular dystrophy patients (4 male, 5 female) including those carrying emerin and FHL1 (X-linked) and several lamin A (autosomal dominant) mutations were stained for the proteins linked to the disorder.",
            "he majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.",
            "EDMD is also distinctive for its association with defects of the cardiac conduction system that can result in sudden death. It can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion and is caused by mutations in proteins of the nuclear membrane.",
            "BACKGROUND: Emery-Dreifuss muscular dystrophy (EDMD2) is a rare form of muscular dystrophy that is inherited as an autosomal dominant trait.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is inherited in an X-linked or autosomal manner.",
            "The inheritance pattern of Emery-Dreifuss muscular dystrophy (EDMD) is X linked, whereas EDMD2 is autosomal dominant.",
            "Emery-Dreifuss muscular dystrophy (EDMD), a rare inherited disease, is characterized clinically by humero-peroneal muscle atrophy and weakness, multijoint contractures, spine rigidity and cardiac insufficiency with conduction defects. There are at least six types of EDMD known so far, of which five have been associated with mutations in genes encoding nuclear proteins. The majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is an inherited disorder affecting skeletal and cardiac muscles and characterized by muscular atrophy, contractures, and cardiomyopathy with conduction defects. It can be X-linked or autosomal.",
            "Emery-Dreifuss muscular dystrophy is characterized by the clinical triad of early onset contractures of elbows, Achilles tendons and spine, wasting and weakness with a predominantly humero-peroneal distribution and life-threatening cardiac conduction defects and/or cardiomyopathy. Two main types of inheritance have been described: the X-linked form is caused by mutations in the STA gene on locus Xq28 and the gene for the autosomal dominant form (LMNA gene) has been localized on chromosome 1q11-q23.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is an inherited disorder characterized by slowly progressive skeletal muscle weakness in a humero-peroneal distribution, early contractures and prominent cardiomyopathy with conduction block. Mutations in EMD, encoding emerin, and LMNA, encoding A-type lamins, respectively, cause X-linked and autosomal dominant EDMD.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is a muscular disorder characterized by 1) early contracture of the elbows. Achilles tendons and post-cervical muscles, 2) slowly progressive muscle wasting and weakness with a humeroperoneal distribution, and 3) life-threatening cardiomyopathy with conduction block. Most of families with EDMD show X-linked recessive inheritance with mutations in the STA gene on chromosome Xq28, which encodes a protein named emerin. A rare autosomal dominant form of EDMD (AD-EDMD) is caused by mutations in lamin A/C gene (LMNA) on chromosome 1q21.",
            "Mutations in EMD, encoding emerin, and LMNA, encoding A-type lamins, respectively, cause X-linked and autosomal dominant EDMD.",
            "Activation of MAPK in hearts of EMD null mice: similarities between mouse models of X-linked and autosomal dominant Emery Dreifuss muscular dystro",
            "Autosomally inherited EDMD is caused by mutations in LMNA, which encodes A-type nuclear lamins, intermediate filament proteins associated with inner nuclear membrane.",
            "Emery-Dreifuss muscular dystrophy (EDMD2) is a rare form of muscular dystrophy that is inherited as an autosomal dominant trait",
            "Emery-Dreifuss muscular dystrophy (EDMD) is inherited in an X-linked or autosomal manner. X-linked EDMD is caused by mutations in EMD, which encodes an integral protein of the nuclear envelope inner membrane called emerin. Autosomally inherited EDMD is caused by mutations in LMNA, which encodes A-type nuclear lamins, intermediate filament proteins associated with inner nuclear membrane.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is the third most common X-linked muscular dystrophy. This disorder is characterized by childhood onset of early contractures, humeroperoneal muscle atrophy, and cardiac conduction abnormalities. Weakness is slowly progressive, but there is a broad spectrum of clinical severity. Patients and carriers are at risk of sudden death. Regular cardiac evaluation is mandatory to assess the risk of cardiac arrhythmias. Unique atrial pathology is seen at autopsy. The mutated gene in EDMD is localized to the long arm of the X chromosome. Mutations in the gene lead to abolished synthesis of the gene product, emerin. Emerin is localized to the nuclear membrane of skeletal, cardiac, and smooth muscle. The term Emery-Dreifuss syndrome describes patients who have the EDMD phenotype without X-linked inheritance. There is no treatment for the underlying disease, but early placement of pacemakers may be lifesaving.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is a progressive muscle-wasting disorder defined by early contractures of the Achilles tendon, spine, and elbows. EDMD is also distinctive for its association with defects of the cardiac conduction system that can result in sudden death. It can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion and is caused by mutations in proteins of the nuclear membrane.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is characterized by early contractures of elbows and Achilles tendons, slowly progressive muscle wasting and weakness, and a cardiomyopathy with conduction blocks which is life-threatening. Two modes of inheritance exist, X-linked (OMIM 310300) and autosomal dominant (EDMD-AD; OMIM 181350). EDMD-AD is clinically identical to the X-linked forms of the disease. Mutations in EMD, the gene encoding emerin, are responsible for the X-linked form. We have mapped the locus for EDMD-AD to an 8-cM interval on chromosome 1q11-q23 in a large French pedigree, and found that the EMD phenotype in four other small families was potentially linked to this locus. This region contains the lamin A/C gene (LMNA), a candidate gene encoding two proteins of the nuclear lamina, lamins A and C, produced by alternative splicing. We identified four mutations in LMNA that co-segregate with the disease phenotype in the five families: one nonsense mutation and three missense mutations. These results are the first identification of mutations in a component of the nuclear lamina as a cause of inherited muscle disorder. Together with mutations in EMD (refs 5,6), they underscore the potential importance of the nuclear envelope components in the pathogenesis of neuromuscular disorders.",
            "One family presented a rare autosomal dominant variant of Emery-Dreifuss muscular dystrophy, another with X-linked recessive inheritance showed unusual intrafamilial variability.",
            "The majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.",
            "Autosomal dominant EDMD caused by LMNA mutations is more common than the X-linked form and often more severe, with an earlier onset.",
            "The most common etiology of autosomal dominant EDMD is an LMNA gene mutation; LMNA encodes the intermediate filament protein lamins A and C, which constitute the major scaffolding protein of the inner nuclear membrane.",
            "Most of families with EDMD show X-linked recessive inheritance with mutations in the STA gene on chromosome Xq28, which encodes a protein named emerin.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is inherited in an X-linked or autosomal manner. X-linked EDMD is caused",
            "Emery-Dreifuss muscular dystrophy (EDMD) is a progressive muscle-wasting disorder defined by early contractures of the Achilles tendon, spine, and elbows. EDMD is also distinctive for its association with defects of the cardiac conduction system that can result in sudden death. It can be inherited in an X-linked, autosomal dominant, or autosomal recessive fashion",
            "Emery-Dreifuss muscular dystrophy (EDMD) is the third most common X-linked muscular dystrophy. This disorder is",
            "There are at least six types of EDMD known so far, of which five have been associated with mutations in genes encoding nuclear proteins. The majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance.",
            "EDMD (Emery-Dreifuss muscular dystrophy) is caused by mutations in either the gene encoding for lamin A/C (LMNA) located at 1q21.2-q21.3 or emerin (EMD) located at Xq28. Autosomal dominant EDMD caused by LMNA mutations is more common than the X-linked form and often more severe, with an earlier onset.",
            "Clinically indistinguishable X-linked and autosomal forms of EDMD have been described. Mutations in the STA gene, encoding the nuclear envelope protein emerin, are responsible for X-linked EDMD, while mutations in the LMNA gene encoding lamins A and C by alternative splicing have been found in patients with autosomal dominant, autosomal recessive, and sporadic forms of EDMD.",
            "Emery-Dreifuss muscular dystrophy (EDMD) is a neuromuscular degenerative condition with an associated dilated cardiomyopathy and cardiac conduction defect. It can be inherited in either an X-linked or autosomal manner by mutations in the nuclear proteins emerin and lamin A/C, respectively. ",
            "Different subtypes of EDMD have been described, with the two most common forms represented by the X-linked EDMD1, caused by mutations in the EMD gene encoding emerin, and the autosomal EDMD2, due to mutations in the LMNA gene encoding lamin A/C. "
        ]
    },
    "65d12b451930410b13000031":
    {
        "question": "Can valproate be used during pregnancy?",
        "llm_evidence": "Valproate, also known as valproic acid, is an anticonvulsant medication that is generally advised against during pregnancy due to its associated risks. Key insights include:\n\n1. **Teratogenicity**: Studies have shown that valproate is highly teratogenic, significantly increasing the risk of congenital malformations such as neural tube defects, spinal bifida, and other serious abnormalities in the developing fetus when taken during the first trimester.\n\n2. **Developmental Risks**: Beyond physical defects, exposure to valproate in utero is linked to developmental issues, including an increased risk of autism spectrum disorders and cognitive impairment in children.\n\n3. **Guidelines and Recommendations**: Health authorities, such as the FDA and the European Medicines Agency (EMA), strongly discourage the use of valproate in pregnant women or those planning to become pregnant. Alternative treatments are recommended whenever possible.\n\n4. **Risk Mitigation**: For women of childbearing age who are prescribed valproate, healthcare providers often recommend effective contraception and discuss the risks associated with its use during pregnancy.\n\nIn conclusion, while some cases may require careful consideration of the benefits versus risks, the consensus among medical guidelines is that the use of valproate during pregnancy poses significant risks to fetal health and development.",
        "paper_evidence":
        [
            "Compared to lamotrigine, there was an increased risk of malformations associated with valproate (n = 2,031, aRR = 2.05, 95% CI = 1.70-2.46) and topiramate (n = 509, aRR = 1.81, 95% CI = 1.26-2.60), which increased in a dose-dependent manner.",
            "Valproate was associated with several malformation subtypes, including nervous system, cardiac, oral clefts, clubfoot, and hypospadias, whereas lamotrigine and carbamazepine were not.INTERPRETATION: Topiramate is associated with an increased risk of MCM similar to that associated with valproate, but lower doses may mitigate the risks for both drugs.",
            "INTRODUCTION: Prenatal exposure to valproate and related substances is associated with a risk of malformations and/or neurodevelopmental disorders.",
            "Increased awareness and compliance among healthcare professionals regarding risk minimization measures could limit prenatal exposure to valproate.",
            "CONCLUSIONS: Our proof-of-concept analysis based on GePaRD showed a strong association between intrauterine exposure to VPA and occurrence of spina bifida.",
            "Proposal for reference values for the developmental effects of valproate based on human data using a benchmark dose approach.",
            "Major congenital malformations (MCMs) in offsprings of mothers exposed to valproate during pregnancy have been reported in international scientific literature.",
            "Valproate, in monotherapy and polytherapy, has been associated with elevated risk of major congenital malformations and neurodevelopmental disorders in children born to mothers who took it. Topiramate and phenobarbital are also associated with elevated risks of congenital malformations and neurodevelopmental disorders, though the risks are lower than those of valproate. ",
            "Valproic acid (VPA), a widely prescribed first-line antiepileptic drug for epilepsy and various neurological conditions, has been associated with a 4-fold increase in the risk of NTDs when used during pregnancy",
            "This finding suggests the need for reappraisal of the use of valproate in women who may become pregnant or are pregnant whilst the drug is taken.",
            "Valproate of sodium should be avoided, if possible, during pregnancy.",
            "At valproate doses of 1400 mg and below per day, the mean rate of pregnancies with fetal malformations was 6.42% and did not seem to be dose-dependent.",
            "Valproic acid (VPA, valproate, Depakote) is a commonly used anti-seizure medication (ASM) in the treatment of epilepsy and a variety of other neurological disorders. While VPA and other ASMs are efficacious for management of seizures, they also increase the risk for adverse pregnancy outcomes, including neural tube defects (NTDs).",
            "Sodium valproate is a known teratogen, and is discouraged in pregnancy, but what choice is open to women who rely on this medication to stabilise their mood?CONCLUSIONS: The large majority of women of childbearing age with bipolar disorder should not be prescribed sodium valproate as the risks to the unborn fetus far outweigh the benefits of the medication, as other drugs have similar if not better efficacy to stabilize the mother's mood, with lower risks to the fetus.",
            "The use of valproate is contraindicated during pregnancy due to teratogenicity and neurocognitive delay and deficits.",
            "Spina bifida is the only specific major congenital malformation significantly associated with exposure to Carbamazepine monotherapy Despite the small number of studies on the teratogenic effects of new antiepileptic drugs, the analysis of the literature shows that exposure of the fetus to the new antiepileptic drugs is associated with a lower risk of major congenital malformations compared to the use of older drugs.EXPERT OPINION: Where possible, Valproate should be avoided in women of childbearing potential.",
            "BACKGROUND: The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonatal distress. In addition, intrauterine exposure to valproic acid has been associated with an increased risk of central nervous system abnormalities, primarily neural t",
            "PURPOSE: Valproate is an effective wide-spectrum anti-epileptic drug that is also known to be teratogenic. Its administration in epileptic women remains contr",
            "Therefore, we strongly recommend avoidance of valproic acid and supplementation of folic acid during pregnancy.",
            "Therefore, we recommend that valproic acid must be avoided during pregnancy, as new generation of anticonvulsant drugs have emerged into the market.",
            "BACKGROUND: The use of valproic acid during pregnancy has been associated with adverse fetal outcomes, including major and minor congenital malformations, intrauterine growth retardation (IUGR), hyperbilirubinemia, hepatotoxicity, transient hyperglycemia, and fetal and neonat",
            "Women of childbearing age taking valproate should be warned of its teratogenicity and advised to plan pregnancies, take a higher dose of folate, discuss reducing the dose of valproate or changing the medication with their physician, and have antenatal screening.",
            "It also includes the importance of awareness among middle-aged women with mental illness regarding the teratogenic effects of sodium valproate use and the relevance of discussion by physicians with patients regarding the usage of this drug despite being aware of the complications.",
            "Sodium valproate is a teratogen responsible for a wide range of abnormalities, including neural tube defects.",
            "Sodium valproate, a widely used anticonvulsant and mood regulator, is a well-recognized teratogen that can result in severe limb deformities, craniosynostosis, neural tube defects and neurodevelopmental retardation. Therefore, we recommend that valproic acid must be avoided during pregnancy, as new generation of anticonvulsant drugs have emerged into the market.",
            "Sodium valproate, a widely used anticonvulsant and mood regulator, is a well-recognized teratogen that can result in facial dysmorphism, craniosynostosis, neural tube defects, and neurodevelopmental retardation.",
            "Valproic acid use during pregnancy results in an absolute risk for spina bifida of 1-2%. This increased risk is comparable to the recurrence risk for neural tube defects and warrants informed counselling and access to prenatal diagnosis.",
            "Within several years after receiving U.S. Food and Drug Administration (FDA) approval in the late 1970s, valproate was shown to increase the risk for major congenital malformations and learning disabilities in the offspring of women who used the drug during pregnancy.",
            "The teratogenic effects of valproic acid appear to be dose dependent, with higher risks at dosage levels >1000 mg/day."
        ]
    },
    "65f7725ec4010b4d78000020":
    {
        "question": "Which dietary compounds are associated with colorectal cancer incidence?",
        "llm_evidence": "Several dietary compounds have been associated with colorectal cancer incidence, including:\n\n1. **Red and Processed Meat**: High consumption of red meat (such as beef, pork, and lamb) and processed meats (like bacon, sausages, and deli meats) is linked to increased colorectal cancer risk. The heme iron found in red meat and the presence of nitrites and nitrates in processed meats are thought to play a role in this association.\n\n2. **Dietary Fiber**: A diet rich in dietary fiber, particularly from whole grains, fruits, and vegetables, is associated with a reduced risk of colorectal cancer. Fiber helps to promote healthy bowel movements and may have protective effects against cancer by aiding in the elimination of potential carcinogens.\n\n3. **Fruits and Vegetables**: High intake of fruits and vegetables may lower colorectal cancer risk, likely due to their high content of vitamins, antioxidants, and phytochemicals that exhibit anti-inflammatory and anti-carcinogenic properties.\n\n4. **Calcium and Vitamin D**: Some studies suggest that higher calcium and vitamin D intake may be protective against colorectal cancer, potentially influencing cellular processes that control cell growth and differentiation.\n\n5. **Alcohol Consumption**: Excessive alcohol intake is associated with an increased risk of colorectal cancer. The mechanism may involve the formation of acetaldehyde, a potential carcinogen generated during alcohol metabolism.\n\n6. **Sugars and High Glycemic Index Foods**: Diets high in sugars and refined carbs may be linked to an increased risk of colorectal cancer, possibly due to their role in promoting obesity and insulin resistance, both of which are risk factors for cancer.\n\nCollectively, these insights indicate that dietary choices play a significant role in the incidence of colorectal cancer, highlighting the importance of a balanced diet rich in fiber, fruits, and vegetables, while limiting red and processed meats and alcohol.",
        "paper_evidence":
        [
            "This umbrella review found convincing evidence of an association between lower CRC risk and higher intakes of dietary fiber, dietary calcium, and yogurt and lower intakes of alcohol and red meat.",
            "high red meat intake was positively associated with risk of breast cancer, endometrial cancer, colorectal cancer, colon cancer, rectal cancer, lung cancer, and hepatocellular carcinoma, and high processed meat intake was positively associated with risk of breast, colorectal, colon, rectal, and lung cancers.",
            "Higher risk of colorectal, colon, rectal, lung, and renal cell cancers were also observed with high total red and processed meat consumption.",
            "Epidemiological studies have shown that a high fat (or meat) intake is associated positively and a high starch, fibre (non-starch polysaccharide), vegetable and fruit intake negatively with colorectal cancer incidence.",
            "Consumption of high amounts of red and processed meat and low intake of fiber and multiple protective phytochemicals found in fruits, vegetables, and whole grains might be responsible for the high incidence of this neoplasm in the Western world.",
            "Although the etiology of colorectal cancer is multifactorial, experimental evidence suggests a role for dietary factors in the promotion of this disease. The complex interrelations governing energy balance and the consumption of fat, fiber, and micronutrients make it difficult to define the precise role of specific dietary factors in the etiology of colorectal neoplasms. Epidemiologic studies have demonstrated a correlation between the prevalence of colorectal cancer and per capita consumption of meat and fat. Case-control studies investigating the relation between colorectal cancer and dietary fat consumption have yielded inconsistent results. Prospective studies have failed to demonstrate a relation between fat consumption and subsequent risk for colorectal cancer. There is an inverse correlation between fiber intake and the prevalence of colorectal carcinoma. A more detailed analysis of the influence of various types of dietary fiber on the subsequent risk for colorectal cancer will provide a better understanding of this relation. Fiber derived from fruits and vegetables may provide more effective protection than cereal fibers. Correlational studies have established an association between total caloric intake and the prevalence of colorectal carcinoma. The design of future studies investigating the influence of individual dietary constituents on the risk for colorectal cancer must control for variations in energy balance as a confounding variable. Recent evidence suggests that a variety of micronutrients, including calcium, vitamin D, selenium, and vitamins A, C, and E, exert an anticarcinogenic effect. Studies designed to evaluate the influence of alcohol consumption on colorectal carcinogenesis have yielded inconclusive results. The potential influence of food preparation methods on colorectal carcinogenesis requires further evaluation. There is no conclusive evidence to support any of the hypotheses proposed to explain the role of dietary factors in colorectal carcinogenesis. Intervention trials designed to monitor intermediate markers for colorectal cancer such as increased epithelial-cell proliferation rates and the development of aberrant crypt architecture provide the opportunity for testing these hypotheses in relatively short-term studies. The results from such studies can be utilized in the design of large-scale, long-term prospective studies to evaluate the influence of dietary factors on the development of colorectal neoplasms. These trials should generate the information required to develop strategies for diet modification to reduce the incidence of colorectal carcinoma.",
            "The association between diet and colorectal cancer has been studied in depth for many decades, with equivocal results. It has been hypothesized that cancers arising in the distal and proximal colon have different pathologies, and therefore different risk factors. As such, it is possible that diet-related factors might influence colorectal neoplasia differently depending on the subsite. Recent evidence indicates that women may be more likely to develop proximal cancers than men. Additionally, the link between certain dietary factors and colorectal neoplasia in women seems to vary by menopausal status. Given these observations, women may be affected differently than men by diet-related factors. The objective of this article was therefore to review the data for diet and colorectal adenomas and cancer, and then attempt to address the potential differences in the association of diet-related factors and colorectal neoplasia in men and women. For total energy intake, selenium, and fiber, it seems that there may be slightly stronger effects in men as compared with women, whereas calcium and folate seem to affect both sexes similarly. With regard to vitamin D and colorectal cancer, women may exhibit stronger associations than men. Perhaps the most evidence for a sex-specific effect is observed for obesity, where more substantial direct relationships between body size and colorectal neoplasia have been reported for men than for women. However, this observation may be influenced by the differential effects in women by menopausal status. Further research on sex-specific dietary effects is warranted.",
            "Alcoholic beverages enhance the risk of cancer of the oral cavity, pharynx, larynx and oesophagus, while the relation is less well established for cancer in the stomach, pancreas, colon, rectum and breast.",
            "For alcohol, there seems to be a stronger association with rectal cancer than with colon cancer, and for meat a somewhat stronger association with distal colon and rectal cancer, relative to proximal colon cancer.",
            "Further, meat consumption is associated with increased risk but this, too, is not explained solely by its fat content.",
            "Incidences of colorectal cancer were positively associated with fat and oil intake, of both plant and animal types; a positive link was noted with animal protein but the association with plant protein consumption was inverse, as was also the case for carbohydrate and cereals; no simple association was evident with total energy intake.",
            "The endogenous formation of N-nitroso compounds is a possible explanation because red and processed meat, but not white meat or fish, cause a dose-dependent increase in faecal ATNCs (apparent total N-nitroso compounds) and the formation of nitroso-compound-specific DNA adducts in humans",
            "High intakes of total lipid (ORT3 vs T1 = 4.15, 95% CI: 1.33-12.96, p for trend = 0.034), saturated fatty acid (ORT3 vs T1 = 2.96, 95% CI: 1.24-7.04, p for trend = 0.016) and monounsaturated fatty acid (ORT3 vs T1 = 3.04, 95% CI: 1.23-7.54, p for trend = 0.018) were significantly associated with increased incidence of colorectal cancer",
            " eating a diet high in total lipid, saturated fatty acids and monounsaturated fatty acids is associated with higher incidence of colorectal cancer",
            "In conjunction with obesity and physical inactivity, which induce a state of insulin resistance, certain dietary patterns that stimulate insulin secretion, including high intakes of red and processed meats, saturated and trans-fats, and highly processed carbohydrates and sugars, may increase the risk of colon cancer. There is evidence suggesting that some component of red meat may independently increase the risk of colorectal cancer, and some micronutrients may be important as protective agents",
            ". Conversely, acidic food, reheated food, meat, spicy food, and alcohol are associated with the increment case of cancer",
            " Increased colorectal cancer risk regarding the lowest vs the highest intake quartile emerged for: vitamin B12 (3.41), cholesterol (3.15), total fat (2.87), saturated fat (1.98), animal protein (1.95), energy (1.85), alcohol (1.70), iron (1.49), refined carbohydrates (1.39)."
        ]
    },
    "65f494d7c4010b4d78000013":
    {
        "question": "What is the relationship between  Electroporation (EP) and DNA vaccines?",
        "llm_evidence": "Electroporation (EP) is a physical method that enhances the delivery of DNA vaccines into cells by applying an electrical field, which temporarily disrupts the cell membrane. This process increases the permeability of the cell membrane, allowing plasmid DNA to enter more efficiently. Key insights about the relationship between EP and DNA vaccines include:\n\n1. **Increased Transfection Efficiency**: EP significantly improves the uptake of DNA plasmids, leading to higher expression levels of encoded antigens and, consequently, stronger immune responses.\n\n2. **Robust Immune Response**: Studies have shown that electroporated DNA vaccines elicit both humoral (antibody-mediated) and cellular (T-cell mediated) immune responses more effectively than traditional vaccination methods.\n\n3. **Versatile Application**: EP can be adapted for various vaccine delivery modalities, such as intramuscular or intradermal routes, making it a flexible tool in vaccine development.\n\n4. **Clinical Success**: Several clinical trials have demonstrated the safety and immunogenicity of electroporated DNA vaccines against infectious diseases and cancers, indicating successful translation from laboratory to real-world application.\n\nOverall, the integration of electroporation in DNA vaccine technology has significantly enhanced vaccine efficacy, making it a critical tool in modern vaccinology.",
        "paper_evidence":
        [
            "Electroporation (EP) is an effective way to increase the immunogenicity of DNA",
            "n this study, we challenged this concept by characterizing the immunological response induced by a plasmid DNA vaccine delivered using electroporation",
            "Intradermal delivery of DNA vaccines via electroporation (ID-EP) has shown clinical promise, but the use of needle electrodes is typically required to achieve consistent results",
            "In vivo electroporation (EP) has been shown to augment the immunogenicity of plasmid DNA vaccines, but its mechanism of action has not been fully characterized.",
            "These data establish EP as a potent method for stimulating humoral responses induced by DNA vaccination in humans.",
            "Electroporation (EP), a promising approach that dramatically enhances expression of the encoded antigen as well as the potency and immunogenicity of DNA vaccines, could facilitate clinical implementation of DNA vaccination.",
            "Electroporation (EP) has emerged as an effective method for delivering DNA vaccines, significantly enhancing humoral and cellular responses.",
            "DNA Electroporation may prove to be the \"missing link\" in the evolution of DNA vaccines allowing for enhanced immune responses from DNA vaccination in humans thereby resulting in protection from disease post-pathogen exposure.",
            "In vivo EP has the key features of improved DNA uptake, increased antigen expression and a local inflammation.",
            "DNA vaccines have been proposed as a promising approach for introducing foreign antigens into the host for inducing protective immunity against infectious and cancer diseases. Nevertheless, because of their poor immunogenicity, plasmid DNA vaccination strategies need further implementations. Recent data suggest electrotransfer as a useful tool to improve DNA-based vaccination protocols, being able to stimulate both the humoral and cellular immune responses.",
            "Importantly, EP dramatically enhanced the neutralizing potency of the humoral response, since antibodies induced by low DNA dose (10 μg) were able to highly neutralize DHBV and to recognize ten antigenic regions, including four neutralization epitopes",
            "In vivo electroporation of plasmid DNA (DNA-EP) is an efficient and safe method for vaccines resulting in increased DNA uptake, enhanced protein expression and increased immune responses to the target antigen in a variety of species.",
            "Herein, we report a screening system based on DNA vaccines and a micro-electroporation/electrophoresis system (MEES), which greatly improved the efficacy of DNA vaccines, elevating humoral and cellular immune responses by over 400- and 35-fold respectively",
            "Electroporation can improve intramuscular DNA vaccination efficacy but the exact antigen presentation mechanism remains unclear. We reported here that a similar immuno-potentiation effect was also observed by stimulating the skeletal muscles with electric pulses (EP) a few days prior to DNA inoculation (EP + n days + DNA). The application of EP by itself activated proinflammatory chemokine genes and stress genes. It also triggered an influx of inflammatory monocytes/macrophages (MPs). After DNA inoculation, the plasmids were seen taken up by these inflammatory MPs, which migrated to the draining LNs subsequently. The antibody responses results were fast and strong. Furthermore, MPs isolated from the draining LNs of EP + n days + DNA treated mice were capable of stimulating Ag specific CD4+ T cell proliferation in vitro. Based on these observations, we proposed that the local inflammation resulted from EP treatment played an important role in facilitating antigen presentation of the DNA vaccines.",
            "One of the uses of EP in vivo is plasmid DNA electrotransfer to the skin for DNA vaccination. EP of tissues induces reduction of blood flow and, in combination with plasmid DNA, induction of an immune response. One of the EP protocols for plasmid DNA electrotransfer to the skin is a combination of high-voltage (HV) and low-voltage (LV) pulses. However, the effects of this pulse combination on skin-vessel blood flow are not known.",
            "In vivo electroporation (EP) is used to enhance the uptake of nucleic acids and its association with DNA vaccination greatly stimulates immune responses to vaccine antigens delivered through the skin. However, the effect of EP on cutaneous cell behavior, the dynamics of immune cell recruitment and local inflammatory factors, have not been fully described.",
            "Recent delivery techniques such as the gene gun and in vivo electroporation (EP)/electrotransfer (ET) have completely changed the efficiency of DNA vaccines in humans. In vivo EP exerts multiple effects that contribute to its efficiency. The two central factors are most likely the increased DNA uptake due to the transient membrane destabilization, and the local tissue damage acting as an adjuvant.",
            "Non-viral in vivo administration of plasmid DNA for vaccines and immunotherapeutics has been hampered by inefficient delivery. Methods to enhance delivery such as in vivo electroporation (EP) have demonstrated effectiveness in circumventing this difficulty. However, the contact-dependent nature of EP has resulting side effects in animals and humans. Noncontact delivery methods should, in principle, overcome some of these obstacles. This report describes a helium plasma-based delivery system that enhanced humoral and cellular antigen-specific immune responses in mice against an intradermally administered HIV gp120-expressing plasmid vaccine (pJRFLgp120).",
            "The immune responses elicited following delivery of DNA vaccines to the skin has previously been shown to be significantly enhanced by the addition of electroporation (EP) to the treatment protocol. Principally, EP increases the transfection of plasmid DNA (pDNA) into the resident skin cells. In addition to increasing the levels of in vivo transfection, the physical insult induced by EP is associated with activation of innate pathways which are believed to mediate an adjuvant effect, further enhancing DNA vaccine responses.",
            "Electroporation (EP) is an effective way to enhance the immunogenicity of DNA vaccines, but because of the different configurations of the devices that are used for EP, it is necessary to carefully select the conditions of the procedure, including characteristics such as voltage, current strength, number of pulses, etc.",
            "Our laboratory has been evaluating DNA plasmid based Pfs25 vaccine in mice and non-human primates. Previously, we established that in vivo electroporation (EP) delivery is an effective method to improve the immunogenicity of DNA vaccine encoding Pfs25 in mice. In order to optimize the in vivo EP procedure and test for its efficacy in more clinically relevant larger animal models, we employed in vivo EP to evaluate the immune response and protective efficacy of Pfs25 encoding DNA vaccine in nonhuman primates (olive baboons, Papio anubis). The results showed that at a dose of 2.5mg DNA vaccine, antibody responses were significantly enhanced with EP as compared to without EP resulting in effective transmission blocking efficiency. Similar immunogenicity enhancing effect of EP was also observed with lower doses (0.5mg and 1mg) of DNA plasmids.",
            "The immune responses elicited following delivery of DNA vaccines to the skin has previously been shown to be significantly enhanced by the addition of electroporation (EP) to the treatment protocol.",
            "In vivo electroporation (EP) has proven to significantly increase plasmid transfection efficiency and to augment immune responses after immunization with plasmids.",
            "Two main strategies to increase DNA-based vaccine potency are the employment of immuno-adjuvants such as heat shock proteins (HSPs) and a method of improving the delivery of naked plasmid DNA by electroporation.",
            "In addition to increasing the levels of in vivo transfection, the physical insult induced by EP is associated with activation of innate pathways which are believed to mediate an adjuvant effect, further enhancing DNA vaccine responses.",
            "electroporation (EP) has been shown to generate potent and efficacious immune responses in the clinic. Needle-free jet injection has also been reported to improve DNA vaccine delivery over standard needle and syringe in clinical trials. Here",
            "Of these, EP mediated delivery has generated considerable enthusiasm and appears to have had a great impact in vaccine immunogenicity and efficacy by increasing antigen delivery upto a 1000 fold over naked DNA delivery alone.",
            "One novel in vivo delivery method for plasmid vaccines is electroporation, which is the application of short pulses of electric current immediately after, and at the site of, an injection of a genetic vaccine. This method has been shown to significantly augment the transfection efficacy and the subsequent vaccine-specific immune responses.",
            "Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration.",
            "ecruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation."
        ]
    },
    "65f84d20c4010b4d7800004a":
    {
        "question": "Is measles immunisation the best public health approach to reduce incidence of measles worldwide?",
        "llm_evidence": "Measles immunisation is widely regarded as the most effective public health approach to reduce the incidence of measles worldwide. Key insights supporting this conclusion include:\n\n1. **High Efficacy of Vaccination**: The measles vaccine is approximately 97% effective after two doses. This high efficacy significantly reduces the number of cases and the spread of the virus within communities.\n\n2. **Herd Immunity**: Achieving a vaccination coverage of at least 95% in a population is crucial for establishing herd immunity, which protects those who are unable to be vaccinated (e.g., infants, immunocompromised individuals) by reducing overall circulation of the virus.\n\n3. **Decline in Mortality and Morbidity**: The introduction of the measles vaccine has led to a dramatic decline in mortality and morbidity rates associated with measles. According to the World Health Organization (WHO), global measles deaths dropped by 73% from 2000 to 2018 due to improved vaccination coverage.\n\n4. **Cost-Effectiveness**: Immunisation programs are cost-effective public health interventions. The return on investment from measles vaccines in terms of healthcare savings and societal benefits is substantial.\n\n5. **Global Health Initiatives**: International health organizations, including WHO and UNICEF, emphasize the importance of vaccination as part of routine childhood immunization programs, aiming to eliminate measles as a public health threat.\n\nOverall, comprehensive immunisation strategies, including outreach and education to increase vaccine uptake, are essential in achieving significant reductions in measles incidence globally.",
        "paper_evidence":
        [
            "renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, thereby preventing outbreaks and accelerating progress toward measles elimination",
            "Measles is a highly contagious, vaccine-preventable disease",
            "an estimated 57 million measles deaths were averted by vaccination during 2000-2022",
            "Measles is a highly contagious, but vaccine-preventable disease",
            "the administration of two doses of measles vaccines is the most effective strategy to prevent and eliminate measles",
            "The use of early measles vaccination at 4 months of age could be an effective strategy to prevent severe morbidity and death from both measles and RSV infections in many LMICs.",
            "Measles is best prevented through vaccination, and the major reductions in measles incidence and mortality have renewed interest in regional elimination and global eradication.",
            "Since 2000, vaccination campaigns against measles, which is highly contagious but preventable through the measles-mumps-rubella (MMR) vaccine, have reduced both the global incidence of the disease and measles deaths by 80 percent.",
            "In other parts of the world the incidence of this disease has been dramatically reduced following effective measles immunisation programmes.",
            "This achievement attests to the enormous importance of measles vaccination to public health.",
            "Measles is a highly contagious disease that results from infection with measles virus and is still responsible for more than 100 000 deaths every year, down from more than 2 million deaths annually before the introduction and widespread use of measles vaccine.",
            "This highly effective and well-tolerated vaccine has greatly reduced the number of measles cases and saved millions of lives.",
            "Worldwide during the 1980s remarkable progress was made in controlling measles through increasing routine measles vaccination to nearly 80%.",
            "Measles immunization has dramatically reduced measles occurrence, but improved control is necessary to prevent the estimated 1 million deaths still occurring each year.",
            "The global measles vaccination program has been extraordinarily successful in reducing measles-related disease and deaths worldwide.",
            "Routine immunization with MCV has been the cornerstone for the control and prevention of measles. Two doses of MCV are 97% effective in preventing measles, qualifying MCV as one of the most effective vaccines ever developed.",
            "BACKGROUND: Measles is a highly contagious and serious infection. Before the introduction of vaccination, measles caused yearly epidemics putting vulnerable children at risk of brain damage and death. Despite safe and cost-effective vaccines, measles remains a leading cause of death in childr",
            "INTRODUCTION: One of the goals of the Global Measles and Rubella Strategic Plan is the reduction in global measles mortality, with high measles vaccination coverage as one of its core components. While measles mortality has been reduced more than 79%, the disease remains a major cause of childhood vaccine preventable disease burden globally. Measles immunization requires a two-dose schedule and only countries with strong, stable immunization programs can rely on routine services to deliver th",
            "In 2000, the United Nations General Assembly adopted the Millennium Development Goals (MDG), with MDG4 being a two-thirds reduction in child mortality by 2015, and with measles vaccination coverage being one of the three indicators of progress toward this goal.",
            "In 2001, to accelerate the reduction in measles cases achieved by vaccination, the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) developed a strategy to deliver 2 doses of measles-containing vaccine (MCV) to all children through routine services and supplementary immunization activities (SIAs) and improved disease surveillance.",
            "Health care and community collaboration led to coverage rates of measles vaccination increasing from 80% to 95% within three months and a significant decline in incidence.",
            "Remarkable progress in reducing the number of people dying from measles has been made through measles vaccination, with an estimated 164,000 deaths attributed to measles in 2008.",
            "An immunisation programme to eliminate measles, mumps, and rubella from Finland within 10 years was",
            "Measles vaccination programs have been among the greatest public health achievements reducing, eliminating endemic measles in the whole of the Americas and across much of the globe.",
            "Vaccination is one of history's most successful public health interventions. Since 2000, vaccination campaigns against measles, which is highly contagious but preventable through the measles-mumps-rubella (MMR) vaccine, have reduced both the global incidence of the disease and measles deaths by 80 percent.",
            "Increased measles immunization has led to a significant decline in measles incidence and mortality.",
            "The incidence of measles worldwide has decreased dramatically since the introduction of effective vaccines.",
            "Two doses of MCV are 97% effective in preventing measles, qualifying MCV as one of the most effective vaccines ever developed.",
            "Because measles is one of the most contagious human diseases, maintenance of high (≥95%) 2-dose MCV coverage is crucial for controlling the spread of measles and successfully reaching measles eliminatio",
            "Strengthening immunization programs and keeping vaccination coverage rates above 95% with a two-dose schedule will be necessary for measles control strategies in the Americas."
        ]
    },
    "64179034690f196b5100002b":
    {
        "question": "What type of DMD can golodirsen be used for?",
        "llm_evidence": "Golodirsen is a targeted therapy designed for patients with Duchenne Muscular Dystrophy (DMD) who have specific mutations in the dystrophin gene, particularly those that are amenable to exon 53 skipping. It functions by promoting the production of a shorter but functional form of the dystrophin protein, which is crucial for muscle function. Clinical trials have demonstrated that golodirsen can improve dystrophin protein levels in muscle tissue, supporting its use as a treatment option for DMD caused by these mutations.",
        "paper_evidence":
        [
            "Golodirsen (Vyondys 53™), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping",
            "In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, ",
            "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression",
            "Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA.",
            "Golodirsen (Vyondys 53™), an antisense oligonucleotide of the phophorodiamidate morpholino oligomer (PMO) subclass designed to induce exon 53 skipping, has been developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD).",
            "In December 2019, intravenous golodirsen received its first global approval in the USA for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, based on positive results from a phase I/II clinical trial.",
            "Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) and has developed from in vitro proof-of-concept studies to clinical trials targeting various single exons such as exon 45 (casimersen), exon 53 (NS-065/NCNP-01, golodirsen), and exon 51 (eteplirsen).",
            "Two exon 53 skipping PMOs, golodirsen and viltolarsen, have received conditional approval for treating patients due to their ability to restore dystrophin protein expression.",
            "Golodirsen is a provisionally approved PMO-based drug for approx. 8% of all DMD patients amenable to exon 53 skipping.",
            "The aim of this Phase 1/2, 2-part, multicenter trial was to report clinical safety and efficacy of long-term golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD).",
            "OBJECTIVE: To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.METHODS: Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation.",
            "Sarcolemmal localization of dystrophin was demonstrated by significantly increased dystrophin-positive fibers (week 48, p < 0.001) and a positive correlation (Spearman r = 0.663; p < 0.001) with dystrophin protein change from baseline, measured by Western blot and immunohistochemistry.CONCLUSION: Golodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed increased exon 53 skipping, dystrophin production, and correct dystrophin sarcolemmal localization.CLINICALTRIALSGOV IDENTIFIER: NCT02310906.CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dystrophin as confirmed by 3 different assays.",
            "golodirsen treatment among ambulatory patients with exon 53 skip-amenable Duchenne muscular dystrophy (DMD). Part 1 was a 12-week, randomized, double-blind, placebo-controlled,",
            "DMD gene. In particular, PMOs for skipping exon 44 have been developing in clinical trials, such as the drug NS-089/NCNP-02. Two exon 53 skipping PMOs, golodirsen and viltolarsen,",
            "Very recently, golodirsen and viltolarsen, for treatment of DMD patients amenable to skipping exon 53, have been approved by regulatory agencies in the USA and Japan, respectively.",
            "OBJECTIVE: To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 5",
            "However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years."
        ]
    },
    "65d137871930410b1300003e":
    {
        "question": "What are active ingredients of Trikafta?",
        "llm_evidence": "Trikafta is a prescription medication primarily used to treat cystic fibrosis in patients aged 12 years and older who have specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The active ingredients in Trikafta are:\n\n1. **Elexacaftor**: A CFTR corrector that helps the defective protein respond better to the normal cellular processes, enhancing the amount of protein at the cell surface.\n\n2. **Tezacaftor**: Another CFTR corrector that works in conjunction with elexacaftor to improve the folding and trafficking of the CFTR protein to the cell surface.\n\n3. **Ivacaftor**: A CFTR potentiator that helps to increase the function of the mutant CFTR protein at the cell surface, facilitating chloride ion transport across the epithelial cell membranes.\n\nThese active ingredients work synergistically to improve lung function and reduce respiratory symptoms in individuals with cystic fibrosis.",
        "paper_evidence":
        [
            "The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta®, Kaftrio®) significantly improve outcomes, including survival in a broad range of cystic fibrosis patients. ",
            "CONTEXT: Elexacaftor/Tezacaftor/Ivacaftor (ETI; Trikafta™) enhances aberrant cystic fibrosis transmembrane conductance regulator (CFTR) function and may improve the insulin secretory defects associated with a deterioration in clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF).",
            "INTRODUCTION: A triple combination of CFTR modulators ELE/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor, Trikafta™) has been evaluated in clinical trials for people with cystic fibrosis (pwCF) and was approved to the European and US market. ",
            "The method has been validated following international (EMA) guidelines for bioanalytical method validation and has been tested on plasma samples from 62 CF patients treated with the three-drug combination IVA/TEZ/ELX, marketed as Kaftrio® or Trikafta®, in steady-state condition. ",
            "Trikafta, a triple-combination drug, consisting of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor) and the gating potentiator VX-770 (ivacaftor) provided unprecedented clinical benefits for patients with the most common cystic fibrosis (CF) mutation, F508del.",
            "Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.",
            "Trikafta, the combination of elexacaftor (VX-445), tezacaftor (VX-661) and ivacaftor (VX-770), was approved for therapy of cystic fibrosis (CF) patients with at least one allele of the CFTR mutation F508del.",
            "We present a novel case of an urticaria multiforme-type drug reaction to the new cystic fibrosis medication Trikafta (elexacaftor + tezacaftor + ivacaftor).",
            "The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele.",
            "The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta®, Kaftrio®) significantly improve outcomes, including survival in a broad range of cystic fibrosis patients. These drugs have complicated metabolic profiles that make the potential for drug interactions an important consideration for prescribers, care providers and patient",
            "CONTEXT: Elexacaftor/Tezacaftor/Ivacaftor (ETI; Trikafta™) enhances aberrant cystic fibrosis transmembrane conductance regulator (CFTR) function and may improve the insulin secretory defects associated with a deterioration in clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF).OBJECTIVE: This longitudinal case-control study assessed changes in β-cell function and secretory capacity measures over two visits in individuals with PI-CF who were initiated on ETI after the baseline visit (2012-2018) and 1) restudied between 2019-2021 (ETI group) vs. 2) those restudied between 2015-2018 and not yet treated with CFTR modulator therapy (controls).METHODS: Nine ETI participants (mean ± SD age 25 ± 5 years) and eight matched controls were followed up after median(IQR) 5(4-7) and 3(2-3) years, respectively (p < 0.01), with ETI initiation a median of 1 year before follow-up.",
            "A fixed-dose combination tablet of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector tezacaftor and the CFTR potentiator ivacaftor with the next-generation CFTR corrector elexacaftor (hereafter referred to as elexacaftor/ivacaftor/tezacaftor) [Trikafta™] has been developed by Vertex Pharmaceuticals Inc. to treat patients with the most common cystic fibrosis mutation (F508del).",
            "Based on its clinical benefits, Trikafta - the combination of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor) - was FDA approved for treatment of patients with cystic fibrosis (CF) carrying deletion of phenylalanine at position 508 (F508del) of the CF transmembrane conductance regulator (CFTR) on at least 1 allele.",
            "The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta®, Kaftrio®) significantly improve outcomes, including survival in a broad range of cystic fibrosis patient",
            "Trikafta - the combination of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor)",
            "pyrin domain-containing protein 3) inflammasome. Objectives: To explore the effect of the CFTR modulator elexacaftor/tezacaftor/ivacaftor (Trikafta)"
        ]
    },
    "65f77397c4010b4d78000025":
    {
        "question": "What proportion of alteration in NTRK genes are attributable to colorectal cancer?",
        "llm_evidence": "NTRK gene alterations are relatively rare in colorectal cancer, accounting for a small percentage of cases. While NTRK fusions, primarily identified in other cancers such as mammary tumors and certain sarcomas, have been well-documented, their occurrence in colorectal cancer is significantly lower, with studies showing that these alterations are present in approximately 1-4% of colorectal cancer cases. This low prevalence indicates that while NTRK gene alterations can occur, colorectal cancer is not a primary driver of these mutations compared to other cancer types. Overall, the burden of NTRK alterations attributable to colorectal cancer is minimal, highlighting the need for further research to understand the role and impact of these mutations in this particular cancer type.",
        "paper_evidence":
        [
            " In common cancers, rates were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates.",
            "The proportion of patients with targets for genetically matched therapies differed among subtypes (salivary duct carcinoma: 82%, adenoid cystic carcinoma 28%, mucoepidermoid carcinoma 50%, acinic cell carcinoma 33%)",
            "Of 15,223 patients analyzed, 38 (0.25%) had NTRK gene fusions in 11 tumor types, the most common were breast cancer, colorectal cancer (CRC), and sarcoma",
            "TRK positivity was observed in 11 of 58 (19%) MLH1-methylated MSI-high CRCs, 4 of 23 (17%) sessile serrated lesions with dysplasia (SSLDs), and 5 of 132 (4%) sessile serrated lesions (SSLs).",
            "colorectal cancers, prevalence of the NTRK fusions is well below 5%. Selective inhibition of TRK signaling may therefore be beneficial among patients whose tumors vary in histologies, but share underlying oncogenic NTRK gene alterations. Currently,",
            "Of the 7008 tumors screened for NTRK expression using a pan-Trk antibody, 16 (0.23%) had Trk immunoreactivity."
        ]
    },
    "65f1d234c4010b4d78000005":
    {
        "question": "Please list the Janus Kinase inhibitors used to treat Inflammatory Bowel Disease(IBD)",
        "llm_evidence": "Janus Kinase (JAK) inhibitors are a class of medications that target specific pathways involved in the inflammatory response and have been shown to be effective in treating Inflammatory Bowel Disease (IBD). The notable JAK inhibitors used for IBD include:\n\n1. **Tofacitinib (Xeljanz)**: Originally approved for rheumatoid arthritis, Tofacitinib is also indicated for ulcerative colitis. It works by inhibiting JAK1 and JAK3, thereby reducing the inflammatory process.\n\n2. **Risankizumab (Skyrizi)**: This JAK inhibitor has shown effectiveness in the treatment of ulcerative colitis and is currently undergoing various clinical trials for Crohn's disease. \n\n3. **Filgotinib (Jyseleca)**: It has been evaluated for the treatment of ulcerative colitis and works primarily on JAK1 inhibition.\n\n4. **Upadacitinib (Rinvoq)**: Approved for rheumatoid arthritis, Upadacitinib is in the process of being studied for its efficacy in treating moderate to severe ulcerative colitis.\n\nRecent studies suggest that these JAK inhibitors can provide significant improvements in clinical outcomes for patients with IBD, emphasizing their role in the management of this chronic condition.",
        "paper_evidence":
        [
            "Although there are currently no approved JAK inhibitors for Crohn's disease, upadacitinib and filgotinib have shown increased remission rates in these patients. Other JAK inhibitors, including gut-selective molecules, are currently being studied IBD.",
            "he Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms.",
            "Tofacitinib, a non-selective small molecule JAK inhibitor, and upadacitinib and filgotinib, which are selective JAK-1 inhibitors, have been approved by the US Food and Drug Administration (FDA)",
            "Tofacitinib, a pan-JAK inhibitor, has spearheaded the new JAK class for IBD treatment.",
            " We conducted a comparative phosflow study of four JAKinibs (filgotinib, upadacitinib, tofacitinib, and deucravacitinib) to observe subtle mechanistic differences that may dictate their clinical behavior. Resected mesenteric lymph node (MLN) cells from 19 patients (9 CD, 10 UC) were analyzed by flow cytometry in the presence or absence of different cytokine stimuli and titrated JAKinibs.RESULTS: We found a higher potency of the JAK 1/3-preferential inhibitor, tofacitinib, for JAK 3-dependent cytokine signaling pathways in comparison to filgotinib, but a higher potency of the JAK 1-preferential inhibitors, filgotinib and upadacitinib, for JAK 3-independent cytokine signaling pathways. Deucravacitinib, a TYK2-preferential inhibitor, demonstrated a much narrower selectivity by inhibiting only IL-10 and IFN-βpathways, albeit more potently than the other JAKinibs .",
            "Upadacitinib, a novel and selective inhibitor of Janus kinase 1, has demonstrated promising efficacy in managing inflammatory bowel disease (IBD)",
            "Tofacitinib was the first pan-Janus kinase (Jak) inhibitor approved for the treatment of IBD, targeting the 4 isoforms of cytokine-associated Jaks (Jak1, Jak2, Jak3, and tyrosine-protein kinase 2).",
            "Tofacitinib, dosed orally, intracecally, or applied to the colonic lumen in vitro, produced dose-dependent, and maximal inhibition of oxazolone or IFNγ-induced STAT1 phosphorylation in the colon.CONCLUSIONS: Localized colonic JAK inhibition, by intracecal delivery of tofacitinib, provides colonic target engagement and efficacy in a mouse colitis model at doses which do not impact splenic NK cell counts.",
            "Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated as a targeted immunomodulator for IBD.",
            "Tofacitinib, a pan-JAK inhibitor, has been recently approved for the treatment of moderate-to-severe UC.",
            ". Tofacitinib, a pan-JAK inhibitor, has shown good efficacy and safety in UC clinical trials and has been recently approved for the treatment of UC patient",
            "Tofacitinib is an oral pan-JAK inhibitor, primarily of JAK1 and JAK3, that was recently approved by the Food and Drug Administration (FDA) for the chronic treatment of UC in 2018.",
            "The oral formulation of tofacitinib has recently been approved for the treatment of moderate-to-severe ulcerative colitis.",
            "Tofacitinib is the only medicine in the class of Janus kinase (JAK) inhibitors that has been approved for use in moderate-to-severely active ulcerative colitis (UC). The potential of other JAK inhibitors to treat UC has not been fully explored.",
            "Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.",
            "INTRODUCTION: Janus Kinase inhibitors (JAKi) are a new class of oral therapies for the treatment of moderate-severe ulcerative colitis with additional potential for the treatment of moderate-severe Cr",
            "Tofacitinib, inhibiting signaling via different types of JAKs, has been already approved for ulcerative colitis, and several other small-molecule are still under investigation.",
            "Tofacitinib has been shown to be therapeutically efficacious, to have a tolerable safety profile, and to be available for adult patients with moderate-to-severe UC.",
            "The inflammatory diseases ulcerative colitis and Crohn's disease constitute the two main forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing inflammation of the gastrointestinal tract, significantly impacting on patient quality of life and often requiring prolonged treatment. Existing therapies for IBD are not effective for all patients, and an unmet need exists for additional therapies to induce and maintain remission. Here we describe the mechanism of action of the Janus kinase (JAK) inhibitor, tofacitinib, for the treatment of IBD and the effect of JAK inhibition on the chronic cycle of inflammation that is characteristic of the disease. The pathogenesis of IBD involves a dysfunctional response from the innate and adaptive immune system, resulting in overexpression of multiple inflammatory cytokines, many of which signal through JAKs. Thus JAK inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in IBD, thereby interrupting the cycle of inflammation. Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated as a targeted immunomodulator for IBD. Clinical development of tofacitinib and other JAK inhibitors is ongoing, with the aspiration of providing new treatment options for IBD that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits. ",
            "Deucravacitinib, a novel, oral, selective TYK2 inhibitor, and brepocitinib and PF-06826647, TYK2 inhibitors that bind to the active site in the catalytic domain, are in development for IBD and other immune-mediated inflammatory diseases.",
            "Currently, in Japan, three Janus kinase inhibitors, namely tofacitinib, filgotinib, and upadacitinib, are available for the treatment of patients with active ulcerative colitis.",
            "ass of drugs.AREAS COVERED: This review describes the JAK-STAT pathway and analyzes the efficacy and safety of new small molecules such as filgotinib, upadacitinib, TD-1473, peficitinib, and Pf-06651600/Pf-06700841, showing data",
            "ld be preferred in first line, filgotinib, tofacitinib or ustekinumab in second line. A steroid-dependent course in both diseases requires azathioprine or vedolizumab, in second ",
            "Tofacitinib is the first compound of a promising class of new small molecules approved for the treatment of IBD. This pan-Janus kinase (JAK) inhibitor (JAKi) targets the four isoforms of cytokine associated JAKs (JAK1, JAK2, JAK3 and TYK2). Next generations JAKi with marked selectivity for specific JAK isoforms or gut-restricted effect are in development, with promising results in phase I and II clinical trials.",
            "Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease. Generally, Janus kinase inhibitors are being used for the treatment of rheumatoid arthritis and other immunological diseases, with the therapeutic promising effects. Currently, in Japan, three Janus kinase inhibitors, namely tofacitinib, filgotinib, and upadacitinib, are available"
        ]
    },
    "65f83281c4010b4d78000040":
    {
        "question": "Are only babies and young children at risk of severe malaria in endemic areas?",
        "llm_evidence": "Severe malaria primarily affects vulnerable populations, including babies and young children, who have limited immunity against Plasmodium parasites in endemic areas. However, it is not exclusively these age groups that are at risk. Adults, particularly those who are pregnant, elderly, or have compromised immune systems, can also experience severe malaria. In endemic regions, repeated exposure to malaria leads to a degree of immunity over time, but this immunity can wane, especially in adults who have not been exposed for extended periods. Moreover, factors such as nutritional status, co-infections, and access to healthcare can further increase the risk of severe outcomes in individuals of any age. Therefore, while babies and young children are particularly susceptible, other demographic groups can also be significantly impacted by severe malaria.",
        "paper_evidence":
        [
            "malaria in pregnancy remains a significant cause of low birth weight, stillbirth, and severe anaemia",
            "mortality rates from severe malaria (SM) remain significantly high",
            "SM in adults and children",
            "Cerebral malaria in adults",
            "Brain involvement is common in adults with SNCM ",
            "Cerebral malaria (CM) is a rapidly progressive and severe form of Plasmodium falciparum infection",
            "CM, often associated with fatal outcomes even in treated subjects, is usually diagnosed at autopsy.Case presentation: We present the case of a 36-year-old man",
            "Acute episodes of severe malaria, repeated malaria infections leading to severe anemia, and infection during pregnancy which predisposes to low birth weight, a major risk factor for neonatal death, account for the majority of malaria-related deaths in young African children.",
            "Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially during the first or second pregnancy",
            "Malaria is a potentially life-threatening disease with approximately half of the world's population at risk. Young children and pregnant women are hit hardest by the disease.",
            "BACKGROUND: Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially during the first or second",
            "In India, both adults and children are affected by severe malaria."
        ]
    },
    "64414bdb57b1c7a315000058":
    {
        "question": "What types of glucosteroids are used for the management of Duchenne muscular dystrophy?",
        "llm_evidence": "Duchenne muscular dystrophy (DMD) management commonly involves the use of glucocorticoids, particularly prednisone and deflazacort. Prednisone is widely used and has been found to improve muscle strength and function while delaying the progression of the disease. Deflazacort, a newer glucocorticoid, has a similar efficacy but may be associated with fewer side effects, such as less weight gain and better preservation of bone health. Both medications work by reducing inflammation and modulating immune responses, ultimately prolonging ambulation and improving quality of life for patients with DMD. Ongoing research is also exploring the potential benefits of other glucocorticoids and corticosteroid regimens to optimize treatment outcomes.",
        "paper_evidence":
        [
            "Prednisone and deflazacort in Duchenne muscular dystrophy: ",
            "Prednisone and deflazacort are steroids that help to reduce muscle inflammation and are used as treatments for DMD",
            "Deflazacort and prednisone/prednisolone are the current standard of care for patients with Duchenne muscular dystrophy (DMD) based on evidence that they improve muscle strength, improve timed motor function, delay loss of ambulation, improve pulmonary function, reduce the need for scoliosis surgery, delay onset of cardiomyopathy, and increase survival.",
            "This analysis considered patients from the UK NorthStar database (2003-2020) on one of five regimes: \"GC naïve\", \"deflazacort daily\" (DD), \"deflazacort intermittent\" (DI), \"prednisolone daily\" (PD) and \"prednisolone intermittent\" (PI). ",
            "From this review, it is clear that until a definitive treatment for Duchenne muscular dystrophy is available, the use of deflazacort and prednisone with judicious dietary control and close clinical monitoring for side effects seems the best intervention for interim preservation of function in such a common devastating disorder of young growing boys.",
            "Glucocorticoid steroids, like prednisone, are known to delay loss of ambulation in patients with Duchenne muscular dystrophy but are accompanied by prominent adverse effects.",
            "Corticosteroid therapy (prednisone and deflazacort) is the only effective pharmacologic treatment for DMD.",
            "Glucocorticoid steroids such as prednisone and deflazacort are recommended for treating Duchenne Muscular Dystrophy where their use prolongs ambulation and life expectancy.",
            ": These results helped the researchers to learn more about the differences between how well prednisone and deflazacort work in males with DMD based on their medical records.",
            "Prednisone (Pred) and Deflazacort (Dfz) are commonly used glucocorticoids (GCs) for Duchenne muscular dystrophy (DMD) treatment and management.",
            "In recent years, various clinical trials have documented the benefit of glucocorticoid therapy in the palliation of Duchenne muscular dystrophy (DMD). Prednisone therapy, daily or on alternate days, has been confirmed to be of value in enhancing muscle strength and function in DMD for up to two years.",
            "Prednisolone has been shown to improve strength in Duchenne dystrophy, the improvement starting within 10 days of treatment and reaching a maximum by 3 months, and then plateauing.",
            "Glucocorticoids such as prednisone and deflazacort have powerful anti-inflammatory benefits and are the standard of care for DMD, but their long-term use can result in severe adverse side effects; thus, vamorolone was designed as a unique dissociative steroidal anti-inflammatory drug, to retain efficacy and minimise these adverse effects."
        ]
    },
    "65cfd4b21930410b13000020":
    {
        "question": "Cilta-cel was developed for treatment of which disease?",
        "llm_evidence": "Cilta-cel, or ciltacabtagene autoleucel, is a CAR T-cell therapy specifically developed for the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Clinical trials have demonstrated its efficacy in patients with relapsed or refractory multiple myeloma, particularly after they have undergone previous treatments. The therapy works by genetically modifying a patient's T-cells to target and attack cancerous plasma cells, leading to significant improvements in response rates and progression-free survival in affected individuals.",
        "paper_evidence":
        [
            " Additional indirect treatment comparisons conducted separately for ide-cel and cilta-cel have demonstrated that these CAR-T therapies hold promise for substantial clinical benefit relative to currently available treatments for RRMM.",
            "OBJECTIVE: This study used the latest available data cuts from the CARTITUDE-1 and KarMMa clinical trials to update previously published matching-adjusted indirect treatment comparisons (MAICs) assessing the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the FDA-approved idecabtagene vicleucel (ide-cel) dose range of 300 to 450 × 106 CAR-positive T-cells in the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.e. triple-class exposed)",
            "CONCLUSIONS: These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes over longer follow-up and highlight its therapeutic potential in triple-class exposed RRMM patients.",
            "PURPOSE: CARTIFAN-1 aimed to evaluate the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (RRMM).",
            "CONCLUSION: These data demonstrate a favorable risk-benefit profile for a single infusion of cilta-cel, resulting in early, deep, and durable responses in heavily pretreated patients with RRMM in China.",
            "Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.",
            "Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.",
            "Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies-idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel)-have been approved by the US Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody",
            "BACKGROUND: In the single-arm, phase 1b/2 CARTITUDE-1 study, ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen chimeric antigen receptor T-cell (CAR-T) therapy, showed encouraging efficacy in US patients with multiple myeloma (MM) who previously received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 monoclonal antibody (triple-class exposed).PATIENTS AND METHODS: A dataset of US patients refractory to an anti-CD38 monoclonal antibody (MAMMOTH) was used to identify patients who would meet eligibility for CARTITUDE-1 and received subsequent non-CAR-T therapy.",
            "BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma.",
            "BACKGROUND: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.METHODS: This single-arm, open-label, phase 1b/2 study done at 16 centres in the USA enrolled patients aged 18 years or older with a diagnosis of multiple myeloma and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who received 3 or more previous lines of therapy or were double-refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody.",
            "Ciltacabtagene autoleucel (cilta-cel) is a Chimeric antigen receptor T-cell therapy with the potential for long-term disease control in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM).",
            "INTRODUCTION: Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell (CAR-T) immunotherapy. It is indicated for treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monocl",
            "INTRODUCTION: This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus dexamethasone [STORM Part 2], and melphalan flufenamide plus dexamethasone [HORIZON]), each with distinct mechanisms of action, for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monocl",
            "Two BCMA-directed CAR T-cell products - idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) - have received US Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody).",
            "Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapies-idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel)-have been approved by the US Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma (RRMM) after 4 or more prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.",
            "nancies. Ciltacabtagene autoleucel (cilta-cel), a second-generation CAR-T cell with double B cell maturation antigen (BCMA) targeting binding domains, showed an 88% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (MM), which were carried out in our i",
            "The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) has approved two BCMA-targeting CAR T cell products, idecabtagene vicleucel (Ide-cel) and ciltacabtagene autoleucel (Cilta-cel), for use in RRMM.",
            "The autologous CAR-T cell therapy against BCMA (ide-cel and cilta-cel) shows the best efficacy with an overall response rate and a median progression-free survival in RRMM.",
            "eptor (CAR) T cell therapies, because their engineered cells may include allogeneic T cells. Ciltacabtagene autoleucel (cilta-cel) demonstrated early, deep, durable responses and manageable safety in heavily pretreated relapsed/refractory multiple myeloma patients. We retrospectiv"
        ]
    },
    "65f772d3c4010b4d78000022":
    {
        "question": "Which oncogene somatic mutations are associated to in situ carcinoma evolution from colonic polyp adenomas?",
        "llm_evidence": "In the evolution of colonic polyp adenomas to in situ carcinoma, several key oncogene somatic mutations play a critical role. The most prominent mutations are found in the following oncogenes:\n\n1. **KRAS**: Mutations in the KRAS gene are among the earliest events in the adenoma-to-carcinoma sequence. Approximately 30-40% of colorectal cancers exhibit KRAS mutations, which are often detected in adenomatous polyps, particularly tubular adenomas. This mutation leads to uncontrolled cell growth and proliferation.\n\n2. **BRAF**: BRAF mutations, especially the BRAF V600E variant, are associated with a subset of colorectal cancers, particularly those arising from serrated lesions. This mutation is linked to the serrated pathway of colorectal cancer development and can lead to the progression of sessile serrated adenomas to carcinoma.\n\n3. **PIK3CA**: Somatic mutations in the PIK3CA gene, which encodes a subunit of the phosphatidylinositol 3-kinase, are also recurrently observed in colorectal cancers and can contribute to tumorigenesis through the activation of the PI3K/Akt signaling pathway.\n\n4. **TP53**: While TP53 is primarily known as a tumor suppressor gene, mutations in TP53 are also common later in the progression from adenoma to carcinoma. These mutations usually occur after KRAS and BRAF mutations and are associated with the transition to invasive cancer.\n\nOverall, the progression from colonic polyp adenomas to in situ carcinoma often involves a series of genetic alterations, primarily in oncogenes such as KRAS and BRAF, alongside mutations in tumor suppressor genes like TP53. The presence of these mutations not only facilitates the understanding of tumor progression but also enhances the potential for targeted therapies in colorectal cancer management.",
        "paper_evidence":
        [
            "The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples.",
            "APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53",
            "APC gene 42.9-56.0-54.5%; KRAS gene 32.7-32.0-45.5%; TP53 gene 8.2-20.0-18.2%",
            "Sequential mutations of the APC and KRAS were judged-based on a database search-to be characteristic of the adenoma-carcinoma sequence in colorectal carcinogenesis.",
            "Colorectal carcinogenesis in familial adenomatous polyposis (FAP) follows a conventional adenoma-carcinoma sequence",
            "Of the remaining nine neoplasms, six had a K-ras mutation in the adenomatous portion only and three had one pattern in the adenomatous portion and a different pattern in the in situ carcinoma portion.CONCLUSIONS: LOH of the APC gene is an early and persistent feature in the evolution of a benign colorectal adenoma into an in situ carcinoma.",
            "Our study clearly demonstrates that tubulovillous and villous adenomas, as well as both the benign and malignant parts of in situ carcinomas, are statistically more likely to contain a somatic KRAS gene mutation than colorectal carcinomas.",
            "A KRAS mutation was found in 61.9% of 134 adenomas, 67.8% of 84 in situ carcinomas, and just 31.6% of 171 carcinomas.",
            "Activating mutations in either the BRAF (in SSAs) or the KRAS oncogene (in TSAs) have been determined as the initiating molecular alterations, followed by epigenetic methylation of CpG islands in promoter regions of genes which are implicated in cell cycle control or DNA repair.",
            "Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.",
            "The adenomatous polyposis coli (APC) gene and mismatch repair genes are found to be dysfunctional early in the neoplastic process; either as inherited or somatic mutations.",
            "Adenomas had lower mutational rates than did colorectal cancers and showed recurrent alterations in known cancer driver genes (APC, KRAS, FBXW7, TCF7L2) and AIs in chromosomes 5, 7, and 13.",
            "mutations (V600E) in the BRAF oncogene. Both of these features are seen in sporadic colorectal carcinomas with microsatellite instability (MSI) which is potentially consistent with an origin of these cancers from precursor SSA/Ps. Dysplasia is detected in a subset of SSA/Ps with a high risk of progression to carcinoma. An uncommon serrated polyp is the traditional serrated adenoma that is typically found in the left colon, has a tubulovillous architecture, and frequently harbors mutant KRAS To date, the epidemiology of these serrated lesions is poorly understood, and limited observational data suggest a potential chemopreventive benefit of nonsteroidal anti-inflammatory drugs. The current primary strategy to reduce the risk of colorectal carcinoma from serrated polyps is to enhance their detection at colonoscopy and to ensure their complete removal. This review provides insight into the epidemiologic, clinical, histopathologic, and molecular features of serrated polyps and includes data on their endoscopic detection and chemoprevention. Cancer Prev Res; 10(5); 270-8. ©2017 AACR.",
            "We found that ras-gene mutations occurred in 58 percent of adenomas larger than 1 cm and in 47 percent of carcinomas. However, ras mutations were found in only 9 percent of adenomas under 1 cm in size.",
            "Individuals with a Ki-ras mutated adenoma were more likely to overexpress p53 (OR, 2.46; 95% CI, 1.36-4.46), and 94.8% of adenomas with both alterations were classified as advanced (P <or= 0.0001)."
        ]
    },
    "65f1eb84c4010b4d78000008":
    {
        "question": "What is prurigo nodularis?",
        "llm_evidence": "Prurigo nodularis is a chronic skin condition characterized by the presence of intensely itchy nodules (bumps) on the skin. These lesions typically arise in response to repetitive scratching or rubbing, often due to underlying conditions like atopic dermatitis or chronic kidney disease. The nodules can be quite painful, leading to a cycle of itching and further skin damage. Histologically, the condition is marked by thickened skin with an inflammatory infiltrate. Treatment options include topical corticosteroids, antihistamines for itch relief, and, in some cases, systemic therapies such as immunosuppressants or phototherapy. Effective management often requires addressing the underlying triggers to reduce itch and prevent lesion formation.",
        "paper_evidence":
        [
            "Prurigo nodularis (PN) is a chronic neuroimmune skin disease characterized by bilaterally distributed pruritic hyperkeratotic nodules on extremities and trunk. N",
            "Prurigo nodularis (PN) is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules. I",
            "Prurigo nodularis (PN) is an extremely pruritic, chronic inflammatory skin disease.",
            "BACKGROUND: Prurigo nodularis (PN), or nodular prurigo, is a chronic, debilitating, inflammatory skin disease.",
            "Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules.",
            "Prurigo nodularis is a chronic skin condition characterized by severely pruritic nodules that cause a profound negative impact on quality of life.",
            "Prurigo nodularis (PN), or chronic prurigo, is a distinct disease characterized by the presence of chronic pruritus and multiple localized or generalized pruriginous lesions.",
            "Prurigo nodularis is a chronic dermatologic condition involving the development of multiple cutaneous nodules in the setting of intractable pruritus.",
            "PN evolves along with chronic pruritus in the context of diverse dermatological, systemic, neurological or psychiatric conditions.",
            "Prurigo nodularis is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology.",
            "BACKGROUND: Prurigo nodularis (PN) is a chronic inflammatory skin disease with nodular itch",
            "INTRODUCTION: Prurigo nodularis is an unusual disorder of unknown aetiology, which is notoriously resistant to therapy, and is characterized by extremely pruritic nodules with well-defined clinical symptoms and histopatholog",
            "Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by severely itchy and often painful bumps on the arms, legs, and trunk",
            "Prurigo nodularis (PN) is a chronic inflammatory skin condition that has a significant unmet needs for effective treatment options.",
            "Prurigo nodularis of Hyde is an unusual disorder of unknown aetiology characterized by extremely pruritic nodules with well defined clinical and histopathological aspects.",
            "Prurigo nodularis is a chronic inflammatory skin disease consisting of severely pruritic nodules that can be very debilitating for patients. The basis of this skin condition is immunological dysregulation and neural amplification, driven by T-lymphocytes, mast cells, eosinophilic granulocytes, macrophages, and cytokines mediating itchy processes.",
            "BACKGROUND: Prurigo nodularis (PN), or nodular prurigo, is a chronic, debilitating, inflammatory skin disease. It can be very difficult to manage, and represents a challenge for th",
            "Prurigo nodularis is a chronic condition characterized by a papulonodular pruriginous eruption of unknown aetiology. This condition is a difficult disease to treat and causes frustration to both the patient and the treating doctor.",
            "Prurigo nodularis (PN) is an understudied, chronic inflammatory skin disease that disproportionately affects African Americans and presents with intensely pruritic nodules of unknown etiology.",
            "Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. ",
            "INTRODUCTION: Prurigo nodularis (PN) or chronic prurigo of nodular type (CNPG) is a subtype of chronic prurigo with severe pruritus and neuroimmune underlying pathophysiology occurring in a plethora of dermatological, systemic, neurologic, and psychiatric conditions.AREAS COVERED: We review the increasing repertoire of biologics in the treatment of CNPG focusing on those targeting interleukins 4, 13, 31, oncostatin M and IgE.",
            "Prurigo nodularis (PN) is a chronic skin disease that manifests with severe itchy, firm, hyperkeratotic nodules distributed on the trunk and the extremities symmetrically.",
            "Characterized by the clinical presentation of individual to multiple symmetrically distributed, hyperkeratotic, and intensely itchy papules and nodules, prurigo nodularis (PN) is a rare disease that emerges in patients with chronic pruritus due to continuous scratching over a long period of time.",
            "We report a case of prurigo nodularis of Hyde as the presenting sign of Hodgkin's disease in a 22-year-old girl.",
            "Prurigo nodularis is the most severe degree of chronic prurigo.",
            "INTRODUCTION: Prurigo nodularis (PN) is a chronic inflammatory skin condition that presents with pruritus and hyperkera",
            "BACKGROUND: Prurigo nodularis (PN) is a chronic dermatologic condition manifesting as multiple papulonodular lesions occurring on the background of inten",
            "Prurigo nodularis (PN) is an understudied inflammatory skin disease characterized by pruritic, hyperkeratotic nodules.",
            "Prurigo nodularis is an intensely pruritic dermatosis characterized by lichenified and excoriated papules and nodules.",
            "Prurigo nodularis (PN) is a chronic condition characterized by the presence of nodular lesions accompanied by intense pruritus.",
            "Prurigo nodularis is an uncommon pediatric cutaneous disorder that is associated with intense pruritus.",
            "Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules that favor the extensor surfaces of the extremities and the trunk.",
            "Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized oftentimes by symmetrically distributed, severely pruritic nodules.",
            "Prurigo nodularis is a chronic condition characterized by intensely pruritic, lichenified, or excoriated papules and nodules of unknown etiology. It is assumed to represent a cutaneous reaction pattern to repeated scrubbing or scratching caused by pruritus.",
            "BACKGROUND: Prurigo nodularis is a debilitating skin condition that is classified as rare by the Genetic and Rare Diseases Information Center (GARD) and the National Organization for Rare Dise",
            "Chronic prurigo is a debilitating skin disease characterized by the presence of chronic pruritus and scratching-related pruriginous lesion"
        ]
    },
    "65f8447fc4010b4d78000043":
    {
        "question": "What is the main cause of spillover events?",
        "llm_evidence": "Spillover events primarily occur due to the transmission of pathogens from wildlife to humans, often facilitated by ecological changes and human activities. Key insights into the main causes include:\n\n1. **Habitat Alteration**: Deforestation, urbanization, and agriculture encroach on natural habitats, increasing human-wildlife interactions which heightens the risk of zoonotic diseases spilling over to people.\n\n2. **Globalization and Trade**: The movement of goods and people across borders can introduce novel pathogens to new environments. The wildlife trade, in particular, is a significant vector for the transfer of diseases.\n\n3. **Climate Change**: Alterations in climate patterns can shift wildlife populations and their habitats, bringing them into closer contact with human communities. Warmer temperatures may also expand the range of vectors like mosquitoes that transmit diseases.\n\n4. **Biodiversity Loss**: Loss of biodiversity can disrupt ecosystems, leading to increased contact between humans and wildlife, and potentially allowing more infectious agents to transfer to humans.\n\nThese factors collectively contribute to the increasing frequency and intensity of spillover events, highlighting the interconnectedness of human health, wildlife health, and ecosystem health.",
        "paper_evidence":
        [
            "the extent of land use for food production and the agricultural practices employed that shape four archetypal food systems, each with a distinct risk profile with respect to zoonotic spillovers and differing dimensions of sustainability",
            "Pathogen spillover from wildlife to domestic animals and humans",
            "the highest spillover risk occurs at intermediate levels of habitat loss",
            "We conclude that that the processes of domestication, horizontal gene transfer and microbial succession might be important mechanisms behind the many spillover events driven and accelerated by climate change, biodiversity loss and globalization.",
            "Human land modification is a known driver of animal-to-human transmission of infectious agents (zoonotic spillover).",
            "Spillover events are associated to varying degrees with high habitat fragmentation, biodiversity loss through land use change, high livestock densities, agricultural inputs, and wildlife hunting-all facets of food systems.",
            "The emerging infections that lead to substantive epidemics or pandemics are typically zoonoses that cross species boundaries at vulnerable points of animal-human interface. The sharing of space between wildlife and humans, and their domesticated animals, has dramatically increased in recent decades and is a key driver of pathogen spillover."
        ]
    },
    "644108b157b1c7a315000053":
    {
        "question": "What are the most commonly used pain scales for the measurement of pain in ICU?",
        "llm_evidence": "In the Intensive Care Unit (ICU), reliable measurement of pain is crucial for effective treatment, and several pain scales have been validated for use in critically ill patients. The most commonly used pain scales include:\n\n1. **Numeric Rating Scale (NRS)**: Patients rate their pain on a scale from 0 (no pain) to 10 (worst possible pain). This scale is simple and effective for patients who are alert and able to communicate their pain levels.\n\n2. **Visual Analog Scale (VAS)**: This involves a line, typically 10 cm long, where patients mark their pain intensity. It provides a visual representation of pain and is useful for patients who may have difficulty with numeric ratings.\n\n3. **Faces Pain Scale-Revised (FPS-R)**: Often used for non-verbal patients or those with communication difficulties, this scale uses facial expressions to indicate levels of pain, allowing caregivers to assess discomfort more intuitively.\n\n4. **Behavioral Pain Scale (BPS)**: Designed for patients who are sedated or unable to communicate verbally, BPS assesses pain through specific behaviors such as facial expressions, arm movements, and compliance with the ventilator.\n\n5. **Critical-Care Pain Observation Tool (CPOT)**: This scale scores patients across four categories (facial expressions, body movements, muscle tension, and compliance with ventilation), making it suitable for assessing pain in non-communicative patients, particularly those under sedation or with cognitive impairments.\n\nThese scales are essential for accurately identifying and managing pain in ICU patients, promoting comfort, and enhancing recovery outcomes.",
        "paper_evidence":
        [
            "This study aims to compare the diagnostic value of the critical-care pain observation tool (CPOT) and the behavioral pain scale (BPS) for pain assessment among unconscious patients.",
            " CPOT and BPS have acceptable discriminant validity in differentiating nonnociceptive and nociceptive procedural pain although the effect size of CPOT is larger than that of BPS. Although both instruments have low reliability, the reliability of BPS is better.",
            " To determine the concordance of Zurich Observation Pain Assessment (ZOPA) with the behavioural Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT) to detect pain in nonverbal ICU patients.",
            "ZOPA is concordant with the BPS and the CPOT to indicate pain but detects pain earlier due to the low threshold value.",
            "Based on available evidence and investigations, CPOT and BPS tools have good validity and reliability to be used in pain assessment in Nonverbal Intubated Critically Adult Patients after Open-Heart Surgery. ",
            "Current research shows that the two tools best validated for patients unable to self-report pain are the Behavioral Pain Scale (BPS) and the Critical Care Pain Observation Tool (CPOT). ",
            "In critically ill mechanically ventilated patients, both CPOT and BPS can be used for assessment of pain intensity with different sensitivity and specificity. ",
            "Critically ill patients in ICU experience a different range of pain in routine daily care. BPS and CPOT scales could be used successfully for monitoring of pain in this group of patients."
        ]
    },
    "65d373e21930410b13000049":
    {
        "question": "What medication were tested in the PEMMELA trial?",
        "llm_evidence": "The PEMMELA trial investigated the efficacy of pembrolizumab, an immune checkpoint inhibitor, in patients with advanced melanoma. This trial specifically focused on the combination of pembrolizumab and talimogene laherparepvec (T-VEC), an oncolytic virus therapy. The aim was to evaluate the safety and effectiveness of this combination therapy in enhancing the immune response against melanoma, compared to pembrolizumab alone. Key insights from the trial indicated that combining these therapies could potentially improve response rates and overall survival in patients with unresectable melanoma.",
        "paper_evidence":
        [
            "Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study."
        ]
    },
    "65f77328c4010b4d78000023":
    {
        "question": "What is the pathophysiological mechanism by which the microbiota produce malignant lesions in colonic mucosa?",
        "llm_evidence": "The pathophysiological mechanism by which microbiota contribute to the development of malignant lesions in the colonic mucosa involves several key processes:\n\n1. **Dysbiosis**: An imbalance in the gut microbiota, known as dysbiosis, can lead to an overgrowth of pathogenic bacteria and a reduction in beneficial ones. This imbalance is associated with chronic inflammation.\n\n2. **Inflammation**: Certain microbiota, such as those that produce lipopolysaccharides (LPS), can provoke an inflammatory response, resulting in the production of pro-inflammatory cytokines. Chronic inflammation is a known risk factor for colorectal cancer, as it can lead to DNA damage and promote tumorigenesis.\n\n3. **Metabolite Production**: The gut microbiota produce various metabolites, including short-chain fatty acids (SCFAs) and potentially harmful substances like secondary bile acids. While SCFAs can be protective against cancer, an overabundance of secondary bile acids can promote tumor growth.\n\n4. **Carcinogenic Compounds**: Certain bacterial species can generate carcinogenic compounds, such as N-nitroso compounds, through metabolic processes. These compounds can directly damage the DNA of colonic epithelial cells, leading to mutations and malignant transformation.\n\n5. **Immune Modulation**: The microbiota can influence the host's immune system, either enhancing anti-tumor immunity or facilitating tumor progression through immune evasion. Altered immune responses can allow malignant lesions to develop and proliferate.\n\n6. **Epithelial Barrier Dysfunction**: Dysbiosis and resultant inflammation can lead to damage of the epithelial barrier, allowing microbial translocation and further immune stimulation, creating a cycle that promotes malignancy.\n\nTogether, these mechanisms illustrate how gut microbiota play a critical role in the complex interplay between inflammation, immune response, and tissue damage, ultimately contributing to the development of malignant lesions in the colonic mucosa.",
        "paper_evidence":
        [
            "Perturbations of the colonic microbiota can contribute to the initiation and progression of colorectal cancer, leading to an increase in pathogenic bacteria at the expense of protective bacteria. This can contribute to disease through increasing carcinogenic metabolite/toxin production, inducing inflammation, and activating oncogenic signaling. ",
            "Most pathogenic bacteria have heightened iron acquisition mechanisms and therefore tend to outcompete protective bacteria for free iron",
            "alterations in communication between the mucosal immune system and gut microbial communities have been implicated as the core defect that leads to chronic intestinal inflammation and cancer development",
            "multiple proposed pathogenic microorganisms including sulfidogenic bacteria such as Bilophila wadsworthia, as well as Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis, and Clostridium septicum.",
            "We focus on some of the mechanisms by which the colonic microbiota drives the progression towards colorectal malignancy including generation of reactive metabolites and carcinogens, alterations in host carbohydrate expression and induction of chronic mucosal inflammation.",
            "This review evaluates the pathophysiology of how a diet-associated shift in gut microbiota, so-called the microbial sulfur diet, provokes injuries and inflammation to the colonic mucosa and contributes to the development of CRC.",
            "While certain members of the colonic microbiota have been shown to promote the host's health there are also numerous studies that have implicated other members of the colonic microbiota in the development of colorectal cancer, a prominent malignancy within the western world.",
            "We believe that using probiotics or altering the gut microbiota will likely be effective tools in the fight against CRC treatment.PURPOSE: In this review, we revisited the association between gut microbiota and colorectal cancer whether cause or effect.",
            "In this review we consider the evidence for the role of bacteria in colorectal cancer from molecular and animal model studies.",
            "The various factors which influence gut microbiome in patients with CRC and possible mechanism in relation with development of CRC.CONCLUSION: The clinical significance of the intestinal microbiota may aid in the prevention and management of CRC.",
            "Gut microbiota drive the development of inflammation within the colon and such inflammation is implicated in colonic neoplastic development.",
            "Bacterial sulfur metabolism is recognized as a critical mechanism of EOCRC pathogenesis.",
            "nting CRC. Hydrogen sulfide, produced by autochthonous sulfidogenic bacteria, triggers proinflammatory pathways and hyperproliferation, and is",
            "microbial encroachment towards the colonic epithelium may promote inflammation and oxidative stress and even translocation of species across the colonic lumen.",
            "Chronic consumption of excess ethanol increases the risk of colorectal cancer. The pathogenesis of ethanol-related colorectal cancer (ER-CRC) is thought to be partly mediated by gut microbes. Specifically, bacteria in the colon and rectum convert ethanol to acetaldehyde (AcH), which is carcinogenic.",
            "Commensal gut microflora and dietary fiber protect against colonic inflammation and colon cancer through unknown targets. Butyrate, a bacterial product from fermentation of dietary fiber in the colon, has been implicated in this process.",
            "Sequencing studies have revealed microbial compositional and ecological changes in patients with CRC, whereas functional studies in animal models have pinpointed the roles of several bacteria in colorectal carcinogenesis, including Fusobacterium nucleatum and certain strains of Escherichia coli and Bacteroides fragilis.",
            "Microbiota, IL10KO, and their combination altered 0.4%, 0.4%, and 4% of CpG island methylation, respectively. These are comparable to what is seen in colon cancer.",
            "Further understanding the precise mechanism(s) of the oral-gut microbial axis in PD, IBD, and colorectal cancer pathogenesis will be pivotal in diagnosis, prognosis, and future treatment.",
            "Recent studies suggest that dysbiosis of the oral microbiota can alter the microbial composition in relative abundance or diversity of the distal gut, leading to the progression of digestive carcinogenesis.",
            "As such, oral microbiota dysbiosis involving specific bacteria, including Fusobacterium nucleatum and Porphyromonas gingivalis, can ultimately lead to gut malignancies.",
            "Specific members of the colonic microbiota may promote IL17A production and IL17A-producing cell functions in the colonic mucosa to promote carcinogenesis.",
            "To learn about gut microbiota signatures in tissues of the colorectal polyp and normal colorectal mucosa, and faeces.",
            "The colonic epithelium is exposed to a mixture of compounds through diet, among which some are procarcinogens, whereas others have a protective effect. Therefore, the net impact of these compounds on human health depends on the overall balance between all factors involved. Strong scientific evidence has demonstrated the relationship between nitrosamines (NA), heterocyclic amines (HCAs), and polycyclic aromatic hydrocarbons (PAHs), which are the major genotoxins derived from cooking and food processing, and cancer. The mechanisms of the relationship between dietary toxic xenobiotics and cancer risk are not yet well understood, but it has been suggested that differences in dietary habits affect the colonic environment by increasing or decreasing the exposure to mutagens directly and indirectly through changes in the composition and activity of the gut microbiota. Several changes in the proportions of specific microbial groups have been proposed as risk factors for the development of neoplastic lesions and the enrichment of enterotoxigenic microbial strains in stool. In addition, changes in the gut microbiota composition and activity promoted by diet may modify the faecal genotoxicity/cytotoxicity, which can be associated with a higher or lower risk of developing cancer. Therefore, the interaction between dietary components and intestinal bacteria may be a modifiable factor for the development of colorectal cancer in humans and deserves more attention in the near future.",
            "Here, we report that non-pathogenic microbiota accelerate age-related methylation drift in the colon when compared with germ-free mice. DNA methylation analyses showed that microbiota and IL10KO were associated with changes in 5% and 4.1% of CpG sites, while mice with both factors had 18% alterations. Microbiota, IL10KO, and their combination altered 0.4%, 0.4%, and 4% of CpG island methylation, respectively. These are comparable to what is seen in colon cancer. Ageing changes were accelerated in the IL10KO mice with microbiota, and the affected genes were more likely to be altered in colon cancer. Thus, the microbiota affect DNA methylation of the colon in patterns reminiscent of what is observed in ageing and colorectal cancer."
        ]
    },
    "65ef83acdffffb9b6b000002":
    {
        "question": "is carotenodermia caused by an excess of lycopene in the diet?",
        "llm_evidence": "Carotenodermia is a condition characterized by a yellowing of the skin, primarily caused by an excess intake of carotenoids, particularly beta-carotene, found in fruits and vegetables such as carrots and sweet potatoes. While lycopene, a carotenoid present in tomatoes and other red fruits, is known for its antioxidant properties, it is not typically associated with causing carotenodermia. The condition arises when there is an overload of certain carotenoids that the body cannot adequately metabolize. Lycopene does not convert to vitamin A in the body like beta-carotene does and has different metabolic pathways. Evidence suggests that while high doses of beta-carotene can lead to carotenodermia, lycopene does not have the same effect, making carotenodermia unrelated to excess lycopene intake.",
        "paper_evidence":
        [
            "Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene. ",
            "We evaluated the relation between plasma levels of carotenoids and carotenodermia in 30 men receiving carotenoid supplementation for 42 d",
            "Four cases of carotenodermia are presented, secondary to marked ingestion of carotenoid-rich vegetables.",
            "This literature review revealed that in carotenodermia associated with high β-carotene intake the discoloration tends to be widespread, mainly in thick areas of the skin (e.g., the palm of the hand), and can last from 14 days to 4.5 years.",
            "Here, I review approximately 100 previous cases of carotenodermia in humans due to high β-carotene intake.",
            "Carotenodermia is a yellow to orange skin discoloration due to epidermal deposition of carotene.",
            "These observations may be useful to investigators planning clinical trials with beta-carotene and to clinicians assessing the significance of carotenodermia in men taking beta-carotene supplements or following diets high in carotenoid-containing foods.",
            "Carotenodermia may arise from excessive dietary intake of carotene containing foods.",
            "Carotenodermia may arise from excessive dietary intake of carotene containing foods. We reported a 22-year-old woman",
            "We evaluated the relation between plasma levels of carotenoids and carotenodermia in 30 men receiving carotenoid supplementation for 42 d. Five subjects each were randomly assigned to one of six treatment groups: 30 mg purified beta-carotene supplement, 12 mg beta-carotene supplement, 272 g cooked carrots, 300 g cooked broccoli, 180 g tomato juice, and placebo. Definite carotenodermia was observed only in the five subjects who took",
            "To study the effects of carotenoids on the initiation of liver carcinogenesis by aflatoxin B1 (AFB1)",
            "The results of an oral loading with beta-carotene (1 mg/kg) provide indirect evidence that the girl's carotenemia is due to a probably genetic defect in the metabolism of carotenoids.",
            "Carotenemia is characterized by an abnormal yellowish orange pigmentation of the skin, most prominently seen on the palms and soles. Although it is associated with several disease such as diabetes, hypothyroidism and anorexia nervosa, it is caused by excessive intake of carotene-rich food such as oranges and carrots in most cases.",
            "Carotenemia is a common benign pediatric condition of yellowing of the skin and elevated beta-carotene levels in the blood. The condition is usually caused by excessive beta-carotene intake but is also more rarely associated with a few serious metabolic disorders.",
            "We describe a 3-year-old girl with long-standing yellow discoloration of her skin and a 3-fold increase in the plasma carotenoid concentration compared to normal, but no history of excessive carotene intake or familial carotenemia."
        ]
    },
    "65f85231c4010b4d7800004d":
    {
        "question": "Which are the two main active ingredients of the standard PrEP (Pre-Exposure Prophylaxis)?",
        "llm_evidence": "The two main active ingredients of standard PrEP (Pre-Exposure Prophylaxis) are tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). TDF is a nucleotide reverse transcriptase inhibitor that helps prevent the replication of HIV by interfering with its ability to utilize the host's cellular mechanisms. FTC, also a reverse transcriptase inhibitor, works synergistically with TDF to enhance protection against the virus. Together, these medications have been shown to significantly reduce the risk of HIV infection in high-risk populations when taken consistently as prescribed.",
        "paper_evidence":
        [
            "Pre-exposure prophylaxis (PrEP) against HIV infection with tenofovir/emtricitabine",
            "emtricitabine/tenofovir",
            "PrEP with daily oral tenofovir/emtricitabine combination is the recommended PrEP regimen, and TDF alone can be considered as an alternative regimen for IDUs and heterosexually active adults.",
            "Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO as a strategy to reduce HIV incidence.",
            "Tenofovir disoproxil fumarate combined with emtricitabine is a highly effective oral pre-exposure prophylaxis (PrEP) agent for preventing the acquisition of HIV.",
            "A novel distribution pathway of tenofovir-disoproxil fumarate and emtricitabine PrEP was implemented, which reduced monthly PrEP costs by 16-fold in Germany.",
            "INTRODUCTION: Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors approved as pre-exposure prophylaxis (PrEP) against human immunodeficienc",
            "A pivotal component in the current drug combination regimens for the treatment of AIDS as well as the ongoing PrEP trials is tenofovir disoproxil fumarate (TDF, Viread®) and its combination with emtricitabine (FTC). The combination of TDF with FTC has been marketed as Truvada",
            "The antiretroviral combination of emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) was approved by the U.S. Food and Drug Administration for use as pre-exposure prophylaxis (PrEP) in individuals at high risk for acquiring human immunodeficiency virus (HIV) in July 2012.",
            "WHO guidelines recommend daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) of HIV in people at high risk of HIV infection.",
            "The US Food and Drug Administration (FDA) approved oral daily tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis of human immunodeficiency virus (HIV) infection in 2012 on the basis of two randomized controlled trials (RCTs), one in men who have sex with men (MSM) and another in HIV serodiscordant heterosexual couples.",
            "Antiretroviral pre-exposure prophylaxis (PrEP) for the prevention of HIV infection was demonstrated to be efficacious and safe earlier this decade from pivotal studies using oral emtricitabine-tenofovir disoproxil fumarate.",
            "BACKGROUND: Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective against acquisition of H",
            "INTRODUCTION: Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors approved as pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV).",
            "BACKGROUND: Antiretroviral pre-exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious for HIV-1 prevention.",
            "Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.",
            "Pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) will soon be available in the Netherlands.",
            "HIV pre-exposure prophylaxis (PrEP) with daily coformulated emtricitabine and tenofovir disoproxil fumarate is a promising biomedical HIV prevention modality; however, it has not yet been shown to be efficacious in the transgender population due to data limitations.",
            "Pre-exposure prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate and emtricitabine administered orally daily is effective in preventing human immunodeficiency virus (HIV) acquisition in both men and women with sufficient adherence; however, the adherence-efficacy relationship in cisgender women has not been well established.",
            "Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is currently the only medication recommended for pre-exposure prophylaxis (PrEP) by the Centers for Disease Control and Prevention (CDC) in people at high risk for HIV acquisition.",
            "Two PrEP medications are currently approved: emtricitabine/tenofovir disoproxil fumarate (Truvada",
            "d event-driven HIV pre-exposure prophylaxis (PrEP) with oral tenofovir-emtricitabine is highly effective to prevent HIV in men who have sex with men (MSM). PrEP care gen",
            "Background: Daily pre-exposure prophylaxis (PrEP) regimen of tenofovir/emtricitabine",
            "Here, we evaluated two drugs that are preferentially used for PrEP: tenofovir (TFV) disoproxil fumarate (TDF) and emtricitabine (FTC).",
            "Here, we report primary results from a blinded phase 3 study evaluating the efficacy and safety of pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV prevention.METHODS: This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in regions of Europe and North America, where there is a high incidence of HIV or prevalence of people living with HIV, or both.",
            "Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission."
        ]
    },
    "6451007857b1c7a315000093":
    {
        "question": "What is the cause of Leigh syndrome?",
        "llm_evidence": "Leigh syndrome, a severe neurodegenerative disorder, is primarily caused by genetic mutations affecting mitochondrial function. These mutations can occur in nuclear DNA or mitochondrial DNA, leading to defects in oxidative phosphorylation, which is critical for energy production in cells. Key insights include:\n\n1. **Genetic Mutations**: Over 75 genes have been associated with Leigh syndrome, including those involved in ATP synthesis and mitochondrial metabolism, such as the SURF1, LRPPRC, and NDUFS1 genes.\n\n2. **Mitochondrial Dysfunction**: The disorder is characterized by impaired mitochondrial function, resulting in insufficient energy supply to the brain and other vital organs, leading to neurodevelopmental delays, seizures, and other profound neurological symptoms.\n\n3. **Inheritance Patterns**: Leigh syndrome can exhibit various inheritance patterns, including autosomal recessive, autosomal dominant, and maternal inheritance, reflecting its heterogeneous genetic basis.\n\n4. **Clinical Presentation**: Symptoms typically emerge in infancy or early childhood and may include developmental regression, hypotonia, ataxia, and lactic acidosis, indicating a broader metabolic dysfunction.\n\nUnderstanding these factors is essential for diagnosing and managing Leigh syndrome, as well as for potential therapeutic interventions targeting mitochondrial health.",
        "paper_evidence":
        [
            "It may result from several defects of mitochondrial enzyme complexes, including pyruvate dehydrogenase complex, and respiratory chain complexes I, II, III, IV, V.",
            "Leigh syndrome may result from different enzyme defects, most notably pyruvate dehydrogenase complex deficiency, cytochrome c oxidase deficiency, complex I deficiency, and complex V deficiency associated with the recently described NARP point mutation.",
            "Leigh syndrome is a subacute necrotising encephalomyopathy proven by post-mortem analysis of brain tissue showing spongiform lesions with vacuolation of the neuropil followed by demyelination, gliosis and capillary proliferation caused by mutations in one of over 75 different genes, including nuclear- and mitochondrial-encoded genes, most of which are associated with mitochondrial respiratory chain function.",
            "Deficiency of pyruvate dehydrogenase complex E1 alpha subunit (PDHA1) is the common cause of Leigh syndrome.",
            "Subacute necrotizing encephalomyelopathy (Leigh's syndrome) is a rare neurodegenerative disease in the adult. The precise metabolic defect is unknown, but abnormalities of a mitochondrial enzyme system related to cytochrome-c oxidase or pyruvate dehydrogenase are described.",
            "Leigh syndrome is the most common clinical presentation of pediatric mitochondrial disease, typically appearing in the first few years of life, and involving severe multisystem pathologies.",
            "A new patient with Leigh's syndrome (subacute necrotizing encephalomyelopathy due to pyruvate dehydrogenase complex deficiency) is presented.",
            "We report a novel m.4296G>A variant in the mitochondrial tRNA isoleucine gene in a child with Leigh syndrome, mitochondrial proliferation, lactic acidosis, and abnormal respiratory chain enzymology.",
            "Leigh syndrome is the most common pediatric presentation of mitochondrial disease. This neurodegenerative disorder is genetically heterogeneous, and to date pathogenic mutations in >75 genes have been identified, encoded by 2 genomes (mitochondrial and nuclear).",
            "Leigh syndrome or subacute necrotizing encephalomyelopathy is a rare, rapidly progressive neurodegenerative disorder. In general, symptoms such as shortness of breath and decreased cardiac function usually occur within 1 year of life. It is a serious disease with a mortality rate of 75% in 2-3 years. The cause of Leigh syndrome is DNA mutation. Approximately 75% of patients have nuclear DNA mutations while 25% have mitochondrial DNA mutations.",
            "Leigh disease presenting in utero due to a novel missense mutation in the mitochondrial DNA-ND3.",
            "It can be caused by more than 75 different gene mutations, of nuclear and mitochondrial origin, involving all respiratory chain complexes, with less than 25% of Leigh syndrome having mitochondrial DNA mutations.",
            "The most common mitochondrial disorder in children is Leigh syndrome, which is a progressive and genetically heterogeneous neurodegenerative disorder caused by mutations in nuclear genes or mitochondrial DNA (mtDNA).",
            "Leigh syndrome (LS) is a neurogenetic disorder of children caused by mutations in at least 75 genes which impair mitochondrial bioenergetics."
        ]
    },
    "65d129621930410b1300002e":
    {
        "question": "What is Primary Diffuse Meningeal Melanomatosis?",
        "llm_evidence": "Primary Diffuse Meningeal Melanomatosis (PDMM) is a rare and aggressive form of melanoma that specifically affects the meninges, which are the protective layers surrounding the brain and spinal cord. Characterized by the widespread dissemination of malignant melanocytic cells in the leptomeninges, PDMM can arise without prior cutaneous melanoma or may occur as a progression from existing melanoma. \n\nKey insights include:\n\n1. **Clinical Presentation**: Patients may exhibit symptoms such as headaches, neurological deficits, seizures, and signs of increased intracranial pressure due to the meningeal involvement.\n\n2. **Diagnosis**: Diagnosis is typically achieved through imaging studies like MRI, which can reveal characteristic meningeal enhancement, and by cerebrospinal fluid (CSF) analysis, which often shows the presence of malignant cells.\n\n3. **Prognosis and Treatment**: The prognosis for PDMM is generally poor, with a median survival of less than one year. Treatment options are limited and typically involve palliative care, as traditional therapies like surgery and radiation may not be effective due to the diffuse nature of the disease. Systemic therapies for metastatic melanoma may provide some benefits in selected cases.\n\n4. **Understanding the Disease**: PDMM underscores the importance of recognizing atypical presentations of melanoma and the potential for metastatic spread to the central nervous system, highlighting the need for vigilance in monitoring patients with a history of melanoma.\n\nOverall, PDMM represents a challenging subtype of melanoma, requiring a multidisciplinary approach for management due to its complex nature and aggressive behavior.",
        "paper_evidence":
        [
            "In case of diffusely invasive lesions of the pia mater with a tumor of melanocytic origin (without signs of extracranial metastases), the tumors are classified as primary diffuse meningeal melanomatosis (PDMM). ",
            "BACKGROUND: Primary meningeal melanomatosis is a rare leptomeningeal tumor, and the diagnosis is challenging due to nonspecific clinical symptoms and radiologic findings.",
            "Primary diffuse meningeal melanomatosis - a rare form of meningeal melanoma: case report.",
            "BACKGROUND: Meningeal melanomatosis is a rare type of central nervous system neoplasm (with incidence ranging between 3 and 5%) that develops in the course of malignant melanoma. ",
            "Primary diffuse meningeal melanomatosis can clinically mimic a wide variety of other conditions, including lymphoma, leukemia, neurosarcoidosis, metastatic carcinoma, acute disseminated encephalomyelitis, subacute meningitis, viral encephalitis, and idiopathic hypertrophic cranial pachymeningitis. ",
            "We report a case of primary diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma of the CNS, in a 68-year-old woman. ",
            "Melanoma malignum constitutes only 0.1% of central nervous system neoplasms. It can occur either as a solid tumour or as a diffuse meningeal melanomatosis. ",
            "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system.",
            "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system",
            "Primary diffuse leptomeningeal melanomatosis is an extremely rare variant of primary melanoma of the central nervous system",
            "Primary diffuse leptomeningeal melanomatosis (PDLM) is a rare disease that affects melanocytes in the leptomeninges",
            "Primary melanocytic neoplasms of the central nervous system (CNS) are rare lesions arising from melanocytes of the leptomeninges. They include diffuse leptomeningeal melanocytosis or melanomatosis, melanocytoma and primary malignant melanoma. We have reviewed the English literature regarding these lesions, which ",
            "BACKGROUND: Primary diffuse leptomeningeal melanomatosis (PDLM) is an extremely rare pathologic condition that can mimic several other neurologic disease states.METHODS: We report a rare case of PDLM without evidence of a primary focus.",
            "In case of diffusely invasive lesions of the pia mater with a tumor of melanocytic origin (without signs of extracranial metastases), the tumors are classified as primary diffuse meningeal melanomatosis (PDMM).",
            "INTRODUCTION: Primary diffuse leptomeningeal melanomatosis is an extremely rare variant of primary melanoma of the central nervous system.",
            "We report a case of primary diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma of the CNS, in a 68-year-old woman.",
            "BACKGROUND: Primary meningeal melanomatosis is a rare leptomeningeal tumor, and the diagnosis is challenging due to nonspecific clinical symptoms and radiolog",
            "Primary diffuse meningeal melanomatosis can clinically mimic a wide variety of other conditions, including lymphoma, leukemia, neurosarcoidosis, metastatic carcinoma, acute disseminated encephalomyelitis, subacute meningitis, viral encephalitis, and idiopathic hypertrophic cranial pachymeningitis. We report on a young patient with primary diffuse meningeal melanomatosis who presented with papilledema, flaccid paraparesis, and cognitive impairment. The importance of imaging of the whole central nervous system, cerebrospinal fluid analysis, and pathohistological examination is emphasized in making the appropriate diagnosis.",
            "Primary meningeal melanomatosis is a rare, aggressive variant of primary malignant melanoma of the central nervous system, which arises from melanocytes within the leptomeninges and carries a poor prognosis.",
            "Primary meningeal melanomatosis is a rare, aggressive variant of primary malignant melanoma of the central nervous system, which arises from melanocytes within the leptomeninges and carries a poor prognosis. ",
            "Melanoma malignum constitutes only 0.1% of central nervous system neoplasms. It can occur either as a solid tumour or as a diffuse meningeal melanomatosis. A case of the latter form of central nervous system melanoma is presented in a 44-year-old man, suffering from headaches, cerebrospinal fluid protein elevation, optic disc oedema, hydrocephalus, seizures, cranial nerves and multilevel spinal root damage. Above mentioned neurological manifestations gradually increased within 18 months after onset of first symptoms of the disease (headache). The clinical course in our patient suggested diffuse leptomeningeal involvement. Despite the use of detailed diagnostic procedures, the correct diagnosis of primary diffuse meningeal melanomatosis was established at postmortem examination.",
            "A case of primary leptomeningeal melanomatosis without cutaneous lesions is reported. The clinical findings for a six months period were: intracranial hypertension syndrome, progressive cranial polineuropathy and a spinal involvement in a six years old child. CT brain scan showed enlarged subarachnoid spaces without contrast enhancement. MRI brain scan evidenced furthermore a focal lesion in right talamus. MRI spinal scan was normal. Examination of CSF showed elevated protein and reduced glucose concentrations as well as mild pleocytosis. Serologies and cultures investigating viral, bacterial, mycobacterial, fungal or parasitic infections resulted negative. CSF cytologic examination failed to show malignant cells. Postmortem diagnosis after neuropathological examination was made. This is an uncommon case of primary leptomeningeal melanomatosis, presenting the difficulty of diagnosis when cutaneous lesions are not present.",
            "We report a case of primary diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma of the CNS, in a 68-year-old woman. The disease mimicked intracranial hypotension syndrome and was diagnosed only at autopsy (CSF cytologic results were negative).",
            "Meningeal melanomatosis is an infrequent tumor originating from the melanocytes in the leptomeninges and one of the recognized primary melanocytic tumors of the central nervous system. ",
            "BACKGROUND: Meningeal melanomatosis is an extra-axial well-encapsulated malignant tumour with diffuse meningeal growth and dark coloration (due to high melanin contents), while meningeal melanocytoma is the focalized ben",
            "These lesions arise from the melanocytes located within leptomeninges and include diffuse melanocytosis and meningeal melanomatosis (seen in neurocutaneous melanosis), melanocytoma, and malignant melanoma.",
            "diffuse meningeal melanomatosis, a rare variant of primary malignant melanoma",
            "INTRODUCTION: Primary diffuse leptomeningeal melanomatosis is an extremely rare variant of primary melanoma of the central nervous system. It is characterized by a variety of nonspecific clinical, radiological, and histopathological features requiring differential diagnosis from a variet",
            "Primary diffuse leptomeningeal melanomatosis is a rare variant of malignant melanoma of the central nervous system, arising from melanocytes of leptomeninges."
        ]
    },
    "65f77236c4010b4d7800001f":
    {
        "question": "Do black race patients have worse survival in colorectal cancer?",
        "llm_evidence": "Research has consistently shown that Black patients with colorectal cancer tend to experience worse survival outcomes compared to their white counterparts. Key insights include:\n\n1. **Disparities in Diagnosis**: Black patients are often diagnosed at later stages of colorectal cancer, which is associated with poorer survival rates. This delay can be attributed to factors such as limited access to healthcare, lack of screening, and differences in symptom recognition.\n\n2. **Biologic Differences**: Studies suggest that there may be biological factors that influence tumor behavior and treatment response in Black patients. These may include genetic variations that affect disease progression and response to therapies.\n\n3. **Socioeconomic Factors**: Disparities related to socioeconomic status, including income, education, and insurance coverage, impact access to timely and effective treatment options, which can affect survival rates.\n\n4. **Healthcare Access**: Black patients may face systemic barriers to healthcare, such as discrimination, which can limit their access to quality treatment and follow-up care, exacerbating survival disparities.\n\n5. **Lifestyle and Comorbidities**: Higher rates of comorbid conditions such as diabetes and hypertension in Black populations can negatively affect overall health, reducing the ability to tolerate potentially life-saving treatments.\n\nThese factors collectively contribute to the observed disparities in survival outcomes for Black patients with colorectal cancer, highlighting the need for targeted interventions to address these inequalities.",
        "paper_evidence":
        [
            "The absolute 5-year survival difference between black and white unmatched patients with CRC was 9.2% (57.3% for black patients vs 66.5% for white patients; P < .0001).",
            "Unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients (hazard ratio [HR] = 1.15; 95% confidence interval (CI) = 1.08 to 1.22; P < .001). Adjustment for patient, tumor, and demographic variables marginally reduced the risk of death (HR = 1.08; 95% CI = 1.01 to 1.15; P = .03). After adjustment for differences in treatment, the increased risk of death for black patients disappeared",
            "In an analysis of data from the National Cancer Database, we found that insurance coverage differences accounted for approximately one half of the disparity in survival rate of black vs white patients with CRC, 18-64 years old;",
            "Compared to Whites, Blacks (AOR: 1.99; 95% CI: 1.64-2.41), Hispanics (AOR: 2.49; 95% CI: 1.94-3.19) and colorectal cancer patients in the other category (AOR: 1.72; 95% CI: 1.35-2.18) were more likely to receive inpatient treatment with chemotherapy/radiotherapy",
            "Propensity-score matching identified 27,640 patients; Black race was associated with worse 5-year overall survival (67.5% vs 70.2%, P = .003) and cancer-specific survival (79.4% vs 82.3%, P < .001).CONCLUSIONS: This US population-based analysis confirms poorer overall survival and cancer-specific survival in Black patients undergoing surgery for nonmetastatic colon cancer despite accounting for trans-sectoral factors that have been implicated in structural racism.",
            "BACKGROUND: Black patients are disproportionally impacted by colorectal cancer, both with respect to incidence and mortality.",
            "Black patients have significantly lower rates of receiving chemotherapy as compared to white patients (61.1% vs 75.37%, p = 0.0018).CONCLUSION: Patients with Stage IV colorectal cancer have worse survival if they are black, older age, and did not receive chemotherapy.",
            "Decreased survival outcomes in Black patients were more pronounced for those who underwent nonstandard treatment, particularly when treating stage III disease (HR: 1.30; 95% CI: 1.19-1.42; P<0.0001).Conclusions: Nonstandard treatment in stage II and III rectal cancer is associated with worse survival compared to standard treatment regimens.",
            "Our objective is to determine if Black compared to White race is associated with worse survival in colon cancer, while accounting for socioeconomic and clinical factors.METHODS: A retrospective analysis was performed of Black or White patients with nonmetastatic colon cancer in the Surveillance, Epidemiology, and End Results cancer registry between 2008 and 2016.",
            "BACKGROUND AND OBJECTIVE: African Americans have worse outcomes in colorectal can",
            "The mortality rate from CRC is highest among African Americans compared to any other racial or ethnic group. Much of the disparity in mortality is likely due to diagnosis at later stages of the disease, which could result from unequal access to screening.",
            " (6.2%) non-Chinese Asians. African-Americans had a greater proportion of metastatic stage at presentation (P < 0.0001) and decreased CRC-specific survival (P < 0.0001 f",
            "r colon and rectal cancer). After adjustment for age, sex, histology, site within the colon, and stage, African-Americans [colon: HR, 1.19; 95% confidence interval (95% CI), 1.14-1.25; rectum: HR, 1.27; 95% CI, 1.17-1.38] had an increased risk of death compared with Caucasians. However, after further adjustment for SES and treatment, the risk of death for African-Americans compared with Caucasians was substantially diminished (colon: HR, 1.08; 95% CI, 1.03-1.13; rectum: H",
            "Black patients experienced lower rates and risk of grade ≥3 fatigue (6.6% vs 13.3%; OR, 0.46; 95% CI, 0.24-0.91) but were equally likely to be treated with a dose reduction (OR, 1.09; 95% CI, 0.72-1.65).CONCLUSIONS: No difference in OS, PFS, or response to therapy was observed between Black patients and White patients in an equal treatment setting of the CALGB/SWOG 80405 randomized controlled trial.LAY SUMMARY: Despite improvements in screening and treatment, studies have demonstrated worse outcomes in Black patients with colorectal cancer.",
            "Among all racial groups in the U.S., African Americans (AA) have the highest incidence of and mortality from colorectal cancer (CRC). Although socioeconomic factors, as the major contributors to racial disparity of CRC, have been widely investigated, there is a dearth of information germane to understanding its biological basis. To better elucidate the clinicopathologic features we extracted demographic, clinical, pathologic and molecular features of 500 consecutive cases of CRC diagnosed at our institution which has an AA-predominant patient population (75% of all patients). We compared data from our AA patients with those of white patients both from our institution and from SEER and the published literature for meaningful comparison. AA patients were more likely to be at an advanced disease stage (25.9% vs. 20.8%, p = 0.041), have low grade tumors (89.2% vs. 77.5%, p<0.001) in cecum (18.7% vs. 16.2%, p<0.001) and <60-years-old than white patients (31.8% vs. 26.3%, p = 0.015). The frequency of KRAS mutation was higher in AA patients than in white patients (56.8% vs. 20.7%, p<0.001). Amongst subtypes of KRAS tested in CRC, codon 12 mutation is more common in AA than white patients (85.2% vs. 68.9%, p = 0.020). Compared with other racial groups, we found AA patients to have worse disease-free survival (HR = 3.682, p = 0.035). Also, AA patients with CRC in distal (sigmoid and rectum) or proximal (cecum) colon have worse overall survival than those with CRC in middle colon (HR = 2.926, p = 0.014), a finding not observed in white patients. In both racial groups, advanced stage, perforation, and hypertension were independent prognostic factors for overall survival (p<0.05). Similarly, low body-mass index at presentation, mucinous adenocarcinoma, lymphovascular invasion, perineural invasion and KRAS mutations were independent factors significantly associated with poor disease-free survival. Collectively, our data provide new insights into the roles of clinicopathologic features, especially anatomic distribution, in predicting outcomes of CRC in AA population.",
            "Survival from CRC in AAs is lower than in Caucasians, and the mean age of CRC development in AAs is younger.",
            "African Americans have the greatest incidence of colorectal cancer than any other racial or ethnic group. This population's survival from colorectal cancer is lower than that in the White population.",
            "Black patients and underinsured patients with colorectal cancer (CRC) present with more advanced disease and experience worse outcomes. The study aim was to evaluate the interaction of health insurance status and race with treatment and survival in metastatic CRC",
            " Chemotherapy use was higher among White compared to Black patients. 3-year mortality rate was higher for Blacks and lower for Hispanics, in comparison with White patients.",
            "In American blacks, there is evidence for a higher prevalence of right-sided colonic tumors and an earlier age of onset of colorectal cancer. In addition, blacks have the highest colon cancer incidence in the United States among ethnic groups and have poorer 5-year survival rates compared with whites.",
            "among patients younger than 50 years old, NHBs experienced significantly worse OS than NHWs (HR: 2.03, 95% CI: 1.30-3.19)",
            ". This study assessed whether non-Hispanic Whites (NHW) and non-Hispanic Blacks (NHB) differ in colon cancer survival in an equal-access health care system and examined whether racial differences varied by demographic and tumor characteristics.",
            "Black patients had significantly lower overall survival compared to White patients, with median overall survival of 1.9 years and 2.5 years respectively. In a multivariate analysis, Black race posed a significant hazard (HR 1.70, CI 1.01-2.90, p=0.0467) for death.",
            ". Black patients had worse long-term survival after colorectal surgery (hazard ratio [HR], 1.21; 95% CI, 1.17 to 1.25; P < .001)",
            " Black patients had lower five-year survival rates when compared with their White counterparts as well as increased rates of being diagnosed with this disease. ",
            "Black patients had a 41% increased risk of presenting at advanced stage per IoD [risk ratio (RR) 1.41, 95% confidence intervals (CI) 1.18, 1.69] and White patients saw a 17% increase (RR 1.17, 95%CI 1.04, 1.31). Black patients were 5% less likely to undergo surgical resection (RR 0.95, 95%CI 0.90, 0.99), whereas Whites were 5% more likely (RR 1.05, 95%CI 1.03, 1.07). Black patients had 43% increased hazards of cancer-specific mortality with increasing IoD (hazard ratio (HR) 1.43, 95%CI 1.17,",
            "The results revealed poor overall survival for AAs compared with EAs, especially for those < 50 years of age. The greater prevalence of proximal CRC at diagnosis among younger AAs (vs. EAs) might contribute to the racial difference in survival",
            "African Americans (AAs) compared with European Americans (EAs) have poorer stage-specific survival from colorectal cancer (CRC)."
        ]
    },
    "65f1dadac4010b4d78000007":
    {
        "question": "Can Antioxidant curcumin kill tumor cells?",
        "llm_evidence": "Curcumin, the active compound found in the spice turmeric, has been extensively studied for its potential anti-cancer properties. Research indicates that curcumin can induce apoptosis (programmed cell death) in various tumor cell lines, including breast, colorectal, and prostate cancers. It achieves this through multiple mechanisms: curcumin inhibits key signaling pathways involved in cell proliferation and survival, such as NF-κB and STAT3, and it modulates the expression of various genes related to cancer progression.\n\nAdditionally, studies have shown that curcumin can enhance the effectiveness of other chemotherapeutic agents and reduce drug resistance in tumor cells. Animal studies and preliminary clinical trials have reported promising results regarding curcumin's ability to target cancer cells selectively while sparing normal cells. However, despite these findings, the bioavailability of curcumin is relatively low, which raises challenges for its therapeutic application.\n\nOverall, the evidence suggests that curcumin has the potential to kill tumor cells and could be a valuable adjunct in cancer therapy, although further research is needed to optimize its delivery and efficacy.",
        "paper_evidence":
        [
            "Curcumin inhibits colon cancer malignant progression and promotes T cell killing by regulating miR-206 expression",
            "Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1.",
            "Curcumin induces apoptosis in human hepatocellular carcinoma cells by decreasing the expression of STAT3/VEGF/HIF-1α signaling.",
            "The CUR/SeNPs present excellent antitumor efficacy, respectively, which supports the nanocomposite matrix to efficiently kill cancer cells ",
            "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities",
            "Drugs such as etoposide, doxorubicin, and mitoxantrone are frontline therapies for a variety of solid tumors and hematological malignancies",
            "In conclusion, we demonstrated for the first time that antioxidants such as trolox can potentiate cancer cell killing by curcumin, a finding which may help in the development of novel drug combination therapies.",
            "This study provided data on the potential cytotoxic activity of the combination of CUR with DSS and may provide a useful tool for the development of a therapeutic combination against melanoma.",
            "The data together suggested that curcumin may inhibit cancer cells proliferation by perturbing microtubule assembly dynamics and may be used to develop efficacious curcumin analogues for cancer chemotherapy.",
            "The combination of curcumin (10 μM) and trolox (10-50 μM) induced apoptosis of cancer cells as evidenced by PARP cleavage and caspase-3 activatio",
            "Curcumin, a natural polyphenol in the spice turmeric, has been found to exhibit anticancer activity.",
            "Curcumin, a phenolic antioxidant compound derived from the rhizome of the turmeric plant Curcuma longa, has proven to be a modulator of intracellular signaling pathways that control cancer cell growth, inflammation, invasion and apoptosis, revealing its anticancer potential.",
            "Curcumin, the active ingredient from the spice turmeric (Curcuma longa Linn), is a potent antioxidant and anti-inflammatory agent. It has been recently demonstrated to possess discrete chemopreventive activities. However, the molecular mechanisms underlying such anticancer properties of curcumin still remain unrealized, although it has been postulated that induction of apoptosis in cancer cells might be a probable explanation.",
            "Curcumin, a well-known dietary pigment derived from Curcuma longa, has been shown to be a potent antiinflammatory, antioxidant, and anticarcinogenic compound. The present study was designed to investigate the cytotoxic potential of curcumin against a range of human tumor cell lines in an attempt to understand its mechanism of action, which may lead to its possible therapeutic applications. We have shown that different cancer cell lines differ in their sensitivity to curcumin. Cell lines established from malignancies like leukemia, breast, colon, hepatocellular, and ovarian carcinomas underwent apoptosis in the presence of curcumin, whereas cell lines from lung, kidney, prostate, cervix, CNS malignancies, and melanomas showed resistance to the cytotoxic effects of curcumin.",
            "Curcumin is a polyphenol derived from the plant Curcuma longa that induces apoptotic cell death in malignant cancer cell lines.",
            "Curcumin, an extract from the turmeric rhizome (Curcuma longa), is known to exhibit anti-inflammatory, antioxidant, chemopreventive and antitumoral activities against aggressive and recurrent cancers. Accumulative data indicate that curcumin may induce cancer cell death.",
            "Curcumin, obtained from the rhizome of Curcuma longa, has potent anticancer activity.",
            "Curcumin suppresses the growth of human malignant glioma cells via ROS-dependent prostate apoptosis response-4 (Par-4) induction and ceramide generation.",
            "These findings support further studies on the therapeutic potential of CUR in combination with standard therapies in breast cancer patients.",
            "Furthermore, expression of the pro-apoptotic protein Bad was up-regulated and expression of the anti-apoptotic proteins Bcl-2 and Bcl-xl was down-regulated in cells that had been treated with trolox plus curcumin.",
            "The combination of curcumin (10 μM) and trolox (10-50 μM) induced apoptosis of cancer cells as evidenced by PARP cleavage and caspase-3 activation.",
            "Although curcumin is generally considered an antioxidant, it is also able to elicit apoptosis through the generation of ROS, thereby functioning as a pro-oxidant in cancer cells.",
            "This review aims to discuss TRAIL and its underlying apoptotic mechanisms, the combinational treatment of Cur and TRAIL in view of their respective limitations, and the underlying apoptotic mechanisms activated by the sensitization of cancers by Cur towards TRAIL-induced apoptosis.",
            "Thus dietary curcumin ameliorates radiation-induced pulmonary fibrosis and increases mouse survival while not impairing tumor cell killing by radiation.",
            "In this study, we tested the hypothesis that a multifunctional nanocomposite platform containing nanoparticles (NPs) with the photothermal agent IR820 and bioactive drug curcumin (Cur) would be able to prevent tumor recurrence, limit bacterial wound infections, and promote wound healing.",
            " Curcuminoids could be a promising anti-cancer agent for the treatment of human colorectal cancer",
            "Furthermore, these anti-cancer effects were higher when using Niosomal (Asc + Cur) than Asc + Cur",
            "Resveratrol, curcumin, and quercetin are the secondary metabolites from medicinal food homology plants, that have been proven their potency in cancer treatment",
            "Curcumin treatment inhibited proliferation and migration of cancer cells in a dose dependent manner",
            "Curcumin, a natural polyphenol in the spice turmeric, has been found to exhibit anticancer activity. Although curcumin is generally considered an antioxidant, it is also able to elicit apoptosis through the generation of ROS, thereby functioning as a pro-oxidant in cancer cells.",
            "Curcumin is a polyphenol derived from the plant Curcuma longa that induces apoptotic cell death in malignant cancer cell lines. It has been shown previously that mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDPm) plays an essential role in defense against oxidative stress by supplying NADPH for antioxidant systems. This study demonstrates that curcumin decreased the activity of IDPm, both as a purified enzyme and in cultured cells. It also shows that curcumin-induced apoptosis in the colon cancer cell line HCT116 is significantly enhanced by suppression of IDPm activity.",
            "Curcumin, the active ingredient from the spice turmeric (Curcuma longa Linn), is a potent antioxidant and anti-inflammatory agent. It has been recently demonstrated to possess discrete chemopreventive activities. However, the molecular mechanisms underlying such anticancer properties of curcumin still remain unrealized, although it has been postulated that induction of apoptosis in cancer cells might be a probable explanation. In the current study, curcumin was found to decrease the Ehrlich's ascites carcinoma (EAC) cell number by the induction of apoptosis in the tumor cells as evident from flow-cytometric analysis of cell cycle phase distribution of nuclear DNA and oligonucleosomal fragmentation. Probing further into the molecular signals leading to apoptosis of EAC cells, we observed that curcumin is causing tumor cell death by the up-regulation of the proto-oncoprotein Bax, release of cytochrome c from the mitochondria, and activation of caspase-3. The status of Bcl-2 remains unchanged in EAC, which would signify that curcumin is bypassing the Bcl-2 checkpoint and overriding its protective effect on apoptosis.",
            "Curcumin, an active ingredient from the rhizome of the plant, Curcuma longa, has antioxidant, anti-inflammatory and anti-cancer activities. It has recently been demonstrated that the chemopreventive activities of curcumin might be due to its ability to inhibit cell growth and induce apoptosis.",
            "Curcumin, the active ingredient of the rhizome of Curcuma longa has anti-inflammatory, antioxidant and antiproliferative activities. Although its precise mode of action remains elusive, studies have shown that chemopreventive action of curcumin might be due to its ability to induce apoptosis in cancer cells. Curcumin was shown to be responsible for the inhibition of AK-5 tumor (a rat histiocytoma) growth by inducing apoptosis in AK-5 tumor cells via caspase activation. This study was designed to investigate the mechanism leading to the induction of apoptosis in AK-5 tumor cells. Curcumin treatment resulted in the hyperproduction of reactive oxygen species (ROS), loss of mitochondrial membrane potential (delta psi(m)) and cytochrome c release to the cytosol, with the concomitant exposure of phosphatidylserine (PS) residues on the cell surface. This study suggests redox signalling and caspase activation as the mechanisms responsible for the induction of curcumin mediated apoptosis in AK-5 tumor cells.",
            "Curcumin, a phenolic compound from the rhizome of the plant Curcuma longa has anti-inflammatory, antioxidant and anti-cancer activities. Although the precise mode of action of this compound is not yet elucidated, studies have shown that chemo-preventive action of curcumin might be due to its ability to induce apoptosis and to arrest cell cycle. This study investigated the cellular and molecular changes induced by curcumin leading to the induction of apoptosis in human lung cancer cell lines-A549 and H1299. A549 is p53 proficient and H1299 is p53 null mutant. The lung cancer cells were treated with curcumin (0-160 microM) for 12-72 h. Curcumin inhibited the growth of both the cell lines in a concentration dependent manner. Growth inhibition of H1299 cell lines was both time and concentration dependent. Curcumin induced apoptosis in both the lung cancer cell lines. A decrease in expression of p53, bcl-2, and bcl-X(L) was observed after 12 h exposure of 40 microM curcumin. Bak and Caspase genes remained unchanged up to 60 microM curcumin but showed decrease in expression levels at 80-160 microM. The data also suggest a p53 independent induction of apoptosis in lung cancer cells.",
            "Curcumin exhibits anti-inflammatory, anticarcinogenic, antiproliferative, antiangiogenic, and antioxidant properties in various cancer cell models.",
            "The anticancer potential of curcumin stems from its ability to suppress proliferation of a wide variety of tumor cells, down-regulate transcription factors NF-kappa B, AP-1 and Egr-1; down-regulate the expression of COX2, LOX, NOS, MMP-9, uPA, TNF, chemokines, cell surface adhesion molecules and cyclin D1; down-regulate growth factor receptors (such as EGFR and HER2); and inhibit the activity of c-Jun N-terminal kinase, protein tyrosine kinases and protein serine/threonine kinases.",
            "Curcumin (diferuloylmethane) is found in large quantities in the roots of Curcuma longa. It possesses strong antioxidant and anti-inflammatory properties, and inhibits chemically-induced carcinogenesis in the skin, forestomach, colon, and liver.",
            "Curcumin (diferuloylmethane), a natural polyphenol present in turmeric, possesses a wide spectrum of pharmacological properties, including antioxidant and antitumor metastatic activities.",
            "BACKGROUND: Curcumin has been shown to exert pleiotropic biological effects, including anti-tumorigen",
            "Curcumin is a natural phenolic compound which shows potent anticancer activities in different tumors, alone or as an adjuvant with other antitumor drugs to prevent or inhibit the survival and cancer progression by various mechanisms.",
            "It has been demonstrated that curcumin regulates signaling pathways in cancer cells, reduces the expression of proteins related to drug resistance, and increases the performance of antitumor drugs at various levels.",
            "Curcumin reverses multidrug resistance mechanisms and increases sensitivity of resistance cells to chemotherapy.",
            "Curcumin inhibited AK-5 tumor growth and induced apoptosis in AK-5 cells.",
            "Curcumin, a natural polyphenol compound found in the spice turmeric, is known for its anti-cancer properties at doses over 10 µM, and often at 50 µM, and it exerts its effects on cancer cells in part by activation of MAP kinase",
            "But curcumin-loaded SLN exhibited antioxidant properties, substantiating the conclusions that curcumin's effect in cancer cells is highly dose dependent.",
            "The results demonstrated that MG-63 osteosarcoma cells were much more sensitive in terms of cytotoxicity to curcumin, while the healthy human osteoblasts exhibited a higher healthy viability after 24 hours of curcumin treatment.",
            "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities.",
            "Curcumin is known to possess various biological functions, including anti-inflammatory, antioxidative, and anti-cancer activities. Natural killer (NK) cells are large lymphocytes that directly kill cancer cells. However, many aggressive cancers, including breast cancer, were reported to escape the successful killing of NK cells in a tumor microenvironment. In this study, we investigated",
            "Together, these results suggest a novel mechanism for curcumin-mediated radiosensitization involving increased ROS and ERK1/2 activation and suggest that curcumin application (either systemically or topically) may be an effective radiation modifying modality in the treatment of cervical cancer.",
            " The ability of curcumin to induce apoptosis in tumor cells and its anti-angiogenic potential will be discussed in this review",
            "It has recently been demonstrated that the chemopreventive activities of curcumin might be due to its ability to inhibit cell growth and induce apoptosis.",
            "y supplementing it with curcumin. Curcumin supplementation exaggerates oxidative stress and apoptosis leading to cancer cell death by modulating p",
            "Curcumin has recently been discovered to have anti-cancer properties through its impact on numerous biological pathways involved in carcinogenesis, metastasis, tumorigenesis, cell cycle regulation, mutagenesis, and oncogene expression.",
            "In the current study, curcumin was found to decrease the Ehrlich's ascites carcinoma (EAC) cell number by the induction of apoptosis in the tumor cells as evident from flow-cytometric analysis of cell cycle phase distribution of nuclear DNA and oligonucleosomal fragmentation.",
            "Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis.",
            " With its low toxicity profile, curcumin (diferuloylmethane), a naturally occurring flavinoid derived from the rhizome of Curcuma longa, has great promise. In vitro and in vivo preclinical studies have shown its inhibitory anticancer, antioxidant, anti-inflammatory, antiproliferative, and proapoptotic activities. "
        ]
    },
    "65f85f77c4010b4d78000053":
    {
        "question": "Should we treat all patients with glaucoma?",
        "llm_evidence": "Glaucoma is a progressive eye disease that can lead to irreversible vision loss, making timely treatment essential for preserving eyesight. However, not all patients exhibit the same severity or risk for visual impairment. Key insights in considering whether to treat all patients with glaucoma include:\n\n1. **Types of Glaucoma**: Different types exist, such as open-angle and angle-closure glaucoma, with varying treatment protocols. Open-angle glaucoma typically requires lifelong management, while angle-closure may necessitate more immediate intervention.\n\n2. **Staging and Risk Assessment**: Treatment decisions often depend on the stage of glaucoma. Patients with early-stage glaucoma may be monitored closely, while those with moderate to advanced disease usually need immediate treatment to prevent vision loss.\n\n3. **Individualized Treatment Plans**: Factors such as age, overall health, and patient preferences should guide treatment plans. Not all patients may require aggressive intervention; some may benefit from observation.\n\n4. **Potential Side Effects**: Treatments, including medications and surgeries, carry risks and potential side effects that need evaluation against the benefits for each individual patient.\n\n5. **Preventive Care and Monitoring**: Some patients, particularly those at high risk, may need proactive management even if they are asymptomatic, highlighting the importance of regular eye exams and personalized care rather than a blanket treatment approach.\n\nIn summary, while glaucoma is a serious condition that often requires treatment, the decision should be individualized based on the type of glaucoma, disease severity, patient characteristics, and the potential risks associated with treatments.",
        "paper_evidence":
        [
            "Trans-scleral diode laser cycloablation (cyclodiode) is effective in the short-term management of refractory glaucoma where alternative treatments are not feasible",
            "Glaucoma is the most common cause of irreversible blindness worldwide. Many patients with glaucoma are asymptomatic early in the disease course",
            "Primary care clinicians should know which patients to refer to an eye care professional for a complete eye examination to check for signs of glaucoma",
            "Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision",
            " Treatment of glaucoma involves lowering intraocular pressure. This can be achieved with various classes of glaucoma medications as well as laser and incisional surgical procedures",
            "Vision loss from glaucoma can be minimized by recognizing systemic conditions and medications that increase a patient's risk of glaucoma and referring high-risk patients for a complete ophthalmologic examination",
            "irreversible vision loss from Glaucoma ",
            "intraocular pressure (IOP) is the only modifiable risk factor identified to prevent glaucomatous vision loss",
            "Medical management remains the first-line of treatment in most adult glaucomas",
            "At present, all resources are directed towards reduction of intraocular pressure (IOP), the only known causal and treatable risk factor for glaucoma, and medical management is frequently the first choice in most cases.",
            "The philosophy of glaucoma management is to preserve the visual function and quality of life (QOL) of the individual with minimum effects on QOL in terms of cost, side effects, treatment regime, follow-up schedules as well as socioeconomic burden.",
            "Thus, intraocular pressure-lowering strategies combined with neuroprotective therapies to protect visual neurons in the retina and brain may help to preserve vision in patients with glaucoma.",
            "In patients with manifest glaucoma, lowering the intraocular pressure prevents the progression of visual field defects, with a number needed to treat of 7.CONCLUSION: The diagnostic evaluation of glaucoma rests on multiple pillars, all of which must be considered for establishing the diagnosis and defining the desired target pressure: these are, among others, the intraocular pressure and ocular function and morphology.",
            "INTRODUCTION: Medical therapy of glaucoma aims to maintain the patient's visual function and quality of life. This generally commences with monotherapy, but it is often difficult to reach the predetermined target pressure with this approach. Fixed combinations (FCs) are therefore selected as the next step of the medical ther",
            "Current management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss.",
            "Treatment of all forms of glaucoma consists of reducing IOP. With proper treatment, progression of this disease can often be delayed or prevented. Treatment options for glaucoma include medications, laser therapy and incisional surgery.",
            "IOP reduction by medical, laser, or surgical therapies remains the only clinically proven treatment of glaucoma.",
            "Over the past decade, results from prospective, randomized, clinical trials have confirmed the value of reducing intraocular pressure (IOP) in patients with ocular hypertension or primary open-angle glaucoma and have outlined the need to consider a target IOP in an individual glaucomatous patient and not an arbitrary value of 21 mm Hg as classically believed.",
            "Intraocular pressure is the main risk factor for glaucoma, and intraocular pressure-lowering treatment remains the mainstay of glaucoma treatment, but even successful intraocular pressure reduction does not stop the progression of glaucoma in all patients.",
            "Knowing the type of glaucoma is vital, especially regarding an individualized treatment, since each patient is unique and needs to be treated accordingly, in order to prevent glaucomatous optic neuropathy and visual field loss.",
            "n mean IOP respectively.CONCLUSIONS: The results from this study support the concept that the majority of glaucoma patients, who are responding inadequately to other glaucoma therapies, could benefit from a change to travoprost monotherapy or from the addition of ",
            "Although the general rule is to initiate glaucoma management with medical treatment, the limits of medical therapy should be considered to identify those patients in need of surgical management.",
            "Treatment for advanced glaucoma can be highly effective, and patients and their care partners should be informed that aggressive IOP lowering to the low teens or even single digits offers the best chance of protecting remaining vision.",
            "BACKGROUND: Treatment of open angle glaucoma (OAG) and/or ocular hypertension (OHT) focuses on achievement of target intraocular pressure (IOP), with the objective of slowing disease "
        ]
    },
    "65cfab681930410b13000012":
    {
        "question": "What is the mechanism of action of Pegozafermin?",
        "llm_evidence": "Pegozafermin is a novel peptide therapeutic that functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. Its mechanism of action primarily involves two key pathways: enhancing insulin secretion and decreasing glucagon release from the pancreas. By binding to GLP-1 receptors, Pegozafermin stimulates insulin production in response to meals, leading to improved glycemic control. Additionally, it slows gastric emptying, which contributes to increased satiety and reduced appetite, promoting weight loss. The drug also has potential effects on reducing liver fat content, making it a promising option for conditions associated with metabolic syndrome, such as non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Thus, Pegozafermin operates through a multifaceted approach, affecting glucose metabolism and energy homeostasis.",
        "paper_evidence":
        [
            "Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment of severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis.",
            "The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.",
            "BACKGROUND: Management strategies for non-alcoholic steatohepatitis (NASH) are based predominantly on lifestyle modification, with no approved disease-modifying drugs yet available. We aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of pegozafermin (BIO89-100), a glycoPEGylated FGF21 analogue, in participants with NASH.",
            "Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.",
            "BACKGROUND: Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. ",
            "Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.",
            "The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers.",
            "Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) under development to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).",
            "BACKGROUND: An approved therapy for nonalcoholic steatohepatitis (NASH) and fibrosis remains a major unmet medical need.AIM: To investigate the histological and metabolic benefits of pegozafermin, a glycoPEGylated FGF21 analogue, in subjects with biopsy-confirmed NASH.METHODS: This proof-of-concept, open-label, single-cohort study, part 2 of a phase 1b/2a clinical trial, was conducted at 16 centres in the United States.",
            "BACKGROUND: Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.",
            "Studies presented here demonstrate that a novel long-acting FGF21 analog, pegozafermin, has similar pharmacologic properties as FGF21 and that repeated, subcutaneous dosing of pegozafermin in diabetic monkeys and healthy humans improves lipid metabolism, glucose metabolism, weight, and liver transaminases.",
            "We aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of pegozafermin (BIO89-100), a glycoPEGylated FGF21 analogue, in participants with NASH.METHODS: This randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study enrolled adults (aged 21-75 years) who had NASH with stage F1-F3 fibrosis, or non-alcoholic fatty liver disease and a high risk of NASH (referred to in this study as phenotypic NASH) due to central obesity with type 2 diabetes, or central obesity with increased alanine aminotransferase (ALT) or a Fibroscan score of 7 kPa or greater, across 12 specialist centres and clinics in the USA.",
            "Pegozafermin (PGZ), a novel glycopegylated version of human fibroblast growth factor 21 (FGF21), has demonstrated potential for addressing metabolic comorbidities, including severe hypertriglyceridemia, insulin resistance, nonalcoholic fatty liver disease, and obesity.",
            "In cell-based assays, pegozafermin had a similar receptor engagement profile as recombinant FGF21, with approximately eightfold higher potency at fibroblast growth factor receptor 1c (FGFR1c).",
            "Pegozafermin (PGZ), a novel glycopegylated version of human fibroblast growth factor 21 (FGF21), has demonstrated potential for addressing metabolic comorbidities, including severe hypertriglyceridemia, insulin resistance, nonalcoholic fatty liver disease, and obesity. FGF21 is a naturally occurring peptide hormone primarily produced by the liver, with a half-life of 0.5 to 2 hours. It can influence metabolic processes through endocrine cellular effects. FGF21 receptors are found in the liver, adipose, skeletal muscles, and pancreatic tissues. Those receptors rely on the beta klotho (KLB) coreceptors, a transmembrane protein, to activate the FGF21 signaling pathway and FGF21's associated transcription factors. PGZ, through its extended half-life of 55 to 100 hours, has evidenced significant improvements in metabolic functions. Its mechanism of action includes promoting adiponectin levels, enhancing insulin sensitivity, increasing triglyceride uptake, and reducing de novo lipogenesis.",
            "Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in development for the treatment",
            "Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21)",
            "Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment",
            "cokinetics, and pharmacodynamics of pegozafermin (BIO89-100), a glycoPEGylated FGF21 analogue, in participant",
            "abolic benefits of pegozafermin, a glycoPEGylated FGF21 analogue, in subjects with biopsy",
            "Pegozafermin (PGZ), a novel glycopegylated version of human fibroblast growth factor 21 (FGF21), has demonstrated potential",
            "Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) under development to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). In cell-based assays, pegozafermin had a similar receptor engagement profile as recombinant FGF21, with approximately eightfold higher potency at fibroblast growth factor receptor 1c (FGFR1c)."
        ]
    },
    "65f70b9cc4010b4d7800001c":
    {
        "question": "What is the indication for Alirocumab?",
        "llm_evidence": "Alirocumab is a monoclonal antibody that targets PCSK9 (proprotein convertase subtilisin/kexin type 9) and is primarily indicated for the treatment of hyperlipidemia, specifically to lower low-density lipoprotein cholesterol (LDL-C) levels in adults with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH). It is used as an adjunct to diet and maximally tolerated statin therapy when additional LDL-C reduction is necessary. Clinical trials have demonstrated that Alirocumab significantly reduces LDL-C levels and can lead to a reduction in cardiovascular events in high-risk patients.",
        "paper_evidence":
        [
            "Effects of Alirocumab on Triglyceride Metabolism:",
            "PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators.M",
            "To achieve target LDL-cholesterol in these two groups of patients will be possible with new drugs - PCSK9 inhibitors, which decrease LDL-cholesterol by an additional 50-60 %. The first two PCSK9 inhibitors (alirocumab and evolocumab) already had been approved for clinical use by European regulatory authorities.",
            "Alirocumab for the treatment of hypercholesterolaemia.",
            "Areas covered: In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent®; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT.",
            "INTRODUCTION: Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction is the standard of care in primary and secondary prevention of cardiovascular disease; nevertheless, a large number of patients treated with statins are unable to reach the recommended LDL-C targets.",
            "Currently, alirocumab is approved by the US Food and Drug Administration (FDA) as an adjunct to diet and maximally tolerated statin therapy for use in adults with heterozygous familial hypercholesterolemia (FH) or those with atherosclerotic CV disease who require additional LDL-C lowering; it has also been recently approved by the European Medicines Agency (EMA) for use in patients with heterozygous FH, non-familial hypercholesterolemia or mixed dyslipidemia in whom statins are ineffective or not tolerated.",
            "Expert commentary: Alirocumab causes a marked reduction in LDL-C, presents good safety and tolerability, and represents a promising approach for LDL-C lowering, particularly in patients with intolerance to statin or elevated LDL-C despite maximal statin therapy; nevertheless, further long-term data on safety and efficacy are necessary, such as data on the improvement of cardiovascular outcomes.",
            "Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent®) and evolocumab (Repatha®), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowering.",
            "Alirocumab (Praluent; Sanofi/Regeneron, Bridgewater, NJ) and evolocumab (Repatha; Amgen, Thousand Oaks, CA) are currently available and approved for use in patients with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease.",
            "Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.",
            "The authors review the pharmacological features, clinical efficacy, and safety of alirocumab in lowering LDL-C, and discuss its therapeutic perspectives based on the most recent clinical trials.",
            "Alirocumab (Praluent®) is a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi that has been approved in the US as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C",
            "Alirocumab (Praluent) for high cholesterol",
            "BACKGROUND AND OBJECTIVES: Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the prevention of cardiovascular risk and exhibiting target-mediated drug disposition (TMDD).",
            "Alirocumab for the treatment of hypercholesterolemia.",
            "INTRODUCTION: Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-risk patients.",
            "Alirocumab: targeting PCSK9 to treat hypercholesterolemia.",
            "The high cost and the current lack of long-term safety and efficacy data will restrict the use of alirocumab to patients who have high cardiovascular risk from established atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia and who are unable to achieve LDL-C targets with maximally tolerated dose of statins with or without other lipid-lowering drugs.",
            "Thus, alirocumab is a valuable emerging option for use in patients with hypercholesterolemia, particularly patients with statin intolerance or inadequately-controlled LDL-C despite statin therapy; however, more data are needed to establish its potential cardiovascular benefits.",
            "An evaluation of alirocumab for the treatment of hypercholesterolemia.",
            "The clinical use of two monoclonal antibodies (alirocumab and evolocumab, approved in 2015) and one small interfering RNA (inclisiran, approved in 2020) which can inhibit PCSK9 function proved that they are very effective in lowering low density lipoprotein cholesterol (LDL-C)",
            "reas covered: In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent®; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alte",
            "INTRODUCTION: Alirocumab is a fully human immunoglobulin G1 monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved for the treatment of hypercholesterolemia in high-",
            "Alirocumab and evolocumab are 2 human monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9). These antibodies can potently lower low-density lipoprotein cholesterol (LDLc) serum concentrations. The aims of this analysis were to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model for both antibodies, to simulate and investigate different dosage and application regimens, and finally, to note the effects on LDLc levels. Alirocumab was clinically studied and approved with 2 doses, 75 and 150 mg every 2 weeks (Q2W), whereas evolocumab was tested and approved with 2 dosing intervals, 140 mg Q2W and 420 mg Q4W.",
            "Background: Even though the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, have been approved to reduce plasma low-density lipoprotein cholesterol (LDL-C) and the risk of atherosclerotic cardiovascular disease in high-risk patients, real-world data showing comparisons of the lipid-lowering effects between alirocumab and evolocumab are scarce because of the low prescription rates of PCSK9 inhibitors in clinic",
            "A new class of lipid-lowering drugs, inhibitors of PCSK9 has been generating impressive clinical trial data over the last several years, and alirocumab (Praluent) has become the first to be approved by the US FDA.",
            "Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent®) and evolocumab (Repatha®), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowerin",
            "In 2015 the U.S. Food and Drug Administration approved the first two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab (Praluent®; Sanofi/ Regeneron) and evolocumab (Repatha®; Amgen), for use in patients with heterozygous and homozygous familial hypercholesterolemia and for patients intolerant of statins or those with a major risk of cardiovascular disease (CVD) but unable to lower their LDL cholesterol (LDL-C) to optimal levels with statins and ezetimib",
            "The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab has been shown to substantially reduce low-density lipoprotein cholesterol (LDL-C).",
            "BACKGROUND AND OBJECTIVES: Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the preven",
            "Alirocumab clinical trials with different doses on different administration schedules were shown to significantly reduce LDL cholesterol both as a mono-therapy and in combination with statins or ezetimibe.",
            "Large and comprehensive trials over the last 5 years also indicated good tolerability and safety and resulted in the 2015 regulatory approval in the USA and Europe for the marketing of two mAbs, evolocumab and alirocumab, for the treatment of LDL-C.SUMMARY: The background, clinical trials and approved indications for the current PCSK9 inhibitors are reviewed along with their likely role in the management of LDL-C and cardiovascular disease prevention.",
            "In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high-risk patients with familial hypercholesterolemia (FH) and clinical atherosclerotic cardiovascular disease requiring additional lowering of low-density lipoprotein cholesterol.",
            "esterol (LDL-C). The currently available PCSK9 inhibitors alirocumab and evolocumab were shown to reduce LDL-C concentrations by approximately 55-60% relative to placebo use when used as monotherapy or added to other lipid-lo"
        ]
    },
    "65f86a90c4010b4d78000057":
    {
        "question": "Is there an approved vaccine against Helicobacter pylori?",
        "llm_evidence": "As of October 2023, there is no approved vaccine specifically against Helicobacter pylori (H. pylori), a bacterium implicated in peptic ulcer disease and gastric cancer. While various research groups have been exploring vaccine candidates targeting H. pylori, including both short peptide and whole-cell approaches, none have successfully completed the entire clinical trial process for regulatory approval. \n\nKey insights include:\n\n1. **Research and Development**: Several vaccine candidates have shown promise in preclinical models, but challenges persist in human trials, such as achieving sustainable immunity and the bacterium's ability to evade the immune response.\n\n2. **Current Treatment Options**: The standard treatment for H. pylori infection involves a combination of antibiotics and acid-reducing medications. Due to increasing antibiotic resistance, the need for a vaccine has been emphasized in the medical community.\n\n3. **Global Burden**: H. pylori infections are prevalent worldwide, making the development of an effective vaccine a public health priority. However, the complexity of the immune response prompted by H. pylori complicates vaccine development efforts.\n\nIn conclusion, while progress continues in understanding and addressing H. pylori infections, as of now, there is no licensed vaccine available.",
        "paper_evidence":
        [
            "H. pylori, the development of an efficacious vaccine is a valid option to protect from disease or infection and ultimately prevent gastric cancer. However, despite more than 30 years of research, no vaccine has entered the market yet",
            "advances of H. pylori vaccines from two aspects, candidates of antigens and adjuvants, to provide references for the development of vaccine against this bacterium",
            "Despite an extensive list of attempts to develop a vaccine, no approved vaccine against H. pylori is available.",
            "Unfortunately, no vaccine against H. pylori is currently licensed, and protective immunity mechanisms against H. pylori are only partially understood.",
            "After the discovery of Helicobacter pylori (H. pylori), and the evidence of its relationship with gastric diseases, antibiotic-based therapies were developed, which efficacy was however limited by antibiotic resistance and lack of patient compliance. A vaccine would overcome these drawbacks, but currently there is not any H. pylori vaccine licensed.",
            "An effective vaccine against H pylori is years away.",
            "but currently there is not any H. pylori vaccine licensed.",
            "A vaccine would overcome these drawbacks, but currently there is not any H. pylori vaccine licensed."
        ]
    },
    "65cec1fb1930410b13000005":
    {
        "question": "What disease can be treated with Tebentafusp?",
        "llm_evidence": "Tebentafusp is an innovative immunotherapy specifically indicated for the treatment of metastatic uveal melanoma, a rare and aggressive form of eye cancer. It functions as a bispecific T cell engager (BiTE) that targets both the melanoma cells and the patient's T cells, enhancing the immune response against the cancer. Clinical trials have demonstrated that Tebentafusp significantly improves survival outcomes in patients with this disease, marking it as the first approved therapy for metastatic uveal melanoma, which historically had limited treatment options.",
        "paper_evidence":
        [
            "Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.",
            "BACKGROUND: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting.",
            "Treatment with ICI followed by tebentafusp may result in longer PFS/OS compared to the inverse treatment sequence.",
            "Tebentafusp, a bispecific molecule, has recently become the first treatment in decades to improve overall survival for mUM. ",
            "CONCLUSIONS: Tebentafusp achieved the best results compared to combined ICB and other systemic treatments, although these results have to be interpreted with caution due to the approximative methodical approach and high heterogeneity of included studies.",
            "Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.",
            "Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). ",
            "These advances have driven the development of a number of novel emerging treatments, including tebentafusp, the first systemic therapy to achieve regulatory approval for this disease. ",
            "INTRODUCTION: Tebentafusp is a novel bispecific immune mobilizing T cell receptor (TCR)-based agent developed for the treatment of metastatic uveal melanoma, a highly fatal disease with no currently approved treatment options.",
            "On January 25, 2022, the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).",
            "Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.",
            "Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM).",
            "Tebentafusp, a bispecific T-cell receptor fusion protein directed against gp100 and CD3, can improve survival in patients with metastatic uveal melanoma and was recently approved for the treatment of HLA-A*02:01-positive uveal melanoma patients.",
            "Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patients with inoperable or metastatic forms of the aggressive eye cancer.",
            "Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.",
            "BACKGROUND: Tebentafusp demonstrated a superior overall survival (OS) benefit (hazard ratio [HR] 0.51) compared to investigator's choice (82% pembrolizumab) in a randomized, Phase 3 trial (IMCgp100-202; N=378) in untreated metastatic uveal mel",
            "Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:01) metastatic uveal melanoma, with a proven benefit in overall survival versus the investigator's choice.",
            "INTRODUCTION: Tebentafusp is a novel bispecific immune mobilizing T cell receptor (TCR)-based agent developed for the treatment of metastatic uveal melanoma, a highly fatal disease with no currently approved trea",
            "Using tebentafusp as a case study, a CD3-bispecific approved for uveal melanoma, the model successfully captures the dynamics of five cytokines",
            "BACKGROUND: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to h",
            "Tebentafusp was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.",
            "Tebentafusp-tebn is now approved by the US Food and Drug Administration in HLA-A*02:01-positive uveal melanoma patients as first-line therapy in the metastatic setting.",
            "In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the human leucocyte antigen (HLA) A*0201 allele."
        ]
    },
    "65f856a1c4010b4d7800004e":
    {
        "question": "When was Havana Syndrome first recognized?",
        "llm_evidence": "Havana Syndrome was first recognized in late 2016 when U.S. and Canadian diplomats stationed in Havana, Cuba, began reporting unusual symptoms such as dizziness, headaches, fatigue, and cognitive difficulties. The phenomenon drew significant attention after multiple individuals experienced similar ailments, raising concerns about a possible sonic attack or exposure to a harmful agent. The U.S. government initiated investigations into the matter, officially defining the syndrome in 2017 as they sought to understand its causes and potential implications for national security and diplomatic personnel.",
        "paper_evidence":
        [
            " In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury. ",
            "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties,",
            "This fact was illustrated in 2016 when U.S. diplomats serving in Havana, Cuba reported hearing strange noises accompanied by a constellation of unexplained health effects",
            "Since 2016, numerous American and Canadian diplomats and secret (intelligence) agents in Cuba, China, and other places in the world have experienced an abrupt onset of unusual clinical symptoms including, tinnitus, visual problems, vertigo, and cognitive difficulties, after they encountered strange sounds; this has been called \"Havana syndrome\" (HS).",
            "In late 2016, diplomats in Havana, Cuba, began presenting with a unique symptom complex after perceiving a strange noise and/or feeling a pressure field in their domicile.",
            "Introduction: In 2016 diplomatic personnel serving in Havana, Cuba, began reporting audible sensory phenomena paired with onset of complex and persistent neurological symptoms consistent with brain injury.",
            "BACKGROUND: In the Autumn of 2016, diplomatic personnel residing in Havana began to present with symptoms of dizziness, ear pain, and tinnitus that emerged after perception of high frequency noise and/or a pressure sensation."
        ]
    },
    "65f86f03c4010b4d7800005b":
    {
        "question": "Is Marburg virus a member of the family of the Ebola virus (Filoviridae)?",
        "llm_evidence": "Yes, the Marburg virus is indeed a member of the Filoviridae family, the same family that includes the Ebola virus. Both viruses are classified as filoviruses, which are characterized by their filamentous structure. The Filoviridae family is known for causing severe hemorrhagic fevers in humans and non-human primates. Key insights include the following: \n\n1. **Genetic Similarity**: Both Marburg and Ebola viruses share significant genetic similarities, which allows them to be categorized under the same family.\n2. **Pathogenicity**: Viruses from the Filoviridae family, including Marburg and Ebola, are known for their high mortality rates and ability to cause outbreaks of disease.\n3. **Transmission and Symptoms**: Both viruses have similar modes of transmission, primarily through direct contact with bodily fluids, and cause similar clinical symptoms such as fever, bleeding, and organ failure.\n\nIn summary, the Marburg virus and Ebola virus are both part of the Filoviridae family, sharing characteristics that underline their classification and the severe impact they can have on health.",
        "paper_evidence":
        [
            "Several filoviruses infect bats (e.g., Marburg virus",
            "African Filovirus (Ebola and Marburg)",
            "filoviruses (ebolaviruses and Marburg virus)",
            "The Filoviridae family encompasses Ebola strains such as Sudan, Zaire, Bundibugyo, Tai Forest (formerly known as Ivory Coast), Reston, and Bombali, in addition to the closely related Marburg and Ravn virus strains",
            "Marburg and Ebola filoviruses are two of the deadliest infectious agents and several outbreaks have occurred in the last decades",
            "Viruses in the family Filoviridae, including the commonly known Ebola (EBOV) and Marburg (MARV) viruses, can cause severe hemorrhagic fever in humans and nonhuman primates",
            "Marburg virus, the prototype of the family Filoviridae, differs genetically, serologically, and morphologically from Ebola viruses.",
            "UNLABELLED: Ebola virus (EBOV) and Marburg virus (MARV) belong to the Filoviridae family and can cause outbreaks of severe hemorrhagic fever, with high mortality rates in humans.",
            "Marburg virus (MARV) and Ebola virus (EBOV) belong to the family Filoviridae.",
            "Ebola viruses (EBOV) and Marburg virus belong to the family Filoviridae, order Mononegavirales.",
            "Marburg virus (MARV) and Ebola virus (EBOV) are members of the family Filoviridae (\"filoviruses\") and cause severe hemorrhagic fever with human case fatality rates of up to 90%.",
            "The Marburg virus is a lipid-enveloped virus from the Filoviridae family and is closely related to the Ebola virus.",
            "Comparative analyses showed that there are two lineages within the Marburg virus species of filoviruses.",
            "Ebola virus and Marburg virus are members of the family of Filoviridae and are etiological agents of a deadly hemorrhagic fever disease.",
            "Ebola virus (EBOV) and Marburg virus (MARV) belong to the family Filoviridae.",
            "Marburg virus and Ebola virus, members of the family Filoviridae, cause highly lethal hemorrhagic fever.",
            "Members of the family Filoviridae, including Ebola virus (EBOV) and Marburg virus (MARV), cause severe hemorrhagic fever in humans and nonhuman primates.",
            "Marburg virus (MARV) and the ebolaviruses belong to the family Filoviridae (the members of which are filoviruses) that cause severe hemorrhagic fever.",
            "Filoviruses are filamentous enveloped viruses belonging to the family Filoviridae, in the order Mononegavirales. Some filovirus members, such as Ebola virus and Marburg virus, cause severe hemorrhagic fever in humans and non-human primates.",
            "UNLABELLED: Ebola virus (EBOV) and Marburg virus (MARV) belong to the Filoviridae family and can cause outbreaks of severe hemorrhagic fever, with high mortality rate",
            "Marburg virus (MARV) and Ebola virus (EBOV), members of the viral family Filoviridae, cause fatal hemorrhagic fevers in humans and nonhuman primates.",
            "The members of the filoviruses are recognized as some of the most lethal viruses affecting human and non-human primates. The only two genera of the Filoviridae family, Marburg virus (MARV) and Ebola virus (EBOV), comprise the main etiologic agents of severe hemorrhagic fever outbreaks in central Africa, with case fatality rates ranging from 25 to 90%.",
            "Ebolaviruses and marburgviruses belong to the family Filoviridae and cause high lethality in infected patients.",
            "The Marburg virus, which is a member of the same virus family as the Ebola virus called Filoviridae, causes the severe infectious disease known as Marburg virus disease (MVD)",
            "The Ebola virus and its close relative, the Marburg virus, both belong to the family Filoviridae and are highly hazardous and contagious viruses",
            "Marburg virus (MARV) and Ebola virus (EBOV) of the Filoviridae family are the most lethal viruses in terms of mortality rate.",
            "Ebolavirus and Marburgvirus (belonging to the Filoviridae family) emerged four decades ago and cause epidemics of haemorrhagic fever with high case-fatality rates. The genome of filoviruses encodes seven proteins. No significant homology is observed between filovirus proteins and any known macromolecule. Moreover, Marburgvirus and Ebolavirus show significant differences in protein homology.",
            "Ebola viruses (EBOV) and Marburg virus belong to the family Filoviridae, order Mononegavirales. The genus Ebolavirus consists of four species: Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Ivory Coast ebolavirus (ICEBOV) and Reston ebolavirus (REBOV).",
            "Marburg virus (MARV; family Filoviridae) causes sporadic outbreaks of Marburg hemorrhagic fever in sub-Saharan Africa with case fatality rates reaching 90%.",
            "The Filoviridae family of viruses, which includes the genera Ebolavirus (EBOV) and Marburgvirus (MARV), causes severe and often times lethal hemorrhagic fever in humans.",
            "Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, represent a significant challenge to global public health.",
            "Ebola virus (EBOV) and Marburg virus (MARV), belonging to the Filoviridae family, emerged four decades ago and caused severe viral hemorrhagic fever in human and other primates.",
            "Ebola virus (EBOV) and Marburg virus (MARV) belong to the family Filoviridae and cause severe hemorrhagic fever in humans and nonhuman primates.",
            "The taxonomy of the family Filoviridae (marburgviruses and ebolaviruses) has changed several times since the discovery of its members, resulting in a plethora of species and virus names and abbreviations.",
            "BACKGROUND: Ebola and Marburg viruses (family Filoviridae, genera Ebolavirus and Marburgvirus) cause haemorrhagic fevers in humans, often associated with high mort",
            "The ability of viruses in the Filoviridae family (Ebola virus [EBOV] and Marburg virus [MARV]) to cause severe human disease and their pandemic potential makes all emerging filoviral pathogens a concern to humanity.",
            "The only two genera of the Filoviridae family, Marburg virus (MARV) and Ebola virus (EBOV), comprise the main etiologic agents of severe hemorrhagic fever outbreaks in central Africa",
            "UNLABELLED: Marburg virus (MARV), a member of the filovirus family, causes severe hemorrhagic fever with up to 90",
            "Marburg virus (MARV), a member of the Filoviridae family that also includes Ebola virus (EBOV)",
            "Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae",
            "The family Filoviridae is comprised of two genera: Marburgvirus and Ebolavirus.",
            "As members of the filovirus family, marburgviruses have caused similar devastating outbreaks, albeit with lower case numbers.",
            "ebolavirus (SUDV) and Marburg virus (MARV), are members of the Filoviridae family",
            "Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, represent a significant",
            "Ebola (EBOV) and Marburg (MARV) viruses are members of the Filoviridae family which cause outbreaks",
            "Marburg virus (MARV) and Ebola virus (EBOV), members of the viral family Filoviridae, cause fatal",
            "Ebola and Marburg viruses are members of the family Filoviridae, which cause severe hemorrhagic fevers",
            "GROUND: The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg v",
            "Filoviridae family members Ebola (EBOV) and Marburg (MARV) viruses and Arenaviridae family member Lassa virus (LASV) are",
            "The taxonomy of the family Filoviridae (marburgviruses and ebolaviruses) has changed several times since the discovery",
            "filoviruses Ebola virus (EBOV) and Marburg virus (MARV) cause highly lethal disease typified by unimpeded viral replication and severe hemorrhagic fever. Previously, we showed that expression of the homologous glycoprotein (GP) and matrix protein VP40 from a single filovirus, either EBOV or MARV, resulted in formation of",
            "Marburg virus (MARV), a member of the Filoviridae family that also includes Ebola virus (EBOV), causes lethal hemorrhagic fever with case fatality rates that have exceeded 50% in some outbreaks.",
            "Ebola and Marburg viruses are members of the Filoviridae family and easily distinguishable from viruses of other families by the characteristic morphology of the virion.",
            "The only two genera of the Filoviridae family, Marburg virus (MARV) and Ebola virus (EBOV), comprise the main etiologic agents of severe hemorrhagic fever outbreaks in central Africa, with case fatality rates ranging from 25 to 90%.",
            "Filoviridae currently includes five official and one proposed genera. Genus Ebolavirus includes five established and one proposed ebolavirus species for Bombali virus (BOMV), Bundibugyo virus (BDBV), Ebola virus (EBOV), Reston virus (RESTV), Sudan virus (SUDV) and Taï Forest virus (TAFV), and genus Marburgvirus includes a single species for Marburg virus (MARV) and Ravn virus (RAVV).",
            "Eight viruses are currently assigned to the family Filoviridae Marburg virus, Sudan virus and, in particular, Ebola virus have received the most attention both by researchers and the public from 1967 to 2013.",
            "The family Filoviridae contains many important human viruses, including Marburg virus (MARV) and Ebola virus (EBOV)."
        ]
    },
    "65d140e71930410b1300003f":
    {
        "question": "What medications were tested in the COSMIC-313 trial?",
        "llm_evidence": "The COSMIC-313 trial investigated the combination of cabozantinib, a tyrosine kinase inhibitor, with immune checkpoint inhibitors. Specifically, it evaluated cabozantinib in conjunction with nivolumab (an anti-PD-1 antibody) and ipilimumab (an anti-CTLA-4 antibody) in patients with previously untreated advanced renal cell carcinoma (RCC). The trial aimed to assess the safety, tolerability, and efficacy of this triplet therapy compared to standard treatment options. Key insights indicated that the addition of cabozantinib may enhance anti-tumor activity by targeting multiple pathways, potentially leading to improved patient outcomes in RCC management.",
        "paper_evidence":
        [
            "The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma.",
            "A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity. ",
            "As concern the triplet therapy (i.e. nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of benefit in the poor risk group supports the critical role of immunotherapy (but not of VEGFR-TKIs) in this poor prognosis subgroup of patients.",
            "CONCLUSIONS: Among patients with previously untreated, advanced renal-cell carcinoma who had intermediate or poor prognostic risk, treatment with cabozantinib plus nivolumab and ipilimumab resulted in significantly longer progression-free survival than treatment with nivolumab and ipilimumab alone. Grade 3 or 4 adverse events were more common in the experimental group than in the control group. (Funded by Exelixis; COSMIC-313 ClinicalTrials.gov number, NCT03937219.).",
            "nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of benefit in the poor risk group supports the critical role of immunotherapy (but not of VEGFR-TKIs) in this poor prognosis subgroup of patients",
            "The COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with nivolumab plus ipilimumab control as fist-line systemic therapy in metastatic clear cell renal cell carcinoma",
            "In COSMIC-313, a randomized phase III trial for patients with untreated advanced ccRCC, the triplet combination of ipilimumab, nivolumab, and cabozantinib was compared with a contemporary control arm of ipilimumab and nivolumab.",
            "A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity.",
            "A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity",
            "nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of benefit in the poor risk group supports the critical role of immunotherapy (but not of VEGFR-TKIs) in this poor prognosis subgroup of patients.",
            "COSMIC-313 phase 3 randomized controlled trial tested the triplet combination of cabozantinib with nivolumab and ipilimumab in comparison with",
            "therapy (i.e. nivolumab+ipilumumab+cabozantinib), the updated analysis of the COSMIC-313 study confirmed a significant PFS advantage in the subgroup of mRCC patients at intermediate IMDC risk, while the lack of"
        ]
    },
    "65f492bbc4010b4d78000011":
    {
        "question": "Explain the action of Domperidone.",
        "llm_evidence": "Domperidone is a medication primarily used as an antiemetic and gastroprokinetic agent. It works by blocking dopamine D2 receptors in the gastrointestinal tract and the chemoreceptor trigger zone of the central nervous system. By antagonizing these receptors, Domperidone enhances gastric emptying, decreases nausea and vomiting, and increases the movement of the stomach and intestines. Unlike metoclopramide, Domperidone has a limited ability to cross the blood-brain barrier, which minimizes central nervous system side effects such as sedation. Its effects are particularly beneficial in managing conditions like gastroparesis, nausea related to chemotherapy, and symptoms of Parkinson's disease when related to gastric motility. Overall, Domperidone’s mechanism of action revolves around promoting gut motility and alleviating symptoms of nausea with reduced central nervous system impact.",
        "paper_evidence":
        [
            "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary.",
            "Domperidone is a dopamine D2 receptor inhibitor that stimulates pituitary gonadotropins.",
            "OBJECTIVE: Domperidone is a dopamine antagonist with anti-nausea and anti-emetic activity.",
            "Domperidone, a new dopamine antagonist.",
            "Domperidone is a dopamine antagonist that has recently been released in Canada.",
            "Domperidone, a peripheral dopamine receptor antagonist, has been successfully used for decades in the US and marketed in many countries for the treatment of gastroparesis.",
            "OBJECTIVE: Domperidone is a dopamine antagonist with anti-nausea and anti-emeti",
            "Domperidone is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects.",
            "Domperidon is a pure dopaminantagonist. It accelerates gastric emptying but has less effect on bowel motility.",
            "According to the current concepts, 3H-domperidone is a selective ligand of D2 dopamine receptors mediating the psychotropic effect of neuroleptics.",
            "INTRODUCTION: Domperidone is a dopamine D2-receptor antagonist developed as an antiemetic and pro",
            "Bromopride (BRO) and domperidone (DOMP) are dopamine D2 blocking agents used in gastroenterology clinics because of their anti emetic effect as well as their central and peripheral actions of increasing gastrointestinal motor activity. The rationale for these experiments was to compare BRO- and DOMP-effects on plasma, brain, and intestinal cholinesterase activity in vitro. BRO and DOMP effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM for BRO and from 0.006 to 125 microM for DOMP. The results demonstrate that both BRO and DOMP can inhibit cholinesterase activity in all tissues studied, with DOMP being more potent than BRO in plasma and intestinal tissues. These data suggest the existence of a cholinergic mechanism of action for these dopamine blocking agents.",
            "INTRODUCTION: Domperidone is a dopamine D2-receptor antagonist developed as an antiemetic and prokinetic agent.",
            "Major drug classes include: (i) Muscarinic receptor antagonists-originated from historical accounts of plant extracts containing atropine and hyoscine with development stimulated by the need to prevent sea-sickness among soldiers during beach landings; (ii) Histamine receptor antagonists-searching for replacements for the anti-malaria drug quinine, in short supply because of wartime shipping blockade, facilitated the discovery of histamine (H1) antagonists (e.g., dimenhydrinate), followed by serendipitous discovery of anti-emetic activity against motion sickness in a patient undergoing treatment for urticaria; (iii) Phenothiazines and dopamine receptor antagonists-investigations of their pharmacology as \"sedatives\" (e.g., chlorpromazine) implicated dopamine receptors in emesis, leading to development of selective dopamine (D2) receptor antagonists (e.g., domperidone with poor ability to penetrate the blood-brain barrier) as anti-emetics in chemotherapy and surgery; (iv) Metoclopramide and selective 5-hydroxytryptamine3(5-HT3) receptor antagonists-metoclopramide was initially assumed to act only via D2 receptor antagonism but subsequently its gastric motility stimulant effect (proposed to contribute to the anti-emetic action) was shown to be due to 5-hydroxytryptamine4 receptor agonism.",
            "Domperidone, a dopamine D2 receptor antagonist that does not cross the blood brain barrier is relatively free of the central side-effect liability of metoclopramide.",
            "Domperidone is a dopamine antagonist that does not readily enter the central nervous system. Given parenterally or orally it increases gastric emptying of liquids and increases lower oesophageal sphincter pressure in healthy subjects. The antiemetic and pharmacodynamic profile of domperidone is similar to that of metoclopramide, although domperidone has a lower propensity to cause extrapyramidal side effects.",
            "OBJECTIVE: Domperidone is a dopamine antagonist with anti-nausea and anti-emetic activity. There have been several reports of sudden cardiac death (SCD) associated with the compound. Recently it was estimated to increase SCD nearl",
            "The effect of domperidone, a peripheral dopamine receptor antagonist, has been studied in the aspirin, phenylbutazone and reserpine induced gastric ulcers in rats. The gastric anti-ulcer activity of domperidone was evident following a single dose as well as a 5-day pretreatment against all the three ulcerogenic drugs. However, the protection in the five-day pretreatment group was greater than in the single dose pretreatment group. It appears that the gastrokinetic properties of domperidone play a significant role in producing this anti-ulcer effect.",
            "Dopamine, noradrenaline, adrenaline and apomorphine antagonised the contraction responses at all frequencies; the concentration-response curves were steep and the use of higher concentrations was precluded by changes in base line tension per se. That noradrenaline was approximately 10 fold more potent than dopamine, that the dopamine response was not antagonised by the dopamine antagonists haloperidol, domperidone or (-)sulpiride, but was mimicked by the alpha 2-agonist guanfacine and partially antagonised by the alpha 2-adrenoceptor antagonist yohimbine (which could also antagonise the inhibitory actions of guanfacine) would indicate that a component of dopamine's action to reduce cholinergic activity is effected via alpha 2-adrenoceptor mechanisms.",
            "The mechanism of action of clebopride on the motility of guinea pig stomach was examined by the receptor binding assay for bovine brain membrane and by measuring gastric contractility and the release of acetylcholine from the stomach. The receptor binding assay revealed that clebopride bound to the D2 dopamine receptor with a high affinity and to the alpha-2 adrenoceptor and 5-HT2 serotonin receptor with relatively lower affinity, and not to D1 dopamine, alpha-1 adrenergic, muscarinic acetylcholine, H1 histamine, or opioid receptor. In strips of the stomach, clebopride at 10(-8) M to 10(-5) M enhanced the electrical transmural stimulation-evoked contraction and the release of acetylcholine. This enhancement was attributed to the blockade of the D2 dopamine receptor and alpha-2 adrenoceptor because: 1) Maximum responses obtained with specific D2 dopamine receptor antagonist, domperidone, and with specific alpha-2 adrenoceptor antagonist, yohimbine, were smaller than that with clebopride, and the sum of the effects of these two specific receptor antagonists is approximately equal to the effect of clebopride. 2) The facilitatory effect of clebopride was partially eliminated by pretreatment of the sample with domperidone or yohimbine, and the facilitatory effect of clebopride was not observed in preparations treated with the combination of domperidone and yohimbine. Clebopride also antagonized the inhibitory effects of dopamine and clonidine on the electrical transmural stimulation-evoked responses. These results indicate that clebopride acts on post ganglionic cholinergic neurons at D2 and alpha-2 receptors in this preparation to enhance enteric nervous system stimulated motility.",
            "The effects of domperidone, a peripheral dopamine receptor blocker which poorly crosses the blood-brain barrier, on copulatory and exploratory behaviour were studied in apomorphine (oestrogen + progesterone) treated ovariectomized rats. The dose of domperidone (1.0 mg/kg) which clearly prevented the inhibitory action of apomorphine on the lordotic response did not influence the effect of apomorphine in an exploratory test situation. This finding indicates that peripherally (intraperitoneally) administered domperidone influences dopaminergic mechanisms implicated in the copulatory behaviour of the female rat, but not dopaminergic mechanisms involved in exploratory behaviour.",
            "INTRODUCTION: Domperidone is a dopamine D2-receptor antagonist developed as an antiemetic and prokinetic agent. Oral domperidone is not approved in the United States, but it is used in many countries to treat nausea and vomiting, gastroparesis and as a galactogogue (to promo",
            "Administration of a dopamine (DA) antagonist, domperidone, increased circulating levels of LH in hyperprolactinaemic-amenorrhoeic women with pituitary microadenomas but not in normal women in the early follicular phase of the menstrual cycle. This drug does not readily cross the blood-brain barrier and therefore the site of action of domperidone could be the pituitary gland or the median eminence.",
            "Domperidone is a dopamine antagonist that does not readily enter the central nervous system.",
            "Domperidone is a peripheral antagonist of dopamine which does not cross the blood-brain barrier.",
            "Domperidon is a pure dopaminantagonist.",
            "The effect of domperidone, a peripheral dopamine receptor antagonist, has been studied in the aspirin, phenylbutazone and reserpine induced gastric ulcers in rats.",
            "UNLABELLED: Domperidone (dopamine antagonist), metoclopramide and clebopride (both dopamine antagonists and stimulators of the intramural choliner",
            "Domperidone (Motilium), a dopamine receptor blocking agent, increased the resting tone of the lower oesophageal sphincter in 15 dogs and 6 baboons.",
            "The antiemetic and pharmacodynamic profile of domperidone is similar to that of metoclopramide, although domperidone has a lower propensity to cause extrapyramidal side effects.",
            "Bromopride (BRO) and domperidone (DOMP) are dopamine D2 blocking agents used in gastroenterology clinics because of their anti emetic effect as well as their central and peripheral actions of increasing gastrointestinal motor activity."
        ]
    },
    "65f86ba3c4010b4d78000059":
    {
        "question": "Which age group should never be tested for HIV infection?",
        "llm_evidence": "There are certain age groups where routine HIV testing is not recommended, particularly in very young children. The Centers for Disease Control and Prevention (CDC) and various health organizations emphasize that infants and young children (particularly those under the age of 2) should never undergo testing unless they are considered at high risk for HIV exposure, such as those born to HIV-positive mothers. This is due to the potential for false positives and the complexities involved in interpreting test results in this age group. Additionally, testing is not typically warranted for individuals in the general population who are not at risk, as it can lead to unnecessary anxiety and medical procedures. Instead, the focus is on prevention, education, and targeted screening for high-risk populations.",
        "paper_evidence":
        [
            "social and clinical inequalities of more children infected with HIV and more children losing their fight against AIDS",
            "two out of five children living with HIV worldwide are unaware of their status",
            "maternal HIV testing",
            "pregnant people with HIV",
            "PPHIV experienced higher rates of LBW and VLBW newborns, and higher late pregnancy-related death",
            "adults diagnosed late with HIV",
            "HIV diagnosis could help develop effective strategies to reduce this burden of late presentation - particularly among heterosexual individuals, non-Europeans, and older people",
            "Amongst MSM, those who were older, of an ethnicity other than European, acquired HIV",
            "penile cancer within HIV-positive individuals is significantly greater than in those without HIV",
            "HIV and penile carcinoma, with a higher risk of cancer in Hispanic, compared with Caucasian, HIV-positive men",
            "The vulnerability of female sex workers (FSWs) to HIV infection increases if unprotected heterosexual anal intercourse (HAI) is practiced",
            "Our analysis found that in Cameroon, women in polygamous relationships, Muslim women, married women with inadequate HIV knowledge, those who had never been tested for HIV and women with lower socioeconomic status are less likely to negotiate for safe sex",
            "Health-care providers should routinely screen all patients aged 13-64 years for HIV in accordance with CDC recommendations.",
            "BACKGROUND: The perinatal short-course zidovudine (ZDV) chemoprophylaxis that can reduce HIV-1 vertical transmission by 51% has been widely practiced in developing countries such as Thailand because of its simpler and less cost.OBJECTIVES: To investigate the effects of short-course regimen of oral ZDV for prophylaxis of HIV-1 subtype E vertical transmission among 'break-through' HIV-1 infected infants.STUDY DESIGN: The study analyzed clinical and virological outcomes of 80 infants, whose mothers received ZDV prophylaxis starting at 36 weeks gestation (group Z) and 37 infants whose mothers never received anti-retroviral drugs (group C), at the ages of 1-2, 4-6, and 12 months.RESULTS: Of the 12 HIV-1 infected infants, 5/7 (71.4%) from group Z and 1/5 (20%) from group C progressed to a symptomatic clinical stage by the age 4-6 months.",
            "To reduce the number of persons with undiagnosed HIV infection, CDC issued recommendations in September 2006 to implement HIV screening as part of routine medical care for all persons aged 13-64 years.",
            "Yet many adolescents and young adults with high-risk behaviors for HIV are unaware of their HIV status and have never had an HIV test.",
            "HIV testing was assessed online among men accessing a sexual networking website for men who have sex with men.",
            "An estimated 83.7% of sexually active older adults never tested for HIV.",
            "BACKGROUND: The human immunodeficiency virus (HIV) infection usually infects persons in the reproductive age group (15-49 years), but elderly people are also ",
            "d HIV-infected adolescents in Zimbabwe. In resource-poor settings with maturing epidemics, the presence of skin disease should be regarded as a strong indication for HIV testing and especially as it",
            "This is the prime childbearing age group with an increasing mortality due to HIV.",
            "No significant difference was observed in the association between HIV infection and gender (chi2=0.58, df = 1, P < 0.05). The highest prevalence of HIV infection (8.9%) was recorded among individuals in the 21-30 years age category, while the least HIV infection prevalence (5.3%) was observed among persons above 40 years old. There was no significant difference in the association between HIV infection and age (chi2=0.68, df = 3, P < 0.05).",
            "CDC's 2006 recommendations for human immunodeficiency virus (HIV) testing state that all persons aged 13-64 years should be screened for HIV at least once, and that persons at higher risk for HIV infection, including sexually active gay, bisexual, and other men who have sex with men (MSM), should be rescreened at least annually (1).",
            "Providers should target men aged ≤ 34 years, with primary education, visiting facilities for the first time and who have never been tested for HIV.",
            "The CDC recommends that persons aged 13-64 receive an HIV test at least once in their lifetime and that some groups test annually or more frequently",
            "The US Centers for Disease Control and Prevention recommends persons aged 13 to 64 years be tested for HIV at least once as part of routine health care; however, it is unclear how effectively these testing recommendations have been implemented in EHE priority areas.",
            "HIV testing continues to be a challenge among the young population in Tanzania. As of 2017, only 30% of 15-19-year-olds reported getting tested and receiving their results. This study will examine the demographic and socio-behavioral characteristics associated with HIV testing among adolescents and young adults in Tanzania. Interview data from the 2016-2017 Tanzania HIV Impact Survey (THIS) were analyzed on 10,128 adolescents and young adults 15-24 years of age, representing 10.5 million youth in Tanzania. Weighted logistic regression was used to model the relationship of HIV testing with demographic and socio-behavioral characteristics. Half (50%) of respondents reported ever having been tested for HIV. HIV testing was significantly lower among males compared with females (AOR = 0.5;95% confidence interval [CI] = 0.5-0.6; p<0.001), 15-19 year olds compared with 20-24 year olds (AOR = 0.4;95% CI = 0.4-0.5; p<0.001), no education compared with secondary or post-secondary education (AOR = 0.4;95% CI = 0.3-0.6; p<0.001), rural residents compared with urban residents (AOR = 0.7;95% CI = 0.6-0.9; p<0.001) and those who don't use condoms during sexual intercourse compared with those who do (AOR = 0.6;95% CI = 0.5-0.8; p<0.001). Among HIV-infected youth, younger age group, rural residents, education less than primary, single, high income, and sex workers were significantly associated with never testing for HIV. This study highlights the majority of characteristics affecting HIV testing among young people in Tanzania have not changed over the years, thus it is necessary to re-examine the current approaches to HIV testing. The COVID-19 pandemic will add to this challenge as it collides with the ongoing HIV epidemic and competes for needed medical supplies and health care provider resources. In light of this current situation, intensified and targeted HIV testing programs for at risk young populations in Tanzania should be prioritized.",
            "Mandatory pre-marital HIV screening could generate social stigmatization and infringement of the fundamental human rights of infected individuals. Voluntary counselling and confidential HIV testing and especially pre- and post-test counselling as the basis of pre-marital HIV testing are more desirable.",
            "The Centers for Disease Control and Prevention recommends routine human immunodeficiency virus (HIV) testing of every client presenting for services in venues where HIV prevalence is high. Because older adults (aged ≥50 years) have particularly poor prognosis if they receive their diagnosis late in the course of HIV disease, any screening provided to younger adults in these venues should also be provided to older adults",
            "HIV-infected children, adolescents, and young adults who are severely immunocompromised (based on age-specific CD4 lymphocyte enumeration) attributable to HIV infection should not receive measles vaccine.",
            "HIV is often assumed to only affect younger people, and many older people do not realize that they might risk acquiring the virus.",
            "The HIV infection primarily affects young adults, but older adults are also susceptible.",
            "Physicians are less likely to discuss sexual risk behaviors with older adults and to test them for HIV compared with younger adults.",
            "In 2007 the Centers for Disease Control and Prevention in the United States reported that 16.8% of new diagnoses of HIV that year were in individuals aged over 50 years.",
            "Adolescents and young adults are the fastest growing age group of human immunodeficiency virus (HIV) positive individuals in the US, and many who are infected do not know their HIV status.",
            "Older Americans, 50 years of age and older, account for 10% of the 400,000 reported cases of AIDS nationwide (Centers for Disease Control and Prevention, 1994).",
            "Since 2006, CDC has recommended that health-care providers screen for HIV all patients aged 13-64 years unless prevalence of undiagnosed HIV infection in their patients has been documented to be <0.1%.",
            "In 2006, CDC recommended that all persons aged 13–64 years be screened for HIV in health-care settings in which the prevalence of undiagnosed HIV infection is >0.1%, and that persons with increased risk for HIV be retested at least annually.",
            "Currently, the Centers for Disease Control and Prevention recommends that persons between 15 and 64 years get tested for human immunodeficiency virus (HIV) at least once in their lifetime and persons with HIV risk factors get tested more frequently."
        ]
    },
    "65d12ae11930410b13000030":
    {
        "question": "Can fingolimod be used during pregnancy?",
        "llm_evidence": "Fingolimod is an immunomodulatory medication primarily used to treat multiple sclerosis. However, its use during pregnancy is highly controversial and generally not recommended. Key insights include:\n\n1. **Teratogenic Risks**: Studies have indicated that fingolimod may pose risks of teratogenic effects, with animal studies showing adverse outcomes such as fetal malformations and negative impacts on embryonic development.\n\n2. **Pharmacokinetics**: Fingolimod is known to cross the placenta, which raises concerns about potential exposure to the developing fetus. The drug has a long half-life, which can prolong fetal exposure even after discontinuation.\n\n3. **Pregnancy Registry Findings**: The European Pregnancy Registry has recorded various adverse outcomes associated with fingolimod use during pregnancy, including complications and malformations.\n\n4. **Recommendations**: Most health guidelines, including those from the FDA and the manufacturer, advise against the use of fingolimod during pregnancy and suggest that women of childbearing potential should use effective contraception while on the medication.\n\n5. **Alternative Treatments**: Healthcare providers often recommend alternative therapies that have a more established safety profile during pregnancy for women with multiple sclerosis.\n\nIn summary, due to potential risks of teratogenicity and the implications for fetal development, fingolimod is generally not recommended for use during pregnancy.",
        "paper_evidence":
        [
            "Interferon beta 1a SC was preferred over other treatments for patients with mild to moderate MS and planning for pregnancy (56.6%) or breastfeeding (60.2%). Fingolimod was not a choice for these patients. ",
            "In total, 45 patients (18.8%) permanently discontinued treatment because of AEs related to study drug; two patients reported pregnancy after treatment initiation and subsequently discontinued the treatment; no deaths were reported.CONCLUSION: GOLEMS study demonstrated the sustained effectiveness and manageable safety profile of fingolimod under real-world conditions over 48 months in patients with MS.",
            "Concerns about COVID-19 had a noticeable impact on administering high efficacy drugs like rituximab and fingolimod. However, in male patients this approach has not been the case. It may be related to more aggressive disease course in this group. The other possible explanation could be planning for pregnancy in female cases.",
            "BACKGROUND: Authorizations of fingolimod, teriflunomide and cladribine were accompanied by risk minimization measures concerning their teratogenic potential.",
            "Fingolimod : contraindicated during pregnancy due to suspected risk of congenital malformations. ",
            "Drugs with a known potential of teratogenicity such as fingolimod or teriflunomide should be avoided and recommended wash-out times for medications such as cladribine, alemtuzumab or ocrelizumab should be considered. ",
            "Caution should be exercised when prescribing fingolimod and natalizumab to patients with multiple sclerosis who are of childbearing potential because of the risk of disease rebound when they are discontinued",
            "Current evidence supports the contraindication for fingolimod during pregnancy; data on other DMTs remains limited.",
            "Fingolimod is suspected to be harmful for fetal development, and the use of this drug should be stopped no later than two months before discontinuing the contraception.",
            "Conception should be discouraged for patients on fingolimod, because of the limited information available on human pregnancy outcomes.",
            "If a patient becomes pregnant while taking fingolimod, and requires continued DMD treatment, a switch to interferon β or natalizumab after a variable washout period may be prescribed, depending on the level of disease activity.",
            "it is recommended that multiple sclerosis patients undergoing treatment with fingolimod use contraceptive methods for at least two months after discontinuation of the medication.",
            "BACKGROUND AND METHODS: Limited data are available on the safety of fingolimod in pregnant women. We estimated the risk of adverse pregnancy outcomes in women with multiple sclerosis (MS) exposed to fingolimod either shortly before or during pregnancy in prospectively collected cases from clinical trials, observational studies, surveillance programs, and spontaneous reports.RESULTS: The prevalence of major malformations among live births does not appear to be significantly higher than those in the general population ",
            "Discontinuation of fingolimod ≥2 months before pregnancy is recommended to minimize potential teratogenicity",
            "BACKGROUND AND OBJECTIVE: Discontinuation of fingolimod ≥2 months before pregnancy is recommended to minimize potential teratogenicity. The magnitude of MS pregnancy relapse risk, particularly severe relapses, after fingolimod cessation is unclear, as is whether this risk is reduced by pregna",
            "Fingolimod : contraindicated during pregnancy due to suspected risk of congenital malformations."
        ]
    },
    "65f38059c4010b4d7800000e":
    {
        "question": "What does capnography measure?",
        "llm_evidence": "Capnography measures the concentration of carbon dioxide (CO2) in exhaled air, providing real-time feedback on a patient’s ventilatory status. It quantifies the partial pressure of CO2 and displays it as a waveform on a monitor. Key insights include:\n\n1. **End-tidal CO2 (ETCO2)**: This is the maximum concentration of CO2 at the end of expiration, reflecting the effectiveness of ventilation and the metabolic state of the patient.\n   \n2. **Monitoring Trends**: Capnography is crucial in various clinical settings, including anesthesia, emergency medicine, and critical care, for detecting hypoventilation, hyperventilation, and changes in pulmonary function.\n\n3. **Application in Intubation**: It serves as a valuable tool during intubation to confirm tube placement in the trachea, as proper ventilation results in a characteristic capnographic waveform.\n\n4. **Clinical Relevance**: Abnormal capnography readings can indicate respiratory failure, circulation issues, or metabolic disturbances, thus guiding appropriate medical interventions. \n\nOverall, capnography is an essential non-invasive monitoring tool for assessing ventilation and ensuring patient safety in clinical environments.",
        "paper_evidence":
        [
            "A secondary analysis of a randomized study was performed to study the relationship between volumetric capnography (VCAP) and arterial CO2 partial pressure (PCO2) during cardiopulmonary resuscitation",
            " By continually monitoring end-tidal carbon dioxide concentrations, capnography can detect abnormal ventilation or apnoea early. ",
            "Capnography is the measurement and numerical display of end-tidal carbon dioxide (EtCO2).",
            "Capnography measures exhaled carbon dioxide and is most useful when applied directly to patient care.",
            "Capnography is the measurement of carbon dioxide (CO2) concentration in a gas mixture.",
            "Capnography, often referred to by emergency clinicians as end-tidal carbon dioxide monitoring, is a noninvasive method of measuring cardiopulmonary and metabolic parameters that can be utilized in many clinical applications.",
            "Capnography measures exhaled carbon dioxide and provides early identification of airway obstruction and hypoventilation.",
            "An end-tidal CO2 monitor (capnometer) is used most often as a noninvasive substitute for PaCO2 in anesthesia, anesthetic recovery, and intensive care. Additionally, the wide spread on-site use of portable capnometers in emergency and trauma situations is now observed.",
            "Capnometers measure carbon dioxide (CO2) in expired air and provide clinicians with a noninvasive measure of systemic metabolism, circulation, and ventilation.",
            "Capnography provides a continuous and non-invasive measure of arterial partial pressure of carbon dioxide (PaCO2) throughout the entire respiratory cycle.",
            "MONITORING RESPIRATORY and metabolic function by using capnography to measure end tidal carbon dioxide is standard practice in anaesthesia.",
            "Capnometers measure carbon dioxide (CO2) in expired air and provide clinicians with a noninvasive measure of systemic metabolism, circulation, and ventilation. ",
            "PURPOSE OF REVIEW: Volumetric capnography (VCap) measures the kinetics of carbon dioxide (CO2) elimination on a breath-by-breath basis.",
            "Capnography measures carbon dioxide concentration or partial pressure of the respiratory gas continuously and non-invasively.",
            "Capnography is the non-invasive measurement of a sample of the exhaled carbon dioxide which has multiple clinical uses including as a method to confirm placement of a tracheal tube and/or to assess ventilation, perfusion and metabolism.",
            "BACKGROUND: Capnography provides a continuous, non-invasive monitoring of the CO2 to assess adequacy of ventilation and provide added safety features in mechanically ventilated patients by allowing for quick identification of unplanned",
            "Capnography, a noninvasive monitoring technique designed to measure expired carbon dioxide (CO2) levels, has been used previously to identify respiratory placement of nasogastric tubes in adults; however, its use in children is understudied.",
            "Capnometers measure carbon dioxide (CO2) in inspired and expired air.",
            "INTRODUCTION: Capnography is used to monitor the endtidal carbon dioxide tension (EtCO2) i",
            "This review of capnography includes the methods available to determine carbon dioxide in expired air, and an analysis of the physiology of capnograms, which are followed by a description of the applications of capnography in clinical practice."
        ]
    },
    "65f8611dc4010b4d78000055":
    {
        "question": "Should men be immunized against Human Papilloma Virus?",
        "llm_evidence": "Immunizing men against Human Papilloma Virus (HPV) is supported by several key insights:\n\n1. **Prevalence of HPV**: HPV is one of the most common sexually transmitted infections, affecting both men and women. Approximately 50% of sexually active individuals will contract HPV at some point in their lives. \n\n2. **Health Risks for Men**: While HPV is often associated with cervical cancer in women, it can also lead to other serious health issues in men, including genital warts and several types of cancers (such as anal, penile, and oropharyngeal cancers).\n\n3. **Transmission**: Men can transmit HPV to their female partners, contributing to the risk of cervical cancer in women. By vaccinating men, the overall prevalence of the virus can be reduced, thereby protecting both men and women.\n\n4. **Vaccination Efficacy**: The HPV vaccine has been shown to be effective in reducing the incidence of HPV-related diseases in both genders. Vaccination during adolescence is particularly effective because it is most successful when given before the onset of sexual activity.\n\n5. **Public Health Strategy**: Widespread immunization of young men, in combination with the vaccination of women, aligns with public health strategies aimed at reducing the overall burden of HPV-related diseases and achieving herd immunity.\n\nIn conclusion, immunizing men against HPV is a critical aspect of comprehensive HPV prevention efforts that promotes health equity, protects against various cancers, and contributes to the reduction of HPV transmission within the community.",
        "paper_evidence":
        [
            "As scientific knowledge of HPV-related cancers has advanced, it has become evident that HPV vaccination is a priority for both genders",
            "HPV is known to contribute to male cancers of the mouth, throat, anus, and penis, as well as causing genital warts",
            "The human papillomavirus (HPV) vaccine is one of the most effective public health measures for preventing HPV-related cancers and other diseases",
            "Almost all cases of cervical and anal cancer have been linked to the human papillomavirus (HPV)",
            "both men and women can also develop cancers of the anus, oral cavity, and oropharynx that are attributed to HPV",
            "Gardasil(®) is a quadrivalent vaccine against HPV types 6, 11, 16, and 18 and is recommended for use in females 9-26 years of age, for the prevention of cervical, vulvar, and vaginal cancers and intraepithelial neoplasia and condyloma acuminata and recently for vaccination in boys and men 9-26 years of age for the prevention of genital warts.",
            "HPV vaccines are safe and efficacious against type-specific HPV-induced anogenital warts, precancerous lesions, and cervical cancer.",
            "HPV infection is considered to contribute to almost 100% cervical cancers and at least 80% of anal and 40-60% of vulvar, vaginal, and penile cancers.",
            "On October 25, 2011, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommended that the quadrivalent human papillomavirus vaccine (Gardasil; Merck & Co, Inc, Whitehouse Station, NJ) be used routinely in males.",
            "ACIP recommends routine vaccination with HPV4 or HPV2 for females aged 11 or 12 years and with HPV4 for males aged 11 or 12 years.",
            "HPV vaccine efficacy varies in relationship to when the vaccine is administered, with greater efficacy obtained if administered prior to sexual debut. Historically, this vaccine was created to protect women from cervical cancer. As scientific knowledge of HPV-related cancers has advanced, it has become evident that HPV vaccination is a priority for both genders. HPV is known to contribute to male cancers of the mouth, throat, anus, and penis, as well as causing genital warts.",
            "HPV vaccine is recommended for routine vaccination at age 11 or 12 years. ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously.",
            "heir lives. Canada's National Advisory Committee on Immunization (NACI) has recommended a three-dose immunization schedule with HPV vaccine for females 9 years of age and older and for males between 9 and 26 years of age, since 2007 and 2012, r",
            "BACKGROUND: Rates of routine human papillomavirus (HPV) vaccination of adolescent males in the United States are low. Leading health organizations advocate consistent and strong physician recommendations to improve HPV vaccine di",
            "BACKGROUND: For human papillomavirus (HPV) vaccination to have maximum benefit to public health, both men and women should be vaccinated. Although efficacy trials in men are still ongoing, the HPV vaccine will likely be licensed for men in the ",
            "In the United States, human papillomavirus (HPV) vaccine has been recommended for females since 2006 and for males since 2011.",
            "vaccine recommendations.CONCLUSION: HPV is responsible for 50.8% of penile cancers globally, 79.8% of PeIN, and 90% of genital warts. In 2009 the Food and Drug Administration licensed the quadrivalent HPV vaccine for use in males, with a potential efficacy of 90% and 77.5% to reduce genital warts and anal intraepithelial neoplasia, respectively. However, the uptake of HPV vaccination in men is low, and gender-neutral vaccination is estimated to be impleme",
            "Accordingly, for prevention purposes and social fairness and equality, as both sexes are affected by the disease, the vaccination of 12-year-old males against HPV should be recommended in order to guaranty protection to everyone.",
            "The quadrivalent vaccine against HPV has proved to be effective in preventing external genital lesions in males aged 16-26 years in 90.4%; (95%; CI: 69.2-98.1) of cases.",
            "MSM are a high-risk population for HPV infection and related diseases. MSM can be effectively protected by quadrivalent and nine-valent HPV vaccines.",
            " boys and girls. The quadrivalent HPV vaccination is approved and recommended for both boys and",
            "BACKGROUND: For human papillomavirus (HPV) vaccination to have maximum benefit to public health, both men and women should be vaccinated. Although efficacy trials in men are still ongoing, the HPV vaccine will likely be licensed for men in the near future. Little is known about men's interest in HPV vaccination. This study assessed whether informing men about the benefits of male HPV vaccination for their female sexual partner(s) boosted interest in the HPV vaccine beyond informing them about the benefits t",
            "PURPOSE: We assessed U.S. physicians' attitudes and perceptions regarding potential human papillomavirus (HPV) vaccination of males.METHODS: We surveyed a random sample of 2,714 pediatricians and family practitioners identified in administrative claims of a U.S. health plan as HPV vaccinators of females; 595 pediatricians and 499 family practitioners participated.RESULTS: Most physicians would recommend HPV vaccination to males aged 11-12 (63.9%), 13-18 (93.4%),",
            "HPV vaccination of boys should help reduce anal cancer in homosexual men and cervical cancer in women, it will have little or no impact on penile or prostate cancer. Male circumcision can reduce cervical, penile and possibly prostate cancer. Promotion of both HPV vaccination and male circumcision will synergistically maximize genital cancer prevention.",
            "Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males >26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.",
            "Despite the proven safety and efficacy of available vaccines, HPV remains the most common sexually transmitted infection. Underlying the high prevalence of HPV infection is the poor adherence to the Centers for Disease Control recommendation to vaccinate all 11- to 12-year-old males and females. In fact, only about 38 and 14% of eligible females and males, respectively, receive the complete, three-dose immunization. ",
            "BACKGROUND: Despite the high risks associated with human papillomavirus (HPV), the HPV vaccination rate of men is far lower than women. Most previous review studies have focused on female vaccination and related affecting factors. However, previous studies have reported that the factors affecting HPV vaccination differ by gender.OBJECTIVE: The aim of this review was to identify the factors affecting HPV vaccine initiation in men through a syste",
            "AIMS: Human papilloma virus (HPV) is 1 of the most common sexually transmitted infection responsible for different types of cancer: cervical, penile, vulvar, anal and oropharyngeal.",
            "The 9vHPV and qHPV vaccines showed comparable safety profiles.CONCLUSIONS: In addition to immune responses to HPV 31/33/45/52/58, a three-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccine in men aged 16-26years.",
            "The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that human papillomavirus (HPV) vaccination routinely be targeted to females and males aged 11 years or 12 years as part of the adolescent immunization platform to help reduce the incidence of anogenital cancers and genital warts associated with HPV infection.",
            "ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously.",
            "The Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend routine HPV vaccination for girls and boys at the target age of 11-12 years (but it may be given from the age of 9 years) as part of the adolescent immunization platform in order to help reduce the incidence of anogenital cancer and genital warts associated with HPV infection.",
            "The Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend routine HPV vaccination for girls and boys at the target age of 11-12 years (but it may be given from the age of 9 years) as part of the adolescent immunization platform in order to help reduce the incidence of anogenital cancer and genital warts associated with HPV infection.",
            "We also present the recommendations of the Québec Immunization Committee (CIQ) in this regard, which are: to provide targeted vaccination for MSM up to 26 years of age and in-school vaccination of preadolescent boys since this is the best approach to take to have a real impact on the burden related to HPV in the MSM population and to provide direct protection for all men.",
            "Even though a fall in cervical cancer rates has been reported worldwide, the subsequent rise in HPV-associated head and neck cancers among men and women have been reported from developed countries, necessitating the vaccination of adolescent boys as well.",
            "Extension of immunization offer to young women and to adolescent male subjects has become an important additional opportunity for several countries, with a special focus needed on homosexual men with HIV infection who are at particularly increased risk of HPV-related diseases.",
            "Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada.",
            "Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.",
            "Human Papilloma Virus (HPV) has been implicated in the initiation of several types of cancers in both females and males. Therefore, it is imperative that national immunization programs should ensure that both young women and young men receive full immunization for herd immunity in their teenage years.",
            "Male sexual behavior, with consequent HPV infection and disease contribute to considerable disease burden in females. Hence, inclusion of males in prophylactic HPV vaccination programs should prevent HPV-related disease in males as well as substantially reducing disease burden in females.",
            "Human Papillomavirus (HPV) vaccination is of paramount importance to reduce HPV-associated cancers in both genders.",
            "Therefore, inclusion of males in an HPV vaccination program is likely to have significant health and economic benefits over and above those observed from current female-only programs."
        ]
    },
    "65cfd68a1930410b13000021":
    {
        "question": "Is sectoral Heterochromia associated with Crohn's disease?",
        "llm_evidence": "Sectoral heterochromia, characterized by a difference in coloration in segments of the iris, is not widely recognized as a direct association with Crohn's disease in scientific literature. However, there are anecdotal reports and case studies suggesting possible connections between various autoimmune conditions, including Crohn's disease, and phenotypic variations in ocular features. \n\nKey insights include:\n\n1. **Autoimmune Link**: Crohn's disease is an autoimmune disorder that can lead to extraintestinal manifestations affecting multiple systems, including the eyes. Certain ocular manifestations associated with autoimmune diseases can include changes to pigmentation, though the specific association with sectoral heterochromia is not firmly established.\n\n2. **Genetic Factors**: Some studies indicate that genetic predisposition may influence both autoimmune conditions and iris pigmentation, suggesting a potential, albeit indirect, relationship. \n\n3. **Clinical Observations**: There are isolated clinical observations where patients with Crohn's disease have exhibited unique eye features, including alterations in iris pigmentation. These observations could warrant further investigation but do not indicate a causal relationship.\n\nIn conclusion, while there is no conclusive evidence directly linking sectoral heterochromia to Crohn's disease, the potential for a connection via autoimmune mechanisms and genetic factors merits additional research to clarify possible associations.",
        "paper_evidence":
        [
            "A case of unilateral sectoral iris heterochromia in an infant with Beckwith-Wiedemann syndrome.",
            "PURPOSE: To report a case of unilateral sectoral iris heterochromia in an infant with Beckwith-Wiedemann syndrome (BWS).",
            "CONCLUSIONS: This is the first reported case of iris heterochromia in a BWS patient.",
            "The first case is an example of Waardenburg's type II (without dystopia canthorum) with bilateral sectoral iris heterochromia and fundus bicolor, hyperpigmented skin patches, characteristic facies and deafness. "
        ]
    },
    "65f377d5c4010b4d78000009":
    {
        "question": "List the most effective treatment methods for Madelung disease.",
        "llm_evidence": "Madelung disease, also known as Launois-Bensaude syndrome, is characterized by the formation of lipomas, particularly around the neck and shoulders. The most effective treatment methods include:\n\n1. **Surgical Excision**: This is the primary treatment method for patients with significant symptoms or aesthetic concerns. Complete removal of the lipomas can relieve pressure on surrounding structures and improve appearance.\n\n2. **Liposuction**: In cases where the lipomas are large and fibrous, liposuction may be employed to reduce the volume of fat. This technique can be less invasive and allows for quicker recovery compared to traditional surgery.\n\n3. **Weight Management**: Though not a direct treatment, maintaining a healthy weight may help manage symptoms and prevent further lipoma development, as the condition can be exacerbated by obesity.\n\n4. **Medication**: While there is no specific drug treatment for Madelung disease, some anecdotal evidence suggests that medications targeting lipid metabolism could be beneficial for managing fat deposits, although further research is needed to confirm this.\n\nOverall, surgical options remain the most widely accepted and effective methods for treating Madelung disease, particularly for symptomatic relief and cosmetic improvement.",
        "paper_evidence":
        [
            "Madelung disease (MD) was first described by Brodie in 1846 as a rare multiple lipoma. It is a benign tumor characterized by symmetrical diffuse adipose tissue deposition in the proximal extremities and neck. Until now, the etiology and pathogenesis of the disease have not been fully explained, resulting in difficulties in diagnosis and treatment; moreover, palliative treatment, such as surgical resection of adipose tissue or liposuction, is still the mainstream treatment for MD.",
            "Madelung's disease is a rare disfiguring disorder that affects both function and esthetic appearance in the head and/or shoulder, neck, and arms regions. Lipectomy is typically necessary but such treatment can encounter difficulties due to the large sizes of the tumors, interspersed with important organs in the surrounding region",
            "Benign symmetrical lipomatosis (Madelung disease) is a rare metabolic disorder characterized by the presence of multiple, symmetric, nonencapsulated fat masses in the face, neck, and shoulders. The clinical course is slow, typically one of slow progressive enlargement with cosmetic and functional sequelae. The authors describe a case in which an open surgical approach was performed to treat this disorder, with good results. There are many aspects of treatment currently lacking a consensus, and the authors discuss these, principally in relation to the location of the fat, the role of liposuction versus surgery, the staging of surgical procedures, and the placement of the incisions.",
            "Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease; however, choice of surgery should be based on comprehensive consideration of the disease, such as severity, mass location, and patient expectations.LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article.",
            "Severe complications were not observed.CONCLUSIONS: According to our experience, surgical resection is the main method of improving the appearance, ensuring eradication of the tumor, and reducing the possibility of recurrence.",
            "Severe complications were not observed.CONCLUSIONS: According to our experience, combined lipectomy and liposuction represents a successful procedure in treating benign symmetric lipomatosis in the head and neck region.Nevertheless, advantages and drawbacks of the two techniques should be equally considered prior to surgery.",
            "A patient with benign symmetrical lipomatosis of the neck (Madelung's disease) was successfully treated with liposuction rather than classic surgical lipectomy.",
            "Madelung's Disease - Case Series and Treatment by Tumescent Liposuction or Lipectomy.",
            "Rhytidectomy approach for recurrent Madelung disease.",
            "e helpful for diagnosis and cognition. Lipectomy and liposuction are considered to be the most effective treatment methods for Madelung disease; however, choice of surgery should be based on comprehensive consideration of the disease, such as severity, m",
            "Madelung's disease is a rare disfiguring lipomatosis of unknown etiology. The only effective therapy is the palliative surgical removal of the fatty tissue by lipectomy or liposuction. Experience with eighteen surgically treated patients shows that despite a high rate of complications and the tendency to recur, both techniques might be very useful.",
            "Benign symmetrical lipomatosis (Madelung's disease) is a rare condition of unclear aetiology characterized by numerous, unencapsulated lipomatous deposits. The only effective treatment is by surgical intervention; however, there is no consensus in the optimal approach.",
            "We think that combined lipectomy and liposuction is a successful procedure for treating benign symmetrical lipomatosis in the head and neck region."
        ]
    },
    "65f847c5c4010b4d78000046":
    {
        "question": "What are common side effects of the progesterone-only pill (POP)?",
        "llm_evidence": "The progesterone-only pill (POP), also known as the mini-pill, is a type of hormonal contraceptive that primarily uses the hormone progestin. Common side effects associated with the use of POP include irregular menstrual bleeding, such as spotting or changes in the frequency and duration of periods. Other potential side effects may include headaches, breast tenderness, mood swings, and acne. Some users may also experience gastrointestinal issues like nausea. It is important to note that while side effects can occur, many women tolerate POP well, and some may have no side effects at all. Additionally, because POP does not contain estrogen, it is often recommended for women who cannot take estrogen-containing contraceptives, such as those who smoke or are over 35 years old.",
        "paper_evidence":
        [
            "progestin-only pills (POPs) is still relatively infrequent, mainly for their unpredictable effect on menstrual bleeding",
            "Breakthrough bleeding is a side effect of progesterone-only pills (POPs) in 40% of women, and is reduced to 10% with combined hormonal contraceptives (CHCs)",
            "PURPOSE: Progestin-only pills (POPs), compared to combined, are not associated with an increased risk of venous thromboembolism, but are associated with a poor cycle control.",
            "The Risk of Breakthrough Bleeding Justifies the Use of Combined Hormonal Contraception Over Progesterone-Only Pills While Breastfeeding.",
            "The most commonly reported complaints in women using all POPs are bleeding problems.",
            "The main reason for this is that women on POP often have abnormal bleeding patterns, with an increased frequency of bleeding, lengthened cycles, breakthrough bleeding, spotting and prolonged bleeding.",
            "Progestin-only pills (POPs), compared to combined, are not associated with an increased risk of venous thromboembolism, but are associated with a poor cycle control",
            "POPs are often associated with breakthrough bleeding (BTB), and irregular spotting is often a reason for their cessation.",
            "ative studies are available. Progestogen-only pills are associated with a more irregular bleeding pattern than contraceptive pills containing oestrogens, especially during the"
        ]
    },
    "65d128f81930410b1300002d":
    {
        "question": "What is the mechanism of action of Peresolimab?",
        "llm_evidence": "Peresolimab is a monoclonal antibody that functions as an immune checkpoint inhibitor, specifically targeting the programmed cell death protein 1 (PD-1) receptor. By binding to PD-1, Peresolimab blocks its interaction with PD-L1 and PD-L2 ligands, thereby enhancing T-cell activation and proliferation. This mechanism counteracts the tumor-induced immune suppression, allowing the immune system to recognize and attack cancer cells more effectively. Additionally, Peresolimab has shown promise in treating various malignancies by reinvigorating exhausted T cells in the tumor microenvironment, contributing to improved anti-tumor responses.",
        "paper_evidence":
        [
            "BACKGROUND: Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. ",
            "CONCLUSIONS: Peresolimab showed efficacy in a phase 2a trial in patients with rheumatoid arthritis. These results provide evidence that stimulation of the PD-1 receptor has potential efficacy in the treatment of rheumatoid arthritis. ",
            "BACKGROUND: Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway.",
            "BACKGROUND: Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of this pathway would be a no"
        ]
    },
    "65f1d021c4010b4d78000004":
    {
        "question": "Explain the difference between eosinophilic esophagitis and reflux-induced esophagitis.",
        "llm_evidence": "Eosinophilic esophagitis (EoE) and reflux-induced esophagitis are both conditions affecting the esophagus, but they have distinct etiologies and characteristics. EoE is an allergic inflammatory condition characterized by an elevated number of eosinophils (a type of white blood cell) in the esophagus. It is often related to food allergies or environmental allergens and can lead to symptoms such as dysphagia (difficulty swallowing), food impaction, and chest pain. The diagnosis is typically confirmed through endoscopy and biopsy showing eosinophilic infiltration.\n\nIn contrast, reflux-induced esophagitis is a result of gastroesophageal reflux disease (GERD), where stomach acid irritates the esophageal lining. This condition is primarily caused by a malfunctioning lower esophageal sphincter that allows acidic stomach contents to back up into the esophagus. Symptoms include heartburn, regurgitation, and sometimes chest pain. Diagnosis is often made based on symptoms and may be supported by endoscopy revealing inflammation and erosions in the esophagus.\n\nKey insights that differentiate the two include: \n1. **Pathophysiology**: EoE involves an allergic reaction with eosinophilic infiltration, while reflux-induced esophagitis is due to acid damage.\n2. **Symptoms**: EoE typically presents with food-related symptoms, whereas reflux-induced esophagitis primarily manifests as heartburn.\n3. **Diagnosis**: EoE is diagnosed via biopsy showing eosinophils, whereas reflux-induced esophagitis is diagnosed through symptom evaluation and visual inspection of esophageal damage. \n\nUnderstanding these differences is crucial for appropriate diagnosis and treatment.",
        "paper_evidence":
        [
            "asal cell hyperplasia may occur in patients with gastroesophageal reflux disease (GERD), a condition in which acid from the stomach enters the esophagus, or eosinophilic esophagitis (EoE), an emerging form of food allergy. ",
            "Eosinophilic esophagitis (EoE) is a food allergen-induced disease of the esophagus. Chronic, eosinophil-predominant inflammation eventually leads to fibrosis, esophageal dysfunction and severe morbidity. S",
            "BACKGROUND AND OBJECTIVES: Diagnosing eosinophilic esophagitis (EoE) depends on intraepithelial eosinophil count of ≥15 eosinophils per high-power field (HPF); however, differentiating EoE from gastroesophageal reflux disease (GERD) continues to be a challenge because no true \"criterion standard\" criteria exist.",
            "Eosinophilic esophagitis (EoE) is distinguished from gastroesophageal reflux disease (GERD) by persistent esophageal eosinophilia despite medical therapy with proton-pump inhibitors for 4-6 weeks.",
            "The notion that GERD and EoE can be distinguished by the response to proton pump inhibitor (PPI) treatment is based on the mistaken assumption that gastric acid suppression is the only important therapeutic effect of PPIs, and therefore only GERD can respond to PPIs.",
            "While studies from the '80s identified the presence of esophageal eosinophilia as being a histologic marker for the diagnosis of GERD, studies in the '90s demonstrated that high levels of esophageal eosinophilia were characteristic for a novel immune/antigen-mediated esophageal disease, EoE, that was seemingly quite distinct from GERD.",
            "BACKGROUND & AIMS: Features of eosinophilic esophagitis (EoE) and gastroesophageal reflux disease (GERD) overlap; because they cannot be differentiated on the basis of eosinophil counts alone, it can be a challenge to distinguish these disorders. We aimed to characterize the clinical, endoscopic, and histologic features of EoE and GERD and to identify factors that might be used to differentiate them.METHODS: We performed a retrospective case-control study on data collected from 2000 to 2007. Cases were patients of any age with EoE, as defined by recent consensus guidelines; controls were patients of any age with GERD. Clinical and endoscopic data were collected, and all esophageal biopsy specimens were reassessed by gastrointestinal pathologists. Cases and controls were compared, unconditional logistic regression was performed to develop a model to predict EoE, and receiver operator characteristic curves were constructed.RESULTS: Data from 151 patients with EoE and 226 with GERD were analyzed. Compared with GERD, features that independently predicted EoE included younger age; symptoms of dysphagia; documented food allergies; observations of esophageal rings, linear furrows, white plaques, or exudates by upper endoscopy; an absence of a hiatal hernia, observed by upper endoscopy; a higher maximum eosinophil count; and the presence of eosinophil degranulation observed in biopsy specimens. The area under the curve for this model was 0.934.CONCLUSIONS: We identified a set of readily available and routinely measured variables that differentiate EoE from GERD. Use of this type of analysis with patients suspected to ",
            "Eosinophilic esophagitis (EE) and gastroesophageal reflux disease (GERD) have overlapping clinical, manometric, endoscopic and histopathologic features. The diagnosis of EE is nowadays based upon the presence of 15 or more eosinophils per high power field (eo/HPF) in esophageal biopsies. We report the cases of two young males suffering from dysphagia and recurrent food impaction with reflux esophagitis and more than 20 eo/HPF in upper-mid esophagus biopsies, both of which became asymptomatic on proton pump inhibitor (PPI) therapy. The first patient also achieved a histologic response, while EE remained in the other patient after effective PPI treatment, as shown by 24-h esophageal pH monitoring. Topical steroid therapy combined with PPI led to complete remission in this latter patient. GERD and EE may be undistinguishable, even by histology, so diagnosis of EE should only be established after a careful correlation of clinical, endoscopic and pathologic data obtained under vigorous acid suppression. These diagnostic difficulties are maximal when both diseases overlap. Limited data are available about this topic, and the interaction between EE and GERD is a matter of debate. In this setting, upper-mid esophagus step biopsies and esophageal pH monitoring of patients on PPI therapy are pivotal to evaluate the role of each disease. A PPI trial is mandatory in patients with a histopathologic diagnosis of EE; in those unresponsive to PPI treatment, EE should be suggested. However, a clinical response to PPI may not rule out quiescent EE, as shown in this report.",
            " diseases. The mucosa affected by eosinophilic esophagitis (EoE) is composed of a stratified squamous epithelia and contains intraepithelial eosinophils. To date, no studies have identified the esophageal microbiome in patients with EoE or the impact of treatment on these organisms. The aim of this study was to identify the esophageal microbiome in EoE and determine whether treatments change this profile. We hypothesized that clinically relevant alterations in bacterial populations are present in different forms of esophagitis.DESIGN: In this prospective study, secretions from the esophageal mucosa were collected from children and adults with EoE, Gastroesophageal Reflux Disease (GERD) and normal mucosa using the Esophageal String Test (EST). Bacterial load was determined using quantitative PCR. Bacterial communities, determined by 16S rRNA gene amplification and 454 pyrosequencing, were compared between health and disease.RESULTS: Samples from a total of 70 children and adult subjects were examined. Bacterial load was increased in both EoE and GERD relative to normal subjects. In subjects with EoE, load was increased regardless of treatment status or degree of mucosal eosinophilia compared with normal. Haemophilus was significantly increased in untreated EoE subjects as compared with normal subjects. Streptococcus was decreased in GERD subjects on proton pump inhibition as compared with normal subjects.CONCLUSIONS: Diseases associated with mucosal eosinophilia are characterized by a different microbiome from that found in the normal mucosa. Microbiota may contribute to es",
            "Eosinophilic esophagitis (EoE) and reflux esophagitis (RE) overlap clinically and histologically. RE is characterized by epithelial infiltration with small numbers of neutrophils and eosinophils, EoE by a prominent eosinophilic infiltrate. Lymphocytic esophagitis (LE), a new entity characterized by peripapillary lymphocytosis, questions the role lymphocytes play in esophageal inflammation. We test the hypothesis that lymphocyte infiltration in RE differs from EoE. One blinded pathologist read esophageal biopsies from 39 RE and 39 EoE patients. Both groups demonstrated significant numbers of lymphocytes (RE 22.7 +/- 2.2/HPF, EoE 19.8 +/- 1.8/HPF). Eosinophils/HPF in RE and EoE were 2.8 +/- 0.7 and 74.9 +/- 8.2, respectively (P < 0.001). Neutrophils were uncommon in RE (0.26 +/- 0.16/HPF) and EoE (0.09 +/- 0.04; P = 0.07). Eight of the 39 RE specimens had >or=50 lymphocytes in >or=1 HPF. Two were consistent with LE. There was an inverse correlation between numbers of eosinophils and lymphocytes in EoE (R = -0.47; P = 0.002), and no correlation between them in RE (R = 0.18; P = 0.36). The patients with EoE who used antireflux medications had fewer lymphocytes (16.3 +/- 1.3 vs 22.2 +/- 2.3/HPF; P = 0.030) and eosinophils (55.6 +/- 5.2 vs 76.0 +/- 8.7/HPF; P = 0.042) than those who did not. The pathological role of lymphocytes in RE and EoE may be underestimated. Our observation that 5% of the RE specimens meet histopathological criteria for LE potentially blurs the line between these entities. The observation that eosinophil counts are lower in EoE when antireflux meds are used supports the notion that reflux plays a role in the clinical expression of EoE.",
            "Eosinophilic esophagitis (EoE) and reflux esophagitis (RE) overlap clinically and histologically. RE is characterized by epithelial infiltration with small numbers of neutrophils and eosinophils, EoE by a prominent eosinophilic infiltrate."
        ]
    },
    "65f84aa5c4010b4d78000047":
    {
        "question": "What are the most common symptoms of fibroids?",
        "llm_evidence": "Fibroids, also known as uterine leiomyomas, are noncancerous growths in the uterus that can cause a variety of symptoms. The most common symptoms include:\n\n1. **Heavy Menstrual Bleeding:** Many women experience prolonged and heavy menstrual periods (menorrhagia), which can lead to anemia.\n2. **Pelvic Pain or Pressure:** This can manifest as a feeling of fullness or pressure in the pelvic area, particularly if the fibroids are large.\n3. **Frequent Urination:** Location of fibroids can put pressure on the bladder, leading to increased urgency and frequency of urination.\n4. **Pain During Intercourse:** Fibroids can cause discomfort or pain during sexual intercourse due to their position in the uterus.\n5. **Lower Back Pain:** Some women report persistent lower back discomfort, which can be related to the size and location of fibroids.\n6. **Bloating or Swelling:** Fibroids can lead to a visible swelling in the abdomen, making women feel bloated.\n\nThese symptoms can vary in intensity and may not all be present in every woman with fibroids. Seeking medical advice is important for proper diagnosis and management.",
        "paper_evidence":
        [
            "Fibroids can be asymptomatic or present with heavy menstrual bleeding, pelvic pressure, and pain",
            "Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation. It is also associated with reproductive issues like impaired fertility, conceiving complications, and adverse obstetric outcomes. ",
            "Common symptoms associated with fibroids include abnormal uterine bleeding, pelvic pressure and reproductive dysfunction.",
            "The most common reported symptoms of fibroids are heavy menstrual bleeding and painful menstruation, pelvic pain, urinary problems, constipation, as well as infertility and recurrent pregnancy loss.",
            "Approximately 50% of women with fibroids experience symptoms which may include menorrhagia that may result in anemia, bulk symptoms with bladder and bowel dysfunction and abdominal protrusion, dysmenorrhea, and infertility.",
            "In conclusion, women with UFs have significantly higher levels of perceived stress and menstrual distress than controls and HMB plays a major role in determining such conditions.",
            "Uterine fibroids are the most common benign pelvic tumor of the female genital tract and tend to increase with age; they cause menorrhagia, dysmenorrhea, pelvic pressure symptoms, back pain, and subfertility.",
            "Symptoms for up to 50 percent of women experiencing fibroids include heavy menstrual bleeding, pelvic pressure or pain and gastrointestinal and genitourinary changes.",
            "Uterine fibroids (also called leiomyomas or myomas) are the most common disorder among women of reproductive age, with an incidence of between 20% and 80%; they are often detected incidentally in routine healthy examinations, through bimanual pelvic and/or ultrasound examination, because uterine fibroids are rarely associated with symptoms. Sometimes, uterine fibroids may be complicated by a variety of symptoms, including menstrual disturbance (e.g., menorrhagia, dysmenorrhea, intermenstrual bleeding), pressure symptoms, bloated sensation, increased urinary frequency, bowel disturbance, or pelvic pain",
            "Heavy menstrual bleeding (HMB), distress in the pelvis, infertile, and stressed feelings are all indications of fibroids in the uterus, the most prevalent type of benign uterine tumor.",
            "(1) Background: Uterine fibroids are the most common form of benign uterine tumors, causing heavy menstrual bleeding (HMB), pelvic pain, infertility and pressure symptoms.",
            "The main symptoms of uterine fibroids are profuse menstrual bleeding, abnormal uterine bleeding, and pressure symptoms.",
            "The symptoms usually reported by women with fibroids are the following: abnormal gynaecologic haemorrhage, chronic pelvic pain, dyspareunia, as well as urinary and bowel symptoms, urinary frequency or retention and, in some cases, infertility.",
            "Approximately 50% of women with fibroids experience symptoms which can range from heavy menstrual bleeding and bulk-related symptoms such as pelvic pressure with bladder and bowel dysfunction to reproductive dysfunction (e.g., infertility or obstetric complications) and pain.",
            "Fibroids can become symptomatic with symptoms such as menorrhagia and menometrorrhagia, pelvic pain, and reproductive dysfunction.",
            "Though most women with fibroids are asymptomatic, approximately 30% of them will present with severe symptoms which can include abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention.",
            "Symptomatic uterine fibroids present with menstrual problems, anemia, infertility, miscarriages, an enlarged abdomen, pressure symptoms involving the bladder and bowels (such as frequent urination or constipation), and sometimes coital-related problems.",
            "Common symptoms associated with fibroids include pelvic pain, heavy menstrual bleeding, anemia, and pelvic pressure",
            "Uterine fibroids, the most common tumours in women of reproductive age, are asymptomatic in at least 50% of afflicted women. However, in other women, they cause significant morbidity and affect quality of life. Clinically, they present with a variety of symptoms: menstrual disturbances including menorrhagia, dysmenorrhoea and intermenstrual bleeding; pelvic pain unrelated to menstruation; and pressure symptoms such as a sensation of bloatedness, increased urinary frequency and bowel disturbance. In addition, they may compromise reproductive function, possibly contributing to subfertility, early pregnancy loss and later pregnancy complications such as pain, preterm labour, malpresentations, increased need for caesarean section, and postpartum haemorrhage. Large fibroids may distend the abdomen, which may be aesthetically displeasing to many women. Abnormal bleeding occurs in 30% of symptomatic women, and abnormal bleeding, bloating and pelvic discomfort due to mass effect constitute the most common symptoms.",
            "Uterine fibroids (also called leiomyomas or myomas) are the most common disorder among women of reproductive age, with an incidence of between 20% and 80%; they are often detected incidentally in routine healthy examinations, through bimanual pelvic and/or ultrasound examination, because uterine fibroids are rarely associated with symptoms. Sometimes, uterine fibroids may be complicated by a variety of symptoms, including menstrual disturbance (e.g., menorrhagia, dysmenorrhea, intermenstrual bleeding), pressure symptoms, bloated sensation, increased urinary frequency, bowel disturbance, or pelvic pain; therefore definite treatment is requested.",
            "Uterine fibroids (UFs), leiomyomas or myomas, are a type of malignancy that affects the smooth muscle of the uterus, and it is most commonly detected in women of reproductive age. Uterine fibroids are benign monoclonal growths that emerge from uterine smooth muscle cells (myometrium) as well as fibroblasts. Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation.",
            "Heavy or prolonged menstrual bleeding, abnormal uterine bleeding, resultant anemia, pelvic pain, infertility, and/or recurrent pregnancy loss are generally associated with uterine fibroids.",
            "Symptomatic fibroids, with ailments such as abnormal uterine bleeding, dysmenorrhoea, pelvic pain, impaired urination, bowel dysfunction, infertility, and recurrent pregnancy loss, are indicated for medical treatment.",
            "Common symptoms associated with fibroids include pelvic pain, heavy menstrual bleeding, anemia, and pelvic pressure.",
            "The most common symptoms associated with uterine myomas are abnormal uterine bleeding and pelvic discomfort mostly caused by the mass effect.",
            "Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods.",
            "Heavy menstrual bleeding with resultant anemia, dysmenorrhea, chronic pelvic pain, infertility, urinary symptoms and constipation are generally associated with uterine fibroids (UFs).",
            "Fibroid symptoms are protean, and menorrhagia is most frequent.",
            "(fibroids), the most common benign tumor in women of childbearing age, can cause symptoms including dysmenorrhea, menorrhagia, urinary symptoms, pain and infertility.",
            "Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation.",
            "Symptomatic fibroids present with menorrhagia, pelvic pain, leukorrhea, pressure and bloating, increased abdominal girth, and severe dysmenorrhea."
        ]
    },
    "65cfa22b1930410b1300000c":
    {
        "question": "What is the target of Selpercatinib?",
        "llm_evidence": "Selpercatinib is a targeted therapy specifically designed to inhibit the RET (rearranged during transfection) kinase. It is primarily used in the treatment of patients with RET-altered cancers, including non-small cell lung cancer (NSCLC) and certain types of thyroid cancer. Selpercatinib works by blocking the activity of the RET protein, which is involved in cell signaling pathways that promote tumor growth and survival. This selective inhibition leads to reduced proliferation of RET-dependent tumors and has shown significant efficacy in patients with RET fusions and mutations. Clinical trials have demonstrated its effectiveness and favorable safety profile, establishing it as a vital therapy for those with RET-driven malignancies.",
        "paper_evidence":
        [
            "More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy and good tolerability.",
            "Drug exposure of RET inhibitors is expected to increase with CYP 3A4 inhibition, with selpercatinib being the least affected. ",
            "An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).",
            "OBJECTIVE: Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rearrangements.",
            "Three RET-mutant patients received selpercatinib; all showed PR. ",
            "Rapid translation and regulatory approval of selective RET inhibitors, selpercatinib and pralsetinib, have opened up the field of RET precision oncology.",
            "Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.",
            "Selpercatinib (Retevmo®/Retsevmo®) is an orally-administered, selective inhibitor of rearranged during transfection (RET) kinase approved for the treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC).",
            "Thus, currently available evidence suggests that selpercatinib is a promising new RET-targeted therapy option for patients with advanced RET fusion-positive NSCLC.",
            "Selpercatinib is a highly selective RET inhibitor for treatment of metastatic RET-altered MTC. ",
            "Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations.",
            "Conclusions Selective RET inhibitors Pralsetinib and Selpercatinib have shown a good effect on RET fusion-positive NSCLC, with a low incidence of adverse events.",
            "Selpercatinib is a targeted, FDA-approved, oral, small-molecule inhibitor for the treatment of rearranged during transfection (RET) proto-oncogene mutation-positive cancer.",
            "Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.",
            "Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are potent and selective inhibitors that target RET alterations, including fusions and mutations, irrespective of the tissue of origin.",
            "Selpercatinib is a highly selective RET inhibitor that has demonstrated anti-tumor activity in RET-mutated cancers.",
            "Selpercatinib is a small molecule that binds at the RET kinase active site.",
            "In 2020, the US Food and Drug Administration approved selpercatinib, a selective RET inhibitor, for adults with lung and thyroid cancers with RET rearrangements or mutations, making it the first targeted therapy to be approved for RET-altered cancers.",
            "Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib.",
            "Oncogenic RET fusions or mutations are found most often in non-small cell lung cancer (NSCLC) and in thyroid cancer, but also increasingly in various types of cancers at low rates. In the last few years, two potent and selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and received regulatory approval.",
            "INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid",
            "P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).",
            "Selpercatinib and pralsetinib are tyrosine kinase inhibitors selectively targeting RET and with clinical activity in RET-positive NSCLC.CASE PRESENTATION: A male never-smoker in his forties was diagnosed with advanced lung adenocarcinoma.",
            "Fortunately, two selective RET inhibitors (sRETi), namely pralsetinib and selpercatinib, have been approved for treating RET fusion NSCLC due to their remarkable efficacy and safety profiles",
            "Sustained Response with Dose-reduced Selpercatinib in a Pediatric Patient with Metastatic NCOA4-RET Fusion Papillary Thyroid Carcinoma.",
            "In addition to these approvals, dostarlimab for mismatch repair deficiency(dMMR), dabrafenib and trametinib for BRAF V600E, and selpercatinib for RET fusion gene have been approved in the United States as tumor agnostic biomarkers and their treatment",
            "To overcome these issues, new selective RET inhibitors such as pralsetinib (BLU-667) and selpercatinib (LOXO-292) have been developed in clinical trials, with selpercatinib recently approved by the Food and Drug Administration (FDA).",
            "er (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this",
            "Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations have been identified as oncogenic in multiple malignancies. RET gene rearrangements retaining the kinase domain are oncogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, and multiple other cancers. Activating RET mutations are associated with different phenotypes of multiple endocrine neoplasia type 2 as well as sporadic medullary thyroid cancer. RET is thus an attractive therapeutic target in patients with oncogenic RET alterations. Multikinase inhibitors with RET inhibitor activity, such as cabozantinib and vandetanib, have been explored in the clinic for tumors with activating RET gene alterations with modest clinical efficacy. As a result of the nonselective nature of these multikinase inhibitors, patients had off-target adverse effects, such as hypertension, rash, and diarrhea. This resulted in a narrow therapeutic index of these drugs, limiting ability to dose for clinically effective RET inhibition. In contrast, the recent discovery and clinical validation of highly potent selective RET inhibitors (pralsetinib, selpercatinib) demonstrating improved efficacy and a more favorable toxicity profile are poised to alter the landscape of RET-dependent cancers. These drugs appear to have broad activity across tumors with activating RET alterations. The mechanisms of resistance to these next-generation highly selective RET inhibitors is an area of active research. This review summarizes the current understanding of RET alterations and the state-of-the-art treatment strategies in RET-dependent cancers.",
            "o carcinomas. Six inhibitors have been approved for the treatment of RET-driven cancers: vandetanib, cabozantinib, lenvatinib, sorafenib, selpercatinib, and pralsetinib. Only selpercatinib and pralsetinib have been developed specifically for RET, while the remaining are multikina",
            "Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor.",
            "Recently, two potent and selective RET TKIs, pralsetinib (BLU-667) and selpercatinib (LOXO-292), were developed.",
            "nt benefit. Selective RET inhibitors Pralsetinib and Selpercatinib are targeted drugs approved by the US Food and Drug Administration for treating RET-mut",
            "o carcinomas. Six inhibitors have been approved for the treatment of RET-driven cancers: vandetanib, cabozantinib, lenvatinib, sorafenib, selpercatinib, an",
            "Recent advancements in targeted therapies have led to the development of ret proto-oncogene (RET) inhibitors, such as selpercatinib and pralsetinib, which have been approved for the treatment of",
            "OBJECTIVE: Selpercatinib and pralsetinib are new targeted therapies used to treat patients with non-small cell lung cancer (NSCLC) due to RET gene rear",
            "r types. Selpercatinib is a highly selective RET kinase ",
            "INTRODUCTION: Selpercatinib is a RET selective tyrosine kinase inhibitor with nanomolar potency against diverse RE",
            "selective RET protein tyrosine kinase inhibitors (TKIs), pralsetinib (BLU-667) and selpercatinib (LOXO-292, LY3527723) were developed and",
            "Selpercatinib (LOXO-292) is a selective and potent RET inhibitor.",
            "Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. ",
            "er treatment. Selpercatinib (LOXO-292) is a highly selective RET kinase inhibitor indicated in advanced RET-mutant",
            "Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers, but whether they have distinct activity was unknown.",
            "BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung can"
        ]
    },
    "65f5a319c4010b4d78000016":
    {
        "question": "What is IL-35?",
        "llm_evidence": "IL-35, or Interleukin-35, is a member of the interleukin-12 cytokine family, primarily produced by regulatory T cells (Tregs) and regulatory B cells. It plays a crucial role in immune regulation and suppression of inflammatory responses. IL-35 functions by inhibiting the activation and proliferation of other immune cells, particularly effector T cells and dendritic cells, thereby promoting immune tolerance. This cytokine is significant in maintaining homeostasis within the immune system, contributing to the prevention of autoimmune diseases and excessive inflammatory responses. Recent studies have also suggested a potential role for IL-35 in cancer progression by subverting anti-tumor immunity. Overall, IL-35 is essential for controlling immune responses and maintaining the balance between tolerance and immunity.",
        "paper_evidence":
        [
            "INTERLEUKIN-35 DOWNREGULATES THE IMMUNE RESPONSE OF EFFECTOR CD4 + T CELLS VIA RESTRICTING HIGH MOBILITY GROUP BOX-1 PROTEIN-DEPENDENT AUTOPHAGY IN SEPSIS.",
            "The novel role of the anti-inflammatory cytokine IL-35 in sepsis was examined.",
            "Interleukin 35 (IL-35) is involved in the pathogenesis of endometriosis by suppressing immunoreaction and promoting endometrial cell proliferation. ",
            "Interleukin-35 (IL-35), secreted by regulatory T cells (Treg) and B cells, is immunosuppressive under both physiological and pathological conditions.",
            "Interleukin 35 (IL-35) mediates immunosuppression of T cells in autoimmune diseases",
            "IL-35 (Interleukin-35) is a new member of the IL-12 (Interleukin-12) family, which is an immunosuppressive and anti-inflammatory cytokine secreted mainly by Treg (T regulatory cells).",
            "IL-35 is an anti-inflammatory cytokine comprising the p35 subunit of IL-12 and the subunit Epstein-Barr virus (EBV) -induced gene 3(EBI3).",
            "Since its discovery, IL-35 has been shown to exhibit immunosuppressive activities which are distinct from other members of IL-12 family.",
            "IL-35 is a relatively new cytokine that emerges as an important immunomodulator.",
            "Interleukin 35 (IL-35) is the most recently identified member of the IL-12 family of cytokines and offers the potential to be a target for new therapies for autoimmune, inflammatory, and infectious diseases.",
            "Interleukin (IL)-35 is a newly identified inhibitory cytokine used by T regulatory cells to control T cell-driven immune responses.",
            "Interleukin 35 (IL-35) functions in an anti-inflammatory fashion by inhibiting T-cell proliferation, whereas CD4(+) T cells play an important role in cellular immunity.",
            "Interleukin-35 (IL-35), is a recently identified cytokine that belongs to the IL-12 family, it is a potent anti-inflammatory and immunosuppressive cytokine which was first recognized to be produced by regulatory T cells (Tregs) cells, and recently was found to be produced by regulatory B cells (Bregs).",
            "OBJECTIVE: IL-35 (interleukin-35) is an anti-inflammatory cytokine, which inhibits immune responses by inducing regulatory T cells and regulatory B cells and suppressing effector T cells and m",
            "Interleukin-35 (IL-35) is a Treg cell-secreted cytokine that inhibits T cell proliferation and function.",
            "IL-35 can directly suppress effector T-cell proliferation and function and inhibit the differentiation of Th17 cells.",
            "IL-35 is also unique in that it is expressed primarily by regulatory T-cells (Tregs) rather than by antigen-presenting cells (APCs).",
            "BACKGROUND: Interleukin (IL)-35 is a newly indentified cytokine and induces immunotolerance via suppres",
            "BACKGROUND: Interleukin-35 (IL-35) is a recently described heterodimeric cytokine that belongs to the IL-12 family and consists of p35 (IL-12a) and EBI3 (IL-27b) subunits. The expression of IL-35 in humans is inducible in response to inflammatory stimuli. Increased IL-35 levels were documented in several autoimmune inflammatory diseases, suggesting a possible immunomodulatory role in their p",
            "Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells. ",
            "Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells. Accumulating evidence suggests that IL-35 represents an attractive target for anti-atherosclerotic therapy based on its several atheroprotective features.",
            "BACKGROUND: Interleukin-35 (IL-35) is a newly identified IL-12 cytokine family member, which regulates the activity of immune cells in infectious diseases and autoimmune",
            "Interleukin-35 (IL-35) is a lately observed cytokine and is part of the IL-12 cytokine family. IL-35 includes two subunits, p35 and Epstein-Barr virus-induced gene 3, and activates subsequent signaling pathways by binding to receptors to mediate signal transduction, thereby modulating the immunoregulatory functions of T cells, B cells, macrophages, and other immune cell types.",
            "IL-35 is the newest member of IL-12 family. A dimeric protein consisting of two separate subunits has manifested suppressive actions on immune system, which is counterproductive in the context of cancers.",
            "Interleukin (IL)-35 is a novel member of the IL-12 cytokine family, which exhibits a unique immune regulatory function.",
            "BACKGROUND: IL-35 is a novel cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell ",
            "Interleukin-35 (IL-35) is a novel anti-inflammatory cytokine and has been shown to play an important role in maintaining immune homeostasis.",
            "IL35 has recently emerged as a novel regulator of immune responses.",
            "The recently identified cytokines-interleukin (IL)-35 and interleukin (IL)-37-have been described for their anti-inflammatory and immune-modulating actions in numerous inflammatory diseases, auto-immune disorders, malignancies, infectious diseases and sepsis.",
            "BACKGROUND: IL-35 is a newly anti-inflammatory cytokine that belongs to the I",
            "Interleukin-35 (IL-35) is a novel immunosuppressive and anti-inflammatory cytokine.",
            "Interleukin-35 (IL35) can suppress T cell proliferation and elicit the development of inducible regulatory T cells (Tregs).",
            "IL35 is overexpressed in a variety of cancers and may exert its function both on antitumor immune responses as well as directly on tumor cells.",
            "IL-35 includes two subunits, p35 and Epstein-Barr virus-induced gene 3, and activates subsequent signaling pathways by binding to receptors to mediate signal transduction, thereby modulating the immunoregulatory functions of T cells, B cells, macrophages, and other immune cell types.",
            ", IL35 appears to contribute to the loss of immunological self-tolerance in ITP patients by modulating T cells and immunoregulatory cytokine",
            "Among the cytokines, interleukin (IL)-35 is the one most recently discovered that suppresses inflammatory responses of immune cells.",
            "Interleukin 35 (IL-35) is a relatively newly identified cytokine required for the regulatory and suppressive functions of regulatory T cells (Treg), playing an important role in the prevention of autoimmune diseases.",
            "Interleukin-35 (IL-35), an inhibitory cytokine that belongs to the IL-12 family, is capable of potently suppressing T cell proliferation and inducing IL-35-producing induced regulatory T cells (iTr35) to limit inflammatory responses.",
            "meostasis. Interleukin-35 (IL-35), as a newly identified member of IL-12 family, exerts suppressive effect on immune response by means of a specif",
            "Interleukin-35 (IL-35), a cytokine of the interleukin-12 family, is a novel anti-inflammation and immunosuppressive cytokine, maintaining inflammatory suppression and regulating immune homeostasis.",
            "OBJECTIVE: IL-35 is a potent immunosuppressive and anti-inflammatory cytokine, consisting of a p35 subunit and an Epstein-Barr virus-induced gene 3 (EBI3) subunit, which sup"
        ]
    },
    "65f84535c4010b4d78000044":
    {
        "question": "What are the transmission mechanisms of the human Ebola infection?",
        "llm_evidence": "Ebola virus transmission occurs through multiple mechanisms primarily involving direct contact with infected bodily fluids. Key insights include:\n\n1. **Human-to-Human Transmission**: The virus spreads via direct contact with blood, saliva, sweat, vomit, feces, or other bodily fluids of infected individuals. This is particularly prominent during the symptomatic phase of the illness.\n\n2. **Healthcare Settings**: Healthcare workers are at heightened risk due to exposure during treatment of infected individuals, especially in areas lacking adequate infection control measures. Transmission can occur through needle-stick injuries or contact with contaminated medical equipment.\n\n3. **Environmental Contamination**: The virus can survive outside the human body for several hours to days on surfaces, leading to transmission if individuals come into contact with contaminated objects.\n\n4. **Sexual Transmission**: The Ebola virus can persist in certain body fluids like semen for an extended period post-recovery. There have been documented cases of transmission through sexual contact with male survivors.\n\n5. **Contact with Infected Animals**: Initial outbreaks often link to zoonotic transmission from wildlife (e.g., bats, primates), suggesting that handling or consuming infected animals can introduce the virus to humans.\n\nUnderstanding these mechanisms is crucial for implementing effective control measures to prevent Ebola outbreaks.",
        "paper_evidence":
        [
            "EBOV has been described to occur via contact with infected bodily fluids, supported by data indicating that infectious EBOV could be cultured from blood, semen, saliva, urine, and breast milk",
            "human-to-human transmission",
            "persistent EBOV infections and included sexual transmission from EVD survivors",
            "Asymptomatic infection and long-term viral persistence in EVD survivors",
            "persistence of filoviruses and their potential for sexual transmission",
            "nosocomial transmission",
            "The sporadic human outbreaks are believed to result when EBOV \"jumps\" from an infected animal to a person and is subsequently transmitted between persons by direct contact with infected blood or body fluids.",
            "Transmission of EBoV has been reported in various ways, including human to human transmission through close contact with blood and bodily fluids.",
            "Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans. Ebola virus (EBOV) is transmitted through contact with blood or body fluids of a person who contracted or died from EVD, contaminated objects like needles and infected animals or bush meat.",
            "Viruses of the Ebolavirus genus cause sporadic epidemics of severe and systemic febrile disease that are fueled by human-to-human transmission.",
            "People were infected by touching body fluids of blood, secretions, vomit, and other discharges from patients with EVD.",
            "Transmission of EBOV has been described to occur via contact with infected bodily fluids, supported by data indicating that infectious EBOV could be cultured from blood, semen, saliva, urine, and breast milk."
        ]
    },
    "65ce88be1930410b13000002":
    {
        "question": "What is the mechanisms of action of Sotorasib?",
        "llm_evidence": "Sotorasib is a targeted therapy specifically designed to inhibit the mutated form of the KRAS protein, which is commonly associated with various cancers, particularly non-small cell lung cancer (NSCLC). Its mechanism of action primarily involves the following key insights:\n\n1. **KRAS G12C Inhibition**: Sotorasib selectively targets the KRAS G12C mutation, a specific alteration that occurs in the KRAS gene. This mutation leads to continuous activation of downstream signaling pathways that promote cell proliferation and survival.\n\n2. **Binding Mechanism**: The drug binds covalently to the cysteine residue of the KRAS G12C mutant protein, locking it in an inactive state. This disrupts its ability to transmit growth signals through the RAS-MAPK and PI3K-AKT pathways, ultimately leading to reduced tumor growth and survival.\n\n3. **Antitumor Activity**: Clinical studies have shown that Sotorasib effectively reduces tumor size and improves progression-free survival in patients with KRAS G12C-mutated tumors. Its efficacy is particularly notable in NSCLC but is also being explored in other malignancies with the same mutation.\n\n4. **Personalized Medicine**: Sotorasib represents a significant advancement in personalized cancer therapy, providing an option for patients whose tumors harbor the KRAS G12C mutation, emphasizing the move toward targeted and individualized treatment strategies in oncology.\n\nIn summary, Sotorasib functions by specifically inhibiting the KRAS G12C mutation, thereby interfering with critical signaling pathways that drive the growth of certain cancers.",
        "paper_evidence":
        [
            "At progression, the patient continued entrectinib and started sotorasib, a small molecule inhibitor of KRAS p.G12C.",
            "Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occurring genomic alterations. Here, we report on a patient with metastatic NSCLC with a concurrent ROS1 fusion and KRAS p.G12C mutation at diagnosis who experienced a short duration of disease control on entrectinib, a ROS1 TKI. At progression, the patient continued entrectinib and started sotorasib, a small molecule inhibitor of KRAS p.G12C. A patient-derived cell line generated at progression on entrectinib demonstrated improved TKI responsiveness when treated with entrectinib and sotorasib. Cell-line growth dependence on both ROS1 and KRAS p.G12C was further reflected in the distinct downstream signaling pathways activated by each driver. Clinical benefit was not observed with combined therapy of entrectinib and sotorasib possibly related to an evolving KRAS p.G12C amplification identified on repeated molecular testing. This case supports the need for broad molecular profiling in patients with metastatic NSCLC for potential therapeutic and prognostic information.",
            "ecent breakthroughs in the development of mutant-specific KRAS inhibitors include the FDA approved drug Lumakras (Sotorasib, AMG510) for KRAS G12C-mutated non-small cell lung cancer (NSCLC), and MRTX1133, a promising clinical candidate for the treatment of KRAS G12D-mutated cancers.",
            "[Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].",
            "Following the CodeBreak 100 study, since 2021 sotorasib has been available in France, with authorization for early access in treatment of non-small cell lung cancer with a KRAS G12C mutation. ",
            "BACKGROUND: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRASG12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs.",
            "This discovery stemmed from our finding that Survivin expression is downregulated upon treatment of pancreatic cancer cells with the KRASG12C inhibitor Sotorasib. ",
            "Sotorasib was the first-in-class KRAS inhibitor to reach the US and European market, and its pharmacological inhibition is restricted to the KRAS p.G12C mutation.",
            "Evidence indicates that treatment with KRAS G12C inhibitors (sotorasib) triggers the MRAS:SHOC2:PP1C trimeric complex",
            "In summary, sotorasib is a promising KRASG12C inhibitor that increases the available treatment options for patients with KRAS G12C mutation-positive NSCLC who were previously treated with platinum-based chemotherapy and/or immunotherapy.",
            "Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation.",
            "Sotorasib, a first-in-class specific small molecule that irreversibly inhibits KRAS G12C, has since obtained Health Canada approval.",
            "By binding irreversibly to KRASG12C, sotorasib inhibits downstream signalling pathways which are associated with cell growth and differentiation.",
            "Sotorasib (LUMAKRAS™ in the USA and LUMYKRAS™ in the EU) is an orally active, first-in-class G12C-mutant KRAS (KRASG12C) inhibitor.",
            "Sotorasib (LUMAKRAS®) is the first RAS inhibitor that selectively binds to KRAS G12C and irreversibly inhibits the conformational change from the inactive to active form of KRAS.",
            "Using this approach, we characterised how the interactome of KRAS wild-type and mutants is regulated by the clinically approved KRASG12C inhibitor Sotorasib.",
            "Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma.CONCLUSIONS: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation.",
            "Sotorasib (LUMAKRAS™) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer.",
            "Sotorasib, a first-in-class covalent KRAS G12C inhibitor that binds to the switch pocket II in the KRAS G12C-GDP \"off\" state, received US FDA accelerated approval on May 21, 2021 in the US, based on a Phase II dose expansion cohort of CodeBreaK 100 trial.",
            "Their foremost mechanism of action utilizes the Switch II binding pocket and Cys12 residue of GDP-bound KRAS proteins in G12C mutants, confining them to their inactive state. Sotorasib and Adagrasib, both FDA-approved for the treatment of non-small cell lung cancer (NSCLC), have been pivotal in paving the way for KRAS G12C inhibitors in the clinical setting.",
            "BACKGROUND: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at co",
            "We identified compounds, such as flupentixol, amlodipine, and fluvoxamine, for the G12C mutant and paroxetine, flupentixol, and zuclopenthixol for the G12D mutant with significant inhibitory functions. All five compounds bound to the H95 cryptic groove of mutant K-Ras with high efficiency and, like sotorasib, retained a novel binding mechanism with additional hydrophobic interactions at the molecular level.",
            "The recently approved mutant selective small-molecule cysteine-reactive covalent inhibitor of the G12C mutant of K-Ras, sotorasib, provides a case in point.",
            "Sotorasib and Adagrasib, both FDA-approved for the treatment of non-small cell lung cancer (NSCLC), have been pivotal in paving the way for KRAS G12C inhibitors in the clinical setting",
            "Sotorasib is indicated for the treatment of adults with advanced, previously treated, KRAS G12C mutation-positive non-small cell lung cancer (NSCLC) in multiple countries, including the countries of the EU and the USA.",
            "We will comment on the group with KRAS G12C mutation and the targeted therapy with sotorasib for its efficiency and toxicity based on new studies.",
            "Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation, was approved by the U.S. Food and Drug Administration (FDA), as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) containing the KRAS G12C mutation, on the basis of results of a phase II clinical trial (Code- BreaK100). In this article, we review the mechanism of action of KRAS G12C inhibitors and the latest clinical trials with sotorasib to provide a comprehensive understanding of its efficacy and toxicity.",
            "In particular, the covalent KRAS-G12C inhibitors sotorasib and adagrasib are used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS-G12C mutations.",
            "Recent efforts have witnessed a revolutionary strategy for KRAS G12C inhibitors with exhibiting conspicuous clinical responses across multiple tumor types, providing new impetus for renewed drug development and culminating in sotorasib with approximately 6-month median progression-free survival in KRAS G12C-driven lung cancer.",
            "This discovery led to the development of a new class of selective small-molecule inhibitors against the KRAS G12C isoform. Sotorasib and adagrasib are approved in locally advanced or metastatic NSCLC patients who have received at least one prior systemic therapy.",
            "Recently, the discovery of a new pocket under the effector binding switch II region of KRAS G12C has allowed the development of direct KRAS inhibitors such as sotorasib, the first FDA-approved drug targeting KRAS G12C, or adagrasib, initiating a new exciting era.",
            "Sotorasib and adagrasib are novel KRAS inhibitors that recently gained FDA approval for pre-treated KRAS mutant NSCLC patients, and other molecules such as GDC-6036 are currently being investigated with promising results.",
            "Advances over the past decade with KRAS(G12C) mutation-specific inhibitors have culminated in the first FDA-approved RAS drug, sotorasib.",
            "Recent breakthroughs in the development of mutant-specific KRAS inhibitors include the FDA approved drug Lumakras (Sotorasib, AMG510) for KRAS G12C-mutated non-small cell lung cancer (NSCLC)",
            "Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C mutation, was approved by the U.S. Food and Drug Administration (FDA), as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) containing the KRAS G12C mutation, on the basis of results of a phase II clinical trial (Code- BreaK100).",
            "In this article, we review the mechanism of action of KRAS G12C inhibitors and the latest clinical trials with sotorasib to provide a comprehensive understanding of its efficacy and toxicity.",
            "Sotorasib and Adagrasib, both FDA-approved for the treatment of non-small cell lung cancer (NSCLC), have been pivotal in paving the way for KRAS G12C inhibitors in the clinical setting.",
            "Sotorasib, a direct inhibitor of the enzyme Kirsten rat sarcoma viral oncogene (KRAS) with the G12C",
            "how the interactome of KRAS wild-type and mutants is regulated by the clinically approved KRASG12C inhibitor Sotorasib. In",
            "cancer. Until the recent approval of sotorasib, a KRAS G12C inhibitor, lack of targeted",
            "Evidence indicates that treatment with KRAS G12C inhibitors (sotorasib) triggers the MRAS:SHOC2:PP1C trimeric complex.",
            "Sotorasib, has been approved by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency. Another KRAS inhibitor targeting c.34G > T (p.G12C), Adagrasib, is currently being reviewed by the FDA for accelerated approval."
        ]
    },
    "65f039fdc4010b4d78000002":
    {
        "question": "What is the vector for coxiella burnetii transmission?",
        "llm_evidence": "Coxiella burnetii, the causative agent of Q fever, is primarily transmitted to humans through inhalation of contaminated aerosols, particularly from environments contaminated with the bacteria, such as barnyards or livestock facilities. The main vectors for transmission are domesticated animals, especially cattle, sheep, and goats, which shed the bacteria in their feces, urine, milk, and birthing products. The bacteria can survive in the environment for long periods, making it possible for people to become infected even without direct contact with infected animals. Additionally, tick bites are considered a potential, though less common, route of transmission. Understanding these transmission dynamics is crucial for controlling outbreaks and ensuring public health safety.",
        "paper_evidence":
        [
            "transmitted by ticks include bacteria of the genus Borrelia and the species Francisella tularensis, Anaplasma phagophytophilum and Coxiella burnetii; ",
            "Prevalence of Coxiella-infections in ticks - review and meta-analysis.",
            "Excretion of C. burnetii in tick feces and saliva is well documented but the role of these findings or the epidemiological context is discussed controversia",
            "Exploring the diversity of tick-borne pathogens: The case of bacteria (Anaplasma, Rickettsia, Coxiella and Borrelia) protozoa (Babesia and Theileria) and viruses (Orthonairovirus, tick-borne encephalitis virus and louping ill virus) in the European continent.",
            "Vector competence of the African argasid tick Ornithodoros moubata for the Q fever agent Coxiella burnetii.",
            "Although C. burnetii transmission is mainly airborne, ticks may act as vectors and play an important role in the natural cycle of transmission of coxiellosis among wild vertebrates and livestock.",
            "Finally, we detected only a sporadic presence of C. burnetii DNA in tick faeces, but no living bacterium was further isolated in culture assays, suggesting that excretion in faeces is not a common mode of transmission in O. moubata.",
            "Transstadial Transmission from Nymph to Adult of Coxiella burnetii by Naturally Infected Hyalomma lusitanicum.",
            "Coxiella burnetii (Derrick) Philip, the causative agent of Q fever, is mainly transmitted by aerosols, but ticks can also be a source of infection.",
            "Furthermore, the transmission of C. burnetii is most likely via vectors (i.e., ticks).",
            "Query (Q) fever is a vector-borne zoonosis caused by the obligate intracellular pathogen Coxiella burnetii. Animals, including dogs, cats, cattle, and sheep, can be infected by C. burnetii.",
            "Q fever is a global zoonotic infection caused by the intracellular Gram-negative bacterium Coxiella burnetii. Historically, it is considered a vector-borne disease, but the role of ticks in transmission has not fully been elucidated yet.",
            "Q fever is a widespread zoonotic disease caused by Coxiella burnetii that most commonly infects not only a variety of mammals but also arthropods and in particularly ticks.",
            "In this study, we re-evaluated the vector competence of the African soft tick Ornithodoros moubata for an avirulent strain of C. burnetii. To this end, we used an artificial feeding system to initiate infection of ticks, specific molecular tools to monitor further infections, and culture assays in axenic and cell media to check for the viability of C. burnetii excreted by ticks. We observed typical traits associated with vector competence: The exposure to an infected blood meal resulted in viable and persistent infections in ticks, trans-stadial transmissions of infection from nymphs to adults and the ability of adult ticks to transmit infectious C. burnetii.",
            "The dramatic spread of Q fever in Poland among cattle kept in isolation from natural environment (ticks, wild animals) has suggested the possibility that the infection may also be transmitted sexually. To test this hypothesis series of experiments have been performed in controlled laboratory conditions. Male mice infected with C. burnetii were allowed to mate with healthy female mice.",
            "Background: Q fever is a zoonotic disease caused by Coxiella burnetii infection, with domestic ruminants as the main source of infection and tick bites as one of the transmission vectors.",
            "In addition, while adult female ticks were infected, we did not observe C. burnetii in eggs, suggesting that transovarial transmission is not effective.",
            "In this study, we re-evaluated the vector competence of the African soft tick Ornithodoros moubata for an avirulent strain of C. burnetii.",
            "Coxiella burnetii, the causative agent of Q fever, and Rickettsia spp. are bacterial pathogens that can be transmitted by ticks of the genus Dermacentor (i.e., Dermacentor marginatus and D. reticulatus).",
            "Our data suggest that zebus as well as Amblyomma and Boophilus ticks have to be considered as a natural reservoir or vector for C. burnetii, but the risk of cattle-to-human transmission is low.",
            "ticks in the transmission of Coxiella",
            "BACKGROUND: The bacterium Coxiella burnetii is the etiological agent of Q fever and is mainly transmitted via inhalation of infectious aerosols. DNA of C. burnetii is frequently detected in ticks, but the role of ticks as vectors in the epidemiology of this agent is still controversial. In this study, Ixodes ricinus and Dermacentor marginatus adults a",
            "Coxiella burnetii, a ubiquitous intracellular bacterium infecting humans and a variety of animals. Transmission is primarily but not exclusively airborne, and ticks are usually thought to act as vectors. We argue that, although ticks may readily transmit C. burnetii in experimental systems, they only occasionally transmit"
        ]
    },
    "65f82fe1c4010b4d7800003f":
    {
        "question": "Methotrexate is an antifolate medication.",
        "llm_evidence": "Methotrexate is an antifolate medication that works by inhibiting the enzyme dihydrofolate reductase (DHFR), which is crucial for the synthesis of folate. By blocking this enzyme, methotrexate reduces the production of tetrahydrofolate, a form of folate necessary for DNA synthesis and repair. This mechanism makes methotrexate effective in treating various conditions, including certain cancers, autoimmune diseases like rheumatoid arthritis, and ectopic pregnancies. Its antifolate properties also lead to its use in combination therapies where suppression of rapidly dividing cells is necessary. Additionally, methotrexate's ability to deplete folate can result in side effects, necessitating supplementation with folic acid in some cases to mitigate toxicity.",
        "paper_evidence":
        [
            "Methotrexate (MTX) is an antifolate",
            "antifolate medications, such as methotrexate",
            "Methotrexate (MTX) is an antimetabolite and antifolate drug used in the treatment of cancer and autoimmune diseases.",
            "INTRODUCTION: Methotrexate is an antifolate medication frequently used in the treatment of malignant and nonmalignant diseases.",
            "Methotrexate is a well known antifolate.",
            "Antifolate methotrexate (MTX), a drug commonly used in chemotherapy of several types of cancer, is a strong inhibitor of folate metabolism.",
            "Methotrexate (MTX), an antifolate drug, is the first-line disease-modifying agent for the treatment of rheumatoid arthritis (RA) worldwide.",
            "Methotrexate is an antimetabolite and antifolate drug that is widely used in the treatment of malignancies and auto-immune disorders.",
            "Methotrexate (MTX), the antifolate drug widely used as both an anticancer chemotherapeutic drug and as an immunosuppressive agent, mimics natural folates to inhibit critical cellular biosynthetic pathways.",
            "Methotrexate, the most studied folate antagonist, is effective in many malignancies.",
            "Methotrexate inhibits dihydrofolate reductase, which leads to accumulation of polyglutamated folates, causing further inhibition of thymidylate synthase and glycinamide ribonucleotide formyltransferase.",
            "INTRODUCTION: Antifolates are structural analogs of folates, which have been used as antitumor drugs for more than 60 years. The antifolate drug most commonly used for treating human tumors is methotrexate (MTX), which is utilized widely in first-line treatment protocols of high-grade osteos",
            "BACKGROUND: For decades, methotrexate (MTX; amethopterin) has been known as an antifolate inhibitor of dihydrofolate reductase (DHFR), and it is widely used for the treatment of various malignancies and autoimmu",
            "Antifolates, such as methotrexate (MTX), are the treatment of choice for numerous cancers. MTX inhibits dihydrofolate reductase (DHFR), which is essential for cell growth and proliferation.",
            "Methotrexate (MTX) is an antifolic drug used in the treatment of immune-mediated and neoplastic diseases.",
            "Methotrexate (MTX) is an antifolate cytotoxic medication used to treat certain types of cancer and at lower doses for rheumatic diseases.",
            "(1) Background: Antifolate methotrexate (MTX) is the most common disease-modifying antirheumatic drug (DMARD) for treating human rheumatoid arthritis (RA).",
            "Methotrexate is an antifolate agent used in the treatment of various cancers and some autoimmune diseases.",
            "Methotrexate (MTX) is an antifolate drug used for several diseases.",
            "Methotrexate is an antifolate that inhibits methylation reactions and reactions of amino acid, purine and pyrimidine metabolism.",
            "Methotrexate (MTX) is an antifolic drug that in recent years has been largely employed in the treatment of Rheumatoid Arthritis (RA).",
            "Methotrexate (MTX), a folate antagonist, is often used as second-line treatment in patients with sarcoidosis",
            "The folate antagonist high-dose methotrexate (HD-MTX) is integral to induction chemotherapy for primary CNS lymphoma (PCNSL); however, it can be associated with leukoencephalopathy",
            "6MP is combined with weekly oral methotrexate (MTX), an antifolate drug, to augment therapeutic activity",
            "Methotrexate (MTX) is an antifolate that is inescapable and widely used to treat autoimmune diseases and is the gold standard medicine for the arthritic condition",
            "Most of our understanding of folate metabolism in the parasite Leishmania is derived from studies of resistance to the antifolate methotrexate (MTX)",
            "Recent studies have shown that known antifolate compounds, including methotrexate, inhibit the activity of W",
            "Methotrexate (MTX) is an antifolate and immunosuppressive drug prescribed for various malignancies and immune diseases",
            "BACKGROUND: Methotrexate is an antifolate antimetabolite that inhibits the activity of dihydrofolate reductase by acting as a false substrate, which leads to defects of DNA synthesis, specifically the inhibition of purine and pyrimidine synthesis.",
            "Methotrexate (MTX), a folate antagonist drug, has been widely used for treating various cancers.",
            "Methotrexate (MTX) is a specific folate antagonist that competitively inhibits dihydrofolate reductase (DHFR) activity.",
            "Antifolates, such as methotrexate (MTX), are the treatment of choice for numerous cancers.",
            "Methotrexate (MTX) is a folate antagonist inhibiting nucleic acid and methionine synthesis.",
            "Methotrexate (MTX) is a folate inhibitor which has gained a major role in the treatment of rheumatoid arthritis (RA).",
            "Methotrexate (MTX), a folate antagonist which blocks de novo nucleotide biosynthesis and DNA replication, is an anchor drug in acute lymphoblastic leukemia (ALL) treatment.",
            "Methotrexate (MTX), a folic acid antagonist, is among the most active known drugs for clinical cancer therapy.",
            "The folate inhibitor methotrexate (MTX) is an important component of osteosarcoma (OS) treatment regimens.",
            "Methotrexate (MTX), a folic acid antagonist, is widely used in the treatment of neoplasms, psoriasis and rheumatoid arthritis.",
            "Methotrexate (MTX) is a folate antagonist drug used for several diseases, such as cancers, various malignancies, rheumatoid arthritis (RA) and inflammatory bowel disease.",
            "Methotrexate (MTX) is a folic acid antagonist used in high doses as antimetabolite in anti-cancer treatment as well as in low doses for the treatment of rheumatoid arthritis and adults' psoriasis.",
            "Methotrexate (MTX) is a folic acid antagonist, the mechanism of action is to inhibit DNA synthesis, repair and cell proliferation by decreasing the activities of several folate-dependent enzymes.",
            "Methotrexate (MTX) is an antifolate cytotoxic medication used to treat certain types of cancer and",
            "e (MTX) is an antifolate and immunosuppressive drug prescribed for various malignancies and im",
            "Methotrexate (MTX) is a clinically important antifolate that has been used in combination with other chemotherapeutic agents in the treatment of malignancies including acute lymphocytic leukemia, osteosarcoma, carcinomas of the breast, head and neck, choriocarcinoma and non-Hodgkin's lymphoma.",
            "Methotrexate (MTX) is the prototype folate antagonist cytotoxic drug, employed in the therapy of solid tumors and leukaemias, and recently also as an immunosuppressive agent in organ transplantation, in the treatment of some autoimmune diseases and in the therapy of severe asthma.",
            "A number of drugs such as aminopterin, methotrexate (amethopterin), pyrimethamine, trimethoprim and triamterene act as folate antagonists and produce folate deficiency by inhibiting this enzyme.",
            "The folate antagonist methotrexate is a cytotoxic drug used in the treatment of several cancer types.",
            "Amethopterin (methotrexate, MTX) is an antimetabolite and antifolate drug with antiflammatory properities and is used to treat autoimmune diseases, such as psoriasis, rheumatoid arthritis and certain types of cancer, such as breast, lymphoma and lung.",
            "A number of antifolate drugs, which inhibit the key enzymes in the 'thymidylate cycle', dihydrofolate reductase (DHFR) and thymidylate synthase (TS), have been developed as part of the search for analogues with superior antitumor efficacy to a 'classical' antifolate, methotrexate (MTX), and those which are active against the MTX-resistant tumor cells."
        ]
    },
    "65d131451930410b13000034":
    {
        "question": "Is GC1118 effective for glioblastoma?",
        "llm_evidence": "GC1118, a monoclonal antibody targeting the human epidermal growth factor receptor (HER) pathway, has shown promise in clinical settings for treating glioblastoma multiforme (GBM). Glioblastoma is notoriously resistant to conventional therapies, leading to a need for innovative approaches. Recent studies indicate that GC1118 may enhance anti-tumor immunity and inhibit tumor growth by blocking the HER signaling pathway. In preclinical trials, GC1118 demonstrated the ability to impede cell proliferation and promote apoptosis in glioblastoma cell lines. Additionally, early-phase clinical trials have reported some tumor shrinkage and improved patient outcomes when GC1118 was used in combination with other therapies, suggesting its potential as an effective treatment option for glioblastoma. However, more extensive clinical trials are needed to establish its overall efficacy and safety profile in larger patient populations.",
        "paper_evidence":
        [
            "CONCLUSION: This study did not meet the primary endpoint (PFS6); however, we found that immune signatures were significantly upregulated in the tumors with regression upon GC1118 therapy, which signifies the potential of immune-mediated antitumor efficacy of GC1118."
        ]
    },
    "65f70d71c4010b4d7800001e":
    {
        "question": "Is COACH syndrome a rare autosomal recessive genetic disease characterized by liver fibrosis and related to portal hypertension.",
        "llm_evidence": "COACH syndrome, which stands for cholangitis, obliterative bronchitis, autoimmune hepatitis, cryptogenic cirrhosis, and hepatopulmonary syndrome, is indeed a rare autosomal recessive genetic disease. It is characterized by a combination of liver dysfunction, including fibrosis and cirrhosis, often leading to portal hypertension. The disease is primarily linked to mutations in the EPHX1 gene, which affects hepatic functions and can lead to the accumulation of bile acids in the liver, resulting in liver injury and the associated complications. Portal hypertension occurs as a consequence of increased portal venous pressure due to liver fibrosis and cirrhosis. Hence, COACH syndrome is characterized by significant liver-related symptoms and a rare genetic inheritance pattern.",
        "paper_evidence":
        [
            "The clinical features of cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis (COACH) characterize the rare autosomal recessive multisystem disorder called COACH syndrome.",
            "COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension. ",
            "COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension",
            "Physicians should be aware of COACH syndrome when they examine young patients who present with hepatopathy, portal hypertension of unknown origin and cerebellar ataxia.",
            "We describe a 28-yr-old female with COACH syndrome resulting in chronic renal and hepatic insufficiency",
            "Hepatic insufficiency and liver transplantation in a patient with COACH syndrome.",
            "BACKGROUND: COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertension.",
            "The acronym COACH defines an autosomal recessive condition of Cerebellar vermis hypo/aplasia, Oligophrenia, congenital Ataxia, Coloboma and Hepatic fibrosis.",
            "OBJECTIVE: To identify genetic causes of COACH syndromeBACKGROUND: COACH syndrome is a rare autosomal recessive disorder characterised by Cerebellar vermis hypoplasia, Oligophrenia (developmental delay/mental retardation), Ataxia, Coloboma, and Hepatic fibrosis.",
            "MKS3/TMEM67 mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement.",
            "The main feature of COACH is congenital hepatic fibrosis (CHF), resulting from malformation of the embryonic ductal plate.",
            "BACKGROUND: COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal h",
            "Of these three previous patients, one died from hepatic failure due to de novo HCV infection 3 years after LT.CONCLUSIONS: LT should be considered an effective treatment for COACH syndrome in patients with severe portal hypertension.",
            "However, only a few patients with COACH syndrome undergoing liver transplantation (LT) have been reported.MATERIALS AND METHODS: We herein report the outcomes of four children who underwent LT for COACH syndrome at our institute and review three previously reported cases to elucidate the role of LT in COACH syndrome.RESULTS: All four patients in our institute were female, and three received living donors LT. All patients were diagnosed with COACH syndrome by genetic testing.",
            "This combination of findings suggested a diagnosis of COACH syndrome which is characterized by hypoplasia of cerebellar vermis, oligophrenia, congenital ataxia, coloboma, and hepatic fibrosis.",
            "The COACH syndrome is a very rare disorder with cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis.",
            "BACKGROUND: COACH syndrome is a rare autosomal recessive genetic disease characterized by liver fibrosis, which leads to severe complications related to portal hypertensi",
            "COACH syndrome is an autosomal recessive developmental disorder, a subtype of Joubert syndrome and related disorders, characterized by cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis.",
            "This pattern of defects is consistent with COACH syndrome (Cerebellar vermis hypoplasia, Oligophrenia, congenital Ataxia, Coloboma, Hepatic fibrocirrhosis) which has previously been reported in five other cases."
        ]
    },
    "65f86f62c4010b4d7800005c":
    {
        "question": "Which symptoms could indicate depression in young children?",
        "llm_evidence": "Depression in young children can manifest through a variety of symptoms that may differ from those seen in older individuals. Key insights include:\n\n1. **Mood Changes**: Persistent sadness, irritability, or mood swings are common. Children may seem more withdrawn or show a lack of interest in activities they once enjoyed.\n\n2. **Behavioral Symptoms**: Increased anger, tantrums, or disruptive behavior can be indicative of underlying depression. Some children may also exhibit regressive behaviors, such as bedwetting or thumb sucking.\n\n3. **Changes in Sleep Patterns**: Insomnia, nightmares, or excessive sleeping can signal depression. Difficulty waking up or reluctance to go to school may also be present.\n\n4. **Appetite and Weight Changes**: Eating disturbances, such as a significant increase or decrease in appetite, can reflect emotional distress.\n\n5. **Cognitive Impairments**: Trouble concentrating, making decisions, or remembering things may be signs of depression. Young children might express these through difficulties in school or play.\n\n6. **Physical Complaints**: Unexplained physical symptoms like stomachaches or headaches are common among depressed children and may be used to express emotional pain.\n\nRecognizing these signs early is crucial for intervention and support, as young children may lack the verbal skills to articulate their feelings directly.",
        "paper_evidence":
        [
            "Major depressive disorder is common, debilitating, and affects feelings, thoughts, mood, and behaviors. Childhood and adolescence are critical periods for the development of depression",
            "The domain of negative self-concept during the toddler period evidenced by self-deprecation and difficulty making choices emerged as the two strongest variables predictive of preschool depression.",
            "Childhood depression is an episodic disorder characterized by 10 criteria, symptoms of dysphoric mood, self-deprecatory ideation, agitation, loss of energy, reduced socialization, altered school performance, altered school attitude, sleep disturbance, appetite disturbance, and somatic compliants persisting for at least one month.",
            "Reductions in positive affect are a salient feature of preschool-onset major depressive disorder. Yet, little is known about the psychophysiological correlates of this blunted positive affect and whether reduced physiological responding to pleasant stimuli may differentiate depressed and healthy young children. ",
            "Depressive disorders can be observed in early childhood and are associated with significant concurrent and prospective impairment; however, little is known about day-to-day variations in common depressive behaviors in children. This study examined the day-to-day variability of two common depressive behaviors in preschool-aged children, sadness and irritability, and factors associated with the daily occurrence of these behaviors.",
            "Findings suggest that clinical-level symptoms of depression may arise as early as age 24 months. The domain of negative self-concept during the toddler period evidenced by self-deprecation and difficulty making choices emerged as the two strongest variables predictive of preschool depression."
        ]
    },
    "65d136bc1930410b1300003c":
    {
        "question": "What are active ingredients of Paxlovid?",
        "llm_evidence": "Paxlovid is an oral antiviral medication used to treat COVID-19. It consists of two active ingredients: nirmatrelvir and ritonavir. \n\n1. **Nirmatrelvir**: This compound is a protease inhibitor that specifically targets the SARS-CoV-2 virus, inhibiting its replication by blocking the activity of the main protease necessary for viral protein processing. \n\n2. **Ritonavir**: While originally developed as an HIV protease inhibitor, ritonavir is included in Paxlovid primarily to boost the effectiveness of nirmatrelvir. It inhibits the metabolic breakdown of nirmatrelvir, allowing higher concentrations of the antiviral to remain in the body for an extended period.\n\nTogether, these ingredients work synergistically to reduce the viral load in patients with COVID-19, ultimately improving clinical outcomes and reducing the risk of severe illness.",
        "paper_evidence":
        [
            " Paxlovid® is composed of two tablets, nirmatrelvir and ritonavir. ",
            "The anti-COVID drugs explored via other approaches include nirmatrelvir (used in combination with ritonavir as Paxlovid), tixagevimab and cilgavimab (both used in combination with each other) and others.",
            "Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer.",
            "Introduction: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019. ",
            "Paxlovid, as used in the clinic, is a combination of Nirmatrelvir (viral protease inhibitor) and Ritonavir (a \"booster\" inhibitor of Nirmatrelvir metabolism).",
            "PAXLOVID, comprised of nirmatrelvir and ritonavir (used as a pharmacokinetic enhancer), is an oral therapy currently in development as a therapeutic option for those infected with SARS-CoV-2 to prevent progression to severe disease, hospitalization, and death.",
            "Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.",
            "Pfizer's drug for the treatment of patients infected with COVID-19, Paxlovid, contains most notably nirmatrelvir, along with ritonavir.",
            "On December 22, 2021, the United States Food and Drug Administration approved the first main protease inhibitor, i.e., oral antiviral nirmatrelvir (PF-07321332)/ritonavir (Paxlovid), for the treatment of early severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.",
            "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease inhibitor PF-07321332 (nirmatrelvir), in combination with ritonavir (Paxlovid), was recently granted emergency use authorization by multiple regulatory agencies for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients.",
            "Paxlovid, a combination of Nirmatrelvir and Ritonavir, was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID-19 on December 22, 2021.",
            "Paxlovid is a nirmatrelvir (NMV) and ritonavir (RTV) co-packaged medication used for the treatment of coronavirus disease 2019 (COVID-19). The active component of Paxlovid is NMV and RTV is a pharmacokinetic booster.",
            "The anti-COVID drugs explored via other approaches include nirmatrelvir (used in combination with ritonavir as Paxlovid)",
            "antiviral treatment. Most case reports of rebound COVID-19 have been associated with cessation of treatment with the combined oral antiviral agent nirmatrelvir/ritonavir (Paxlovid).",
            "Paxlovid, a copackaged medication of nirmatrelvir tablets (150 mg) and ritonavir tablets (100 mg) developed by Pfizer, is one of the first orally accessible COVID-19 antiviral medicines to be approved for emergency usage.",
            "Introduction: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019.",
            "PURPOSE: PAXLOVID™ is nirmatrelvir tablets co-packaged with ritonavir tablets. Ritonavir is used as a pharmacokinetics (PK) enhancer to reduce metabolism and increase exposure of nirma",
            "disease 2019. The active antiviral component nirmatrelvir in Paxlovid is co-formulated with ritonavir, a strong cytochrome P450 (CYP) "
        ]
    },
    "65f37997c4010b4d7800000b":
    {
        "question": "What is an Albatross plot used for?",
        "llm_evidence": "An Albatross plot, also known as a 'funnel plot,' is primarily used in the field of meta-analysis and health research to visualize the relationship between study size (or precision) and effect size. It helps identify potential publication bias by displaying the results of individual studies against their sample sizes or standard errors. In an Albatross plot, the y-axis represents the effect size (e.g., odds ratios or mean differences), while the x-axis represents the inverse of the standard error. The expected distribution under the null hypothesis forms a funnel shape; asymmetry in the distribution can indicate the presence of biases, such as unpublished negative results. Overall, Albatross plots serve as a tool for researchers to assess the robustness of their findings and the validity of their conclusions in systematic reviews.",
        "paper_evidence":
        [
            "The albatross plot: A novel graphical tool for presenting results of diversely reported studies in a systematic review.",
            "We provide examples of albatross plots using data from previous meta-analyses, allowing for comparison of results, and an example from when a meta-analysis was not possible.",
            "For interpretation of the results across studies, we produced albatross plots for all studies combined and by age-groups, sex of the parents, sex of the child, methodology of assessment of parental PA, and type of PA.RESULTS: Thirty-nine papers were included with sample size of parent-child dyads ranging from 15 to 1267 (mean = 319 dyads, median = 227 dyads).",
            "We propose a novel plot, the albatross plot, which requires only a 1-sided P value and a total sample size from each study (or equivalently a 2-sided P value, direction of effect and total sample size). The plot allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies.",
            "To assess the quality of evidence, Cochrane Collaboration's Risk of Bias Tool was used. Due to the heterogeneity of reported outcomes, meta-analysis was performed for only some outcomes and a narrative synthesis with albatross plots was presented.",
            "We propose a novel plot, the albatross plot, which requires only a 1-sided P value and a total sample size from each study (or equivalently a 2-sided P value, direction of effect and total sample size). The plot allows an approximate examination of underlying effect sizes and the potential to identify sources of heterogeneity across studies. This is achieved by drawing contours showing the range of effect sizes that might lead to each P value for given sample sizes, under simple study designs."
        ]
    },
    "65f85df3c4010b4d78000051":
    {
        "question": "What should you do if you find an individual that you suspect has overdosed?",
        "llm_evidence": "If you suspect an individual has overdosed, follow these key steps:\n\n1. **Assess the Situation:** Ensure the environment is safe for you to approach the individual and check for responsiveness—shake their shoulders and shout to wake them up.\n\n2. **Call for Help:** If the person is unresponsive or you suspect a serious overdose, call emergency services immediately. Provide them with as much information as possible about the situation and the substances involved, if known.\n\n3. **Check Vital Signs:** Monitor the person’s breathing and pulse. If they are not breathing or breathing abnormally (e.g., slow or gasping), be prepared to administer CPR.\n\n4. **Administer Naloxone:** If available and you suspect an opioid overdose, you can use Naloxone (Narcan). This medication can rapidly reverse the effects of opioid overdose and can be administered by nasal spray or injection.\n\n5. **Position the Individual:** If the person is unconscious but breathing, place them in the recovery position (on their side) to prevent choking in case they vomit.\n\n6. **Stay With Them:** Remain with the individual until help arrives, providing reassurance and monitoring their condition. Do not leave them alone, as their status could deteriorate.\n\n7. **Do Not Administer Substances:** Avoid giving the individual food, water, or any stimulants, as these can complicate the situation.\n\nActing quickly and following these steps can significantly improve the chances of recovery for someone experiencing an overdose.",
        "paper_evidence":
        [
            "The implementation of naloxone programs, such as 'take-home naloxone' (THN), has emerged as a key intervention in reducing opioid overdose deaths. These programs aim to train individuals at risk of witnessing or experiencing an opioid overdose to recognize an opioid overdose and respond with naloxone. Naloxone effectively reverses opioid overdoses ",
            "Another medication mode of minimizing risk of overdose is take-home naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose, and take-home naloxone programs aim to prevent fatal overdose",
            "Data indicated the aided survived the suspected overdose in 87.4% of cases.CONCLUSIONS: With appropriate training, law enforcement personnel were able to recognize opioid overdoses and prevent fatalities by administering naloxone and carrying out time-sensitive medical interventions.",
            "Current American Heart Association recommendations call for laypeople and others who cannot reliably establish the presence of a pulse to initiate cardiopulmonary resuscitation in any individual who is unconscious and not breathing normally; if opioid overdose is suspected, naloxone should also be administered.",
            "An adjunct to respiratory support that can reduce this high mortality rate is the administration of naloxone by Emergency Medical Services (EMS) practitioners for patients with suspected opioid overdose.",
            "Efforts to equip drug users to manage overdoses effectively, including training in first aid and the provision of naloxone, and the reduction of police involvement at overdose events may have a substantial impact on overdose-related morbidity and mortality.",
            "Opiate overdose can be reversed by administering naloxone, an opiate antagonist."
        ]
    },
    "65cebf371930410b13000004":
    {
        "question": "What is the mechanism of action of sparsentan?",
        "llm_evidence": "Sparsentan is a dual endothelin receptor antagonist and angiotensin II receptor blocker, designed primarily for the treatment of kidney diseases such as focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. Its mechanism of action involves selectively inhibiting both the endothelin type A (ETA) and type B (ETB) receptors and blocking the angiotensin II type 1 (AT1) receptor. \n\nBy antagonizing the ETA receptor, sparsentan reduces vasoconstriction and mitigates the profibrotic effects of endothelin-1, a peptide involved in renal and cardiovascular diseases. Inhibition of the AT1 receptor decreases the effects of angiotensin II, leading to reduced blood pressure and decreased fluid retention. This dual-action not only helps lower blood pressure but also offers renal protective effects, ultimately aiming to slow the progression of kidney damage and improve renal function. Clinical studies have indicated that this combination approach may lead to better outcomes in terms of proteinuria reduction and kidney preservation compared to traditional therapies.",
        "paper_evidence":
        [
            "Introduction: Sparsentan is a novel single-molecule dual endothelin angiotensin receptor antagonist with hemodynamic and anti-inflammatory properties and is not an immunosuppressant. ",
            "Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS).",
            "Sparsentan is a single-molecule dual endothelin type-A and angiotensin II type 1 receptor antagonist (DEARA) under clinical development for focal segmental glomerulosclerosis and IgA nephropathy. ",
            "Sparsentan is a single-molecule dual endothelin angiotensin receptor antagonist (DEARA) currently under investigation as a treatment for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).",
            "Sparsentan is a single-molecule dual antagonist of the endothelin type A receptor and angiotensin II type 1 receptor under investigation for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.",
            "A Randomized, Multicenter, Double-Blind, Parallel, Active-Control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS (DUPLEX) study evaluates the long-term antiproteinuric efficacy, nephroprotective potential, and safety profile of sparsentan compared with an AT1 receptor blocker alone in patients with FSGS.METHODS: DUPLEX is a multicenter, international, phase 3, randomized, double-blind, active-controlled study of sparsentan in patients with FSGS.",
            "Sparsentan is a single-molecule dual endothelin type-A and angiotensin II type 1 receptor antagonist (DEARA) under clinical development for focal segmental glomerulosclerosis and IgA nephropathy.",
            "Sparsentan, a dual-acting antagonist of the angiotensin II receptor and endothelin type A receptors, was found to suppress the amplitude of peak and late INa effectively.",
            "Interestingly, Sparsentan, the dual angiotensin II (Ang II) receptor and endothelin type A receptor antagonist, can also reduce TRM cell responses by intervening IL-15 signaling, exploring its new pharmacological functions.",
            "BACKGROUND: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy.",
            "Sparsentan is a dual endothelin/angiotensin II receptor antagonist indicated to reduce proteinuria in patients with primary IgA nephropathy at high risk of disease progression."
        ]
    },
    "65f70915c4010b4d7800001a":
    {
        "question": "Please summarize MuSK Antibody positive Myasthenia Gravis.",
        "llm_evidence": "MuSK (Muscle-Specific Kinase) antibody positive Myasthenia Gravis (MG) is an autoimmune disorder characterized by the presence of antibodies that target the MuSK protein, critical for neuromuscular junction formation and maintenance. This condition predominantly affects women and typically presents in younger adults, though it can occur at any age. Symptoms include pronounced muscle weakness, which can fluctuate and is exacerbated by activity, often affecting muscles controlling eye movements, facial expression, and swallowing.\n\nKey insights include:\n\n1. **Pathophysiology**: In MuSK antibody positive MG, the immune system mistakenly attacks MuSK, disrupting acetylcholine receptor clustering at the neuromuscular junction, leading to impaired communication between nerves and muscles.\n\n2. **Clinical Features**: Patients commonly experience ocular symptoms (e.g., ptosis, diplopia), generalized muscle weakness, and bulbar symptoms (e.g., dysphagia). Unlike acetylcholine receptor antibody positive MG, patients with MuSK antibodies may have less severe ocular impairment but more significant bulbar and limb weakness.\n\n3. **Diagnosis**: Diagnosis often involves serological testing for MuSK antibodies, as well as electromyography (EMG) tests that show a decremental response in muscle stimulation.\n\n4. **Management**: Treatment options include symptomatic management with acetylcholinesterase inhibitors, immunosuppressive therapies (e.g., corticosteroids, azathioprine), and in some cases, plasma exchange or intravenous immunoglobulin (IVIG) during myasthenic crises.\n\n5. **Prognosis**: While MuSK antibody positive MG can be more treatment-resistant compared to the more common AChR antibody positive variant, many patients respond well to immunotherapy, leading to improved muscle strength and quality of life.\n\nIn summary, MuSK antibody positive Myasthenia Gravis is a distinct subtype of MG with specific pathogenic mechanisms, demographic tendencies, and treatment approaches that differentiate it from other forms of the disease.",
        "paper_evidence":
        [
            "for anti-muscle specific tyrosine kinase (MuSK) antibody (Ab) in a large cohort of anti-acetylcholine receptor (AChR) Ab-negative generalized myasthenia gravis (MG), and also to investigate clinical contexts for the diagnosis of MuSK MG",
            "We compared the plasma concentrations of 15 myokines in 63 patients with acetylcholine receptor antibody (Ab)-positive MG and 14 with muscle-specific tyrosine kinase Ab-positive MG (MuSK MG) with those in 15 healthy controls",
            "In this report, we describe three patients with anti-muscle-specific kinase (MuSK)",
            " Myasthenia gravis (MG) with muscle-specific tyrosine kinase (MuSK) antibodies (MMG) is predominantly seen in women of childbearing age. ",
            "Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability. The pathogenic antibodies mostly belong to the immunoglobulin subclass (Ig)G4, a feature which attributes them their specific properties and pathogenic profile. ",
            "OBJECTIVE: Muscle-specific receptor tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) accounts for 5%-15% of autoimmune MG. MuSK mediates the agrin-signaling pathway and also anchors the collagenic tail subunit (ColQ) of acetylcholinesterase (AChE).",
            "Muscle specific tyrosine kinase antibody positive myasthenia gravis (MuSK- MG) is characterized by autoantibodies against the MuSK protein of the neuromuscular junction resulting in weakness of bulbar and proximal muscles.",
            "Muscle-specific tyrosine kinase- (MuSK-) antibodies-positive Myasthenia Gravis accounts for about one third of Seronegative Myasthenia Gravis and is clinically characterized by early onset of prominent bulbar, neck, shoulder girdle, and respiratory weakness.",
            "myasthenia gravis.RECENT FINDINGS: MuSK antibodies are found in a variable proportion of AChR antibody negative myasthenia gravis patients who are often, but not exclusively, young adult females, with bulbar, ne",
            "ted to randomized clinical trials.SUMMARY: MuSK antibodies define a form of myasthenia gravis that can be difficult to diagnose, can be life threate",
            "Background and Objectives: Muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MuSK + MG) is a form of MG with bulbar-predominant symptoms often resistant ",
            "PURPOSE OF REVIEW: Some of the 20% of myasthenia gravis patients who do not have antibodies to acetylcholine receptors (AChRs) have antibodies to muscle specific kinase (MuSK), but a full understanding of their frequency, the associated clinical phenotype and the mechanisms of action of the antibodies has not",
            "Muscle-specific kinase (MuSK) Myasthenia Gravis (MG) represents a prototypical antibody-mediated disease characterized by predominantly focal muscle weakness (neck, facial, and bulbar muscles) and fatigability.",
            "The role of thymectomy in the management of these patients remains uncertain.SUMMARY: MuSK antibody positive patients represent a unique subset of myasthenia gravis.",
            "Muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MuSK + MG) is a form of MG with bulbar-predominant symptoms often resistant to conventional treatments",
            "We investigated the presence of antibodies (Abs) against muscle-specific tyrosine kinase (MuSK) in Japanese myasthenia gravis (MG) patients. MuSK Abs were found in 23 (27%) of 85 generalized seronegative MG (SNMG) patients but not in any of the ocular MG patients. MuSK Ab-positive patients were characterized as having female dominance (M:F, 5:18), age range at onset 18 to 72 (median 45) years old, and prominent oculobulbar symptoms (100%) with neck (57%) or respiratory (35%) muscle weakness. Limb muscle weakness was comparatively less severe (52%), thymoma absent. Most patients had good responses to simple plasma exchange and steroid therapy. MuSK IgG from all 18 patients was exclusively the IgG 4 subclass and bound mainly with the MuSK Ig 1-2 domain. Serial studies of 12 individuals showed a close correlation between the variation in MuSK Ab titers and MG clinical severity (P = 0.01 by Kruskal-Wallis). MuSK Ab titers were sharply decreased in patients who had a good response to early steroid therapy or simple plasma exchange, but there was no change, or a rapid increase on exacerbation after thymectomy. Measurement of MuSK Ab titers aids in the diagnosis of MG and the monitoring of clinical courses after treatment.",
            "Muscle-specific tyrosine kinase myasthenia gravis (MuSK-Ab MG) is a rare subtype of myasthenia gravis with distinct pathogenesis and unique clinical features. Diagnosis can be challenging due to its atypical presentation as compared to seropositive myasthenia gravis. It responds inconsistently to steroids, but plasma exchange and immunosuppressive therapies have shown promising results.",
            "PURPOSE OF REVIEW: Important concepts regarding the pathogenesis, clinical features, diagnosis and treatment of muscle-specific tyrosine kinase (MuSK) antibody positive myasthenia gravis will be reviewed. Special attention will be paid to clinical phenotypes and treatment, particularly encouraging responses that have been reported to rituximab.RECENT FINDINGS: Worldwide studies confirm three major phenotypes in MuSK antibody positive myasthenia gravis (MMG) patients: indistinguishable from acetylcholine receptor antibody positive patients, prominent faciopharyngeal weakness, usually with marked muscle atrophy, and relatively isolated neck extensor and respiratory weakness. MMG predominates in women and weakness is typically more severe, with more frequent respiratory crises than non-MuSK myasthenia gravis. Patients with sub-acute bulbar, shoulder, and neck weakness pose unique challenges in terms of differential diagnosis and electrodiagnosis. Electrodiagnostic studies evaluating for disorders of neuromuscular transmission should focus on proximal limb and facial muscles, as well as clinically weak muscles. The response to acetylcholinesterase inhibitors is often disappointing. Long-term outcomes appear favorable though patients typically require more aggressive immunosuppression. Uncontrolled observations report encouraging results with rituximab in the treatment of refractory MMG. The role of thymectomy in the management of these patients remains uncertain.SUMMARY: MuSK antibody positive patients represent a unique subset of myasthenia gravis. Identification of these patients has important diag",
            "INTRODUCTION: Approximately 39% to 49% of patients with previously diagnosed acetylcholine receptor antibody-negative myasthenia gravis have been found to be muscle-specific tyrosine kinase (MuSK) antibody positive. These patients have a presentation that typically includes oculobulbar weakness, poorer response to cholinesterase inhibitors, and higher risk for acute clinical decompensation that necessitates plasma exchange. MuSK patients can require more aggressive maintenance immunosuppression earlier-on to maintain stability, often w",
            "Antibodies (Abs) to muscle-specific tyrosine kinase (MuSK) are detected in approximately 40% of generalized acetylcholine receptor antibody-negative myasthenia gravis (MG). Anti-MuSK Abs are nearly always associated with generalized symptoms, with prevalent involvement of craniobulbar, cervical and respiratory muscles and with a striking preponderance in women. The typical course of MuSK-MG is acute onset, rapid progression, brittle course in the first years, early respiratory crises and unprovoked relapses in spite of high-dose immunosuppression. Patients often require long-term management with multiple immunosuppressive (IS) agents and many of them remain dependent on IS treatment. The majority of anti-MuSK Abs are of the non-complement-binding IgG4 subclass.",
            "MuSK antibody-positive myasthenia gravis (MG) accounts for 5-15% of autoimmune MG. As AChR deficiency is typically mild and as cholinesterase inhibitors are generally ineffective or worsen myasthenic symptoms, we asked if the patient's MuSK-IgG interferes with binding of ColQ to MuSK.",
            "BACKGROUND AND OBJECTIVE: Recently, the presence of antibodies to a muscle-specific tyrosine kinase (MuSK) has been reported in some patients with seronegative generalized myasthenia gravis. Our objective was to describe a group of patients who were positive for anti-MuSK antibodies.PATIENTS AND METHOD: Detection of antibodies using a radioimmunoassay was performed in the serum of 26 patients with generalized myasthenia gravis. We identified",
            "BACKGROUND: Adult and pediatric patients suffering from MuSK (muscle-specific kinase) -antibody positive myasthenia gravis exhibit similar features to individuals with acetylcholine receptor (AChR) antibodies, but they differ in several characteristics such as a predominant bulbar, respiratory and neck weakness, a generally worse disease severity and a tendency to develop mus",
            "BACKGROUND: Anti-muscle specific kinase antibody positive myasthenia gravis (MuSK MG) is often characterized by a relatively severe and progressive course, refractoriness to standard myasthenia gravis (MG) medications, and an increased risk of myasth",
            "INTRODUCTION: Muscle-specific tyrosine kinase (MuSK) autoantibody related myasthenia gravis is characterized by bulbar and respiratory manifestations, a poor response to anticholinergics, and a generally good response to plasma exchange ",
            "This survey reinforces several cardinal features of MuSK-Ab-positive MG, including prominent bulbar involvement and anticholinesterase nonresponsiveness. Facial or tongue atrophy was rare. Most patients respond favorably to immunotherapy. The best clinical response was to corticosteroids and plasma exchange, and the poorest response was to IVIG. Long-term outcome is favorable in about 60% of cases."
        ]
    },
    "65f8418fc4010b4d78000041":
    {
        "question": "Is it advisable to bring the fever down when it is supposedly meant to assist in the fight of disease?",
        "llm_evidence": "Fever is a natural response of the body to infection, acting as a defensive mechanism that can help inhibit the growth of pathogens and enhance immune function. Research indicates that moderate fevers can optimize the activity of immune cells, such as T-lymphocytes and macrophages, which are crucial in battling infections. Lowering a fever, especially with medications like acetaminophen or ibuprofen, can provide comfort but may also interfere with the body's ability to fight the underlying illness. \n\nHowever, there are instances where reducing a high fever (typically above 102°F or 39°C) is necessary to prevent complications, especially in vulnerable populations like young children or individuals with certain medical conditions. Therefore, the general recommendation is to monitor the fever and treat it if it becomes excessively high or leads to discomfort, rather than automatically lowering it for every mild or moderate fever. \n\nIn summary, while managing fever can be important for comfort, it is advisable to allow some fevers to run their course when they are moderate, as they can be beneficial in the immune response to infection.",
        "paper_evidence":
        [
            "Fever is the most common presenting symptom in children and causes distress in patients and parents",
            "antipyretics are indicated only for discomfort",
            "relief from distress is the primary indication for prescribing pharmacotherapy, and antipyretics should not be administered with the sole intention of reducing body temperature",
            "The two thermoregulatory responses represent two complementary strategies of survival in systemic inflammation: fever ensures the active attack against the pathogen; hypothermia secures the defense of the host's vital systems.",
            "In contrast, high temperature in non-infectious intensive care patients is associated with higher mortality.",
            "There is little evidence that fever facilitates recovery from disease or assists the immune system in mounting a response.",
            "Although fever is one of the main presenting symptoms of COVID-19 infection, little public attention has been given to fever as an evolved defense. Fever, the regulated increase in the body temperature, is part of the evolved systemic reaction to infection known as the acute phase response. The heat of fever augments the performance of immune cells, induces stress on pathogens and infected cells directly, and combines with other stressors to provide a nonspecific immune defense. Observational trials in humans suggest a survival benefit from fever, and randomized trials published before COVID-19 do not support fever reduction in patients with infection. Like public health measures that seem burdensome and excessive, fevers involve costly trade-offs but they can prevent infection from getting out of control. For infections with novel SARS-CoV-2, the precautionary principle applies: unless evidence suggests otherwise, we advise that fever should be allowed to run its course.",
            "Even though this is a common practice, lowering body temperature has not improved survival in laboratory animals or in patients with infections.",
            "Observational trials in humans suggest a survival benefit from fever, and randomized trials published before COVID-19 do not support fever reduction in patients with infection.",
            "The heat of fever augments the performance of immune cells, induces stress on pathogens and infected cells directly, and combines with other stressors to provide a nonspecific immune defense.",
            "Like public health measures that seem burdensome and excessive, fevers involve costly trade-offs but they can prevent infection from getting out of control.",
            "Fever, however, is not the primary illness but is a physiologic mechanism that has beneficial effects in fighting infection. There is no evidence that fever itself worsens the course of an illness or that it causes long-term neurologic complications. Thus, the primary goal of treating the febrile child should be to improve the child's overall comfort rather than focus on the normalization of body temperature.",
            "According to research, we are at a crossroad, with strong research evidence accumulating over the last few decades supporting a positive role for fever and the ongoing pressures of current practice to lower body temperature.",
            "While understanding of the mechanisms of fever has progressed in recent years, much uncertainty remains as to whether fever in itself (as distinct from its cause) is beneficial or harmful, and what circumstances warrant antipyretic therapy.",
            "No evidence shows that it is beneficial to treat febrile children with paracetamol. Treatment should be given only to children who are in obvious discomfort and those with conditions known to be painful.",
            "No studies showed any clear benefit for the use of paracetamol in therapeutic doses in febrile children with viral or bacterial infections or with malaria."
        ]
    },
    "65cfd13f1930410b1300001d":
    {
        "question": "Can syphilis cause proctitis?",
        "llm_evidence": "Yes, syphilis can cause proctitis, particularly in individuals who engage in anal intercourse. Proctitis is defined as inflammation of the rectum, and it can be caused by sexually transmitted infections (STIs), including syphilis. In cases of secondary syphilis, patients may exhibit mucous membrane lesions that can affect the rectal area, leading to symptoms such as pain, discharge, and bleeding. Furthermore, syphilis can coexist with other STIs that are known to cause proctitis, such as gonorrhea and chlamydia, increasing the likelihood of rectal inflammation in infected individuals. The recognition and treatment of syphilis are crucial in preventing complications such as proctitis and transmission to sexual partners.",
        "paper_evidence":
        [
            "A 26-year-old man in Australia who has sex with men had severe perianal ulceration, proctitis, and skin lesions develop. Testing revealed primary syphilis, mpox, and primary HIV infection. ",
            "Syphilitic proctitis presenting as locally advanced rectal cancer: A case report.",
            "We present a case of severe syphilitic proctitis leading to large bowel obstruction with imaging findings mimicking locally advanced rectal cancer.",
            "CONCLUSION: Severe proctitis leading to large bowel obstruction is a possible presentation of syphilis, and a high degree of clinical suspicion is necessary to be able to accurately identify the cause. ",
            "ABSTRACT: We analyzed microbiologic etiologies of proctitis among patients seen in an urban sexual health clinic during 2011 to 2021. Among 759 cases, 179 (24%) tested positive for Neisseria gonorrhoeae , 171 (23%) for Chlamydia trachomatis , 21 (3%) for herpes simplex virus, 30 (4%) for syphilis, and 73 (10%) for multiple pathogens; no pathogen was identified in 425 (56%).",
            "The patient tested positive for syphilis and was diagnosed with syphilitic proctitis",
            "Final pathology on the rectal biopsies demonstrated positive Warthin-Starry and spirochete immunohistochemical stain.DISCUSSION: This case illustrates key aspects in the care of a patient with syphilitic proctitis mimicking an obstructing rectal cancer, including the need for high clinical suspicion, thorough evaluation including sexual and sexually transmitted disease history, multidisciplinary communication, and management of the Jarisch-Herxheimer reaction.CONCLUSION: Severe proctitis leading to large bowel obstruction is a possible presentation of syphilis, and a high degree of clinical suspicion is necessary to be able to accurately identify the cause.",
            "Syphilitic proctitis involving the rectal mucosa often presents with pain on defecation, rectal bleeding, or ulceration.",
            "We present a case of asymptomatic syphilitic proctitis diagnosed upon a routine screening colonoscopy.",
            "A Case of Asymptomatic Syphilitic Proctitis.",
            "The patient tested positive for syphilis and was diagnosed with syphilitic proctitis.",
            "We present a case of severe syphilitic proctitis leading to large bowel obstruction with imaging findings mimicking locally advanced rectal cancer.PRESENTATION OF CASE: A 38-year-old man who had sex with men presented to the emergency department with a 2 week history of obstipation.",
            "Case of secondary syphilis presenting with unusual complications: syphilitic proctitis, gastritis, and hepatitis.",
            "Syphilitic proctitis is a rare presentation of sexually transmitted infection that poses a diagnostic challenge as it mimics rectal cancer clinically, radiologically and endoscopically.",
            "Syphilitic proctitis is a rare disease that usually presents as proctitis, ulcer, and neoplasm but lacks pathognomonic clinical symptoms.",
            "anagement of the Jarisch-Herxheimer reaction.CONCLUSION: Severe proctitis leading to large bowel obstruction is a possible presentation of syphilis, and a high degree of clinical suspicion ",
            "Two adult male homosexuals with syphilitic proctitis and without any detectable anal lesions are reported."
        ]
    },
    "65f493cac4010b4d78000012":
    {
        "question": "What disorder is considered off label use for domperidone?",
        "llm_evidence": "Domperidone is primarily approved for the treatment of nausea and vomiting, but it is often used off-label for various other disorders, notably for the management of gastrointestinal motility disorders and for enhancing lactation in breastfeeding mothers. The use of domperidone to increase milk production is particularly common, as it acts as a dopamine antagonist that can increase levels of prolactin, a hormone crucial for milk production. Although this off-label use is not officially sanctioned by regulatory agencies, many healthcare providers may prescribe it for this purpose based on clinical experience and patient needs. Additionally, some may explore its potential benefits in treating symptoms associated with conditions like gastroesophageal reflux disease (GERD) or functional dyspepsia, where gastric emptying delays and nausea are present. However, it's important to note that the off-label use of domperidone is accompanied by safety considerations, as it can lead to cardiac side effects, particularly in patients with pre-existing heart conditions.",
        "paper_evidence":
        [
            "Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation. ",
            "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women. ",
            "Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production",
            "However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication (\"off label\") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis.",
            "Based on this, the purpose of this review is to summarize all evidence on the efficacy of domperidone for the treatment of GI disorders in infants and children and to report an overview of its pharmacological properties and safety profile.",
            "OBJECTIVES: Domperidone and metoclopramide are prokinetics commonly prescribed off-label to infants and younger children in an attempt to treat gastro-oesophageal reflux symptoms.",
            "Objectives: Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation.",
            "However, among (pediatric) gastroenterologists, domperidone is also used outside its authorized indication (\"off label\") for treatment of symptoms associated with gastro-esophageal reflux disease, dyspepsia, and gastroparesis",
            "on, such as domperidone, an off-label galactagogue, are often prescribed. Domperidone is controv",
            "Domperidone is an antiemetic that is commonly used as an off-label prescription to induce lactation. Neuropsychiatric adverse",
            "Domperidone is a dopamine-2 antagonist used off-label to increase breast milk production. Dosages commonly",
            "Domperidone is a prokinetic agent used as a second-line treatment option for gastroparesis in those unable to tolerate",
            "Domperidone is a peripheral dopamine-2 receptor antagonist with prokinetic and antiemetic properties. Its prokinetic effects are mainly manifest in the upper gastrointestinal (GI) tract. Currently its use is restricted",
            "BACKGROUND: Domperidone is commonly used off-label to stimulate milk production in mothers who have low ",
            "Domperidone is a dopamine-2 (D2) receptor antagonist that stimulates the release of stored prolactin in the anterior pituitary. It is prescribed off-label in Canada and Australia to promote lactation in prolactin-deficient women.",
            "astfeeding. Medications that can increase milk production, such as domperidone, an off-label galactagogue, are often",
            "A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation.",
            "PURPOSE: The aim of this study is to examine the relationship between domperidone (commonly used off-label for lactation stimulation), ventricular arrhythmia and all-cause mortality during the postpartu",
            "OBJECTIVES: Domperidone and metoclopramide are prokinetics commonly prescribed off-label to infants and younger children in an attempt to treat gastro-oesophageal refl",
            "The use of domperidone as a galactagogue is worrisome as drug-induced long QT syndrome occurred mostly in women. In these circumstances, an improvement of breastfeeding practices seems to be more effective and safer than the use of an off-label domperidone treatment.",
            "The use of domperidone in accordance with the terms of its marketing authorisation, or off-label to increase breast milk production, exposes patients to serious cardiac risk."
        ]
    },
    "65f8721ec4010b4d7800005d":
    {
        "question": "Which neurotransmitters are thought to play a role in obsessive compulsive disorder?",
        "llm_evidence": "Obsessive-Compulsive Disorder (OCD) is thought to involve several neurotransmitters, with the most prominent being serotonin, dopamine, and glutamate.\n\n1. **Serotonin**: Research suggests that serotonin dysregulation is a key factor in OCD. Many effective treatments, such as selective serotonin reuptake inhibitors (SSRIs), enhance serotonin levels, indicating its critical role in symptom management.\n\n2. **Dopamine**: Studies have shown that altered dopamine activity may contribute to the compulsions and repetitive behaviors characteristic of OCD. The role of dopamine in the brain's reward pathways can influence obsessive thoughts and compulsive actions.\n\n3. **Glutamate**: Emerging evidence indicates that glutamatergic dysfunction may also play a part in OCD. Glutamate is the primary excitatory neurotransmitter in the brain, and abnormalities in its signaling may impact the neural circuits involved in the disorder.\n\nOverall, the interaction between these neurotransmitters suggests a complex neurobiological underpinning of OCD, where imbalances can lead to the manifestation of obsessive thoughts and compulsive behaviors.",
        "paper_evidence":
        [
            "A large body of evidence suggests that the neuropathology of obsessive-compulsive disorder (OCD) lies in the complex neurotransmitter network of the cortico-striatal-thalamo-cortical (CSTC) circuit, where dopamine (DA), serotonin (5HT), glutamate (Glu), and gamma-amino butyric acid (GABA) dysfunction have been implicated in the disorder.",
            "Neurotransmitters implicated in OCD include serotonin, dopamine, and glutamate.",
            "The serotonin (5-HT) neurotransmitter system has been implicated in the pathophysiology of several neuropsychiatric disorders, especially obsessive-compulsive disorder (OCD).",
            "The differential effects of serotonin-reuptake inhibitors on obsessive-compulsive disorder (OCD) were sufficient to presume that a serotonin regulatory disorder is the most essential part of the pathophysiology of OCD. In patients with OCD, however, a high-dose of serotonin-reuptake inhibitor monotherapy may not be sufficient, and approximately half of patients were noted to be treatment-resistant. As results from previous studies have shown, there have been positive treatment responses to the dopaminergic antagonists. This suggests that other neurotransmitter systems, such as dopamine, are involved in the pathophysiology of OCD.",
            "Involvement of the brain serotonin (5-HT) neurotransmitter system in obsessive-compulsive disorder (OCD) was originally suggested on the basis of therapeutic effects found with the semiselective serotonin uptake inhibitor, clomipramine.",
            "Similarly, the involvement of serotonergic neurotransmitters in OCD suggests that these neurotransmitters are central to defining spectrum disorders.Again, however, serotonin plays a role in many functions (including impulse control) and mediates many different disorders.",
            "BACKGROUND: While serotonin is the neurotransmitter most commonly implicated in obsessive-compulsive and related disorders, there is also evidence for dopaminergic mediation of these conditions.",
            "The MRS measures did not vary by subgroup and showed no correlations with demographic and clinical variables.CONCLUSIONS: These results indicate that GABA abnormalities within the anterior cingulate cortex contribute to the pathophysiology of OCD.",
            "Recent evidence suggests that the ubiquitous excitatory neurotransmitter glutamate is dysregulated in OCD, and that this dysregulation may contribute to the pathophysiology of the disorder.",
            "BACKGROUND: There is a major role for serotonin in the mechanism of anti-obsessional drug action. Drugs that block uptake of noradrenaline are not effective in the treatment of obsessive-compulsive disorder (OCD), while drugs that potently bock serotonin reuptake ar",
            "Significant overlap in neurotransmitter dysfunction (serotonin, glutamate, and dopamine) has been documented between schizophrenia and OCD.",
            "Neurochemical studies have shown that OCD is linked to changes of the central modulatory transmitter system, especially, the serotonin and dopamine system, which probably contribute to a direct and indirect dysregulation in various neural networks.",
            "in the cortico-striato-thalamo-cortical circuit in the brain. Neurotransmitters implicated in OCD include serotonin, dopamine, and glutamate.",
            "Recently, there is extensive evidence showing a key role of glutamate pathways abnormalities within the cortico-striatal-thalamo-cortical circuitry and temporal lobes in OCD pathogenesis.",
            "In obsessive-compulsive disorder (OCD), the success of pharmacological treatment with serotonin re-uptake inhibitors and atypical antipsychotic drugs suggests that both the central serotonergic and dopaminergic systems are involved in the pathophysiology of the disorder."
        ]
    },
    "65d126d21930410b1300002c":
    {
        "question": "Can denosumab cause jaw necrosis?",
        "llm_evidence": "Denosumab is a medication primarily used to treat osteoporosis and certain types of cancer-related bone conditions by inhibiting osteoclast formation and activity, thereby reducing bone resorption. However, it has been associated with the risk of osteonecrosis of the jaw (ONJ), a condition where the jawbone becomes exposed and begins to die due to a reduced blood supply. This risk is particularly elevated in patients undergoing dental procedures, those with existing dental issues, or those receiving high doses of denosumab for cancer treatment. Key insights indicating a link between denosumab and jaw necrosis include:\n\n1. **Clinical Studies**: Research has shown a statistically significant incidence of ONJ in patients receiving denosumab, especially when compared to the general population.\n  \n2. **Guidelines and Warnings**: The prescribing information for denosumab explicitly warns about the potential risk of ONJ and advises patients to maintain good oral hygiene and undergo dental evaluations before starting treatment.\n\n3. **Mechanism of Action**: The inhibition of osteoclast activity by denosumab may disrupt the normal bone remodeling process, potentially increasing the risk of bone necrosis under certain conditions.\n\n4. **Patient Factors**: Risk factors such as concurrent use of other medications (like bisphosphonates), the patient's dental health, and duration of therapy play significant roles in the likelihood of developing ONJ.\n\nThese points collectively highlight that while denosumab can be an effective treatment for certain conditions, it carries a risk of jaw necrosis, which clinicians and patients need to carefully monitor.",
        "paper_evidence":
        [
            "BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but potentially serious, adverse event that can occur after exposure to bone-modifying agents (BMAs; e.g., bisphosphonates, denosumab, and antiangiogenic therapies). ",
            "Osteonecrosis of the jaw (ONJ) is a severe complication of therapy with antiresorptive agents (e.g. bisphosphonates and denosumab), which are used to manage bone metastases from cancer, to reduce the incidence of skeletal-related events.",
            "Aggressive denosumab-related jaw necrosis - a case series.",
            "We are presenting four cases of MRONJ related to denosumab treatment showing increasingly aggressive pictures of the disease. ",
            "A total of 383 cases were registered: 369 were described as BRONJ, 5 as avascular necrosis, and 9 were unknown. Bisphosphonates had been given orally in 207 (56%), intravenously in 125 (34%), both orally and intravenously in 27 (7%), and was unknown in 9 (2%); one had been given denosumab. ",
            "Osteonecrosis of the jaw has recently been described in patients receiving subcutaneous administration of RANKL-inhibitors (denosumab).",
            "Medication-related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long-term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life",
            "PURPOSE: Osteonecrosis of the jaw has been recently reported in patients receiving denosumab for the treatment of metastatic bone disease and osteoporosis.",
            "33 (5%) patients on denosumab developed osteonecrosis of the jaw versus none on placebo.",
            "Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.",
            "Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?",
            "PURPOSE: To report a case of osteonecrosis of the jaw (ONJ) occurring in an implant area possibly related to denosumab, a relatively new antiosteoporot",
            "Osteonecrosis of the jaw (ONJ) is a rare but serious clinical condition. It affects patients treated with bisphosphonates, and also with denosumab, mainly in oncological doses.",
            "We report a case of osteonecrosis of the jaw (ONJ) associated with denosumab therapy in a 62-year-old female patient being treated for bone metastases from breast cancer.",
            "Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?.",
            "PURPOSE: To report a case of osteonecrosis of the jaw (ONJ) occurring in an implant area possibly related to denosumab, a relatively new antiosteoporotic agent.MATERIALS AND METHODS: Two months following the extraction of both maxillary first molars, a bilateral maxillary sinus floor elevation was performed on a 64-year-old female patient under a biannual  60 mg denosumab antiosteoporotic treatment.",
            "Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case.",
            "After 3 months, the implants underwent prosthetic rehabilitation at one side, and a series of failures that led to an ONJ instalment at the other side.RESULTS: The ONJ persisted over 7 months and was only resolved by a surgical approach consisting of a piezoelectric osteotomy and platelet-rich fibrin with a tension-free wound closure.CONCLUSIONS: A cumulative effect of denosumab is likely to be associated with a jaw osteonecrosis, which in this case was manageable using a surgical approach with no need to interrupt the appropriate drug treatment course.",
            "Osteonecrosis of the jaw (ONJ) is a severe complication of therapy with antiresorptive agents (e.g. bisphosphonates and denosumab), which are used to manage bone metastases from cancer, to reduce the incidence of skeletal-related events. Available data indicate that 0-27, 5% of patients exposed to antiresorptive agents may develop ONJ, depending on the number of infusions and the duration of therapy.",
            "Denosumab-related osteonecrosis of the jaws (DRONJ) is a recently described entity that shares many common clinical and radiological features with bisphosphonate-related osteonecrosis of the jaws (BRONJ).",
            "We report the first case of teriparatide adjuvant role in the management of a denosumab-induced osteonecrosis of the jaw in a male subject with idiopathic osteoporosis.",
            "brin with a tension-free wound closure.CONCLUSIONS: A cumulative effect of denosumab is likely to be associated with a jaw osteonecrosis, which in this case was manageable using a surgical approach with no need",
            "Osteonecrosis of the jaw as a result of treatment with receptor activators of nuclear factor kappa-B ligand (RANKL) inhibitors (denosumab)",
            "A severe side effect of denosumab is the osteonecrosis of the jaw (DRONJ).",
            "Ultrasonic Piezoelectric Bone Surgery Combined With Leukocyte and Platelet-Rich Fibrin and Pedicled Buccal Fat Pad Flap in Denosumab-Related Osteonecrosis of the Jaw.",
            "While Medication Related Osteonecrosis of the Jaw (MRONJ) is most commonly seen in patients treated with bisphosphonates, in the past decade, it has become apparent that other types of medication, most notably denosumab, can cause comparable disorders.",
            "Osteonecrosis of the jaws (ONJ) is an adverse side event of bisphosphonates and denosumab, antiresorptive agents that effectively reduce the incidence of skeletal-related events in patients with metastatic bone cancer and multiple myeloma.",
            "BACKGROUND: Denosumab (DMB) is a bone antiresorptive agent used to treat osteoporosis or metastatic cancer of the bones. However, denosumab-associated osteonecrosis of the jaw (DRONJ) has become a common complication in canc",
            "Denosumab is a new bone antiresorptive agent that has received approval by the Food and Drug Administration for use in patients with osteoporosis and metastatic cancer to the bones. Like the bisphosponates that are used as antiresorptive medications, denosumab has been associated with osteonecrosis of the jaws (ONJ).",
            "Denosumab (Amgen, Thousand Oaks, California, USA) is a new bone antiresorptive agent used in patients with osteoporosis or metastatic cancer to the bones. As with the bisphosphonates that are used as antiresorptive medications, denosumab has been associated with osteonecrosis of the jaws (ONJ)."
        ]
    },
    "65f37871c4010b4d7800000a":
    {
        "question": "What is DEXTR",
        "llm_evidence": "DEXTR (Decentralized Exchange Token Registry) is a platform that facilitates the creation and management of decentralized exchanges (DEXs) and their associated tokens. Its primary goal is to promote transparency and interoperability among DEXs by providing a standardized registry for token information. Key insights about DEXTR include:\n\n1. **Decentralization**: DEXTR adheres to the core principles of decentralization, allowing users to trade tokens directly without intermediaries, thus enhancing security and privacy.\n\n2. **Token Standardization**: It establishes a uniform protocol for tokens, enabling seamless integration and transferability across various DEX platforms, which fosters a more interconnected ecosystem.\n\n3. **Governance**: DEXTR may incorporate decentralized governance mechanisms, allowing token holders to participate in decision-making processes regarding platform developments and upgrades.\n\n4. **Liquidity and Accessibility**: By supporting multiple DEXs, DEXTR enhances liquidity accessibility for users, enabling a wider array of trading opportunities and potentially lower transaction costs.\n\n5. **Security Features**: DEXTR often emphasizes robust security protocols, reducing vulnerabilities commonly associated with centralized exchanges, such as hacking and fraud.\n\nOverall, DEXTR aims to empower users in the cryptocurrency space by providing a reliable and user-friendly environment for engaging in decentralized trading activities.",
        "paper_evidence":
        [
            "Evaluation of a semi-automated data extraction tool for public health literature-based reviews: Dextr.",
            "The Dextr tool addresses data-extraction challenges associated with environmental health sciences literature with a simple user interface, incorporates the key capabilities of user verification and entity connecting, provides a platform for further automation developments, and has the potential to improve data extraction for literature reviews in this and other fields.",
            "rs to generate machine-readable, annotated exports. The Dextr tool addresses data-extraction challenges associated with environmental health sciences literature with a simple user interface, in",
            "Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies."
        ]
    },
    "65f85ec7c4010b4d78000052":
    {
        "question": "What is the most common surgical treatment for hydrocephalus?",
        "llm_evidence": "The most common surgical treatment for hydrocephalus is the placement of a ventriculoperitoneal (VP) shunt. This procedure involves inserting a flexible tube that drains excess cerebrospinal fluid (CSF) from the ventricles of the brain into the abdominal cavity, where the fluid can be absorbed. Key insights supporting this approach include its effectiveness in reducing intracranial pressure, the relatively low complication rates associated with the procedure, and its long-established use for both pediatric and adult patients. Alternative treatments, such as endoscopic third ventriculostomy (ETV), are available but are typically reserved for specific cases, making VP shunt placement the most prevalent surgical intervention for managing hydrocephalus.",
        "paper_evidence":
        [
            "Gravitation-assisted shunt valves are designed to prevent hydrostatic over-drainage frequently observed in the long course of shunt-treated hydrocephalus",
            "Shunt treatment for hydrocephalus in children should aim for sustainable flexibility in regard to optional, perspective pressure level adjustment during advancing physical and mental development",
            "hydrocephalic neonates and infants who received initial VP-shunt insertion in the early post-natal phase",
            "primary VP-shunt insertion at a mean age of 10 weeks ",
            "Shunt surgery is preferred for secondary hydrocephalus, especially for secondary normal pressure hydrocephalus",
            "Ventriculoperitoneal (VP) shunt placement is the most common surgical treatment for hydrocephalus.",
            "BACKGROUND: Cerebrospinal fluid (CSF) diversion by shunts is the most common surgical treatment for hydrocephalus.",
            "OBJECTIVE The surgical placement of a shunt designed to resolve the brain's impaired ability to drain excess CSF is one of the most common treatments for hydrocephalus.",
            "The most common treatment for patients with hydrocephalus is the surgical implantation of a cerebrospinal fluid (CSF) shunt.",
            "INTRODUCTION: Ventriculoperitoneal (V-P) shunt surgery is the most common technique used for the treatment of hydrocephalus.",
            "Two hundred eight patients with non-tumoral congenital hydrocephalus underwent CSF shunting below the age of one month.",
            " All patients received VP shunts for hydrocephalus managemen",
            "Cerebrospinal fluid shunt placement is the most common surgical intervention for hydrocephalus.",
            "OBJECTIVE: Ventriculoperitoneal shunt (VPS) surgery is a common treatment for hydrocephalus in children and adults, making it one of the most common procedures in ne",
            "Ventriculoperitoneal shunt (VPS) placement is an effective and most frequently used surgical method in the treatment of hydrocephalus, but the mechanical and infective complications are often seen after this surgical procedure.",
            "Ventriculoperitoneal (VP) shunt surgery remains the most widely used neurosurgical procedure for the management of hydrocephalus.",
            "Hydrocephalus is treated with a ventriculo-peritoneal shunt but shunts in these patients suffer from frequent obstructions and require multiple revisions.",
            "Ventriculoperitoneal (VP) shunt surgery is the most common technique used in the treatment of hydrocephalus.",
            "Ventriculoperitoneal (VP) shunts are among the most frequently performed operations in the management of hydrocephalus.",
            "Hydrocephalus is a common adult neurosurgical condition typically requiring treatment with a cerebrospinal fluid (CSF) shunt, of which the ventriculoperitoneal (VP) shunt is the most common type.",
            "Ventriculoperitoneal (VP) shunts are the most common treatment modality for hydrocephalus.",
            "Background: Ventriculoperitoneal shunt (VPS) insertion and endoscopic third ventriculostomy (ETV) are common surgical procedures used to treat pediatric hydrocephalus.",
            "CONTEXT: Ventriculoperitoneal (VP) shunt and endoscopic third ventriculostomy (ETV) are the established surgical treatments for obstructive hydrocephalus (HCP).",
            "INTRODUCTION: Insertion of a ventriculoperitoneal (VP) shunt, the method of choice in the treatment of hydrocephalus, is often followed by various mechanical and/or infective ",
            "lved without any consequences.CONCLUSION: Insertion of a VP shunt represents the most frequent method of choice of the surgical treatment of hydrocephalus, but also potentially a highly risky procedure followed by various complications about which parents shou",
            "VP shunts are presently regarded as the standard of care for uncomplicated hydrocephalus.",
            "OBJECTIVE: Although ventriculoperitoneal shunt surgery is the most common method for hydrocephalus treatment, it may lead to serious complications and require surgical int"
        ]
    },
    "65d126471930410b1300002b":
    {
        "question": "Is Upadacitinib effective for Crohn’s Disease?",
        "llm_evidence": "Upadacitinib, an oral JAK inhibitor, has shown promising efficacy in treating moderate to severe Crohn’s Disease (CD) based on clinical trials. In pivotal studies such as the U-EXCEL and U-START trials, patients receiving Upadacitinib demonstrated significant improvement in clinical remission rates and response compared to placebo groups. The maintenance of remission was also observed, indicating sustained effectiveness over time. Additionally, Upadacitinib was found to improve quality of life and reduce disease activity in Crohn’s Disease patients. Safety profiles indicated manageable side effects, further supporting its use as a viable treatment option in clinical practice. Overall, these findings suggest that Upadacitinib is effective for managing Crohn’s Disease.",
        "paper_evidence":
        [
            "BACKGROUND: Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and is under evaluation for the management of Crohn's disease [CD] in Phase 3 clinical trials.",
            "CONCLUSION: In this real-world cohort of highly refractory CD patients, upadacitinib was effective in inducing remission and had an acceptable safety profile.",
            "Successful treatment of concomitant alopecia universalis and Crohn's disease with upadacitinib: A case report.",
            "Upadacitinib, an oral JAK1 inhibitor, has demonstrated efficacy in treating Crohn's disease during phase III clinical trials. ",
            "Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center.",
            "Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn's disease. ",
            "In this cohort of medically refractory patients with CD, treatment with upadacitinib resulted in subjective and objective responses in 25 and 42% of patients, respectively. Even at doses that are considered lower than currently being studied for CD, upadacitinib was associated with a favorable benefit-to-risk profile.",
            "Upadacitinib also showed promising results in a phase II trial in moderate to severe CD. ",
            "BACKGROUND & AIMS: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), and has received Food and Drug Administration approval for UC.",
            "Phase II trials demonstrated that upadacitinib induces endoscopic remission in patients with moderate-to-severe Crohn's disease.",
            "Upadacitinib, an oral JAK1 inhibitor, has demonstrated efficacy in treating Crohn's disease during phase III clinical trials.",
            "Upadacitinib also showed promising results in a phase II trial in moderate to severe CD.",
            "BACKGROUND & AIMS: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), and has received Food and Drug Administrati"
        ]
    },
    "65f0369bc4010b4d78000001":
    {
        "question": "Is melatonin beneficial in the treatment of in cerebral ischemia-reperfusion injury:",
        "llm_evidence": "Melatonin is a potent antioxidant that has been shown to have neuroprotective effects in various models of cerebral ischemia-reperfusion injury. Key insights supporting its benefits include:\n\n1. **Antioxidant Properties**: Melatonin scavenges free radicals and enhances mitochondrial function, which helps reduce oxidative stress associated with reperfusion injury.\n\n2. **Anti-inflammatory Effects**: It modulates inflammatory responses by downregulating pro-inflammatory cytokines and upregulating anti-inflammatory molecules, thus protecting neural tissues during ischemia-reperfusion.\n\n3. **Circadian Rhythm Regulation**: Melatonin helps stabilize circadian rhythms, which can improve overall brain function and resilience in response to ischemic events.\n\n4. **Neuronal Survival**: Studies demonstrate that melatonin administration post-injury promotes neuronal survival, reduces apoptosis, and improves functional recovery in animal models of stroke.\n\n5. **Clinical Implications**: Emerging clinical trials suggest that melatonin supplementation may enhance outcomes in stroke patients by mitigating ischemic damage and improving recovery trajectories.\n\nOverall, the accumulating evidence indicates that melatonin is beneficial in the context of cerebral ischemia-reperfusion injury, making it a potential therapeutic agent in stroke management.",
        "paper_evidence":
        [
            "Melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice.",
            "Melatonin is a promising neuroprotective agent that can regulate microglial polarization in central nervous system (CNS) diseases.",
            "Melatonin Attenuates Cerebral Ischemia/Reperfusion Injury through Inducing Autophagy",
            "Melatonin improves cognitive function by suppressing endoplasmic reticulum stress and promoting synaptic plasticity during chronic cerebral hypoperfusion in rats.",
            "Melatonin is neuroprotective against cerebral ischemia-reperfusion injury (CIRI) in non-DM, normoglycemic animals through anti-oxidant effect, anti-inflammation, and anti-apoptosis",
            "Melatonin Attenuates Cerebral Ischemia/Reperfusion Injury through Inducing Autophagy.",
            "Melatonin potentiated intrinsic antioxidant status, inhibited acid mediated rise in intracellular calcium levels, decreased apoptotic cell death and also markedly inhibited protein kinase C (PKC) influenced AQP4 expression in the cerebral cortex and dorsal striatum.SIGNIFICANCE: Melatonin confers neuroprotection by protein kinase C mediated AQP4 inhibition in ischemic stroke.",
            "Melatonin, the secretory product of the pineal gland, is known to be neuroprotective in cerebral ischemia, which is so far mostly attributed to its antioxidant properties.",
            "Melatonin treatment diminished the loss of neurons and decreased the infarct volume as compared with untreated MCAO rats.",
            "Melatonin: a promising neuroprotective agent for cerebral ischemia-reperfusion injury.",
            "These findings suggest that melatonin can improve microvessel abnormalities in the cerebral cortex and hippocampus by lowering the expression of vascular endothelial growth factor and its receptors, thereby improving the cognitive function of patients with Alzheimer's disease.",
            "Post administration of melatonin following ischemic stroke reduces AQP4 mediated brain edema and confers neuroprotection.MATERIALS AND METHODS: An in-silico approach was undertaken to confirm effective melatonin-AQP4 binding.",
            "This brief review summarizes the recently obtained evidence which illustrates the beneficial effects of the endogenously produced antioxidant, melatonin, in reducing tissue damage and reversing cardiac pathophysiology in models of experimental ischemia/reperfusion.",
            "BACKGROUND: Experimental studies have documented the beneficial effects of the endogenously produced antioxidant, melatonin, in reducing tissue damage and limiting cardiac pathophysiology in models of experimental ischemia-reperfusion. Melatonin confers cardioprotection against ischemia-reperfusion injury most likely through its direct free radical scavenging activities and its indirect actions in stimulating antioxid",
            "Melatonin, a natural product of the pineal gland, has been shown to protect against ischemic stroke, but the molecular mechanisms underlying its protective function are not fully understood. In the present study, we tested whether melatonin could protect against ischemia-reperfusion (I/R) injury to rat brain by targeting the autophagy pathway.",
            "The exogenous administration of melatonin in these experimental stroke models reduced infarct volume, lowered the frequency of apoptosis, increased the number of surviving neurons, reduced reactive gliosis, lowered the oxidation of neural lipids and oxidatively damaged DNA, induced bcl-2 gene expression (the activity of which improves cell survival), upregulated excision repair cross-complementing factor 6 (an essential gene for preferential DNA excision repair), restrained poly(ADP ribose) synthetase (which depletes cellular NAD resulting in the loss of ATP) activity, and improved neurophysiologic outcomes.",
            "In these investigations, which have used three species (rat, gerbil, and cat), melatonin was universally found to reduce brain damage that normally occurs as a consequence of the temporary interruption of blood flow followed by the reflow of oxygenated blood to the brain.",
            "Melatonin attenuates molecular and cellular damage resulting from cardiac ischemia-reperfusion in which destructive free radicals are involved.",
            "Taken together, our results document that melatonin provides neuroprotective effects in CCH by attenuating oxidative stress and stress protein expression in neurons.",
            "Neuronal damage was assessed in CA1 pyramidal layer of gerbil hippocampus and evaluated 7 days after ischemia.RESULTS: MT significantly reversed the locomotor activity increases, ameliorated learning and working memory deficit, and reduced the extent of CA1 hippocampal pyramidal cells injury after transient global cerebral ischemia in the Mongolian gerbil.CONCLUSION: MT provides significantly protective effect against both histological and behavioral consequences of global cerebral ischemia-reperfusion injury in gerbils.",
            "Therefore, understanding the underlying intracellular and molecular mechanisms is crucial before investigating the neuroprotective effects of melatonin in cerebral ischemia-reperfusion injury.",
            "Our results suggest that melatonin treatment mediates neuroprotection against ischemia/reperfusion injury partly via inhibition of the consequential inflammatory response.",
            "Intranasally administered melatonin core-shell polymeric nanocapsules: A promising treatment modality for cerebral ischemia.",
            "The role of OPA1-related mitochondrial fusion in brain reperfusion stress has remained elusive. The aim of our study is to explore whether melatonin alleviates cerebral IR injury by modulating OPA1-related mitochondrial fusion. We found that melatonin reduced infarct area and suppressed neuron death during reperfusion stress. Biological studies have revealed that IR-inhibited mitochondrial fusion was largely reversed by melatonin via upregulated OPA1 expression. Knocking down OPA1 abrogated the protective effects of melatonin on mitochondrial energy metabolism and mitochondrial apoptosis. In addition, we also found that melatonin modified OPA1 expression via the Yap-Hippo pathway; blockade of the Yap-Hippo pathway induced neuron death and mitochondrial damage despite treatment with melatonin. Altogether, our data demonstrated that cerebral IR injury is closely associated with defective OPA1-related mitochondrial fusion. Melatonin supplementation enhances OPA1-related mitochondrial fusion by activating the Yap-Hippo pathway, ultimately reducing brain reperfusion stress.",
            "Melatonin regulates a large number of physiological actions and its beneficial properties have been reported. The aim of this study was to investigate whether melatonin mediates neuroprotection in rat hippocampal slices subjected to oxygen-glucose-deprivation (OGD) and glutamate excitotoxicity. Thus, we describe here that melatonin significantly reduced the amount of lactate dehydrogenase released in the OGD-treated slices, reverted neuronal injury caused by OGD-reoxygenation in CA1 and CA3 hippocampal regions, restored the reduction of GSH content of the hippocampal slices induced by OGD, and diminished the oxidative stress produced in the reoxygenation period. Furthermore, melatonin afforded maximum protection against glutamate-induced toxicity and reversed the glutamate released almost basal levels, at 10 and 30μM concentration, respectively. Consequently, we propose that melatonin might strongly and positively influence the outcome of brain ischemia/reperfusion",
            "Melatonin is a potent scavenger of free radicals and an indirect antioxidant. Recent studies have shown that melatonin possesses beneficial effects in experimental models of brain trauma and global cerebral ischemia. The effects of pretreatment with melatonin on volume of cerebral infarction were investigated in the present study. Adult male Sprague-Dawley rats were anesthetized with sodium pentobarbital to undergo right-sided endovascular middle cerebral artery occlusion (MCAO) for 3 hr. A single dose of melatonin (1.5, 5, 15, or 50 mg/kg in 1 mL normal saline) or its vehicle was given via an intraperitoneal injection at 0.5 hr before MCAO. Relative infarction volumes on day 3 after MCAO were significantly reduced in the groups treated with melatonin at 5 (mean +/- S.E.M., 15.7 +/- 2.5%) or 15 (21.4 +/- 3.1 %) mg/kg but not at 1.5 (30.6 +/- 3.5%) or 50 (26.7 +/- 2.8%) mg/ kg when compared with the vehicle group (33.9 +/- 3.5%). There was no significant difference in the arterial blood pressure (BP), heart rate (HR) and relative cerebral blood flow among the experimental groups. These results indicate that pretreatment with melatonin at a dose between 5 and 15 mg/kg protects against focal cerebral ischemia.",
            "Melatonin, a natural product of the pineal gland, has been shown to protect against ischemic stroke, but the molecular mechanisms underlying its protective function are not fully understood. In the present study, we tested whether melatonin could protect against ischemia-reperfusion (I/R) injury to rat brain by targeting the autophagy pathway. The I/R brain injury was induced by the established rat transient middle cerebral artery occlusion model. We found intraperitoneal injection of melatonin can ameliorate rat brain injury as evidenced by multiple morphological and behavioral criteria, such as infarct size, neurological score, serum creatine kinase, and lactate dehydrogenase content, as well as pyknotic-positive cells. Further studies revealed that the beneficial effects of melatonin is through targeting the autophagy pathway by inhibiting expression of beclin-1 and conversion of LC3, as well as activating the PI3K/Akt pro-survival pathway.",
            "Melatonin as a Potential Neuroprotectant: Mechanisms in Subarachnoid Hemorrhage-Induced Early Brain Injury.",
            "f diseases. In this study, the neuroprotective effects of melatonin (Mel) on a rat model of cerebral ischemia/reperfusion injury (CIRI) were assessed by multi-parametric MRI combined with histopathological techniques for longitudinal monitoring of the lesion microe",
            "Melatonin is a strong antioxidant which beneficially protects against middle cerebral artery occlusion (MCAO) followed by hemorrhagic transformation in rats; protection includes the reduction of neurological deficits, infarction, and hematoma volume.",
            "Nonetheless, the mechanisms of the anti-inflammatory effects of EA are unclear. Cerebral I/R injury was induced in rats by middle cerebral artery occlusion (MCAO). Following I/R injury, the rats underwent EA therapy at the Shenting (DU24) and Baihui (DU20) acupoints for seven successive days. The Morris water maze test, magnetic resonance imaging (MRI) and molecular biology assays were utilized to assess the establishment of the rat stroke model with cognitive impairment and the therapeutic effect of EA. EA treatment of rats subjected to MCAO showed a significant reduction in infarct volumes accompanied by cognitive recovery, as observed in Morris water maze test outcomes. The possible mechanisms by which EA treatment attenuates cognitive impairment are by regulating endogenous melatonin secretion through aralkylamine N-acetyltransferase gene (AANAT, a rate-limiting enzyme of melatonin) synthesis in the pineal gland in stroke rats. Simultaneously, through melatonin regulation, EA exerts neuroprotective effects by upregulating mitophagy-associated proteins and suppressing reactive oxygen species (ROS)-induced NLRP3 inflammasome activation after I/R injury. However, melatonin receptor inhibitor (luzindole) treatment reversed these changes. The findings from this research suggested that EA ameliorates cognitive impairment through the inhibition of NLRP3 inflammasome activation by regulating melatonin-mediated mitophagy in stroke rats.",
            "Melatonin has protective effects against cerebral ischemia/reperfusion injury.",
            "e damage in neurons after CI.CONCLUSION: Melatonin treatment following CI reduced the infarct area and induced the autophagic proteins Beclin-1, LC3, and p62 by in",
            "In conclusion, these results indicate that melatonin treatment can protect against CIR-induced brain damage in diabetic mice, which may be achieved by the autophagy enhancement mediated by the SIRT1-BMAL1 pathway.",
            "lls, and better neuronal survival.CONCLUSIONS: T1DM aggravates CIRI. Melatonin treatment is neuroprotective against CIRI in T1DM rats vi",
            "AIMS: The neurohormone melatonin (MEL) has been reported as a promising neuroprotective molecule, however it suffers pharmaceutical limitations such as poor solubility and low bioavailability, which hinder its pharmacological and clinical pote",
            "We found that melatonin reduced infarct area and suppressed neuron death during reperfusion stress.",
            "tosis through SIRT3 activation.SIGNIFICANCE: Our research proved that melatonin promoted SIRT3 expression after tMCAO and alleviated cerebral I/R inju",
            "stroke. Melatonin treatment significantly decreased infarct volume and cerebral apoptosis; mitigated endoplasmic reticulum stress and mitochondrial dysfunction; and inhibited CI/R injury-induced oxidative/nitrative stress and nuclear factor-κB activation, which was eradicated in RORα-defic",
            "al survival.CONCLUSIONS: T1DM aggravates CIRI. Melatonin treatment is neuroprotective against CIRI in T1DM rats vi",
            "Melatonin supplementation enhances OPA1-related mitochondrial fusion by activating the Yap-Hippo pathway, ultimately reducing brain reperfusion stress.",
            "er ischemia.RESULTS: MT significantly reversed the locomotor activity increases, ameliorated learning and working memory deficit, and reduced the extent of CA1 hippocampal pyramidal cells injury after transient global cerebral ischemia in ",
            "Melatonin's efficacy in curtailing neural damage under conditions of transitory interruption of the blood supply to the brain has been documented in models of both focal and global ischemia.",
            "For example, when given at the time of ischemia or reperfusion onset, melatonin reduces neurophysiological deficits, infarct volume, the degree of neural edema, lipid peroxidation, protein carbonyls, DNA damage, neuron and glial loss, and death of the animals.",
            "Considering its high efficacy in overcoming much of the damage associated with ischemia/reperfusion injury, not only in the brain but in other organs as well, its use in clinical trials for the purpose of improving stroke outcome should be seriously considered.",
            "melatonin against ischemia/reperfusion brain injury. The studies",
            " that melatonin plays a critical role in protecting against cerebral ischemia/reper",
            "The brain is highly susceptible to focal or global ischemia. Unless ischemia is promptly reversed, reperfusion produces further cerebral damage. Acute thrombolysis or defibrinogenation is effective only in selective patients with ischemic stroke and carries a significant risk of bleeding complications. Whereas numerous neuroprotectants were shown to be effective in experimental studies, none of them have been shown to work in clinical trials. The major pathogenetic mechanisms of ischemia/reperfusion injury include excitotoxicity, disturbed calcium ion homeostasis, overproduction of nitric oxide and other free radicals, inflammation, and apoptosis. Nitric oxide and other free radicals, the key mediators of excitotoxicity and disturbed calcium ion homeostasis, cause direct injury and also indirectly damage via inflammation and apoptosis. Melatonin is a potent free radical scavenger and an indirect antioxidant. This mini review summarizes the in vivo and in vitro evidence that melatonin protects against ischemia/reperfusion injury. There is convincing evidence from the literature that melatonin treatment is highly effective in different in vivo and in vitro models of excitotoxicity or ischemia/reperfusion in multiple animal species. Melatonin is safe and non-toxic in humans, and its administration via the oral route or intravenous injection is convenient. While more experimental studies should be conducted to further explore the neuroprotective mechanisms and to document any synergistic or additive protection from combining melatonin with thrombolysis, defibrinogenation or other neuroprotectants, interested clinical scientists should consider planning phase II and III studies to confirm the benefit",
            "ischemia and reperfusion. Histological observations of the pyramidal layer of CA-1 showed a reduction of neuronal loss in animals that received melatonin. These results show that melatonin improves brain injury",
            "Brains were harvested for infarct size estimation, water content measurement, biochemical analysis, apoptosis study and western blot experiments.KEY FINDINGS: Melatonin at 60 min post ischemia rendered neuroprotection as evident by reduction in cerebral infarct volume, improvement in motor and neurological deficit and reduction in brain edema.",
            "These results show that melatonin improves brain injury induced by transient cerebral ischemia.",
            "Furthermore, ischemia induced surge in levels of nitrite and malondialdehyde (MDA) were also found to be significantly reduced in ischemic brain regions in treated animals.",
            "Then, we observed the changes in the SIRT3 and downstream relative proteins, infarction volume, neurological score, Nissl, H&E and TUNEL staining, and the expression of apoptosis proteins after tMCAO.KEY FINDINGS: Melatonin upregulated the expression of SIRT3 after tMCAO, and alleviated the neurological dysfunction and cell apoptosis through SIRT3 activation.SIGNIFICANCE: Our research proved that melatonin promoted SIRT3 expression after tMCAO and alleviated cerebral I/R injury by activating the SIRT3 signaling pathway.",
            "Overall, we demonstrate that melatonin can alleviate CIR injury in diabetic mice by activating Akt-SIRT3-SOD2 signaling and subsequently improving mitochondrial damage."
        ]
    },
    "65f84b5ec4010b4d78000048":
    {
        "question": "Are Hemoglobin-Based Oxygen Carriers approved for human use?",
        "llm_evidence": "Hemoglobin-Based Oxygen Carriers (HBOCs) are synthetic or modified hemoglobin products that aim to serve as blood substitutes by carrying oxygen in the bloodstream. While there has been significant research and development around HBOCs, as of October 2023, no HBOC has received widespread regulatory approval for general human use. Some HBOCs, like Hemopure (bovine-derived) and Oxyglobin (canine use), have seen limited approvals, primarily in specific veterinary contexts or for niche applications, but human application remains controversial. Key challenges include adverse effects such as increased blood pressure and oxygen toxicity, leading to scrutiny from health regulators like the FDA and EMA. Ongoing clinical trials continue to assess their safety and efficacy, indicating the potential for future approval, but as of now, they are not widely approved for human use.",
        "paper_evidence":
        [
            "As of today, there is no widely accepted product used as an alternative to human blood in clinical settings with severe anemic condition(s)",
            "products still in active clinical research in the category of hemoglobin-based oxygen carriers",
            "Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.",
            "OxyVita and Sanguinate are still undergoing active clinical studies.",
            "Unfortunately, so far, no HBOC has been approved by FDA and EMA, except for compassionate use.",
            "Safety and cost effectiveness are being evaluated for their use as an alternative to blood transfusion or along with other strategies of blood conservation in cardiac surgery.SUMMARY: One hemoglobin-based oxygen carrier (Hemopure) has been approved for use in humans in South Africa as well as another hemoglobin-based oxygen carrier (Gelenpol) and a perfluorocarbon (Perfluoron) in Russia.",
            "Four cross-linked hemoglobin products have been tested in Phase III clinical trials.CONCLUSION: While no product has yet been approved for clinical use, preliminary studies with oxygen therapeutics show promising results, with effective oxygen carrying capacity and acceptable side effect profiles.",
            "Several of these HBOCs have undergone rigorous preclinical and clinical evaluation, but have not yet received clinical approval in the USA for human use.",
            "While there is no FDA approved hemoglobin-based oxygen carrier approved for use in injured patients at this writing, phase III studies are currently either underway or being developed.",
            "No artificial oxygen carriers are currently approved for clinical use in the United States. Hemopure has been approved for use in South Africa. The companies producing Hemopure and PolyHeme, both of which are hemoglobin-based oxygen carriers, have filed a Biologic License Application in the United States.",
            "For the past thirty years, hemoglobin-based oxygen carriers (HBOCs) have been under development as a red blood cell substitute. Side-effects such as vasoconstriction, oxidative injury, and cardiac toxicity have prevented clinical approval of HBOCs.",
            "HBOC-201, which is a preparation of cell-free bovine hemoglobin, has been approved for clinical use in South Africa.",
            "Hemopure (HBOC-201, bovine Hb glutamer-250; OPK Biotech, Cambridge, MA), one such HBOC, has been approved for clinical use in South Africa and Russia.",
            "HBOC-201 is generally well-tolerated and is approved for use in South Africa, where it is indicated for use in adult surgical patients who are acutely anaemic, and is used to eliminate, delay or reduce the need for allogeneic RBCs.",
            "A Biologics License Application for HBOC-201 is currently under review by the US FDA.",
            "South Africa recently approved one HBOC for use as a transfusion alternative in patients with chronic anemia",
            "Bovine-derived hemoglobin-based oxygen carriers (HBOCs) have been investigated for use in humans (HBOC-201) and approved for veterinary medicine (HBOC-301).",
            "Hemoglobin-based oxygen carriers (HBOCs) are currently not Food and Drug Administration approved",
            "No artificial oxygen carriers are currently approved for clinical use in the United States. Hemopure has been approved for use in South Africa.",
            "Hemoglobin based oxygen carriers (HBOCs) have been developed as alternative oxygen transporting formulations for the acute treatment of anemia and ischemia. Efficacy has been demonstrated in a variety of preclinical models and selected human patients; however, a higher overall incidence of mortality and myocardial infarction in those dosed with HBOCs in later stage clinical trials has prevented widespread regulatory approval.",
            "There are at least three agents presently under development that use different techniques to alter the basic hemoglobin tetramer. While there is no FDA approved hemoglobin-based oxygen carrier approved for use in injured patients at this writing, phase III studies are currently either underway or being developed. There is high likelihood that one or more of these agents will be approved for clinical use in the near future.",
            "HBOCs have been the most extensively studied and tested in preclinical and clinical trials that have shown success in diminishing the number of blood transfusions as well as an overall favorable side-effect profile. This has been demonstrated in vascular, cardiothoracic, and orthopaedic patients. HBOC-201, which is a preparation of cell-free bovine hemoglobin, has been approved for clinical use in South Africa.",
            "Preparations undergoing experimental and clinical assessment include Human Polymerized Haemoglobin (Polyheme), Polymerized Bovine Haemoglobin-based Oxygen Carrier (HBOC-201, Hemopure), Haemoglobin Raffimer (HemoLink), Diaspirin Cross-linked Haemoglobin (HemAssist), Human Recombinant Haemoglobin (rHb), Enzyme Cross-linked Poly-haemoglobin, Maleimide-activated Polyethylene-glycol Modified Haemoglobin (MP4, Hemospan), Zero-linked Haemoglobin (ZL-HbBv) and Recombinant Hybrid of Human-alpha-chains and Bovine-beta-chains and Perflubron (Oxygent). Research into some of these compounds has been discontinued, while others have advanced into clinical phase III trials, but none has achieved market approval for Europe, US or Canada so far.",
            "ted in Phase III clinical trials. Hemoglobin-based oxygen carriers (HBOCs) are either cross-linked or microencapsulated hemoglobin molecules. Modification of the human hemoglobin molecule with intra- and inter-molecular cross-linking eliminates renal toxicity and improves the oxygen dissociation characteristics of the molecule. These modifications are necessary because stroma-free hemoglobin (Hb) does not release oxygen in the physiologic range and dissociates into dimers which can be rapidly filtered by the kidney, leading to renal toxicity. In addition to human Hb, bovine hemoglobin is another source of raw material for HBOC products. Recombinant human Hb has also been produced, using an E. coli expression system, for HBOC manufacturing. Four cross-linked hemoglobin products have been tested in Phase III clinical trials.CONCLUSION: While no product has yet been approved for clinical use, preliminary studies with oxygen therapeutics show promising results, with effective oxygen carrying capacity and acceptable side effect profiles. In the future, the formation of a hybrid product which combines the best features from several of the products currently undergoing development ",
            "Hemopure is in clinical use in South Africa and Russia.",
            "Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States.",
            "HemO2life has recently been approved for organ preservation in organ transplantation in the European Union.",
            "a higher overall incidence of mortality and myocardial infarction in those dosed with HBOCs in later stage clinical trials has prevented widespread regulatory approval.",
            "No artificial oxygen carriers are currently approved for clinical use in the United States.",
            "Hemopure has been approved for use in South Africa.",
            "Side-effects such as vasoconstriction, oxidative injury, and cardiac toxicity have prevented clinical approval of HBOCs.",
            "Hb-based oxygen carriers (HBOCs) can potentially provide therapeutic oxygenation when blood or RBCs are not available. Several of these HBOCs have undergone rigorous preclinical and clinical evaluation, but have not yet received clinical approval in the USA for human use. While these designs are being optimized for clinical translations, several new HBOC designs and molecules have been reported in recent years, with unique properties. The current article will provide",
            "nservation in cardiac surgery.SUMMARY: One hemoglobin-based oxygen carrier (Hemopure) has been approved for use in humans in South Africa as well as another hemoglobin-based oxygen carrier (Gelenpol) and a perfluorocarbon (Perfluoron) in Russia. Phase III trials in Europe and North America will be concluded very soon. We anticipate seeing one or two products approved in Nort",
            "In this article, we reviewed the most developed but failed products and products still in active clinical research in the category of hemoglobin-based oxygen carriers. Among all of the discussed hemoglobin-based oxygen therapeutics, HemAssist, PolyHeme, Hemolink, Hemospan, and Hemoximer were discontinued. Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union. OxyVita and Sanguinate are still undergoing active clinical studies. The field of oxygen therapeutics seems to be entering a phase of rapid growth in the coming 10-20 years.",
            "With a worldwide shortage of donor blood that is expected to increase over time, the creation of oxygen-carriers with long storage life and compatibility without typing and cross-matching, persists as one of the foremost important challenges in biomedicine. However, research has so far failed to produce FDA approved RBCs substitutes (RBCSs) for human usage. As such, due to unacceptable toxicities, the first generation of oxygen-carriers has been withdrawn from the market. Being hemoglobin (Hb) the main component of RBCs, a lot of effort is being devoted in assembling semi-synthetic RBCS utilizing Hb as the oxygen-carrier component, the so-called Hb-based oxygen carriers (HBOCs). However, a native RBC also contains a multi-enzyme system to prevent the conversion of Hb into non-functional methemoglobin (metHb). Thus, the challenge for the fabrication of next-generation HBOCs relies in creating a system that takes advantage of the excellent oxygen-carrying capabilities of Hb, while preserving the redox environment of native RBCs that prevents or reverts the conversion of Hb into metHb. In this review, we feature the most recent",
            "Hemoglobin-based oxygen carriers (HBOCs) derived from purified human or bovine hemoglobin have been studied for clinical use and one product is currently available in the United States and European Union for veterinary use, and another in South Africa for human use.OBJECTIVE: HBOC-201, bovine purified hemoglobin crosslinked and polymerized with glutaraldehyde, has been studied extensively in patients.",
            "Despite decades of research to develop hemoglobin (Hb) based oxygen (O2) carriers (HBOCs) as RBC substitutes, there are no products approved for clinical use.",
            "Among all of the discussed hemoglobin-based oxygen therapeutics, HemAssist, PolyHeme, Hemolink, Hemospan, and Hemoximer were discontinued. Hemopure is in clinical use in South Africa and Russia. Oxyglobin, the sister product of Hemopure, has been approved for veterinary use in the European Union and the United States. HemO2life has recently been approved for organ preservation in organ transplantation in the European Union."
        ]
    },
    "65cfa37c1930410b1300000d":
    {
        "question": "Gantenerumab was developed for treatment of which disease?",
        "llm_evidence": "Gantenerumab is primarily developed for the treatment of Alzheimer's disease. It is a human monoclonal antibody that targets amyloid beta, a protein that forms plaques in the brains of Alzheimer's patients. Clinical studies have focused on evaluating its effectiveness in reducing amyloid plaque burden and improving cognitive function in individuals with mild to moderate Alzheimer's disease. The drug aims to modify the disease's progression rather than just alleviating symptoms, making it a part of ongoing research in neurodegenerative disease interventions.",
        "paper_evidence":
        [
            "Other anti-amyloid antibodies are under investigation in phase III (donanemab, lecanemab, gantenerumab) and have shown preliminary evidence of a cognitive benefit in phase II trials. ",
            "Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.",
            "BACKGROUND: This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer's disease (AD).",
            "BODY: Here, we review over 2 decades of gantenerumab development in the context of scientific discoveries in the broader AD field. ",
            "CONCLUSION: The results from the gantenerumab phase 3 programs are expected by the end of 2022 and will add critical information to the collective knowledge on the search for effective AD treatments.",
            "METHODS: Sixty-six mutation-positive participants enrolled in the gantenerumab and placebo arms of the first Dominantly Inherited Alzheimer Network Trials Unit clinical trial (DIAN-TU-001) underwent both 11C-PiB and 18F-florbetapir PET imaging at baseline and during at least one follow-up visit. ",
            "Two long-term, controlled trials on three anti-β-amyloid monoclonal antibodies (solanezumab, gantenerumab and crenezumab) in subjects carrying Alzheimer's disease-linked mutated genes encoding for amyloid precursor protein or presenilin 1 or presenilin 2 failed to show cognitive or functional benefits. ",
            "The model components were calibrated to data from the literature and internal studies, including quantitative data supporting the underlying AD biology and clinical data from clinical trials for anti-Aβ monoclonal antibodies (mAbs) aducanumab, crenezumab, gantenerumab, and solanezumab.",
            "INTRODUCTION: Recent published clinical trial safety data showed that 41% of Alzheimer patients experienced amyloid-related imaging abnormalities (ARIA), marks of microhemorrhages and edema in the brain, following administration of Biogen's Aduhelm/aducanumab (amino acids 3-7 of the Aβ peptide). Similarly, Janssen/Pfizer's Bapineuzumab (amino acids 1-5 of the Aβ peptide) and Roche's Gantenerumab (amino acids 2-11/18-27 of the Aβ peptide) also displayed ARIA in clinical trials, including microhemorrhage and focal areas of inflammation or vasogenic edema, respectively.",
            "Patients with Alzheimer's disease who have been given monoclonal antibodies targeting amyloid-β (Aβ) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging abnormalities (ARIA), shown on brain magnetic resonance imaging (MRI) scans. ",
            "Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer's disease.",
            "This study investigates a bispecific modular fusion protein composed of gantenerumab, a fully human monoclonal anti- amyloid-beta (Aβ) antibody under investigation for AD treatment, with a human transferrin receptor 1-directed Brainshuttle™ module (trontinemab; RG6102, INN trontinemab)",
            "Gantenerumab is a subcutaneously administered, fully human, anti-Aβ IgG1 monoclonal antibody with highest affinity for aggregated Aβ that has been tested for the treatment of Alzheimer's disease.METHODS: We conducted two phase 3 trials (GRADUATE I and II) involving participants 50 to 90 years of age with mild cognitive impairment or mild dementia due to Alzheimer's disease and evidence of amyloid plaques on positron-emission tomography (PET) or cerebrospinal fluid (CSF) testing.",
            "Amyloid-related imaging abnormalities with edema (ARIA-E) occurred in 24.9% of the participants receiving gantenerumab, and symptomatic ARIA-E occurred in 5.0%.CONCLUSIONS: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline.",
            "BACKGROUND: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).OBJECTIVES: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.DESIGN: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose positron emission tomographic study.",
            "Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.",
            "Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.",
            "Gantenerumab is intended for the treatment of Alzheimer's disease.",
            " gantenerumab, and an anti-tau monoclonal antibody, RO7105705, as well as a robust biomarker platform to aid in the early identification of people at risk or in the early stages of AD",
            "PURPOSE: Gantenerumab, a fully human anti-amyloid-β IgG1 monoclonal antibody that binds to aggregated forms of amyloid-β, is being investigated as a potential disease-modifying treatment for early (prodromal to mild) Alzheimer disease (AD).",
            "Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain. This compound, currently undergoing Phase II and III clinical trials represents a promising agent with a disease-modifying potential in Alzheimer's disease.",
            "Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated clearance of brain Aβ deposits. Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate AD patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of Aβ, were disappointing. Also solanezumab, directed at the mid-region of Aβ, failed in two Phase III trials in mild-to-moderate AD. Another Phase III trial with solanezumab is ongoing in mildly affected AD patients based on encouraging results in this subgroup. Second-generation active Aβ vaccines (CAD106, ACC-001, and Affitope AD02) and new passive anti-Aβ immunotherapies (gantenerumab and crenezumab) have been developed and are under clinical testing. These new anti-Aβ immunotherapies are being tested in prodromal AD, in presymptomatic subjects with AD-related mutations, or in asymptomatic subjects at risk of developing AD. These primary and secondary prevention trials will definitely test the Aβ cascade hypothes",
            " encouraging results in this subgroup of patients. Second-generation active Aβ vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-Aβ immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer's disease patients, in presymptomatic individuals with Alzheimer's disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer's disease to definitely ",
            "INTRODUCTION: The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer's disease (AD) suggested earlier intervention in the disease course. Secondary prevention trials have been started in autosomal-dominant AD (ADAD) individuals without cognitive dysfunction and in cognitively healthy subjects at risk of developing sporadic AD (SAD).AREAS COVERED: Herein, the authors discuss prevention trials in ADAD and SAD, with a focus on the anti-Aβ monoclonal antibodies solanezumab and gantenerumab presently in Phase III clinical development. These therapies are also being tested in the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU).EXPERT OPINION: Anti-Aβ monoclonal antibodies are being tested in subjects at the preclinical stage of ADAD and even in s",
            "Gantenerumab, a fully human monoclonal antibody (mAb) that binds to aggregated amyloid-beta, was tested in two 24-month phase III studies (NCT01224106, NCT02051608) in participants with prodromal and mild Alzheimer's disease (AD), respectively.",
            "The 16 compounds selected include disease-modifying therapies and symptomatic therapies. The research and development pipeline now focuses on disease-modifying therapies such as gantenerumab, aducanumab, ALZ-801, ALZT-OP1, donanemab, lecanemab, simufilam, NE3107, semaglutide, and GV-971, which could put an end to the situation where Alzheimer's patients in China have no effective treatment alternatives.",
            "en-label extension of SCarlet RoAD (a study of gantenerumab in participants with prodromal Alzheimer's disease) and Marguerite RoAD (as study of Gantenerumab in participants with mild Alzheimer's disease) studies were us",
            "Gantenerumab is intended for the treatment of Alzheimer's disease. It is a fully human recombinant"
        ]
    },
    "65f70a55c4010b4d7800001b":
    {
        "question": "Please list the congenital fibrinogen disorders.",
        "llm_evidence": "Congenital fibrinogen disorders are rare hereditary conditions characterized by deficiencies or dysfunctions of fibrinogen, a critical protein in the blood coagulation process. The key types of congenital fibrinogen disorders include:\n\n1. **Congenital Fibrinogen Deficiency ( afibrinogenemia)**: This is a complete absence of fibrinogen, leading to severe bleeding tendencies. Patients often present with excessive bleeding after trauma or surgery.\n\n2. **Hypofibrinogenemia**: This condition involves a reduced level of fibrinogen in the blood, which can cause mild to moderate bleeding symptoms. It may be asymptomatic in some cases.\n\n3. **Dysfibrinogenemia**: In this disorder, normal levels of fibrinogen are present, but the protein is structurally abnormal, leading to impaired clot formation. Symptoms can vary widely, with some patients experiencing bleeding while others may have a tendency for thrombosis.\n\n4. **Afibrinogenemia**: A complete lack of fibrinogen, this condition often results in significant bleeding complications and requires treatment with fibrinogen concentrate or cryoprecipitate.\n\nThese disorders may have varying clinical presentations and inherited patterns, primarily following an autosomal recessive or dominant inheritance. Diagnosis typically involves coagulation studies that assess fibrinogen levels and functionality. Management may require factor replacement therapy or supportive care during bleeding episodes.",
        "paper_evidence":
        [
            "Congenital fibrinogen deficiencies (CFD) are a group of rare bleeding disorders (RBD). Afibrinogenemia as a subclass of these disorders would occurs as a result of mutations in fibrinogen gene. Here in, the sequences of Aα chain of fibrinogen (FGA) in patients with inherited afibrinogenemia disorder in south-eastern of Iran were analysed.",
            " From the first clinical description of afibrinogenemia in 1920, many major achievements have contributed to a better understanding of these complex disorders. T",
            "congenital fibrinogen disorders, focusing on afibrinogenemia and dysfibrinogenemia.",
            "Ranging from bleeding to thrombosis, the clinical features of congenital fibrinogen qualitative disorders, including dysfibrinogenemia and hypodysfibrinogenemia, ar",
            "Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review.",
            "Fibrinogen deficiencies are very rare. Qualitative fibrinogen deficiencies (dysfibrinogenaemia and hypodysfibrinogenemia) are functional disorders that can present with both haemorrhagic symptoms and with thro",
            "In this paper, we focused on familial hypofibrinogenemia, a rare inherited quantitative fibrinogen disorder characterized by decreased fibrinogen levels with a high phenotypic heterogeneity. ",
            "The congenital dysfibrinogenemias, most often associated with bleeding disorders, encompass mutations in the amino-terminal end of fibrinogen α-chain consisting of Gly17-Pro18-Arg19-Val20, known as knob A, which is a critical site for fibrin polymerization. ",
            " case of congenital afibrinogenemia with multiple thrombotic and hemorrhagic disorders.",
            "Congenital fibrinogen disorders are rare pathologies of the hemostasis, comprising quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia and hypodysfibrinogenemia) disorders. ",
            "INTRODUCTION: Congenital fibrinogen disorders (CFDs) are classified as afibrinogenemia or hypofibrinogenemia (Hypo), dysfibrinogenemia (Dys), or hypodysfibrinogenemia (Hypodys), according to functional and antigenic fibrinogen concentrations.",
            "Congenital fibrinogen disorders are rare diseases affecting either the quantity (afibrinogenemia and hypofibrinogenemia) or the quality (dysfibrinogenemia) or both (hypodysfibrinogenemia) of plasmatic fibrinogen.",
            "Afibrinogenemia and hypofibrinogenemia are the consequence of mutations in the homozygous, heterozygous, or compound heterozygous state in one of three genes encoding the fibrinogen chains, which can affect the synthesis, assembly, intracellular processing, stability, or secretion of fibrinogen.",
            "Congenital fibrinogen disorders (CFDs) are divided into qualitative deficiencies (dysfibrinogenemia, hypodysfibrinogenemia) in which the mutant fibrinogen molecule is present in the circulation and quantitative deficiencies (afibrinogenemia, hypofibrinogenemia) with no mutant molecule present in the bloodstream.",
            "Congenital Afibrinogenemia and Hypofibrinogenemia: Laboratory and Genetic Testing in Rare Bleeding Disorders with Life-Threatening Clinical Manifestations and Challenging Management.",
            "Congenital fibrinogen disorders are classified into two types of plasma fibrinogen defects: type I (quantitative fibrinogen deficiencies), that is, hypofibrinogenemia or afibrinogenemia, in which there are low or absent plasma fibrinogen antigen levels, respectively, and type II (qualitative fibrinogen deficiencies), that is, dysfibrinogenemia or hypodysfibrinogenemia, in which there are normal or reduced antigen levels associated with disproportionately low functional activity.",
            "Congenital fibrinogen disorders (afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia and hypodysfibrinogenemia), caused by pathogenic variants in the genes FGA, FGB and FGG, have the potential of causing bleeding diathesis and/or thrombotic events of variable severity.",
            "Congenital fibrinogen disorders are rare diseases affecting either the quantity (afibrinogenaemia and hypofibrinogenaemia) or the quality (dysfibrinogenaemia) or both (hypodysfibrinogenaemia) of fibrinogen.",
            "Congenital fibrinogen disorders are classified into two types of plasma fibrinogen defects: type I (quantitative fibrinogen deficiencies), that is, hypofibrinogenemia or afibrinogenemia, in which there are low or absent plasma fibrinogen antigen levels, respectively, and type II (qualitative fibrinogen deficiencies), that is, dysfibrinogenemia or hypodysfibrinogenemia, in which there are normal or reduced antigen levels associated with disproportionately low functional activity. These disorders are caused by mutations in the three fibrinogen-encoding genes FGA, FGB, and FGG.",
            "Hereditary fibrinogen abnormalities comprise two classes of plasma fibrinogen defects: Type I, afibrinogenemia or hypofibrinogenemia, which has absent or low plasma fibrinogen antigen levels (quantitative fibrinogen deficiencies), and Type II, dysfibrinogenemia or hypodysfibrinogenemia, which shows normal or reduced antigen levels associated with disproportionately low functional activity (qualitative fibrinogen deficiencies).",
            "Congenital qualitative and quantitative fibrinogen disorders represent heterogeneous rare abnormalities caused by mutations in one of the 3 genes encoding individual fibrinogen polypeptide chains, located on chromosome 4q28. It is estimated that congenital fibrinogen disorder accounts for 8% of rare coagulation factor deficiencies.",
            "Hereditary fibrinogen disorders include type I deficiencies (afibrinogenemia and hypofibrinogenemia, i.e. quantitative defects), with low or unmeasurable levels of immunoreactive protein; and type II deficiencies (dysfibrinogenemia and hypodysfibrinogenemia, i.e. qualitative defects), showing normal or altered antigen levels associated with reduced coagulant activity.",
            "INTRODUCTION: Congenital fibrinogen disorders result from genetic mutations in FGA, FGB, or FGG resulting in quantitative fibrinogen deficiencies (afibrinogenemia or hypofibrinogenemia) or qualitative fibrinogen deficiencies (dysfibrinogenemia). Hypodysfibrinogenemia sharing features with hypo- and dysfibrinoge",
            "Congenital fibrinogen disorders can be quantitative (afibrinogenemia, hypofibrinogenemia) or functional (dysfibrinognemia).",
            "Congenital fibrinogen disorders comprise quantitative disorders defined by a complete absence (afibrinogenemia) or by a decreased level (hypofibrinogenemia) of circulating fibrinogen and qualitative disorders characterized by a discrepancy between the activity and the antigenic levels of fibrinogen (dysfibrinogenemia and hypodysfibrinogenemia).",
            "Among congenital fibrinogen deficiencies, quantitative defects (also called type I deficiencies; i.e. congenital afibrino-genemia [CAF] and hypofibrinogenemia) are characterized by the concomitant absence or reduction of coagulant activity and immunoreactive protein, while qualitative defects (type II deficiencies; i.e. dysfibrinogenemia and hypodysfibrino-genemia) show low clotting protein in contrast with normal or moderately reduced antigen.",
            "Inherited fibrinogen disorders can be classified into qualitative and quantitative anomalies: dysfibrinogenemia is characterised by normal circulating levels of fibrinogen with abnormal function; hypofibrinogenemia and afibrinogenemia are characterised by reduced or absent fibrinogen in circulation respectively,while hypodysfibrinogenemia is defined by reduced fibrinogen with reduced function. All are due to mutations in one of the three fibrinogen genes, FGA, FGB and FGG, which are clustered in a region of 50 kb on the long arm of human chromosome 4.",
            "Inherited fibrinogen disorders can be classified into qualitative and quantitative anomalies: dysfibrinogenemia is characterised by normal circulating levels of fibrinogen with abnormal function; hypofibrinogenemia and afibrinogenemia are characterised by reduced or absent fibrinogen in circulation respectively,while hypodysfibrinogenemia is defined by reduced fibrinogen with reduced function.",
            "Congenital fibrinogen deficiency is a rare bleeding disorder, affecting either the quantity (afibrinogenemia, hypofibrinogenemia) or quality (dysfibrinogenemia) of circulating fibrinogen.",
            "Congenital hypofibrinogenemia appears to be a separate entity which can be distinguished from heterozygous individuals of congenital afibrinogenemia and from congenital dysfibrinogenemia.",
            "Congenital dysfibrinogenemia is characterized with undetectable or low fibrinogen level by Clauss assay complicated by bleeding and/or thrombosis.",
            "Congenital afibrinogenemia/hypofibrinogenemia is an extremely rare coagulation disorder.",
            "Congenital afibrinogenemia/hypofibrinogenemia is a rare inherited hematologic disorder in which a patient lacks or has insufficient level of fibrinogen, the blood coagulation factor I.",
            "Since the identification of the first causative mutation for congenital afibrinogenemia, studies have elucidated the underlying molecular pathophysiology of numerous causative mutations leading to fibrinogen deficiency, developed cell-based and animal models to study human fibrinogen disorders, and further explored the clinical consequences of absent, low, or dysfunctional fibrinogen.",
            "Congenital fibrinogen disorders are rare pathologies of the hemostasis, comprising quantitative (afibrinogenemia, hypofibrinogenemia) and qualitative (dysfibrinogenemia and hypodysfibrinogenemia) disorders. The clinical",
            "4. Congenital fibrinogen disorders (CFDs) are divided into qualitative deficiencies (dysfibrinogenemia, hypodysfibrinogenemia) in which the mutant fibrinogen molecule is present in the circulation and quantitative deficiencies (afibrinogenemia, hypofibrinogenemia) with no mutant molecule present in the bloodstream. Phenotypic manifestations are variable, patients may be asymptomatic, or suffer from bleeding or thrombosis. Causative mutations can occur in any of the three fibrinogen genes and can affect one or both alleles. Given the large number of studies reporting on novel causative mutations for CFDs since the review on the same topic published in 2016, we performed an extensive search of the literature and list here 120 additional mutations described in both quantitative and qualitative disorders."
        ]
    },
    "65f82218c4010b4d7800003e":
    {
        "question": "What are the current indications for thalidomide?",
        "llm_evidence": "Thalidomide is currently indicated for several conditions primarily related to its immunomodulatory and anti-inflammatory properties. Key insights include:\n\n1. **Multiple Myeloma**: Thalidomide is used in combination with other therapies for the treatment of newly diagnosed multiple myeloma, particularly in patients not eligible for stem cell transplantation.\n\n2. **Erythema Nodosum Leprosum (ENL)**: It is effective in treating leprosy-related conditions, specifically erythema nodosum leprosum, which is a painful skin condition that can occur in leprosy patients.\n\n3. **HIV-Induced Conditions**: Thalidomide may be used off-label for conditions like HIV-associated wasting syndrome, where it helps in weight gain and improving nutritional status.\n\n4. **Autoimmune Disorders**: There is a growing interest in the use of thalidomide for treating certain autoimmune conditions, such as Behçet's disease, due to its immunosuppressive effects.\n\n5. **Cancer Therapies**: Research continues into its role in the treatment of other malignancies beyond multiple myeloma, exploring its potential for various hematologic and solid tumors.\n\n6. **Safety and Regulatory Status**: Due to its teratogenic effects, thalidomide is tightly regulated, and its use is associated with strict risk management programs to prevent exposure during pregnancy.\n\nOverall, the use of thalidomide has evolved substantially since the 1960s, shifting from its infamous history of causing birth defects to becoming a critical therapeutic agent in specific clinical settings.",
        "paper_evidence":
        [
            "erythema nodosum leprosum, aphthous ulceration and cachexia in HIV disease, inflammatory bowel diseases, and several malignant diseases",
            "Thalidomide is resurging in the management of adult rheumatologic skin conditions, especially lupus erythematosus",
            "aphthous stomatitis and chronic graft-versus-host disease in children",
            "actinic prurigo and epidermolysis bullosa pruriginosa",
            "She was diagnosed with International Staging System (ISS) stage 3 multiple myeloma, which was successfully treated with bortezomib, thalidomide and dexamethasone with regular bisphosphonates that year",
            "With this definition, only three drugs are repurposed for cancer: Bacillus Calmette-Guerin (BCG) vaccine (superficial bladder cancer, thalidomide [multiple myeloma], and propranolol [infantile hemangioma])",
            "The anti-angiogenic effects of thalidomide may make this compound valuable as single-drug therapy or as an adjunct to chemotherapy in patients with cancer, particularly those with metastases or multiple myeloma.",
            "Gradually, thalidomide was reintroduced for the treatment of a few skin diseases including leprous erythema nodosum, severe mucosal ulcers (e.g., associated with HIV infection or Behçet's disease), lymphocytic skin infiltrations, cutaneous lupus erythematosus, and chronic graft-versus-host disease.",
            "Thalidomide has been used in several cutaneous inflammatory disorders (such as erythema nodosum leprosum in lepromatous leprosy, cutaneous lupus erythematosus, severe aphtosis), cancers (relapsed/refractory multiple myeloma) and inflammatory conditions.",
            "Thalidomide is currently being used clinically to treat such conditions as cachexia associated with HIV and cancer, mycobacterial disease, and autoimmune diseases.",
            "Thalidomide was approved for the treatment of multiple myeloma in Japan under a risk management program, named TERMS, in 2008.",
            "Current evidence indicates that thalidomide reduces the activity of the inflammatory cytokine tumor necrosis factor (TNF)-alpha by accelerating the degradation of its messenger RNA. Thalidomide also inhibits angiogenesis. Recently, the drug was approved for sale in the United States for the treatment of erythema nodosum leprosum, an inflammatory complication of Hansen's disease.",
            "Thalidomide, the drug that caused a worldwide epidemic of serious birth defects in the late 1950s and early 1960s, was recently approved by the US Food and Drug Administration (FDA) for use in treating the skin disease erythema nodosum leprosum, a complication of leprosy.",
            "Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects. The Food and Drug Administration approved use in the treatment of erythema nodosum leprosum. Further, it was shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell hystiocytosis, aphthous stomatitis, Behçet syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and others. In May 2006, it was approved for the treating multiple myeloma.",
            "Thalidomide has gained an infamous history due to severe birth defects observed in patients who had taken the drug to control nausea during pregnancy. The medication was withdrawn from the market because of its teratogenicity, but was approved by the FDA in 1998 for the treatment of erythema nodosum leprosum.",
            "Thalidomide was later found to very effectively suppress erythema nodosum leprosum (ENL). The US Food and Drug Administration (FDA) has approved Thalomid (thalidomide) capsules for the acute treatment of the cutaneous manifestations of moderate to severe ENL.",
            "BACKGROUND: Thalidomide is best known as a major teratogen that caused birth defects in up to 12,000 children in the 1960s. More recently, this agent has been approved by the US Food and Drug Administration for the treatment of erythema nodosum leprosum (ENL) through a restricted-",
            "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects. This drug was more recently rediscovered as a powerful immunomodulatory and antiinflammatory agent and was approved by the FDA in 1998 for treatment of erythema nodosum leprosum.",
            "Thalidomide is US Food and Drug Administration (FDA)-approved for use in acute erythema nodosum leprosum and, in combination with dexamethasone, in newly diagnosed myeloma.",
            "Currently, it is used for a few indications; in Brazil, where leprosy is endemic, thalidomide is used for the treatment of erythema nodosum leprosum, and recent cases of thalidomide embryopathy have been reported.METHODS: We analyzed the frequency of births with phenotypes consistent with thalidomide embryopathy (TEP) and correlated this with the distribution of thalidomide and the prevalence of leprosy between 2005 and 2010 in Brazil.RESULTS: A total of 5,889,210 thalidomide tablets were distributed; the prevalence of limb reduction defects was 1.60 (CI95%: 1.54-1.66) and TEP was 0.11 (CI95%: 0.10-0.13) per 10,000 births.",
            "Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications. It was thought to be one of the safest sedatives ever produced as it was effective in small doses, was not addictive, and did not have acute side-effects such as motor impairment, but was quickly removed from market after it was linked to cases of severe birth defects. The Food and Drug Administration approved use in the treatment of erythema nodosum leprosum. Further, it was shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell hystiocytosis, aphthous stomatitis, Behçet syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and others. In May 2006, it was approved for the treating multiple myeloma. ",
            "tion defects. Currently, it is used for a few indications; in Brazil, where leprosy is endemic, thalidomide is used for the treatment of erythema nodosum leprosum, and recent cases of thalidomide embryopathy have ",
            "Thalidomide was later found to very effectively suppress erythema nodosum leprosum (ENL). The US Food and Drug Administration (FDA) has approved Thalomid (thalidomide) capsules for the acute treatment of the cutaneous manifestations of moderate to severe ENL. Thalidomide is currently under investigation for the treatment of a wide variety of diseases, including conditions thought to have an inflammatory or immune basis, malignancies and complications of infection with HIV. Interest in the potential anti-inflammatory, immunomodulatory and anti- angiogenic effects of thalidomide has resulted in off-label use of prescription thalidomide.",
            "Thalidomide currently is used to treat relapsed and refractory multiple myeloma. The drug also is being actively investigated in patients newly diagnosed with multiple myeloma. The therapeutic applications of thalidomide are expected to grow as clinical trials document its activity in treating other neoplastic disorders and diseases.",
            "Thalidomide is an effective agent to treat over 25 seemingly unrelated dermatological conditions that have an inflammatory or autoimmune basis.",
            "Thalidomide, the drug that caused a worldwide epidemic of serious birth defects in the late 1950s and early 1960s, was recently approved by the US Food and Drug Administration (FDA) for use in treating the skin disease erythema nodosum leprosum, a complication of leprosy. The drug has also shown promise in the treatment of other serious diseases. If thalidomide is eventually approved for use in the US and other countries for treatment of diseases more prevalent than erythema nodosum leprosum, or if use of the drug for non-approved indications becomes widespread, hundreds of thousands of women with childbearing ability could be treated. If this should happen, can we prevent another epidemic of birth defects?",
            "BACKGROUND: Thalidomide is best known as a major teratogen that caused birth defects in up to 12,000 children in the 1960s. More recently, this agent has been approved by the US Food and Drug Administration for the treatment of erythema nodosum leprosum (ENL) through a restricted-use program. Its immunomodulatory, anti-inflammatory, and antiangiogenic properties are currently under study in a number of clinical conditions.OBJECTIVE: This article reviews the pharmacology of thalidomide; its approved and off-label uses in dermatologic, oncologic, and gastrointestinal conditions; and adverse events as",
            "Thalidomide currently is used to treat relapsed and refractory multiple myeloma.",
            "BACKGROUND: Thalidomide is a sedative/hypnotic agent that is currently used to treat patients suffering from multiple myeloma, myelodysplastic syndromes and erythema nodos",
            "Thalidomide and its analog, Lenalidomide, are in current use clinically for treatment of multiple myeloma, complications of leprosy and cancers.",
            "Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide.",
            "Thalomid is the FDA-approved commercial formulation of thalidomide currently used in the US to treat erythema nodosum leprosum, a complication of leprosy.",
            "The US Food and Drug Administration (FDA) has approved Thalomid (thalidomide) capsules for the acute treatment of the cutaneous manifestations of moderate to severe ENL.",
            "DRUG WITH A TEMPORARY MARKETING AUTHORISATION: Thalidomide is currently available in France for nominative or cohort use with a temporary marketing authorisation (TMA). It is only prescribed and delivered in hospital settings. SIX OFFICIAL INDICATIONS: Its current indications are principally lepromatous nodular erythema, severe aphtosis, Jessner-Kanoff's cutaneous lymphocyte infiltration, discoid lupus erythematosis, chronic graft-versus-host reactions, and relapsed and or refractory multiple myeloma (after the failure of standard therapies).",
            "Thalidomide is approved for treating erythema nodosum leprosum and multiple myeloma, but it has also emerged as a useful treatment option for many refractory dermatologic disorders.",
            "icularly tumor necrosis factor-alpha. In addition to its approved indication for ENL, thalidomide has been studied in various other conditions, including graft-versus-host disease, discoid lupus erythematosus, sarcoidosis, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic syndromes, acute myeloid leukemia, myelofibrosis with myeloid metaplasia, renal cell carcinoma, malignant gliomas, prostate cancer, Kaposi's sarcoma, colorectal carcinoma, oral aphthous ulcers, Behçet's disease, Crohn's dis",
            "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects. This drug was more recently rediscovered as a powerful immunomodulatory and antiinflammatory agent and was approved by the FDA in 1998 for treatment of erythema nodosum leprosum. Thalidomide has shown great promise in advanced or refractory multiple myeloma either alone or in combination with other agents. It has also demonstrated benefits in a wide variety of disparate conditions such as aphthous and genital ulcers, cancer cachexia, HIV, tuberculosis and chronic graft versus host disease.",
            "Thalidomide was approved by the FDA in July 1998 for the treatment of erythema nodusum leprosum associated with leprosy.",
            "Recently, thalidomide was approved for sale in the United States for the treatment of erythema nodosum leprosum, an inflammatory complication of Hansen's disease.",
            "Thalidomide has established its own niche market particularly for the dermatological manifestations associated with HIV, Behçet's disease, graft-versus-host disease and systemic lupus erythematosus."
        ]
    },
    "65d1357c1930410b13000039":
    {
        "question": "What is the administration route of zavegepant?",
        "llm_evidence": "Zavegepant is administered as a nasal spray. This route allows for rapid absorption and onset of action, making it effective for acute treatment of migraine. Formulated as a selective CGRP receptor antagonist, zavegepant offers a non-invasive alternative to traditional oral medications, providing patients with an effective option for managing migraine symptoms quickly.",
        "paper_evidence":
        [
            "Zavegepant (Zavzpret), a nasal spray, is approved to treat adults with acute migraine with or without aura.",
            "Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is ratified for both indications, all via oral administration and while zavegepant is administered intranasally for migraine attacks. ",
            "In March 2023, zavegepant nasal spray (ZAVZPRET™) received its first approval in the USA for the acute treatment of migraine with or without aura in adults. ",
            "Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.",
            "Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phase 2/3 trial. ",
            "INTERPRETATION: Zavegepant 10 mg nasal spray was efficacious in the acute treatment of migraine, with favourable tolerability and safety profiles. ",
            "Zavegepant is a novel, first-in-class, intranasally administered calcitonin gene-related peptide (CGRP) receptor antagonist that has recently been approved for use in acute migraine attacks.",
            "Moreover, the intranasal method of administration is a characteristic advantage of Zavegepant, as patients suffering from acute migraine attacks cannot easily ingest oral medication, due to severe nausea and vomiting.",
            "In this mini-review, the efficacy and safety of Zavegepant will be compared with those of alternative treatments available for migraines, including oral triptans, intranasal triptans, and other CGRP antagonists currently available in the market.",
            "Ubrogepant is ratified for acute migraine treatment, atogepant is validated for preventive therapy, whereas rimegepant is ratified for both indications, all via oral administration and while zavegepant is administered intranasally for migraine attacks.",
            "Zavegepant (BHV-3500, BMS-742413) is a high affinity antagonist of the CGRP receptor (hCGRP Ki = 0.023 nM) that has demonstrated efficacy in the acute treatment of migraine with intranasal delivery in a Phase 2/3 trial, despite showing low oral bioavailability in rats (FPO = 1.7%).",
            "Focus on zavegepant: the first intranasal third-generation gepant.",
            "Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acute treatment of migraine - a prevalent disease leading to disability and economic burden",
            "BACKGROUND: Zavegepant nasal spray is a novel CGRP receptor antagonist that has been developed for the acu",
            "OBJECTIVE: Evaluate the efficacy, safety, and tolerability of zavegepant nasal spray in the acute treatment of migraine.BACKGROUND: Calci",
            "d vomiting. Zavegepant, an intranasally administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a phas",
            "Newly approved small molecules that antagonize the CGRP receptor, gepants, have advanced from the hepatotoxic first-generation telcagepant to third-generation intranasal zavegepant;",
            " for acute treatment. Zavegepant, a high-affinity, selective, and structurally unique calcitonin gene-related peptide-receptor antagonist in late-stage development, is formulated as a nasal spray for the acute ",
            "e attacks per month. Participants were randomly assigned (1:1) to zavegepant 10 mg nasal spray or matching placebo and self-treated a single migraine attack of moderate or s"
        ]
    },
    "65f59db8c4010b4d78000014":
    {
        "question": "Brunner's gland hamartoma (BGH) is often asymptomatic and so how is it usually diagnosed?",
        "llm_evidence": "Brunner's gland hamartoma (BGH) is typically diagnosed incidentally during imaging studies or endoscopic procedures conducted for other reasons, such as gastrointestinal complaints or routine examinations. Key insights include:\n\n1. **Imaging Techniques**: BGH can be identified through abdominal ultrasound, CT scans, or MRI, which may reveal a pancreaticoduodenal mass. These imaging modalities are sensitive in detecting abnormalities in the duodenum.\n\n2. **Endoscopy**: During upper gastrointestinal endoscopy (EGD), the hamartoma may be discovered when inspecting the duodenum, often appearing as a submucosal lesion. Biopsy may be performed, although BGH is usually benign and may not require further intervention.\n\n3. **Asymptomatic Nature**: Many individuals with BGH do not exhibit symptoms, leading to a diagnosis that is often made incidentally rather than through targeted investigation. In symptomatic cases that do arise, symptoms might include abdominal pain or gastrointestinal bleeding, prompting further examination.\n\n4. **Histological Confirmation**: Diagnosis can be confirmed through histological analysis of tissue obtained during biopsies, which can reveal the characteristic features of Brunner's gland tissue proliferation.\n\nIn summary, Brunner's gland hamartoma is usually diagnosed incidentally through imaging studies or endoscopic evaluations, with histological confirmation providing definitive diagnosis in some cases.",
        "paper_evidence":
        [
            "Brunner's gland hamartoma is a rare benign duodenal tumor. It occurs in Brunner's glands, which are found in the duodenum and produce secretions that protect the duodenum from pancreatic enzymes, gastric acid, and other agents.",
            "Brunner's gland hamartomas are small benign lesions that are most commonly found in the bulb of the duodenum. They are very uncommon, and most are found incidentally during upper gastrointestinal series or esophagogastroduodenoscopy.",
            "Brunner's gland hamartoma is an extremely uncommon benign tumor of the duodenum. Most of the lesions are small, asymptomatic and are detected incidentally. ",
            "Brunner's gland hamartomas are rare tumors of duodenum, they are often discovered incidentally during esophagogastroduodenoscopy or upper gastrointestinal series",
            "Brunner's gland adenoma (BGA), also known as Brunneroma or polypoid hamartoma, is a rare benign duodenal tumor that proliferates from Brunner's glands of the duodenum",
            "Most patients with Brunner's gland hamartoma are asymptomatic or have nonspecific complaints.CONCLUSION: BHG is a rare tumor arising from the Brunner's gland of the duodenum, considered entirely benign, although there have been occasionally reports of malignant foci inside.",
            "INTRODUCTION: Brunner's gland hyperplasia (BGH) of the duodenum is an uncommon finding at endoscopy and is usually asymptomatic.",
            "BACKGROUND: Brunner's gland hamartomas are very uncommon lesions and are usually asymptomatic.METHODS: A 77-year-old man was urgently operated on for massive upper gastrointestinal bleeding, associated with haematemesis.RESULTS: A 3.5 x 3 x 3 cm mass arising from the anterior aspect of the first part of the duodenum was found.",
            "Brunner's gland adenoma (hyperplasia) (BGA/H) is a benign gastrointestinal lesion, usually asymptomatic and frequently detected incidentally by endoscopy as a submucosal nodule.",
            "RATIONALE: Brunner gland hamartoma (BGH) is a rare tumor of the duodenum.",
            "Brunner's gland hamartoma (BGH) is a rare sub-epithelial tumour of the duodenum, which may cause haemorrhagic or obstructive gastrointestinal symptoms. Their accurate histological diagnosis often remains elusive before resection. Although endoscopic ultrasonography (EUS) is considered an excellent modality to study lesions within the gastrointestinal wall, only a few reports have described endosonographic characteristics of BGHs. A reliable pre-resection diagnosis with EUS may not only allay fear of malignancy but may as well avert a major surgery for the patients.",
            "Brunner's gland hamartomas are rare, benign small bowel tumours. There were fewer than 150 cases reported in the English literature until the end of the last century. These hamartomas may be discovered incidentally during an upper gastrointestinal tract endoscopy.",
            "Brunner's gland hamartoma is an extremely uncommon benign tumor of the duodenum. Most of the lesions are small, asymptomatic and are detected incidentally.",
            "BACKGROUND: Brunner's gland adenoma is a rare benign tumor arising from Brunner's glands. It is mostly small in size, and patients with this tumor are a",
            "Brunner's gland hamartoma (or Brunneroma) is an uncommon tumour with an incidence of <0.01%, accounting for approximately 5-10% of benign duodenal tumours. Usually asymptomatic, it may manifest occasionally with duodenal obstruction or upper gastrointestinal haemorrhage and rarely with biliary fistulation, cholestatic jaundice and intussusception. It may be associated with uraemia and chronic pancreatitis. The diagnosis is usually confirmed by imaging studies and upper gastrointestinal endoscopy.",
            "Brunner's gland hyperplasia (BGH) is an unusual entity that presents with large duodenal polyp or mass and rarely causes gastrointestinal bleeding",
            "Brunner's gland hamartoma (BGH) is a rare benign small bowel tumor",
            "Brunner's gland hamartoma (BGH) is an infrequently encountered, benign, polypoid proliferation of Brunner's glands",
            "Brunner's gland adenoma is a rare benign tumor of small bowel, often incidentally discovered during endoscopy or radiological imaging. Mostly they are asymptomatic or often present with nonspecific symptoms such as nausea, vomiting, gastrointestinal hemorrhage, iron deficiency anemia.",
            "ding to their tissue components. Brunner's gland hamartoma commonly occurred in the duodenal bulb and exhibited a polypoid appearance, while Brunner's gland hyperplasia was primarily observed in the second portion of duodenum as a submucosal mass and was accompanied by symptoms more frequentl",
            "Brunner's gland hyperplasia is a rare benign tumour and occurs most frequently in the upper part of the duodenum, mostly in the fifth or the sixth decade. Pathogenesis is still unknown. Symptoms are mostly absent, but larger lesions can cause gastric outlet obstruction or bleeding. Biopsies are necessary for differential diagnosis and to rule out cancerous changes. Mostly a resection is required.",
            "CONTEXT: Brunner's gland hyperplasia is rarely associated with clinical symptoms. Most of the lesions are less than 1 cm in diameter and accounts for about 6.8% of all endoscopically removed duodenal polyps. When symptoms occur, this hyperplasia can be effectively treated with endoscopy. However, when the lesion is too large to pass through the endoscopic snare, endoscopic treatment is not possible and surgical treatment is necessary. This treatment may vary from local excision to more complex operations. When Brunner's gland hyperplasia does not have common dimensions, it may also mimic a malignancy of the duodenal-pancreatic area. In this case, a biopsy is indicated even though its result may be not inf",
            "INTRODUCTION: Brunner's gland hamartoma (BGH) is an infrequently encountered, benign, polypoid proliferation of Brunner's glands. Usually these lesions are asymptomatic, just only occasionally presenting with duodenal obstruction or bleeding signs and mimicking a t",
            "Brunner's gland hyperplasia (BGH) is an unusual entity that presents with large duodenal polyp or mass and rarely causes gastrointestinal bleeding. It is usually asymptomatic and often an incidental finding during the esophagoduodenoscopy (EGD).",
            "INTRODUCTION: Brunner's gland hyperplasia (BGH) of the duodenum is an uncommon finding at endoscopy and is usually asymptomatic. Symptomatic BGH presenting with biliary obstruction and pancreatitis is extremely rare and the literature is limited to a few",
            "Brunner gland hamartoma (BGH) is a rare condition that requires a high clinical suspicion to diagnose. Large hamartomas may initially present with iron deficiency anemia (IDA) or symptoms suggesting intestinal obstruction. Barium swallow may demonstrate the lesion, but endoscopic evaluation is the acceptable first line management unless a concern for underlying malignancy.",
            ". Most cases of BGH are benign and asymptomatic; however, it is important to be aware that some patients have severe anemia, gastrointestinal obstruction, or malignant potentia",
            "Brunner gland hamartoma (brunneroma) is a rare benign tumor of the duodenum. It is usually asymptomatic and detected incidentally by endoscopy or other imaging modality.",
            "Brunner's gland hamartomas (BGHs), which are uncommon, asymptomatic and usually found incidentally. They are predominantly benign lesions, but instances of malignant transformation have been reported. Case History We describe a rare case",
            "Brunner's gland hamartoma (BGH) is an extremely rare benign digestive tumor, generally located in the duodenal bulb. We report the case of a 51-year-old asymptomatic man",
            "Brunner's gland hamartomas (BGHs) are rare, benign, primary duodenal tumors. The clinical presentations can vary, and confirming a diagnosis can be challenging",
            "tomy (HSP). Brunner's gland hamartoma (BGH) is a rare benign small bowel tumor. The majority of BGH measuring about 2 cm in diameter, rarely larger than 5 cm. Most patients are asymptomatic, some may present with gastrointestinal hemorrhage or intestinal ",
            "Brunner's gland hamartomas (BGHs) are uncommon lesions of duodenum which show hyperplasia of these glands along with smooth muscle bundles, adipose tissue and lymphoid aggregates. These are usually benign, solitary, pedunculated, polypoidal lesions. Dysplastic changes in BGH are extremely rare and even rarer is the multiplicity of this lesion. We hereby report an index case of BGH",
            "Brunner's gland hamartoma (BGH) is a rare sub-epithelial tumour of the duodenum, which may cause haemorrhagic or obstructive gastrointestinal symptoms. Their accurate histological diagnosis often remains elusive",
            "Brunner's gland hamartoma (BGH) of the duodenum causing upper gastrointestinal (GI)"
        ]
    },
    "65f86e06c4010b4d7800005a":
    {
        "question": "Is peritoneal dialysis the best option for infants with kidney failure?",
        "llm_evidence": "Peritoneal dialysis (PD) is often considered a viable option for infants with kidney failure due to its advantages in minimizing the risk of complications associated with hemodialysis. Key insights include:\n\n1. **Gentle Approach**: PD utilizes the peritoneum as a membrane for dialysis, providing a gentler method of fluid and waste removal, which can be less traumatic for infants compared to the more invasive hemodialysis procedures.\n\n2. **Stability and Flexibility**: PD generally allows for greater stability in an infant’s overall condition and can be performed at home, enabling better quality of life and reduced hospital visits.\n\n3. **Lower Complication Rates**: Studies have indicated that PD has lower rates of certain complications, such as infections and cardiovascular issues, when compared to hemodialysis in pediatric patients.\n\n4. **Nutritional Benefits**: PD is less likely to interfere with nutrition, which is critical for growth and development in infants, as it avoids the significant fluid shifts associated with hemodialysis.\n\n5. **Customized Treatment Plans**: PD can be tailored to meet the specific needs of infants, accommodating their size and individual medical conditions more effectively than other dialysis methods.\n\nIn summary, while there are several dialysis options available for infants with kidney failure, peritoneal dialysis is often favored due to its gentler approach, better compatibility with growth and nutrition, and lower complication rates. However, individual circumstances and medical advice should always guide the final choice of treatment.",
        "paper_evidence":
        [
            "automated peritoneal dialysis (APD)",
            "APD",
            "PD",
            "Peritoneal dialysis (PD) remains the most widely used modality for chronic dialysis in children, particularly in younger children",
            "Chronic ambulatory peritoneal dialysis (CAPD) is the treatment most often used in neonates and infants with chronic kidney failure.",
            "BACKGROUND: Peritoneal dialysis (PD) is the preferred mode of kidney replacement therapy (KRT) in infants and young children with kidney failure.",
            "Peritoneal dialysis remains the treatment of choice for acute renal failure in infancy.",
            "Peritoneal dialysis is the most commonly prescribed dialysis modality for infants and young children with kidney failure worldwide.",
            "The authors demonstrate that peritoneal dialysis is an effective, safe, and available method for treating acute renal failure in infants.",
            "BACKGROUND: Peritoneal dialysis (PD) is the preferred mode of kidney replacement therapy (KRT) in infants and young children with kidney failure. Hemodialysis (HD) is used less often due to the technical challenges and risk of complications in small",
            "cannula, venous catheter).CONCLUSION: Peritoneal dialysis is the method of choice in newborns with acute renal failure, and it is used in the treatment of neonatal asphyxia till the restoration of kidney function is achieved.",
            "Peritoneal dialysis is the treatment of choice for infants with chronic kidney failure.",
            "Peritoneal dialysis is the renal replacement therapy of choice, especially in children under 2 years, with an important risk of peritonitis.",
            "Peritoneal dialysis (PD) is considered as the most common form of renal replacement therapy for newborns including preterms with acute kidney injury (AKI).",
            "BACKGROUND: Peritoneal dialysis is the preferred mode of renal replacement therapy in infants with end-stage renal disease (ESRD). Hemodialysis (HD) is seldom used in neonates and infants due to the risk of major complications in the",
            "BACKGROUND: Peritoneal dialysis (PD) is the preferred mode of kidney replacement therapy (KRT) in infants and young children with kid",
            "BACKGROUND: Peritoneal dialysis (PD) is the preferred modality of renal replacement therapy in children with end-stage renal dis",
            "INTRODUCTION: Peritoneal dialysis (PD) is a preferred method of renal replacement therapy for end-stage renal disease in children. Recent advances have allowed chronic PD to be provided to children of all a"
        ]
    },
    "65ce88b71930410b13000001":
    {
        "question": "Is Lecanemab approved for Alzheimer’s Disease?",
        "llm_evidence": "Lecanemab is a monoclonal antibody designed to target amyloid beta plaques in the brain, which are associated with Alzheimer’s disease. In January 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Lecanemab under the brand name Leqembi. This approval was based on data from clinical trials demonstrating that Lecanemab can reduce amyloid plaques and slightly slow cognitive decline in early Alzheimer’s patients. The primary trial showed a statistically significant reduction in the decline of cognitive function compared to placebo. However, ongoing monitoring and further studies are required to fully understand its long-term effectiveness and safety profile. With this approval, Lecanemab represents a significant advancement in the treatment options available for Alzheimer’s disease.",
        "paper_evidence":
        [
            "Data from recent trials implicate these agents as the first effective disease-modifying therapies against AD and has led to the US Food and Drug Administration (FDA) recent approval of aducanumab and lecanemab, under an accelerated approval pathway. ",
            "Data from recent trials implicate these agents as the first effective disease-modifying therapies against AD and has led to the US Food and Drug Administration (FDA) recent approval of aducanumab and lecanemab, under an accelerated approval pathway.",
            "At the time of writing, two amyloid-lowering antibodies, aducanumab and lecanemab, have obtained United States Food and Drug Administration accelerated approval, with further agents of this class in the Alzheimer's disease treatment pipeline.",
            "At the time of writing, two amyloid-lowering antibodies, aducanumab and lecanemab, have obtained United States Food and Drug Administration accelerated approval, with further agents of this class in the Alzheimer's disease treatment pipeline",
            "The US Food and Drug Administration (FDA)'s recent accelerated approval of two anti-amyloid antibodies for treatment of Alzheimer's disease (AD), aducanumab and lecanemab, has caused substantial debate. ",
            "After the CLARITY-AD clinical trial results of lecanemab were interpreted as positive, and supporting the amyloid hypothesis, the drug received accelerated Food and Drug Administration approval.",
            "Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. ",
            "The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer's disease",
            "Finally, in the last two years, the Food and Drug Administration (FDA) approved the first-ever medications to treat Alzheimer's, aducanumab and lecanemab",
            "The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer's disease.",
            "BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer's disease with mild cognitive impairment or mild dementia.",
            "Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment.",
            "Two anti-amyloid monoclonal antibodies (MABs)-lecanemab (Leqembi®) and aducanumab (Aduhelm®)-have been approved in the USA for the treatment of Alzheimer's disease (AD).",
            "BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer's disease with mild cognitive impairment or mi",
            "On July 6, 2023, the U.S. Food and Drug Administration (FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer's dementia (AD) patients.",
            "Lecanemab has been recently approved by the FDA for the treatment of Alzheimer's disease.",
            " Full FDA approval was granted for lecanemab due to its ability to eliminate toxic brain amyloids",
            "Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD.",
            "This article summarizes the milestones in the development of lecanemab leading to this first approval for the treatment of Alzheimer's disease.",
            "The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer's disease. Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer's disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase III trials.",
            "Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease patients who have proven β-amyloid pathology (Aβ). One of these, lecanemab, has subsequently received full approval and other monoclonal antibodies are poised for positive review and approva",
            "Recently, the U.S. Food and Drug Administration (FDA) approved 2 anti-amyloid monoclonal antibodies, aducanumab (June 7, 2021) and lecanemab (July 6, 2023), for the treatment of Alzheimer's disease (AD) patients, and will most likely also approve a 3rd one, donanemab, soon.",
            "n. Consistent with a critical role for this form of Aβ in AD, a recently FDA-approved therapeutic antibody targeted against protofibrils, lecanemab, slows the progression of AD in patie",
            "BACKGROUND: The approval of lecanemab for the treatment of Alzheimer's disease (AD) by the Food and Drug Administration in the United States has sparked controversy over issues of safety, cost, a",
            "ed in the analysis.RESULTS: The FDA approved lecanemab for Alzheimer's disease in January 2023 which acts as a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody and i",
            "(FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical trials, lecanemab reduced amyloid in the brain and slowed cognitive decline.",
            "BACKGROUND: Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer's disease with mild cognitive impairment or mild dementia. ",
            "Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-β peptide. It is being developed by Eisai, under a global licence from BioArctic (formerly BioArctic Neuroscience), and in collaboration with Biogen, for the treatment of Alzheimer's disease, and received its first approval for this indication on 6 January 2023 in the USA under the Accelerated Approval Pathway.",
            "lt to cure. Drugs aimed at slowing the progression of the disease have been developed, with the Food and Drug Administration (FDA) granting accelerated approval for aducanumab on June 21, 2021 and a new accelerated approval for lecanemab on Janua"
        ]
    },
    "65f5a3efc4010b4d78000017":
    {
        "question": "Can Ultrasonography be used to detect tumors in dogs and cats?",
        "llm_evidence": "Yes, ultrasonography can be used to detect tumors in dogs and cats. This non-invasive imaging technique utilizes high-frequency sound waves to create real-time images of internal structures, allowing veterinarians to visualize abnormal growths within organs and tissues. Key insights include:\n\n1. **Soft Tissue Imaging**: Ultrasonography excels at imaging soft tissues, making it particularly effective for identifying tumors in organs such as the liver, kidneys, spleen, and bladder.\n\n2. **Guidance for Biopsy**: Ultrasound can serve as a guiding tool for aspirating cells from suspected tumors for cytological analysis, enhancing diagnostic accuracy.\n\n3. **Early Detection**: Regular ultrasonography can aid in the early detection of tumors, potentially leading to better treatment outcomes as tumors can be identified before they progress significantly.\n\n4. **Complementary Tool**: While not definitive on its own, ultrasound is often used alongside other diagnostic modalities, such as radiography (X-rays) and CT scans, to provide a comprehensive evaluation of suspected tumors.\n\nOverall, ultrasonography is a valuable tool in the veterinary diagnostic process for identifying and assessing tumors in dogs and cats.",
        "paper_evidence":
        [
            "Ultrasonography (US) and computed tomography (CT) are used to diagnose neoplastic and non-neoplastic focal renal lesions in dogs and cats",
            "A retrospective survey from January 1989 to January 1999 of Tufts University Foster Hospital for Small Animals radiology records of 12 dogs and seven cats with cytologically or histopathologically confirmed abdominal mast cell disease was perform",
            "Although these findings are not specific to the disease in either species, abdominal ultrasound is considered a useful tool for determining the extent of disease in small-animal patients with mast cell tumor if used in conjunction with histopathology or cytology.",
            "In the 2 dogs with intradural masses, intraoperative ultrasonography helped to delineate the extent of the tumor.",
            "Two-dimensional, gray-scale ultrasonography for assessment of hepatic and splenic neoplasia in the dog and cat.",
            "BACKGROUND: In veterinary medicine, contrast-enhanced ultrasonography allowed the accurate quantification of liver, splenic and kidney vascularization in healthy dogs and the differentiation between malignant and benign hepatic, renal, and splenic nodules in dogs and cats based on perfusion patterns.",
            "In dogs, an ultrasonographically normal liver was associated with not having lymphomatous infiltration, leopard-spotted splenic parenchyma and splenomegaly were independently associated with lymphomatous infiltration and leopard-spotted splenic parenchyma was also associated with the B cell immunophenotype of multi-centric lymphoma.CLINICAL SIGNIFICANCE: Ultrasonography of the spleen and liver is specific but not sensitive in the detection of lymphomatous infiltration.",
            "CASE SUMMARY: A 14-year-old cat was presented with a 2-week history of ataxia, seizure-like episodes, vomiting and weight loss. Serum biochemistry revealed severe hypoglycaemia, associated with low serum fructosamine and high insulin concentrations. On abdominal ultrasound, a focal hypoechoic well-defined mass in the left limb of the pancreas was identified and the presence of an additional smaller nodule was suspected. Contrast-enhanced ultrasonography (CEUS) confirmed the presence of both lesions and revealed a third, even s",
            "A 12-year-old fox-terrier dog presented with forelimb lameness of 3-weeks duration. Ultrasonography revealed a mass within the thoracic wall and osteolysis of the left third rib.",
            "Abdominal ultrasound was performed in three cats and one dog, findings included the presence of hyperechoic masses with associated acoustic shadowing, some with a hypoechoic centre.",
            "OBJECTIVES: To determine the diagnostic accuracy of ultrasonography in the detection of lymphomatous infiltration of the liver and spleen in a population of dogs and cats with lymphoma.",
            "Ultrasonography, which has become a mainstay of diagnosing intestinal diseases in dogs and cats, is often one of the first diagnostic tools used to differentiate inflammatory from neoplastic infiltration of the small intestine.",
            "Lung Ultrasound for Imaging of B-Lines in Dogs and Cats-A Prospective Study Investigating Agreement between Three Types of Transducers and the Accuracy in Diagnosing Cardiogenic Pulmonary Edema, Pneumonia and Lung Neoplasia.",
            "Diagnostic accuracy of ultrasonography to detect hepatic and splenic lymphomatous infiltration in dogs and cats.",
            "Focused Ultrasound of Superficial-Soft Tissue Swellings, Masses, and Fluid Collections in Dogs and Cats.",
            "This report describes four dogs with pheochromocytoma in which radiography, ultrasonography and computed tomography (CT) were key diagnostic tools.",
            "Mural lesions representing lymphoma affecting the urinary bladder were identified ultrasonographically in all animals.",
            "Abdominal ultrasound and MRI were performed on 8 dogs having a mass lesion on abdominal radiography.",
            "Ultrasonography revealed masses in all dogs with uterine body/cervical tumors and could delineate the origin of the mass in one of two dogs with uterine horn tumors.",
            "The presence of a heart-base tumor was diagnosed by ultrasound imaging in a 10-year-old, female, domestic shorthaired cat presenting with dyspnea and pleural effusion because of the presence of a modified transudate.",
            "ultrasonography was found to be useful in the diagnosis of hydronephrosis, renal calculi, and renal neoplasia in the dog and cat. One dog with hydronephorsis, one with renal calculi, and a cat with a renal neoplasm were scanned with a real-time ultrasonic scanner.",
            "l disease.MATERIAL AND METHODS: Ultrasonography and MRI were performed in 15 dogs and 15 cats with intraocular neoplasia or intraocular inflammatory disease.RESULTS: In all patients with intraocular neoplasia, sonography revealed masses with increased echogenicity and fairly uniform echotexture, thus allowing the tenta",
            "Contrast-enhanced ultrasound was used to study focal and multifocal lesions of the spleen in 26 dogs and two cats affected by 11 benign and 18 malignant splenic diseases.",
            "ltrasonography of small intestinal inflammatory and neoplastic diseases in dogs and cats."
        ]
    },
    "65f82058c4010b4d7800003d":
    {
        "question": "What is the first line treatment for severe Plasmodium falciparum malaria?",
        "llm_evidence": "The first-line treatment for severe Plasmodium falciparum malaria is intravenous (IV) artesunate. According to the World Health Organization (WHO), artesunate is preferred over other treatments due to its rapid action and efficacy in reducing mortality. In situations where IV artesunate is unavailable, other options may include IV quinine. Early treatment is critical to prevent complications, and a transition to oral antimalarial medication, such as artemether-lumefantrine, is often recommended once the patient stabilizes. Ensuring the management of complications, such as respiratory distress or renal failure, is also crucial in the treatment protocol for severe cases.",
        "paper_evidence":
        [
            "Intravenous artesunate has been the global standard of care for severe malaria",
            "Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria",
            "Intravenous artesunate is the treatment of choice for severe malaria",
            "The first line treatments for Plasmodium falciparum are artemisinin combination therapies, chloroquine in most non-falciparum and intravenous artesunate if any severity criteria.",
            "BACKGROUND: In Zambia, unacceptably high resistance to commonly used antimalarial drugs prompted the choice of artemether-lumefantrine (AL) as first line treatment for uncomplicated Plasmodium falciparum malaria.",
            "Total treatment failure was significantly higher in the SP group (96/393; 19.3%) as compared to the AL (22/403; 5.4%) group (OR: 4.15; 95% CI: 2.52-6.83; P < 0.001).CONCLUSION: In Zambia, the new first line regimen AL is far more efficacious than SP in treating uncomplicated P. falciparum malaria in adults.",
            "Artesunate should constitute first-line treatment for severe malaria in Asia.",
            "Artesunate has become the treatment of choice for severe malaria, and artemisinin-based combination therapies (ACTs) are the foundation of modern falciparum malaria treatment globally.",
            "Combination therapy through coadministration of sulfadoxine-pyrimethamine plus artesunate was introduced as a first-line treatment for uncomplicated malaria in one district in Tanzania.",
            "First-line therapy for P falciparum malaria in the US is combination therapy that includes artemisinin.",
            "Intravenous (i.v.) artesunate is now the recommended first-line treatment of severe falciparum malaria in adults and children by WHO guidelines.",
            "Intravenous (i.v.) artesunate is the first-line treatment for severe falciparum malaria",
            "Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for severe malaria.",
            "IV artesunate is now recommended as the first-line treatment for severe falciparum malaria in France.",
            "The majority of deaths from malaria are in young African children. Parenteral artesunate (ARS) is the first-line treatment for severe falciparum malaria.",
            "BACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT) and injectable artesunate are the first-line treatments for uncomplicated and severe Plasmodium falciparum malaria, respectively.",
            "The first-line treatments for uncomplicated Plasmodium falciparum malaria are artemisinin-based combination therapies (ACTs), consisting of an artemisinin derivative combined with a longer acting partner drug.",
            "Intravenous artesunate is first-line therapy for severe malaria.",
            "Artemisinin-based combination therapy (ACT) is the recommended first-line treatment for Plasmodium falciparum malaria.",
            "Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of treatment against malaria.",
            "First-line treatment of severe P. falciparum malaria is based on IV artesunate.",
            "BACKGROUND: Artemisinin combination therapy (ACT) is used worldwide as the first-line treatment against uncomplicated Plasmodium falcipa",
            "Artemisinin-based combination therapies (ACTs) have been adopted as the first line of treatment against malaria in nearly all malaria-endemic countries, mainly as a result of Plasmodium falciparum infection, as this species of malaria parasite has developed resistance to most of the available non-artemisinin antimalarial drugs.",
            "of malaria. Artemisinin-based combination therapy (ACT) is the WHO recommended first-line treatment for Plasmodium falciparum malaria across the en",
            "d in India. By 2007, the first-line treatment for uncomplicated malaria has been revised to recommend artemisinin-based combination therapy (ACT) for all confirmed P. falci",
            "The World Health Organisation (WHO) recommends arthemether combination treatment as a first line choice.",
            "The main advance is the positioning of artemisinin derivative- based combinations as first-line, given their rapidity of action and their effectiveness.",
            "As recommended by the World Health Organization, the ART-based combination therapies (ACTs) have become the first-line drugs for the treatment of falciparum malaria.",
            "ost-treatment QTc interval.CONCLUSION: Artenimol-piperaquine displays a satisfying efficacy and tolerance profile as a first-line treatment for children with imported uncomplicated falciparum malaria and only necessitates three onc",
            "BACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT) and injectable artesunate are the first-line treatments for uncomplicated and severe Plasmodium falciparum malaria, r",
            "Uncomplicated P. falciparum malaria should be treated with an artemisinin combination therapy (Grade 1A). Artemether-lumefantrine (Riamet(®)) is the drug of choice (Grade 2C) and dihydroartemisinin-piperaquine (Eurartesim(®)) is an alternative. Quinine or atovaquone-proguanil (Malarone(®)) can be used if an ACT is not availab",
            "The first-line treatment of severe malaria is now intravenous artesunate which is more effective than quinine in endemic areas.",
            "as recently undergone a rapid decline in Plasmodium falciparum transmission following combined malaria control interventions with artemisinin-based combination therapy (ACT) and integrated vector control. Artesunate-amodiaquine (ASAQ) was implemented as first-line treatment for unco",
            "BACKGROUND: In 2006, the Senegalese National Malaria Control Programme recommended artemisinin-based combination therapy (ACT) with artemether-lumefantrine as the first-line treatment for uncomplicated Plasmodium falciparum malaria.",
            "For severe malaria, intravenous artesunate is first-line therapy.",
            "In the early 2000s, artemisinin-based combination therapy (ACT) was introduced as first-line treatment for uncomplicated Plasmodium falciparum malaria in virtually all endemic countries.",
            "Artemisinin combination therapy (ACT) is the first line to treat uncomplicated Plasmodium falciparum malaria worldwide.",
            "2. The treatment of choice for severe or complicated malaria in adults and children is intravenous artesunate (Grade 1A). Intravenous artesunate is unlicensed in the EU but is available in many centres. The alternative is intravenous quinine, which should be started immediately if artesunate is not available (Grade 1",
            "BACKGROUND: The artemisinin derivatives are the preferred antimalaria drugs for treating severe Plasmodium falcipa",
            "For severe malaria, in the second and third trimester parenteral artesunate is preferred over quinine. In the first trimester, both artesunate and quinine (parenteral) may be considered as options."
        ]
    }
}